<SEC-DOCUMENT>0000950123-11-095929.txt : 20111107
<SEC-HEADER>0000950123-11-095929.hdr.sgml : 20111107
<ACCEPTANCE-DATETIME>20111107160843
ACCESSION NUMBER:		0000950123-11-095929
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20110930
FILED AS OF DATE:		20111107
DATE AS OF CHANGE:		20111107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALIMERA SCIENCES INC
		CENTRAL INDEX KEY:			0001267602
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34703
		FILM NUMBER:		111184734

	BUSINESS ADDRESS:	
		STREET 1:		6120 WINDWARD PARKWAY
		STREET 2:		STE 290
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
		BUSINESS PHONE:		6789905740

	MAIL ADDRESS:	
		STREET 1:		6120 WINDWARD PARKWAY
		STREET 2:		STE 290
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>c23183e10vq.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 10pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 10pt"><B>Form&nbsp;10-Q</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(Mark One)
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<!-- xbrl,dc -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%"><B>For the quarterly period ended September&nbsp;30, 2011</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>or</B></DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 10pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 12%"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>
Commission File Number: 001-34703</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 10pt"><B>Alimera Sciences, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
<I>(Exact name of registrant as specified in its charter)</I></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20-0028718</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><I>(State or other jurisdiction of</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>(I.R.S. Employer</I></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><I>incorporation or organization)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>Identification No.)</I></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>6120 Windward Parkway, Suite&nbsp;290</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Alpharetta, GA</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>30005</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><I>(Address of principal executive offices)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><I>(Zip Code)</I></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(678)&nbsp;990-5740</B><BR>
<I>(Registrant&#146;s telephone number, including area code)</I>
</DIV>

<DIV align="center" style="font-size: 1pt; margin-top: 10pt"><DIV align="center"><DIV style="font-size: 1pt; margin-top: 10pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required
to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12&nbsp;months (or for such shorter period that the registrant was required to file
such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.
Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File required to be submitted and
posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167; 232.405 of this chapter) during the
preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit
and post such files). Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See the
definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting
company&#148; in Rule&nbsp;12b-2 of the Exchange Act. (Check one):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Large accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Non-accelerated filer <FONT style="font-family: Wingdings">&#254;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Smaller reporting company <FONT style="font-family: Wingdings">&#111;</FONT></FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">(Do not check if a smaller reporting company)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As
of November&nbsp;3, 2011, there were 31,427,355 shares of the registrant&#146;s common stock issued
and outstanding.
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">
<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="C23183tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>QUARTERLY REPORT ON FORM 10-Q</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>INDEX</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" colspan="5"><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183101"><B>PART I. FINANCIAL INFORMATION</B></A></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183102">Item&nbsp;1. Financial Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C23183103">Balance Sheets as of September&nbsp;30, 2011 (unaudited)&nbsp;and December&nbsp;31, 2010</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C23183104">Statements of Operations for the three and nine months ended September&nbsp;30, 2011 and 2010 (unaudited)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C23183105">Statements of Cash Flows for the nine months ended September&nbsp;30, 2011 and 2010 (unaudited)</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#C23183106">Notes to Financial Statements</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183107">Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183108">Item&nbsp;3. Quantitative and Qualitative Disclosures about Market Risk</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183109">Item&nbsp;4. Controls and Procedures</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" colspan="5"><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183110"><B>PART II. OTHER INFORMATION</B></A></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183111">Item&nbsp;1A. Risk Factors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183112">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#C23183113">Item&nbsp;6. Exhibits</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c23183exv31w1.htm">Exhibit 31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c23183exv31w2.htm">Exhibit 31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c23183exv32w1.htm">Exhibit 32.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alim-20110930.xml">EX-101 INSTANCE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alim-20110930.xsd">EX-101 SCHEMA DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alim-20110930_cal.xml">EX-101 CALCULATION LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alim-20110930_lab.xml">EX-101 LABELS LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="alim-20110930_pre.xml">EX-101 PRESENTATION LINKBASE DOCUMENT</A></FONT></TD></TR>
</TABLE>
</DIV>
<DIV align="left">
<!-- /TOC -->
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">

<DIV align="left">
<A name="C23183101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PART I. FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left">
<A name="C23183102"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 1</B></TD>
    <TD>&nbsp;</TD>
    <TD><B><I>Financial Statements</I></B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>

<DIV align="left">
<A name="C23183103"></A>
</DIV>

<!-- xbrl,bs -->
<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>BALANCE SHEETS</B>
</DIV>
<!-- xbrl,body -->

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(In thousands except share and</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>per share data)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CURRENT ASSETS:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">38,107</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">28,514</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Investments in marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,330</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,236</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,078</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred financing costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">231</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">272</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,076</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56,194</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">PROPERTY AND EQUIPMENT &#151; at cost less accumulated depreciation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">218</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">220</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL ASSETS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">40,294</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">56,414</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CURRENT LIABILITIES:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,677</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued expenses (Note 5)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,731</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Outsourced services payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">393</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">841</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Notes payable (Note 7)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,386</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,157</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Capital lease obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,199</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,417</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LONG-TERM LIABILITIES:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Notes payable, net of discount &#151; less current portion (Note 7)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,501</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,767</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other long-term liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">STOCKHOLDERS&#146; EQUITY:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Preferred stock, $.01 par value &#151; 10,000,000 shares
authorized and no shares issued and outstanding at September
30, 2011 and at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock, $.01 par value &#151; 100,000,000 shares authorized
and 31,407,383 shares issued and outstanding at September&nbsp;30,
2011 and 100,000,000 shares authorized and 31,255,953 shares
issued and outstanding at December&nbsp;31, 2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">314</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">313</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">235,155</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">233,338</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">415</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">415</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(205,299</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(188,854</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL STOCKHOLDERS&#146; EQUITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,585</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,212</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL LIABILITIES AND STOCKHOLDERS&#146; EQUITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">40,294</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">56,414</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">See Notes to Financial Statements.
</DIV>
<!-- /xbrl,bs -->


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>

<DIV align="left">
<A name="C23183104"></A>
</DIV>

<!-- xbrl,op -->
<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>STATEMENTS OF OPERATIONS</B>
</DIV>
<!-- xbrl,body -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Three Months Ended September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Nine Months Ended September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(In thousands except share and per share data)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">RESEARCH AND DEVELOPMENT
EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,732</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,481</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">GENERAL AND ADMINISTRATIVE
EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,421</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,260</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,827</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,338</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">MARKETING EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,583</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,038</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">OPERATING EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,257</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,597</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,028</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">INTEREST INCOME</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">INTEREST EXPENSE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(284</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(863</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(618</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">GAIN ON EARLY EXTINGUISHMENT
OF DEBT (NOTE 6)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,343</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">DECREASE IN FAIR VALUE OF
PREFERRED STOCK CONVERSION
FEATURE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,644</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LOSS FROM CONTINUING OPERATIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,540</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,082</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,445</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(11,606</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">INCOME FROM DISCONTINUED
OPERATIONS (NOTE 3)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">NET LOSS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,540</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,082</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,445</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,606</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">REDEEMABLE PREFERRED STOCK
ACCRETION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(466</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">REDEEMABLE PREFERRED STOCK
DIVIDENDS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,638</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">NET LOSS APPLICABLE TO COMMON
SHAREHOLDERS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(6,540</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(6,082</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(16,445</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(10,710</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">NET LOSS PER SHARE APPLICABLE
TO COMMON SHAREHOLDERS &#151;
Basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.21</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.20</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.52</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.56</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">WEIGHTED-AVERAGE SHARES
OUTSTANDING &#151; Basic and
diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,396,517</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,145,856</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31,342,752</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,120,860</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt">See Notes to Financial Statements.
</DIV>
<!-- /xbrl,op -->


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>

<DIV align="left">
<A name="C23183105"></A>
</DIV>

<!-- xbrl,cf -->
<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>STATEMENTS OF CASH FLOWS</B>
</DIV>
<!-- xbrl,body -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CASH FLOWS FROM OPERATING ACTIVITIES:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(16,445</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(7,606</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Income from discontinued operations (Note 3)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Change in fair value of preferred stock conversion feature</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,644</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Gain from early extinguishment of debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,343</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">106</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">145</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stock compensation and other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,478</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">567</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization of deferred financing costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">318</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Non-cash investment gain</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Changes in assets and liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(158</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(320</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">231</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accrued expenses and other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,720</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(53</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Other long-term liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash used in operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,148</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,025</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CASH FLOWS FROM INVESTING ACTIVITIES:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Purchases of investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(39,962</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from maturities of investments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Purchases of property and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(104</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(121</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash provided by (used in) investing activities of continuing operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(40,083</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash provided by investing activities of discontinued operations (Note 3)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash provided by (used in) investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25,724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(36,083</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CASH FLOWS FROM FINANCING ACTIVITIES:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from exercises of stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">210</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from exercise of Series&nbsp;C-1 preferred warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,997</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from exercise of common stock warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">489</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from sale of common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">111</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68,395</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Payment of common stock offering costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,942</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Repayment of pSivida note payable (Note 6)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(15,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Repayment of notes payable (Note 7)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(265</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Payment of debt modification costs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(50</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Payments on capital lease obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61,961</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">NET INCREASE IN CASH</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,593</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,853</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CASH &#151; Beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28,514</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,858</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CASH &#151; End of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">38,107</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,711</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<!-- /xbrl,cf -->

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->


<!-- xbrl,cf -->
<DIV style="display: none"><B>STATEMENTS OF CASH FLOWS</B>
</DIV>
<!-- xbrl,body -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SUPPLEMENTAL DISCLOSURES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash paid for interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">508</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">525</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Supplemental schedule of noncash investing and financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property and equipment acquired under capital leases</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Reclassification of fair value of preferred stock conversion
feature to additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">36,528</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">IPO issuance costs charged to equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,228</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">There were no income tax or dividend payments made for the nine months ended September
30, 2011 and 2010.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">See Notes to Financial Statements.
</DIV>
<!-- /xbrl,cf -->



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl,ns -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>

<DIV align="left">
<A name="C23183106"></A>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS</B>
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>1. Nature of Operations</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Alimera Sciences, Inc. (&#147;Company&#148;) is a biopharmaceutical company that specializes in
the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The Company
was formed on June&nbsp;4, 2003 under the laws of the State of Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&nbsp;21, 2010, the Company&#146;s Registration Statement on Form S-1 (as amended) was
declared effective by the Securities and Exchange Commission (&#147;SEC&#148;) for the Company&#146;s
initial public offering (&#147;IPO&#148;), pursuant to which the Company sold 6,550,000 shares of its
common stock at a public offering price of $11.00 per share. The Company received net
proceeds of approximately $68,395,000 from this transaction, after deducting underwriting
discounts and commissions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the year ended December&nbsp;31, 2006, management and the board of directors of the
Company approved a plan to discontinue the operations of its non-prescription business (see
Note 3). As a result of the completion of the disposal of its non-prescription business in
July&nbsp;2007, the Company no longer has active products and will not have active products until
and unless the Company receives U.S. Food and Drug Administration (&#147;FDA&#148;) approval and
launches its initial prescription product (see Note 4).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company is presently focused on diseases affecting the back of the eye, or retina,
because the Company&#146;s management believes these diseases are not well treated with current
therapies and represent a significant market opportunity. The Company&#146;s most advanced
product candidate is ILUVIEN, which is being developed for the treatment of diabetic macular
edema (&#147;DME&#148;). DME is a disease of the retina which affects individuals with diabetes and
can lead to severe vision loss and blindness. The Company has completed  two Phase 3
pivotal clinical trials (collectively referred to as the &#147;FAME Study&#148;) for ILUVIEN involving
956 patients in sites across the U.S., Canada, Europe and India to assess the efficacy and
safety of ILUVIEN in the treatment of DME.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In June&nbsp;2010, the Company submitted a New Drug Application (&#147;NDA&#148;) for ILUVIEN to the FDA that included data through
month 24 of the FAME Study. In December&nbsp;2010, the FDA issued a Complete Response Letter (&#147;CRL&#148;) in response to the
Company&#146;s NDA. In the CRL, the FDA communicated its decision that the NDA could not be approved in its then present
form. The FDA asked for analyses of the safety and efficacy data through month 36 of the FAME Study, including
exploratory analyses in addition to those previously submitted in the NDA, to further assess the relative benefits and
risks of ILUVIEN. The FDA also sought additional information regarding controls and specifications concerning the
manufacturing, packaging and sterilization of ILUVIEN. In a February&nbsp;2011 meeting with the FDA, the FDA requested
additional data related to the use of the commercial version of the ILUVIEN inserter for which approval was sought in
the NDA. In May&nbsp;2011, the Company submitted to the FDA a complete response to the CRL. The FDA classified the response
as a Class&nbsp;2 resubmission with a Prescription Drug User Fee Act (&#147;PDUFA&#148;) date of November&nbsp;12, 2011. The PDUFA date is
the date by which the Company can reasonably expect to have received
the FDA&#146;s response. In July&nbsp;2011, the FDA notified
the Company that it will not call an advisory committee during its review of the Company&#146;s complete response to the
CRL. In September&nbsp;2011, the Company enrolled its first patient in a physician utilization study aimed at providing the
additional data requested by the FDA with respect to the commercial version of the ILUVIEN inserter. The Company has
enrolled 54 patient eyes in this study evaluating the safety and utility of the commercial version of the inserter and
is targeting to enroll 100 patient eyes before commercial launch.


</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In July&nbsp;2010, using the Decentralized Procedure, the Company submitted a Marketing
Authorization Application for ILUVIEN to the Medicines and Healthcare products Regulatory
Agency (&#147;MHRA&#148;) in the United Kingdom, which serves as the Reference Member State, and to
regulatory authorities in Austria, France, Germany, Italy, Portugal and Spain. In November
2010, the Company received the Preliminary Assessment Report from the MHRA followed by
additional comments from the other health authorities in December&nbsp;2010. In July&nbsp;2011, the
Company submitted its draft responses to the clinical, non-clinical, and quality questions
to the MHRA. The submission included the additional safety and efficacy data through the
final readout at the end of the FAME Study.
In September 2011, the MHRA provided comments to the Company&#146;s clinical responses and indicated that there
were no further comments to the Company&#146;s non-clinical and
quality responses.  The Company is preparing, and
plans to submit in November 2011, its final response to the Preliminary Assessment Report from the MHRA and to the additional comments from the other health authorities.

</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>2. Basis of Presentation</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has prepared the accompanying unaudited interim financial statements and
notes thereto in accordance with accounting principles generally accepted in the United
States of America (&#147;U.S. GAAP&#148;) for interim financial information and the instructions to
Form 10-Q and Article&nbsp;10-01 of Regulation&nbsp;S-X of the SEC. Accordingly, they do not include
all of the information and disclosures required by U.S. GAAP for complete financial
statements. In the opinion of management, the accompanying unaudited interim financial
statements reflect all adjustments, which include normal recurring adjustments, necessary to
present fairly the Company&#146;s interim financial information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The accompanying unaudited interim financial statements and related notes should be
read in conjunction with the Company&#146;s audited financial statements for the year ended
December&nbsp;31, 2010 and related notes included in the Company&#146;s Annual Report on Form 10-K,
which was filed with the SEC on March&nbsp;25, 2011. The financial results for any interim period
are not necessarily indicative of the expected financial results for the full year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&nbsp;21, 2010, the Company effected a 1 for 3.4 reverse split of the Company&#146;s
common and preferred stock. All share and per share amounts in the accompanying financial
statements and notes have been retroactively adjusted for all periods presented to give
effect to the reverse stock split.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>3. Discontinued Operations</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In October&nbsp;2006, management and the board of directors of the Company approved a plan
to discontinue the operations of its non-prescription ophthalmic pharmaceutical business
(&#147;OTC Business&#148;). The plan included the sale of the assets of the Company&#146;s OTC Business and
also the termination of its sales and marketing personnel. The Company previously determined
that the discontinued OTC Business comprised operations and cash flows that could be clearly
distinguished, operationally and for financial reporting purposes, from the rest of the
Company. Accordingly, the results of operations for the discontinued OTC Business have been
presented as discontinued operations. During the nine months ended September&nbsp;30, 2010, the
Company received a $4,000,000 option payment from the acquirer of the assets of the OTC
Business to provide it with an additional two years to develop one of the acquired products.
In July 2011, the acquirer of the assets of the OTC Business notified the Company that it will discontinue the development of the acquired products and not seek FDA approval.
There were no revenues or expenses from discontinued operations during the nine month period
ended September&nbsp;30, 2011. The following table presents basic and diluted earnings per share
from discontinued operations for the nine months ended September&nbsp;30, 2010:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="86%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income from discontinued operations (in thousands)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income from discontinued operations per share &#151; Basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted-average shares outstanding &#151; Basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19,120,860</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>4. Factors Affecting Operations</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To date the Company has incurred recurring losses, negative cash flow from operations,
and has accumulated a deficit of $205,299,000 from the Company&#146;s inception through September
30, 2011. The Company does not expect to generate revenues from its product, ILUVIEN, until
early 2012, if at all, and therefore does not expect to have cash flow from operations until
2012, if at all. As of September&nbsp;30, 2011, the Company had
approximately $38,609,000 in
cash, cash equivalents, and investments in marketable securities. In October&nbsp;2010, the
Company obtained a $32,500,000 senior secured credit facility (&#147;Credit Facility&#148;) to help
fund its working capital requirements (see note 7). The Credit Facility consisted of a
$20,000,000 working capital revolver and a $12,500,000 term loan. The lenders advanced
$6,250,000 under the term loan and the remaining $6,250,000 was available to be advanced
following FDA approval of ILUVIEN, but no later than July&nbsp;31, 2011. In May&nbsp;2011, the Company
and its lenders amended the terms of the Credit Facility to, among other things, extend the
FDA approval deadline for the second advance under the term loan to December&nbsp;31, 2011, and
to increase the amount available under the second advance of the term loan from $6,250,000
to $11,000,000. Management believes it has sufficient funds available to fund its operations
through the projected launch of ILUVIEN and the expected generation of revenue in early
2012. The commercialization of ILUVIEN is dependent upon approval by the FDA, however, and
management cannot be sure that ILUVIEN will be approved by the FDA or that, if approved,
future sales of ILUVIEN will generate enough revenue to fund the Company&#146;s operations beyond
its launch. Due to the uncertainty around FDA approval, management also cannot be certain
that the Company will not need additional funds for the launch of ILUVIEN. If ILUVIEN is not
approved, or if approved, does not generate sufficient revenue, the Company may adjust its
commercial plans so that it can continue to operate with its existing cash resources or seek
to raise additional financing.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>5. Accrued Expenses</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Accrued expenses consisted of the following:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrued clinical investigator expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">518</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,911</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrued compensation expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">873</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">730</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,731</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>6. pSivida Agreement</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In March&nbsp;2008, in connection with the Company&#146;s collaboration agreement with pSivida
U.S., Inc. (&#147;pSivida&#148;), the licensor of the ILUVIEN technology, the Company and pSivida
amended and restated the agreement to provide the Company with 80% of the net profits and
pSivida with 20% of the net profits derived by the Company from the
sale of ILUVIEN.
In connection with the amended and restated agreement,
the Company also agreed to:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pay $12.0&nbsp;million to pSivida upon the execution of the March&nbsp;2008 agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>issue a $15.0&nbsp;million promissory note to pSivida;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>forgive all outstanding development payments, penalties and interest as of
the effective date of the March&nbsp;2008 agreement, which totaled $6.8&nbsp;million;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue responsibility for regulatory, clinical, preclinical,
manufacturing, marketing and sales for the remaining development and
commercialization of the products;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>assume all financial responsibility for the development of the products and
assume 80% of the commercialization costs of the products (instead of 50%
as provided under the February&nbsp;2005 agreement); and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>make an additional milestone payment of $25.0&nbsp;million after the first
product under the March&nbsp;2008 agreement has been approved by the FDA.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The $15,000,000 promissory note accrued interest at 8% payable quarterly and was
payable in full to pSivida upon the earlier of a liquidity event as defined in the note
(including an initial public offering of the Company&#146;s common stock greater than
$75,000,000), the occurrence of an event of default under the Company&#146;s agreement with
pSivida or September&nbsp;30, 2012. If the note was not paid in full by March&nbsp;31, 2010, the
interest rate was to increase to 20% effective as of April&nbsp;1, 2010, and the Company would be
required to begin making principal payments of $500,000 per month. On April&nbsp;27, 2010, the
Company paid pSivida $15,225,000 in principal and interest to satisfy the note payable. As a
result, the Company recognized a gain of $1,343,000 on the extinguishment of this debt in
the accompanying financial statements for the nine month period ended September&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company&#146;s license rights to pSivida&#146;s proprietary delivery device could revert to
pSivida if the Company were to (i)&nbsp;fail twice to cure its breach of an obligation to make
certain payments to pSivida following receipt of written notice thereof; (ii)&nbsp;fail to cure
other breaches of material terms of its agreement with pSivida within 30&nbsp;days after notice
of such breaches or such longer period (up to 90&nbsp;days) as may be reasonably necessary if the
breach cannot be cured within such 30-day period; (iii)&nbsp;file for protection under the
bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer
appointment of a receiver or trustee over its property, file a petition under any bankruptcy
or insolvency act or have any such petition filed against it and such proceeding remains
undismissed or unstayed for a period of more than 60&nbsp;days; or (iv)&nbsp;notify pSivida in writing
of its decision to abandon its license with respect to a certain product using pSivida&#146;s
proprietary delivery device. The Company was not in breach of its agreement with pSivida as
of September&nbsp;30, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Upon commercialization of ILUVIEN, the Company must share 20% of net profits of
ILUVIEN, as defined by the agreement, with pSivida. In connection with this arrangement the
Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the
agreement, incurred prior to product profitability out of pSivida&#146;s share of net profits. As
of September&nbsp;30, 2011 and December&nbsp;31, 2010 the Company was owed $3,556,000 and $2,224,000,
respectively, in commercialization costs. Due to the uncertainty of FDA approval of the NDA
for ILUVIEN, the Company has fully reserved these amounts in the accompanying financial
statements.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>7. Term Loan and Working Capital Revolver</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Term Loan</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On October&nbsp;14, 2010 (&#147;Effective Date&#148;), the Company entered into a Loan and Security
Agreement (&#147;Term Loan Agreement&#148;) with Silicon Valley Bank and MidCap Financial LLP
(&#147;Lenders&#148;). Pursuant to the original terms of the Term Loan Agreement, the Company was
entitled to borrow up to $12.5&nbsp;million, of which $6.25&nbsp;million (&#147;Term Loan A&#148;) was advanced
to the Company on the Effective Date. The Company was entitled to draw down the remaining
$6.25&nbsp;million under the Term Loan (&#147;Term Loan B&#148; and together with Term Loan A, the &#147;Term
Loan&#148;) if the FDA approved the Company&#146;s NDA for ILUVIEN prior to or on July&nbsp;31, 2011. On
May&nbsp;16, 2011, the Company and the Lenders amended the Term Loan Agreement (&#147;Term Loan
Modification&#148;) to, among other things, extend until December&nbsp;31, 2011 the date by which the
FDA must approve the NDA in order for the Company to draw down Term Loan B and increase the
amount of Term Loan B by $4.75&nbsp;million to $11.0&nbsp;million. In addition, the maturity date of
the Term Loan was extended from October&nbsp;31, 2013 to April&nbsp;30, 2014 (&#147;Term Loan Maturity
Date&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The
Company was required to pay interest on Term Loan A at a rate of 11.5% on a monthly
basis through July&nbsp;31, 2011, and then beginning August&nbsp;2011,
the Company is required to repay the principal in 33 equal monthly
installments plus interest at a rate of 11.5%. The Company is
required to pay interest at a rate of 12.5% on the amount borrowed, if any, under Term Loan
B through April&nbsp;30, 2012, and thereafter will be required to repay the principal in equal
monthly installments through the Term Loan Maturity Date, plus interest at a rate of 12.5%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If the Company repays Term Loan A prior to maturity, the Company must pay to the
Lenders a prepayment fee equal to 5.0% of the total amount of principal then outstanding if
the prepayment had occurred within one year after the funding date of Term Loan A (&#147;Term Loan A
Funding Date&#148;), 3.0% of such amount if the prepayment occurs between one year and two years
after the Term Loan A Funding Date and 1.0% of such amount if the prepayment occurs
thereafter (subject to a 50% reduction in the event that the prepayment occurs in connection
with an acquisition of the Company). If Term Loan B is advanced to the Company, then the
amount of the prepayment fee on both Term Loan A and Term Loan B will be reset to 5.0% and
the time-based reduction of the prepayment fee will be measured from the funding date of
Term Loan B (subject to the same 50% reduction in the event of an acquisition of the
Company), rather than from the Term Loan A Funding Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Term Loan Agreement, the
Company granted to the Lenders a first priority security interest in all of its assets,
including its intellectual property, however, the lien on the Company&#146;s intellectual
property will be released if the Company meets certain financial conditions. The occurrence
of an event of default could result in the acceleration of the Company&#146;s obligations under
the Term Loan Agreement and an increase to the applicable interest rate, and would permit
the Lenders to exercise remedies with respect to the collateral under the Term Loan
Agreement. The Company also agreed not to pledge or otherwise encumber its intellectual
property assets. Additionally, the Company must seek the Lenders&#146; approval prior to the
payment of any cash dividends.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On the Effective Date, the Company issued to the Lenders warrants to purchase an
aggregate of up to 39,773 shares of the Company&#146;s common stock. Each of the warrants is
exercisable immediately, has a per-share exercise price of $11.00 and has a term of 10
years. The Company estimated the fair value of warrants granted using the Black-Scholes
option pricing model. The aggregate fair value of the warrants was estimated to be $389,000.
The Company allocated a portion of the proceeds from the Term Loan Agreement to the warrants
in accordance with Accounting Standards Codification (&#147;ASC&#148;) 470-20-25-2, <I>Debt Instruments
with Detachable Warrants</I>. As a result, the Company recorded a discount of $366,000 which is
being amortized to interest expense using the effective interest method. The Lenders also
hold warrants to purchase an aggregate of up to 69,999 shares of the Company&#146;s common stock,
which are exercisable only if Term Loan B is advanced to the Company. Each of these warrants
has a per share exercise price of $11.00 and a term of 10&nbsp;years. In addition, the Lenders
will have certain registration rights with respect to the shares of common stock issuable
upon exercise of all of their warrants. The Company paid to the Lenders an upfront fee of
$62,500 on the Effective Date and an additional fee of $50,000 in connection with the Term
Loan Modification. In accordance with ASC 470-50-40-17, <I>Debt &#151; Modifications and
Extinguishments</I>, the Company is amortizing the unamortized discount on Term Loan A and the
$50,000 modification fee over the remaining term of Term Loan A, as modified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company is required to maintain its primary operating and other deposit accounts
and securities accounts with Silicon Valley Bank, which accounts must represent at least 50%
of the dollar value of the Company&#146;s accounts at all financial institutions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Working Capital Revolver</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Also on the Effective Date, the Company and Silicon Valley Bank entered into a Loan and
Security Agreement, pursuant to which the Company obtained a secured revolving line of
credit (&#147;Working Capital Revolver&#148;) from Silicon Valley Bank with borrowing availability up
to $20,000,000 (&#147;Revolving Loan Agreement&#148;). On
May&nbsp;16, 2011, the Company and Silicon Valley Bank
amended the Revolving Loan Agreement to extend the maturity date of the Working Capital
Revolver from October&nbsp;31, 2013 to April&nbsp;30, 2014.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Working Capital Revolver is a working capital-based revolving line of credit in an
aggregate amount of up to the lesser of (i) $20,000,000, or (ii)&nbsp;85% of eligible domestic
accounts receivable. As of September&nbsp;30, 2011, no amounts under the Working Capital Revolver
were outstanding or available to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Amounts advanced under the Working Capital Revolver will bear interest at an annual
rate equal to Silicon Valley Bank&#146;s prime rate plus 2.50% (with a rate floor of 6.50%).
Interest on the Working Capital Revolver will be due monthly, with the balance due at the
maturity date. On the Effective Date, the Company paid to Silicon Valley Bank an upfront fee
of $100,000. In addition, if the Company terminates the Working Capital Revolver prior to
maturity, it would have paid to Silicon Valley Bank a fee of $400,000 if the
termination occured
within one year after the Effective Date and a fee of $200,000 if the termination occurs
more than one year after the Effective Date (each a &#147;Termination Fee&#148;), provided in each
case that such Termination Fee will be reduced by 50% in the event of an acquisition of the
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Revolving Loan Agreement, the
Company granted to Silicon Valley Bank a first priority security interest in all of its
assets, including its intellectual property, however, the lien on the Company&#146;s intellectual
property will be released if the Company meets certain financial conditions. The occurrence
of an event of default could result in the acceleration of the Company&#146;s obligations under
the Revolving Loan Agreement and an increase to the applicable interest rate, and would
permit Silicon Valley Bank to exercise remedies with respect to the collateral under the
Revolving Loan Agreement. The Company also agreed not to pledge or otherwise encumber its
intellectual property assets. Additionally, the Company must seek Silicon Valley Bank&#146;s
approval prior to the payment of any cash dividends.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>8. Earnings (Loss) Per Share (EPS)</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Basic EPS is calculated in accordance with ASC 260, <I>Earnings per Share, </I>by dividing net
income or loss attributable to common stockholders by the weighted average common stock
outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted
average common shares outstanding for the dilutive effect of common stock options, warrants,
convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In
periods where a net loss from continuing operations is recorded, no effect is given to
potentially dilutive securities, since the effect would be anti-dilutive. Total securities
that could potentially dilute basic EPS in the future that were not included in the
computation of diluted EPS because to do so would have been anti-dilutive were as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;A preferred stock and
convertible accrued dividends</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,002,205</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;B preferred stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,063,383</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;C preferred stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,488,762</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;C-1 preferred stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,187,651</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;C-1 Preferred stock warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56,723</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Common stock warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28,086</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">77,114</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29,366</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">112,644</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stock options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,502,469</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,633,441</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,573,106</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,669,748</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,530,555</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,710,555</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,602,472</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,581,116</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>9. Preferred Stock</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prior to the Company&#146;s IPO, the Company had four series of preferred stock. On April
27, 2010 and in connection with the IPO, all outstanding shares of the Company&#146;s preferred
stock were converted into 22,863,696 shares of common stock and all preferred stock
dividends were eliminated. Significant terms of all series of the preferred stock were as
follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dividends were cumulative and accrued on a daily basis at
the rate of 8% per annum beginning on the date of issuance
and based on the original issue price, as adjusted for any
stock dividend, stock split, combination, or other event
involving the preferred stock. Dividends accrued, whether
or not declared, annually and were due and payable when and
if declared by the Board of Directors, upon a liquidating
event upon redemption of the preferred stock or on the date
that the preferred stock was otherwise acquired by the
Company.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon any liquidation, dissolution, or winding up of the
Company, the preferred stockholders were entitled to a
liquidation preference payment equal to (i)&nbsp;the sum of the
liquidation value plus all accumulated, accrued, and unpaid
dividends and (ii)&nbsp;the pro rata share of any remaining
amounts such holder would have been entitled to receive had
such holder&#146;s shares been converted into common stock
immediately prior to the liquidation, dissolution, or
winding up.</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At any time subsequent to March&nbsp;17, 2013, the holders of a
majority of the preferred stock could have required the
Company to redeem all or any portion of the preferred
stock. If the preferred stock was redeemed, the redemption
would have occurred in equal installments over a three-year
period. The price paid by the Company to redeem the shares
would have been the greater of (i)&nbsp;the original issue
price, plus all accumulated, accrued, and unpaid dividends,
and (ii)&nbsp;the fair market value of the preferred stock being
redeemed at the time of the redemption.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Because the preferred stock provided the holders the right to require the Company to
redeem such shares for cash after March&nbsp;17, 2013 at the greater of (i)&nbsp;the original issue
price plus any accrued but unpaid dividends and (ii)&nbsp;the fair market value of the preferred
stock being redeemed, the embedded conversion feature required separate accounting.
Consequently, the conversion feature had to be bifurcated from the preferred stock and
accounted for separately at each issuance date. The carrying value of the embedded
derivative
was adjusted to fair value at the end of each reporting period and the change in fair
value was recognized in the statement of operations.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&nbsp;8, 2010 warrants to purchase shares of the Company&#146;s Series&nbsp;C-1 preferred
stock were exercised resulting in $10,000,000 in cash proceeds and the issuance of 1,935,700
additional shares of Series&nbsp;C-1 preferred stock. The Company recorded a derivative liability
of $3,471,000 upon the exercise of the warrants and the issuance of 1,935,700 shares of
Series&nbsp;C-1 preferred stock in January&nbsp;2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At each reporting date, the Company adjusted the carrying value of the embedded
derivatives to estimated fair value and recognized the change in such estimated value in its
statement of operations. The estimated fair value of the derivatives at April&nbsp;27, 2010 was
$36,528,000. The Company recognized a gain of $3,644,000 associated with the change in fair
value for the nine months ended September&nbsp;30, 2010. In connection with the IPO, the embedded
derivatives were eliminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with the Company&#146;s IPO in April&nbsp;2010, the Company authorized 10,000,000
shares of $0.01 par value preferred stock. No shares of preferred stock were issued or
outstanding at September&nbsp;30, 2011 and December&nbsp;31, 2010, respectively.
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>10. Stock Options</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended September&nbsp;30, 2011 and 2010, the Company recorded
compensation expense related to stock options of approximately $417,000 and $189,000,
respectively. During the nine months ended September&nbsp;30, 2011 and 2010, the Company recorded
stock compensation expense of approximately $1,416,000 and $447,000, respectively. As of
September&nbsp;30, 2011, the total unrecognized compensation cost related to non-vested stock
options granted was $4,220,000 and is expected to be recognized over a weighted average
period of 2.9&nbsp;years. The following table presents a summary of stock option transactions for
the three and nine months ended September&nbsp;30, 2011 and 2010:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>Three Months Ended September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>Nine Months Ended September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options at
beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,677,474</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3.98</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,281,311</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.39</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,741,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3.81</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,225,778</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Grants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6.74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">155,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.83</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">173,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8.34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Forfeitures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13,708</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,500</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14,444</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercises</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(10,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,879</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(132,011</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.59</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14,610</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.94</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Options at end of
period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,757,474</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,370,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,757,474</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,370,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average
per share fair
value of options
granted during the
period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5.81</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5.35</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5.67</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6.74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table provides additional information as of September&nbsp;30,
2011:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Aggregate</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Contractual</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Intrinsic</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Value</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,757,474</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4.12</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">6.53 years</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">12,089</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercisable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,972,951</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.61</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">5.70 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,921</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected to vest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">721,005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.92</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">8.64 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,053</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table provides additional information as of December&nbsp;31,
2010:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Weighted</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Aggregate</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Contractual</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Intrinsic</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Value</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,741,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3.81</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">6.99 years</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">18,338</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercisable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,722,281</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.88</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">5.88 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,638</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Expected to vest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">963,754</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7.24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">8.92 years</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,334</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>11. Income Taxes</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In accordance with ASC 740 the Company recognizes deferred tax assets and liabilities
for temporary differences between the financial reporting basis and the tax basis of its
assets and liabilities. The Company records a valuation allowance against its net deferred
tax asset to reduce the net carrying value to an amount that is more likely than not to be
realized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Income tax positions are considered for uncertainty in accordance with FASB
Interpretation No.&nbsp;48, Accounting for Uncertainty in Income Taxes &#151; an interpretation of
ASC 740-10. The Company believes that its income tax filing positions and deductions will be
sustained on audit and does not anticipate any adjustments that will result in a material
change to its financial position; therefore, no ASC 740-10 liabilities have been recorded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Significant management judgment is involved in determining the provision for income
taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net
deferred tax assets. Due to uncertainties with respect to the realization of deferred tax
assets due to the history of operating losses, a valuation allowance has been established
against the entire net deferred tax asset balance. The valuation allowance is based on
management&#146;s estimates of taxable income in the jurisdictions in which the Company operates
and the period over which deferred tax assets will be recoverable. In the event that actual
results differ from these estimates or the Company adjusts these estimates in future
periods, a change in the valuation allowance may be needed, which could materially impact
the Company&#146;s financial position and results of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At September&nbsp;30, 2011 and December&nbsp;31, 2010, the Company had federal net operating loss
(&#147;NOL&#148;) carry-forwards of approximately $112,141,000 and $97,813,000 and state NOL
carry-forwards of approximately $95,604,000 and $80,995,000, respectively, that are
available to reduce future income unless otherwise taxable. If not utilized, the federal NOL
carry-forwards will expire at various dates between 2023 and 2030, and the state NOL
carry-forwards will expire at various dates between 2020 and 2030.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">NOL carry-forwards may be subject to annual limitations under Internal Revenue Code
Section&nbsp;382 (or comparable provisions of state law) in the event that certain changes in
ownership of the Company were to occur. The Company has not yet completed a formal
evaluation of the impact of its IPO (Note 1) on the Company&#146;s NOL carry-forwards and whether
certain changes in ownership have occurred that would limit the Company&#146;s ability to utilize
a portion of its NOL carry-forwards.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>NOTES TO FINANCIAL STATEMENTS &#151; (Continued)</B>
</DIV>

<!-- xbrl,n -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>12. Fair Value</B>
</DIV>

<!-- xbrl,body -->
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company adopted Statement of Financial Accounting Standards No.&nbsp;157, Fair Value
Measurements (ASC 820), effective January&nbsp;1, 2008. Under this standard, fair value is
defined as the price that would be received to sell an asset or paid to transfer a liability
(i.e., the &#147;exit price&#148;) in an orderly transaction between market participants at the
measurement date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In determining fair value, the Company uses various valuation approaches. The hierarchy
of those valuation approaches is broken down into three levels based on the reliability of
inputs as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">Level 1 inputs are quoted prices in active markets for identical assets or
liabilities that the reporting entity has the ability to access at the measurement date.
An active market for the asset or liability is a market in which transactions for the
asset or liability occur with sufficient frequency and volume to provide pricing
information on an ongoing basis. The valuation under this approach does not entail a
significant degree of judgment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">Level 2 inputs are inputs other than quoted prices included within Level 1 that are
observable for the asset or liability, either directly or indirectly. Level 2 inputs
include: quoted prices for similar assets or liabilities in active markets, inputs other
than quoted prices that are observable for the asset or liability, (e.g., interest rates
and yield curves observable at commonly quoted intervals or current market) and
contractual prices for the underlying financial instrument, as well as other relevant
economic measures.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">Level 3 inputs are unobservable inputs for the asset or liability. Unobservable
inputs shall be used to measure fair value to the extent that observable inputs are not
available, thereby allowing for situations in which there is little, if any, market
activity for the asset or liability at the measurement date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table presents information about the Company&#146;s assets measured at fair
value on a recurring basis:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>September 30, 2011</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 1</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 2</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 3</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR><TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash equivalents(1)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">37,437</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">37,437</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investments in marketable debt securities(2)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Assets measured at fair value</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">37,437</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">502</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">37,939</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>December 31, 2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 1</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 2</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Level 3</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash equivalents(1)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,393</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,393</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investments in marketable debt securities(2)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,330</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,330</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Assets measured at fair value</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,393</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">26,330</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">53,723</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 10pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>Valuations are based on quoted prices in markets that are not active or for which all significant
inputs are observable, either directly or indirectly. These prices include broker or dealer
quotations, or alternative pricing sources with reasonable levels of price transparency. Pricing
sources include industry standard data providers, security master files from large financial
institutions, and other third party sources which are input into a distribution-curve-based
algorithm to determine a daily market value. This creates a &#147;consensus price&#148; or a weighted average
price for each security.</TD>
</TR>

</TABLE>


<!-- /xbrl,ns -->




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PART I. FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left">
<A name="C23183107"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 2</B></TD>
    <TD>&nbsp;</TD>
    <TD><B><I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I></B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Various statements in this report are &#147;forward-looking statements&#148; within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve
substantial risks and uncertainties. All statements, other than statements of historical
facts, included in this report regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of management
are forward-looking statements. These statements are subject to risks and uncertainties and
are based on information currently available to our management. Words such as, but not
limited to, &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148;
&#147;contemplates,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;targets,&#148; &#147;likely,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;will,&#148;
&#147;would,&#148; &#147;should,&#148; &#147;could,&#148; or the negative of these terms and similar expressions or words,
identify forward-looking statements. The events and circumstances reflected in the Company&#146;s
forward-looking statements may not occur and actual results could differ materially from
those projected in the Company&#146;s forward-looking statements. Meaningful factors which could
cause actual results to differ include, but are not limited to:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay in or failure to obtain regulatory approval of the Company&#146;s product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>uncertainty as to the Company&#146;s ability to commercialize, and market acceptance of, the Company&#146;s product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the extent of government regulations;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>uncertainty as to the relationship between the benefits of the Company&#146;s product candidates and the risks of their
side-effect profiles;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dependence on third-party manufacturers to manufacture the Company&#146;s product candidates in sufficient quantities and
quality;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>uncertainty of clinical trial results;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>limited sales and marketing infrastructure;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inability of the Company&#146;s outside sales force to successfully sell and market ILUVIEN in the U.S. following
regulatory approval; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company&#146;s ability to operate its business in compliance with the covenants and restrictions that it is subject
to under its credit facility.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All written and verbal forward-looking statements attributable to us or any person
acting on our behalf are expressly qualified in their entirety by the cautionary statements
contained or referred to in this section. We caution investors not to rely too heavily on
the forward-looking statements we make or that are made on our behalf. We undertake no
obligation, and specifically decline any obligation, to update or revise publicly any
forward-looking statements, whether as a result of new information, future events or
otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We encourage you to read the discussion and analysis of our financial condition and our
financial statements contained in this report. We also encourage you to read Item&nbsp;1A of Part
II of this report entitled &#147;Risk Factors&#148; and Item&nbsp;1A of Part&nbsp;I of our Annual Report on Form
10-K for the fiscal year ended December&nbsp;31, 2010, which contain a more complete discussion
of the risks and uncertainties associated with our business. In addition to the risks
described above and in Item&nbsp;1A of Part&nbsp;II of this report and Item&nbsp;1A of Part&nbsp;I of our Annual
Report on Form 10-K for the fiscal year ended December&nbsp;31, 2010, other unknown or
unpredictable factors also could affect our results. Therefore, the information in this
report should be read together with other reports and documents that we file with the SEC
from time to time, including Forms 10-Q, 8-K and 10-K, which may supplement, modify,
supersede or update those risk factors. There can be no assurance
that the actual results or
developments anticipated by us will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, us. Therefore, no assurance can
be given that the outcomes stated in such forward-looking statements and estimates will be
achieved.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Overview</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are a biopharmaceutical company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on
diseases affecting the back of the eye, or retina, because we believe these diseases are not
well treated with current therapies and represent a significant market opportunity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our most advanced product candidate is ILUVIEN, which we are developing for the
treatment of diabetic macular edema (&#147;DME&#148;). DME is a disease of the retina that affects
individuals with diabetes and can lead to severe vision loss and blindness. In September
2010, we completed two Phase 3 pivotal clinical trials (collectively, our &#147;FAME Study&#148;) for
ILUVIEN involving 956 patients in sites across the U.S., Canada, Europe and India to assess
the efficacy and safety of ILUVIEN in the treatment of DME.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In June&nbsp;2010, we submitted a New Drug Application (&#147;NDA&#148;) for ILUVIEN to the FDA that included data through month 24 of
the FAME Study. In December&nbsp;2010, the FDA issued a Complete Response Letter (&#147;CRL&#148;) in response to our NDA. In the CRL,
the FDA communicated its decision that the NDA could not be approved in its then present form. The FDA asked for
analyses of the safety and efficacy data through month 36 of the FAME Study, including exploratory analyses in addition
to those previously submitted in the NDA, to further assess the relative benefits and risks of ILUVIEN. The FDA also
sought additional information regarding controls and specifications concerning the manufacturing, packaging and
sterilization of ILUVIEN. In a February&nbsp;2011 meeting with the FDA, the FDA requested additional data related to the
use of the commercial version of the ILUVIEN inserter for which approval was sought in the NDA. In May&nbsp;2011, we
submitted to the FDA a complete response to the CRL. The FDA classified the response as a Class&nbsp;2 resubmission with a
Prescription Drug User Fee Act (&#147;PDUFA&#148;) date of November&nbsp;12, 2011. The PDUFA date is the date by which we can
reasonably expect to have received the FDA&#146;s response. In
July&nbsp;2011, the FDA notified us that it will not call an
advisory committee during its review of our complete response to the CRL. In September&nbsp;2011, we enrolled our first
patient in a physician utilization study aimed at providing the additional data requested by the FDA with respect to
the commercial version of the ILUVIEN inserter. We have enrolled 54 patient eyes in this study evaluating the safety
and utility of the commercial version of the inserter and are targeting to enroll 100 patient eyes before commercial
launch.


</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In July&nbsp;2010, using the Decentralized Procedure, we submitted a Marketing Authorization
Application for ILUVIEN to the Medicines and Healthcare products Regulatory Agency (&#147;MHRA&#148;)
in the United Kingdom, which serves as the Reference Member State, and to regulatory
authorities in Austria, France, Germany, Italy, Portugal and Spain. In November&nbsp;2010, we
received the Preliminary Assessment Report from the MHRA followed by additional comments
from the other health authorities in December&nbsp;2010. In
July&nbsp;2011, we submitted our draft
responses to the clinical, non-clinical, and quality questions to the MHRA. The submission
included the additional safety and efficacy data through the final readout at the end of the
FAME Study.
In September 2011, the MHRA provided comments to our clinical responses and indicated that there were no further
comments to our non-clinical and quality responses.  We are
preparing, and plan to submit in November 2011,
our final response to the Preliminary Assessment Report from the MHRA and to the additional comments from the other health authorities.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If our NDA for ILUVIEN is approved by the FDA, we plan to commercialize ILUVIEN in the
U.S. by marketing and selling it to retinal specialists as early as early 2012. In addition
to treating DME, ILUVIEN is being studied in three Phase 2 clinical trials for the treatment
of the dry form of age-related macular degeneration (&#147;AMD&#148;), the wet form of AMD and retinal
vein occlusion (&#147;RVO&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We intend to seek a collaboration partner for sales and marketing activities outside
North America. We currently contract with development partners or outside firms for various
operational aspects of our development activities, including the preparation of clinical
supplies and have no plans to establish in-house manufacturing capabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We commenced operations in June&nbsp;2003. Since our inception we have incurred significant
losses. As of September&nbsp;30, 2011, we have accumulated a deficit
of $205.3&nbsp;million. We expect
to incur substantial losses through the projected commercialization of ILUVIEN as we:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the clinical development and registration of ILUVIEN;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>build our sales and marketing capabilities for the anticipated commercial launch of ILUVIEN in early 2012;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>add the necessary infrastructure to support our growth;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>evaluate the use of ILUVIEN for the treatment of other diseases; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>advance the clinical development of other new product candidates
that we may license or acquire in the future.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prior to our initial public offering (&#147;IPO&#148;), we funded our operations through the
private placement of common stock, preferred stock, warrants and convertible debt, as well
as by the sale of certain assets of the non-prescription business in which we were
previously engaged. On April&nbsp;21, 2010, our Registration Statement on Form S-1 (as amended)
was declared effective by the Securities and Exchange Commission (&#147;SEC&#148;) for our IPO,
pursuant to which we sold 6,550,000 shares of our common stock at a public offering price of
$11.00 per share. We received net proceeds of approximately $66.1&nbsp;million from this
transaction, after deducting underwriting discounts, commissions and other offering costs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of September&nbsp;30, 2011, we had approximately $38.6&nbsp;million in cash, cash equivalents,
and investments in marketable securities. In addition to our net IPO proceeds, our cash and
cash equivalents include the January&nbsp;2010 receipt of $10.0&nbsp;million in proceeds from the
exercise of outstanding Series&nbsp;C-1 warrants, and a $4.0&nbsp;million option payment from Bausch &#038;
Lomb Incorporated (&#147;Bausch &#038; Lomb&#148;) upon the exercise by Bausch &#038; Lomb of its option to
extend by two years the period during which it may continue to develop an allergy product
acquired from us in 2006.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In October&nbsp;2010, we obtained a $32.5&nbsp;million senior secured credit facility
(&#147;Credit Facility&#148;) to help fund our working capital requirements. The Credit Facility
consisted of a $20.0&nbsp;million working capital revolver and a $12.5&nbsp;million term loan. The
lenders advanced $6.25&nbsp;million under the term loan and the remaining $6.25&nbsp;million was
available for funding following FDA approval of ILUVIEN, but no later than July&nbsp;31, 2011. In
May&nbsp;2011, the lenders and we amended the terms of the Credit Facility to, among other
things, extend the FDA approval deadline for the second advance under the term loan to
December&nbsp;31, 2011, and to increase the amount available under the second advance of the term
loan from $6.25&nbsp;million to $11.0&nbsp;million. In addition, the maturity date of the Credit
Facility was extended from October&nbsp;31, 2013 to April&nbsp;30, 2014. We may draw on the working
capital revolver against eligible, domestic accounts receivable. As of September&nbsp;30, 2011,
no amounts under the working capital revolver were outstanding or available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not expect to generate revenues from our product, ILUVIEN, until early 2012, if
at all, and therefore we do not expect to have positive cash flow from operations before
that time. We believe our cash, cash equivalents, investments in marketable securities and
Credit Facility are sufficient to fund our operations through the projected launch of
ILUVIEN and the expected generation of revenue in early 2012. The commercialization of
ILUVIEN is dependent upon approval by the FDA, however, and we cannot be sure that ILUVIEN
will be approved by the FDA or that, if approved, future sales of ILUVIEN will generate
enough revenue to fund our operations beyond its launch. Due to the uncertainty around FDA
approval, our management cannot be certain that we will not need additional funds for the
launch of ILUVIEN. If ILUVIEN is not approved, or if approved, does not generate sufficient
revenue, we may adjust our commercial plans so that we can continue to operate with our
existing cash resources or seek to raise additional financing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the third quarter of 2011, we terminated our two agreements with Emory University pursuant to which we had
licensed certain nicotinamide adenine dinucleotide phosphate (NADPH)&nbsp;oxidase inhibitors, however we continue our
evaluation of other NADPH oxidase inhibitors for use in the treatment of diseases of the eye, including dry AMD, wet
AMD and diabetic retinopathy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 1%"><B><I>Our Agreement with pSivida US, Inc.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In February&nbsp;2005, we entered into an agreement with pSivida US, Inc. (&#147;pSivida&#148;) for
the use of fluocinolone acetonide (&#147;FAc&#148;) in pSivida&#146;s proprietary delivery device. pSivida
is a global drug delivery company committed to the biomedical sector and the development of
drug delivery products. Our agreement with pSivida provides us with a worldwide exclusive
license to develop and sell ILUVIEN, which consists of a tiny polyimide tube with membrane
caps that is filled with FAc in a polyvinyl alcohol matrix for delivery to the back of the
eye for the treatment and prevention of eye diseases in humans (other than uveitis). This
agreement also provided us with a worldwide non-exclusive license to develop and sell
pSivida&#146;s proprietary delivery device to deliver other corticosteroids to the back of the
eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to
treat DME by delivering a compound to the back of the eye through a direct delivery method
through an incision required for a 25-gauge or larger needle. We do not have the right to
develop and sell pSivida&#146;s proprietary delivery device for indications for diseases outside
of the eye or for the treatment of uveitis. Further, our agreement with pSivida permits
pSivida to grant to any other party the right to use its intellectual property (i)&nbsp;to treat
DME through an incision smaller than that required for a 25-gauge needle, unless using a
corticosteroid delivered to the back of the eye, (ii)&nbsp;to deliver any compound outside the
back of the eye unless it is to treat DME through an incision required for a 25-gauge or
larger needle, or (iii)&nbsp;to deliver non-corticosteroids to the back of the eye, unless it is
to treat DME through an incision required for a 25-gauge or larger needle.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Under the February&nbsp;2005 agreement, we and pSivida agreed to collaborate on the
development of ILUVIEN for DME, and share financial responsibility for the development
expenses equally. The February&nbsp;2005 agreement provided that after commercialization of
ILUVIEN, profits, as defined in the agreement, would be shared equally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In March&nbsp;2008, we and pSivida amended and restated the agreement to provide us with 80%
of the net profits and pSivida with 20% of the net profits derived by
us from the sale of ILUVIEN. Total consideration to pSivida
in connection with the execution of the March&nbsp;2008 agreement was $33.8&nbsp;million, which
consisted of a cash payment of $12.0&nbsp;million, the issuance of a $15.0&nbsp;million note payable,
and the forgiveness of $6.8&nbsp;million in outstanding receivables. The $15.0&nbsp;million promissory
note accrued interest at 8% per annum, payable quarterly and was payable in full to pSivida
upon the earliest of a liquidity event as defined in the agreement, the occurrence of an
event of default under our agreement with pSivida, or September&nbsp;30, 2012. If the note was
not paid in full by March&nbsp;31, 2010, the interest rate was to increase to 20% effective as of
April&nbsp;1, 2010, and we were required to begin making principal payments of $500,000 per
month.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&nbsp;27, 2010, we paid pSivida approximately $15.2&nbsp;million in principal and
interest to satisfy the note payable with the proceeds from our IPO.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We will owe pSivida an additional milestone payment of $25.0&nbsp;million upon FDA approval
of ILUVIEN.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our Credit Facility</I></B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Term Loan</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On October&nbsp;14, 2010 (&#147;Effective Date&#148;), we entered into a Loan and Security Agreement
(&#147;Term Loan Agreement&#148;) with Silicon Valley Bank and MidCap Financial LLP (&#147;Lenders&#148;).
Pursuant to the original terms of the Term Loan Agreement, we were entitled to borrow up to
$12.5&nbsp;million, of which $6.25&nbsp;million (&#147;Term Loan A&#148;) was advanced to us on the Effective
Date. We were entitled to draw down the remaining $6.25&nbsp;million under the Term Loan (&#147;Term
Loan B&#148; and together with Term Loan A, the &#147;Term Loan&#148;) if the FDA approved our NDA for
ILUVIEN prior to or on July&nbsp;31, 2011. On May&nbsp;16, 2011, the Lenders and we amended the Term
Loan Agreement (&#147;Term Loan Modification&#148;) to, among other things, extend until December&nbsp;31,
2011 the date by which the FDA must approve the NDA in order for us to draw down Term Loan B
and increase the amount of Term Loan B by $4.75&nbsp;million to $11.0&nbsp;million. In addition, the
maturity date of the Term Loan was extended from October&nbsp;31, 2013 to April&nbsp;30, 2014 (the
&#147;Term Loan Maturity Date&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We
were required to pay interest on Term Loan A at a rate of 11.5% on a monthly basis
through July&nbsp;31, 2011, and then beginning August&nbsp;2011, we are required to repay the principal in 33 equal monthly
installments plus interest at a rate of 11.5%. We are required to
pay interest at a rate of 12.5% on the amount borrowed, if any, under Term Loan B through
April&nbsp;30, 2012, and thereafter we will be required to repay the principal in equal monthly
installments through the Term Loan Maturity Date, plus interest at a rate of 12.5%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If we repay Term Loan A prior to maturity, we must pay to the Lenders a prepayment fee
equal to 5.0% of the total amount of principal then outstanding if the prepayment had occurred
within one year after the funding date of Term Loan A (&#147;Term Loan A Funding Date&#148;), 3.0% of
such amount if the prepayment occurs between one year and two years after the Term Loan A
Funding Date and 1.0% of such amount if the prepayment occurs thereafter (subject to a 50%
reduction in the event that the prepayment occurs in connection with an acquisition of us).
If Term Loan B is advanced to us, then the amount of the prepayment fee on both Term Loan A
and Term Loan B will be reset to 5.0% and the time-based reduction of the prepayment fee
will be measured from the funding date of Term Loan B (subject to the same 50% reduction in
the event of an acquisition of us), rather than from the Term Loan A Funding Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Term Loan Agreement, we
granted to the Lenders a first priority security interest in all of our assets, including
our intellectual property, however, the lien on our intellectual property will be released
if we meet certain financial conditions. The occurrence of an event of default could result
in the acceleration of our obligations under the Term Loan Agreement and an increase to the
applicable interest rate, and would permit the Lenders to exercise remedies with respect to
the collateral under the Term Loan Agreement. We also agreed not to pledge or otherwise
encumber our intellectual property assets. Additionally, we must seek the Lenders&#146; approval
prior to the payment of any cash dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On the Effective Date, we issued to the Lenders warrants to purchase an aggregate of up
to 39,773 shares of our common stock. Each of the warrants is exercisable immediately, has a
per-share exercise price of $11.00 and has a term of 10&nbsp;years. We estimated the fair value
of warrants granted using the Black-Scholes option pricing model. The aggregate fair value
of the warrants was estimated to be $389,000. We allocated a portion of the proceeds from
the Term Loan Agreement to the warrants in accordance with Accounting Standards Codification
(&#147;ASC&#148;) 470-20-25-2, <I>Debt Instruments with Detachable Warrants</I>. As a result, we recorded a
discount of $366,000 which is being amortized to interest expense using the effective
interest method. The Lenders also hold warrants to purchase an aggregate of up to 69,999
shares of our common stock, which are exercisable only if Term Loan B is advanced to us.
Each of these warrants has a per share exercise price of $11.00 and a term of 10&nbsp;years. We
paid to the Lenders an upfront fee of $62,500 on the Effective Date and an additional fee of
$50,000 in connection with the Term Loan Modification. In accordance with ASC 470-50-40-17,
<I>Debt &#151; Modifications and Extinguishments</I>, we are amortizing the unamortized discount on
Term Loan A and the $50,000 modification fee over the remaining term of Term Loan A, as
modified.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are required to maintain our primary operating and other deposit accounts and
securities accounts with Silicon Valley Bank, which accounts must represent at least 50% of
the dollar value of our accounts at all financial institutions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%"><B><I>Working
Capital Revolver</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Also on the Effective Date, we entered into a Loan and Security Agreement with Silicon
Valley Bank, pursuant to which we obtained a secured revolving line of credit (&#147;Working
Capital Revolver&#148;) from Silicon Valley Bank with borrowing availability up to $20,000,000
(&#147;Revolving Loan Agreement&#148;). On May&nbsp;16, 2011, Silicon
Valley Bank and we amended the Revolving Loan
Agreement to extend the maturity date of the Working Capital Revolver from October&nbsp;31, 2013
to April&nbsp;30, 2014.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Working Capital Revolver is a working capital-based revolving line of credit in an
aggregate amount of up to the lesser of (i) $20,000,000, or (ii)&nbsp;85% of eligible domestic
accounts receivable. As of September&nbsp;30, 2011, no amounts under the Working Capital Revolver
were outstanding or available to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Amounts advanced under the Working Capital Revolver will bear interest at an annual
rate equal to Silicon Valley Bank&#146;s prime rate plus 2.50% (with a rate floor of 6.50%).
Interest on the Working Capital Revolver will be due monthly, with the balance due at the
maturity date. On the Effective Date, we paid to Silicon Valley Bank an upfront fee of
$100,000. In addition, if we terminate the Working Capital Revolver prior to maturity, we
would have paid to Silicon Valley Bank a fee of $400,000 if the
termination occured within one year
after the Effective Date and a fee of $200,000 if the termination occurs more than one year
after the Effective Date (each a &#147;Termination Fee&#148;), provided in each case that such
Termination Fee will be reduced by 50% in the event we are acquired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Revolving Loan Agreement, we
granted to Silicon Valley Bank a first priority security interest in all of our assets,
including our intellectual property, however, the lien on our intellectual property will be
released if we meet certain financial conditions. The occurrence of an event of default
could result in the acceleration of our obligations under the Revolving Loan Agreement and
an increase to the applicable interest rate, and would permit Silicon Valley Bank to
exercise remedies with respect to the collateral under the Revolving Loan Agreement. We also
agreed not to pledge or otherwise encumber our intellectual property assets. Additionally,
we must seek Silicon Valley Bank&#146;s approval prior to the payment of any cash dividends.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Our Discontinued Non-Prescription Business</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At the inception of our company, we were focused primarily on the development and
commercialization of non-prescription over-the-counter ophthalmic products. In October&nbsp;2006,
due to the progress and resource requirements related to the development of ILUVIEN, we
decided to discontinue our non-prescription business. As a result, we received proceeds of
$10.0&nbsp;million from the sale of our allergy products in December&nbsp;2006 and $6.7&nbsp;million from
the sale of our dry eye product in July&nbsp;2007, both to Bausch &#038; Lomb. If one of the allergy
products had received FDA approval, we were entitled to an additional $8.0&nbsp;million payment from
Bausch &#038; Lomb under the sales agreement. In January&nbsp;2010, we received a $4.0&nbsp;million option
payment from Bausch &#038; Lomb upon the exercise by Bausch &#038; Lomb of its option to extend the
period during which it may continue to develop this allergy product by two years. However,
in July&nbsp;2011, Bausch &#038; Lomb notified us that it will discontinue the development of this
allergy product and not seek FDA approval. As a result of the discontinuation of our
non-prescription business, all revenues and expenses associated with our over-the-counter
portfolio are included in the loss from discontinued operations in the accompanying
statements of operations.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Financial Operations Overview</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Revenue</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To date we have only generated revenue from our dry eye non-prescription product. From
the launch of that product in September&nbsp;2004 to its sale in July&nbsp;2007, we generated $4.4
million in net revenues. We do not expect to generate any significant additional revenue
unless or until we obtain regulatory approval of, and commercialize, our product candidates
or in-license additional products that generate revenue. In addition to generating revenue
from product sales, we intend to seek to generate revenue from other sources such as upfront
fees, milestone payments in connection with collaborative or strategic relationships, and
royalties resulting from the licensing of our product candidates and other intellectual
property. We expect any revenue we generate will fluctuate from quarter to quarter as a
result of the nature, timing and amount of any milestone payments we may receive from
potential collaborative and strategic relationships, as well as revenue we may receive upon
the sale of our products to the extent any are successfully commercialized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Research and Development Expenses</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Substantially all of our research and development expenses incurred to date related to
our continuing operations have been related to the development of ILUVIEN. In the event the
FDA approves our NDA for ILUVIEN, we will owe an additional milestone payment of $25.0
million to pSivida. We anticipate that we will incur additional research and development
expenses in the future as we evaluate and possibly pursue the development of ILUVIEN for
additional indications, or develop additional product candidates. We recognize research and
development expenses as they are incurred. Our research and development expenses consist
primarily of:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>salaries and related expenses for personnel;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fees paid to consultants and contract research organizations (&#147;CRO&#148;) in conjunction with independently
monitoring clinical trials and acquiring and evaluating data in conjunction with clinical trials, including
all related fees such as investigator grants, patient screening, lab work and data compilation and statistical
analysis;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs incurred with third parties related to the establishment of a commercially viable manufacturing process
for our product candidates;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs related to production of clinical materials, including fees paid to contract manufacturers;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs related to upfront and milestone payments under in-licensing agreements;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs related to compliance with FDA regulatory requirements;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>consulting fees paid to third-parties involved in research and development activities; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs related to stock options or other stock-based compensation granted to personnel in development functions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We expense both internal and external development costs as they are incurred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We expect that a large percentage of our research and development expenses in the
future will be incurred in support of our current and future technical, preclinical and
clinical development programs. These expenditures are subject to numerous uncertainties in
terms of both their timing and total cost to completion. We expect to continue to develop
stable formulations of  product candidates, test such formulations in preclinical studies
for toxicology, safety and efficacy and to conduct clinical trials for each product
candidate. We anticipate funding clinical trials ourselves, but we may engage collaboration
partners at certain stages of clinical development. As we obtain results from clinical
trials, we may elect to discontinue or delay clinical trials for certain product candidates
or programs in order to focus our resources on more promising product candidates or
programs. Completion of clinical trials by us or our future collaborators may take several
years or more, the length of time generally varying with the type, complexity, novelty and
intended use of a product candidate. The costs of clinical trials may vary significantly
over the life of a project owing to but not limited to the following:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the number of sites included in the trials;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the length of time required to enroll eligible patients;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the number of patients that participate in the trials;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the number of doses that patients receive;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the drop-out or discontinuation rates of patients;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the duration of patient follow-up;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the phase of development the product candidate is in; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the efficacy and safety profile of the product candidate.</TD>
</TR>

</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our expenses related to clinical trials are based on estimates of the services
received and efforts expended pursuant to contracts with multiple research institutions and
contract research organizations that conduct and manage clinical trials on our behalf. The
financial terms of these agreements are subject to negotiation and vary from contract to
contract and may result in uneven payment flows. Generally, these agreements set forth the
scope of work to be performed at a fixed fee or unit price. Payments under the contracts
depend on factors such as the successful enrollment of patients or the completion of
clinical trial milestones. Expenses related to clinical trials generally are accrued based
on contracted amounts applied to the level of patient enrollment and activity according to
the protocol. If timelines or contracts are modified based upon changes in the clinical
trial protocol or scope of work to be performed, we modify our estimates of accrued expenses
accordingly on a prospective basis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">None of our product candidates has received FDA or foreign regulatory marketing
approval. In order to grant marketing approval, a health authority such as the FDA or
foreign regulatory agencies must conclude that clinical and preclinical data establish the
safety and efficacy of our product candidates with an appropriate benefit to risk profile
relevant to a particular indication, and that the product can be manufactured under current
Good Manufacturing Practice (&#147;cGMP&#148;) in a reproducible manner to deliver the product&#146;s
intended performance in terms of its stability, quality, purity and potency. Until our
submissions are reviewed by health authorities, there is no way to predict the outcome of
their review. Even if the clinical studies meet their predetermined primary endpoints, and a
registration dossier is accepted for filing, a health authority could still determine that
an appropriate benefit to risk relationship does not exist for the indication that we are
seeking. We cannot forecast with any degree of certainty which of our product candidates
will be subject to future collaborations or how such arrangements would affect our
development plan or capital requirements. As a result of the uncertainties discussed above,
we are unable to determine the duration and completion costs of our development projects or
when and to what extent we will receive cash inflows from the commercialization and sale of
an approved product candidate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>General and Administrative Expenses</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">General and administrative expenses consist primarily of compensation for employees in
executive and administrative functions, including finance, accounting and human resources.
Other significant costs include facilities costs and professional fees for accounting and
legal services, including legal services associated with obtaining and maintaining patents.
We anticipate incurring a significant increase in general and administrative expenses, as we
add additional employees and continue to operate as a public company. These increases will
include increased costs for insurance, costs related to the hiring of additional personnel
and payments to outside consultants, lawyers and accountants. We also expect to continue to
incur significant costs to comply with the corporate governance, internal control and
similar requirements applicable to public companies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Marketing Expenses</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Marketing expenses consist of compensation for employees responsible for assessing the
commercial opportunity of and developing market awareness and launch plans for our product
candidates, professional fees associated with developing brands for our product candidates
and maintaining public relations efforts. We expect significant increases in our marketing and
selling expenses as we hire additional personnel and establish our sales and marketing
capabilities in anticipation of the commercialization of ILUVIEN. We intend
to capitalize on our management&#146;s past experience and expertise with eye-care products by
marketing and selling ILUVIEN to the approximately 1,600 retinal specialists practicing in
the approximately 900 retina centers across the U.S.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our plan is to develop our own specialized domestic sales and marketing infrastructure,
comprised of approximately 40 people, to market ILUVIEN and other
ophthalmic product candidates or products that
we may acquire or develop in the future. We hired regional managers with extensive
ophthalmic-based sales experience in the third quarter of 2010 and plan to begin adding
sales representatives in the fourth quarter of 2011. We entered into a relationship with
OnCall LLC, a contract sales force company, that will utilize its employees to act as our
sales representatives if we receive approval of the ILUVIEN NDA from the FDA. We expect that
following FDA approval, the OnCall sales force will be able to access and form relationships
with retinal specialists in approximately 900 retina centers for the commercial launch of
ILUVIEN. In connection with the commercial launch of ILUVIEN, we expect to hire additional
personnel to support the activities of customer service, post-marketing pharmacovigilance,
medical affairs, and regulatory compliance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Interest and Other Income</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Interest income consists primarily of interest earned on our cash, cash equivalents and
investments.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">





<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Interest Expense</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Beginning in March&nbsp;2008, we began recognizing interest on our $15.0&nbsp;million note
payable to pSivida at an effective interest rate of 12.64% per annum (this note accrued
interest at the rate of 8% per annum from inception through March&nbsp;31, 2010 and at the rate
of 20% per annum effective as of April&nbsp;1, 2010). On April&nbsp;27, 2010, we paid pSivida
approximately $15.2&nbsp;million in principal and interest to satisfy the note payable. In
October&nbsp;2010, we received the initial advance of $6.25&nbsp;million under our Term Loan from
Silicon Valley Bank and MidCap Financial LLP and began recognizing interest at an effective
interest rate of 13.0% per annum (interest on this term loan is payable monthly at the rate
of 11.5% per annum and included a termination payment of 3.0% of the amount advanced). On
May&nbsp;16, 2011, the Lenders and we amended the Term Loan Agreement to, among other things,
extend until December&nbsp;31, 2011 the date by which the FDA must approve the NDA in order for
us to receive the second advance under the Term Loan and to increase the amount of the
second advance by $4.75&nbsp;million to $11.0&nbsp;million. In addition, the maturity date of the Term
Loan was extended from October&nbsp;31, 2013 until April&nbsp;30, 2014. In connection with the
modification of our Term Loan, the termination payment was increased from 3.0% to 4.0% of
the amount advanced and the effective interest rate on the initial advance increased to
13.4%.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Change in Fair Value of Preferred Stock Conversion Feature</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prior to being converted into common stock in connection with our IPO, our preferred
stock contained certain conversion features which were considered embedded derivatives. We
accounted for such embedded derivative financial instruments in accordance with ASC 815. We
recorded derivative financial instruments as assets or liabilities in our balance sheet
measured at their fair value. We recorded the changes in fair value of such instruments as
non-cash gains or losses in the statement of operations. The preferred stock conversion
feature was eliminated upon the conversion of our preferred stock to common stock in
connection with our IPO in April&nbsp;2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Preferred Stock Accretion</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prior to our IPO, our preferred stock was recorded at issuance at the proceeds received
net of any issuance discounts, issuance costs and the fair value of the conversion features
at issuance. The difference between the amount recorded at issuance and the original issue
price was accreted on a straight-line basis over a period extending from the date of
issuance to the date at which the preferred stock would have become redeemable at the option
of the holder. Accretion of the difference ceased upon the conversion of our preferred stock
to common stock in connection with our IPO in April&nbsp;2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Preferred Stock Dividends</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prior to our IPO, our preferred stock accrued dividends at 8% per annum which were
recorded as an increase in the carrying amount of the respective preferred stock. At the
time our preferred stock was converted into common stock in connection with our IPO, $1.5
million of dividends accrued on our Series&nbsp;A preferred stock prior to November&nbsp;17, 2005 were
converted into 380,301 shares of our common stock. All other preferred stock dividends were
eliminated upon conversion of the underlying preferred stock in April&nbsp;2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Basic and Diluted Net (Loss) Income Applicable to Common Stockholders per Common Share</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We calculated net loss per share in accordance with ASC 260. We have determined that
our previously outstanding Series&nbsp;A, Series&nbsp;B, Series&nbsp;C and Series&nbsp;C-1 preferred stock
represent participating securities in accordance with ASC 260. However, since we operate at
a loss, and losses are not allocated to the preferred stock, the two class method does not
affect our calculation of earnings per share. We had a net loss from continuing operations
for all periods presented; accordingly, the inclusion of common stock options and warrants
would be anti-dilutive. Dilutive common stock equivalents would include the dilutive effect
of convertible securities, common stock options, warrants for convertible securities and
warrants for common stock equivalents. Potentially dilutive weighted average common stock
equivalents totaled approximately 1,573,933 and 11,581,116 for the nine months ended
September&nbsp;30, 2011 and 2010, respectively, and 1,530,555 and 1,710,555 for the three months
ended September&nbsp;30, 2011 and 2010, respectively. Potentially dilutive common stock
equivalents were excluded from the diluted earnings per share denominator for all periods of
net loss from continuing operations because of their anti-dilutive effect. Therefore, for
the three and nine months ended September&nbsp;30, 2011 and 2010, respectively, the weighted
average shares used to calculate both basic and diluted loss per share are the same.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Critical Accounting Policies and Estimates</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our discussion and analysis of our financial condition and results of operations are
based on our financial statements which have been prepared in accordance with accounting
principles generally accepted in the U.S. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and
judgments, including those described below. We base our estimates on historical experience
and on various other assumptions that we believe to be reasonable under the circumstances.
These estimates and assumptions form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual
results and experiences may differ materially from these estimates. We believe that the
following accounting
policies are the most critical to aid you in fully understanding and evaluating our
reported financial results and affect the more significant judgments and estimates that we
use in the preparation of our financial statements.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">





<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Clinical Trial Prepaid and Accrued Expenses</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We record prepaid assets and accrued liabilities related to clinical trials associated
with contract research organizations, clinical trial investigators and other vendors based
upon amounts paid and the estimated amount of work completed on each clinical trial. The
financial terms of agreements vary from vendor to vendor and may result in uneven payment
flows. As such, if we have advanced funds exceeding our estimate of the work completed, we
record a prepaid asset. If our estimate of the work completed exceeds the amount paid, an
accrued liability is recorded. All such costs are charged to research and development
expenses based on these estimates. Our estimates may or may not match the actual services
performed by the organizations as determined by patient enrollment levels and related
activities. We monitor patient enrollment levels and related activities to the extent
possible through internal reviews, correspondence and discussions with our contract research
organization and review of contractual terms. However, if we have incomplete or inaccurate
information, we may underestimate or overestimate activity levels associated with various
clinical trials at a given point in time. In this event, we could record significant
research and development expenses in future periods when the actual level of activities
becomes known. To date, we have not experienced material changes in these estimates.
Additionally, we do not expect material adjustments to research and development expenses to
result from changes in the nature and level of clinical trial activity and related expenses
that are currently subject to estimation. In the future, as we expand our clinical trial
activities, we expect to have increased levels of research and development costs that will
be subject to estimation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Research and Development Costs</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Research and development expenditures are expensed as incurred, pursuant to ASC 730.
Costs to license technology to be used in our research and development that have not reached
technological feasibility, defined as FDA approval for our current product candidates, and
have no alternative future use are expensed when incurred. Payments to licensors that relate
to the achievement of preapproval development milestones are recorded as research and
development expense when incurred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Stock-Based Compensation</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Effective January&nbsp;1, 2005, we adopted the fair value recognition provisions of ASC 718
using the modified prospective application method. We recognize the grant date fair value as
compensation cost of employee stock-based awards using the straight-line method over the
actual vesting period, adjusted for our estimates of forfeiture. Typically, we grant stock
options with a requisite service period of four years from the grant date. We have elected
to use the Black-Scholes option pricing model to determine the fair value of stock-based
awards.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We concluded that this was the most appropriate method by which to value our
share-based payment arrangements, but if any share-based payment instruments should be
granted for which the Black-Scholes method does not meet the measurement objective as stated
within ASC 718, we will utilize a more appropriate method for valuing that instrument.
However, we do not believe that any instruments granted to date and accounted for under ASC
718 would require a method other than the Black-Scholes method.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our determination of the fair market value of share-based payment awards on the grant
date using option valuation models requires the input of highly subjective assumptions,
including the expected price volatility and option life. For the calculation of expected
volatility, because we lack significant company-specific historical and implied volatility
information, we estimate our volatility by utilizing an average of volatilities of publicly
traded companies, including our own, deemed similar to us in terms of product composition,
stage of lifecycle, capitalization and scope of operations. We intend to continue to
consistently apply this process using this same index until a sufficient amount of
historical information regarding the volatility of our own share price becomes available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To estimate the expected term, we utilize the &#147;simplified&#148; method for &#147;plain vanilla&#148;
options as discussed within the Securities and Exchange Commission&#146;s (SEC)&nbsp;Statement of
Accounting Bulletin (SAB)&nbsp;107. We believe that all factors listed within SAB 107 as
pre-requisites for utilizing the simplified method are true for us and for our share-based
payment arrangements. We intend to utilize the simplified method for the foreseeable future
until more detailed information about exercise behavior will be more widely available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Total stock-based compensation expense related to all our stock option awards for the
three and nine months ended September&nbsp;30, 2011 and 2010, respectively, was comprised of the
following:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR><TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">121</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">262</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">278</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">225</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">869</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">126</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total employee stock-based compensation expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">417</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">189</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,416</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">447</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Income Taxes</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recognize deferred tax assets and liabilities for temporary differences between the
financial reporting basis and the tax basis of its assets and liabilities in accordance with
ASC 740. We evaluate the positive and negative evidence bearing upon the realizability of
our deferred tax assets on an annual basis. Significant management judgment is involved in
determining the provision for income taxes, deferred tax assets and liabilities, and any
valuation allowance recorded against net deferred tax assets. Due to uncertainties with
respect to the realization of our deferred tax assets due to our history of operating
losses, a valuation allowance has been established against our deferred tax asset balances
to reduce the net carrying value to an amount that is more likely than not to be realized.
As a result we have fully reserved against the deferred tax asset balances. The valuation
allowances are based on our estimates of taxable income in the jurisdictions in which we
operate and the period over which deferred tax assets will be recoverable. In the event that
actual results differ from these estimates or we adjust these estimates in future periods, a
change in the valuation allowance may be needed, which could materially impact our financial
position and results of operations. Our deferred tax assets primarily consist of net
operating loss (NOL)&nbsp;carry-forwards. At September&nbsp;30, 2011 we had federal NOL carry-forwards
of approximately $112.1&nbsp;million and state NOL carry-forwards of
approximately $95.6&nbsp;million,
respectively, that are available to reduce future income otherwise taxable. If not utilized,
the federal NOL carry-forwards will expire at various dates between 2023 and 2030 and the
state NOL carry-forwards will expire at various dates between 2020 and 2030. If it is
determined that significant ownership changes have occurred since these NOLs were generated,
we may be subject to annual limitations on the use of these NOLs under Internal Revenue Code
Section&nbsp;382 (or comparable provisions of state law). We have not yet completed a formal
evaluation of whether our IPO resulted in certain changes in ownership that would limit our
ability to utilize a portion of our NOL carry-forwards.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In the event that we were to determine that we are able to realize any of our net
deferred tax assets in the future, an adjustment to the valuation allowance would increase
net income in the period such determination was made. We believe that the most significant
uncertainty that will impact the determination of our valuation allowance will be our
estimation of the extent and timing of future net income, if any.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We considered our income tax positions for uncertainty in accordance with ASC 740. We
believe our income tax filing positions and deductions are more likely than not of being
sustained on audit and do not anticipate any adjustments that will result in a material
change to our financial position; therefore, we have not recorded ASC 740 liabilities. We
recognize accrued interest and penalties related to unrecognized tax benefits as interest
expense and income tax expense, respectively, in our statements of operations. Our tax years
since 2003 remain subject to examination in Georgia, Tennessee, and on the federal level. We
do not anticipate any material changes to our uncertain tax positions within the next 12
months.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following selected unaudited financial and operating data are derived from our
financial statements and should be read in conjunction with &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and our financial statements.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three Months Ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Nine Months Ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>September 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2011</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14"><B>(In thousands)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">RESEARCH AND DEVELOPMENT EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,732</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,481</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">GENERAL AND ADMINISTRATIVE EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,421</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,260</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,827</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,338</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">MARKETING EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,583</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,038</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,209</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL OPERATING EXPENSES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,257</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,597</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,028</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">INTEREST INCOME</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">INTEREST EXPENSE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(284</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(863</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(618</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">GAIN ON EARLY EXTINGUISHMENT OF DEBT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,343</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">DECREASE (INCREASE)&nbsp;IN FAIR VALUE
OF DERIVATIVE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,644</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LOSS FROM CONTINUING OPERATIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,540</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,082</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(16,445</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(11,606</TD>
    <TD nowrap>)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Three months ended September&nbsp;30, 2011 compared to the three months ended September&nbsp;30, 2010</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Research and development expenses.</I> Research and
development expenses decreased by approximately $1.1 million, or 33.3%, to approximately $2.2 million for the three months ended
September 30, 2011 compared to approximately $3.3 million for the three months ended September 30, 2010. The decrease was primarily
attributable to decreases of $1.2 million in costs associated with our FAME Study, $380,000 in costs incurred to file marketing
applications for ILUVIEN in Austria, France, Germany, Italy, Portugal, Spain and the U.K. in the third quarter of 2010 and $130,000
in costs for technical development as we reach the final stages of the development of the inserter for ILUVIEN, offset by an increase
of $510,000 in costs related to the physician utilization study which is being conducted to assess the safety and utility of the commercial version of the inserter for ILUVIEN. The decrease in costs for our FAME Study was primarily attributable to decreases of $910,000 for our CROs and
$260,000 for clinical trial site costs as the FAME Study was completed in 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>General and administrative expenses. </I>General and administrative expenses increased by
approximately $160,000, or 12.3%, to approximately $1.4&nbsp;million for the three months
ended September&nbsp;30, 2011 compared to approximately $1.3&nbsp;million for the three months ended
September&nbsp;30, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Marketing expenses. </I>Marketing expenses increased by approximately $1.0&nbsp;million, or
62.5%, to approximately $2.6&nbsp;million for the three months ended September&nbsp;30, 2011 compared
to approximately $1.6&nbsp;million for the three months ended September&nbsp;30, 2010. This increase
was primarily attributable to increases of $490,000 in costs related to our
advertising agency&#146;s development of a detailed advertising and promotional plan for the
commercial launch of ILUVIEN, $400,000 in compensation costs related to the
hiring of additional personnel in advance of the launch of
ILUVIEN and $190,000 in additional pharmaeconomic work to evaluate the pricing of ILUVIEN in the U.S. and Europe.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Interest expense. </I>Interest expense was approximately $280,000 for the three months
ended September&nbsp;30, 2011. Interest expense for the three months ended September&nbsp;30, 2010 was
immaterial. Interest expense for the three months ended September&nbsp;30, 2011 was incurred in
connection with our Credit Facility with Silicon Valley Bank and MidCap Financial LLP,
secured in the fourth quarter of 2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Income from discontinued operations</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We did not have any income or loss from discontinued operations for either the three
months ended September&nbsp;30, 2011 or the three months ended September&nbsp;30, 2010.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">





<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Nine
months ended September&nbsp;30, 2011 compared to the nine months ended September&nbsp;30,
2010</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Research and development expenses.</I> Research and
development expenses decreased by approximately $4.7 million, or 44.8%, to approximately $5.7 million for the nine months ended
September 30, 2011 compared to approximately $10.5 million for the nine months ended September 30, 2010. The decrease was primarily
attributable to decreases of $3.9 million in costs associated with our FAME Study, $1.9 million in costs to file our NDA in the
U.S. and marketing applications for ILUVIEN in Austria, France, Germany, Italy, Portugal, Spain, and the U.K. in 2010, offset by
increases of $620,000 in costs related to the physician utilization study which is being conducted to assess the safety and utility of the commercial version of the inserter for ILUVIEN. The decrease in costs for our FAME Study was primarily attributable to decreases of $910,000 for our CROs and
$260,000 for clinical trial site costs as the FAME Study was completed in 2010 and $500,000 in costs associated with contracting medical science liaisons to engage with retina
specialists in the study of ILUVIEN. The decrease in costs for our FAME Study was primarily attributable to decreases of $2.3 million
for our CROs, $1.1 million for clinical trial site costs and $370,000 for our third party reading center for the analysis of retinal
images as the FAME Study was completed in 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>General and administrative expenses. </I>General and administrative expenses increased by
approximately $1.5&nbsp;million, or 45.5%, to approximately $4.8&nbsp;million for the nine months
ended September&nbsp;30, 2011 compared to approximately $3.3&nbsp;million for the nine months ended
September&nbsp;30, 2010. The increase was primarily attributable to
increases of $610,000 in stock compensation expense, $400,000 in personnel costs
and $260,000 in costs incurred after our IPO in April&nbsp;2010 associated with
operating as a public company including additional audit, tax and legal fees, increased
directors&#146; and officers&#146; insurance costs, and board of directors&#146; compensation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Marketing expenses. </I>Marketing expenses increased by approximately $2.8&nbsp;million, or
127.3%, to approximately $5.0&nbsp;million for the nine months ended September&nbsp;30, 2011 compared
to approximately $2.2 for the nine months ended September&nbsp;30, 2010. The increase was
primarily attributable to increases of $1.3&nbsp;million in compensation costs
related to the hiring of additional key personnel in advance of
the launch of ILUVIEN, $1.0&nbsp;million in costs related to our advertising agency&#146;s development of a
detailed advertising and promotional plan for the commercial launch of ILUVIEN, $200,000 in costs associated with the establishment of our managed care
programs, $180,000 in costs relating to pharmaeconomic studies to evaluate the
pricing of ILUVIEN in the U.S. and Europe, and $170,000 in additional medical
marketing activity as we expand our presence at key industry events and prepare for entry into the European market.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Interest expense. </I>Interest expense increased by approximately $240,000, or 38.7%, to
approximately $860,000 for the nine months ended September&nbsp;30, 2011 compared to
approximately $620,000 for the nine months ended September&nbsp;30, 2010. Interest expense for
the nine months ended September&nbsp;30, 2011 was incurred in connection with our Credit Facility
with Silicon Valley Bank and MidCap Financial LLP, secured in the fourth quarter of 2010.
Interest expense for the nine months ended September&nbsp;30, 2010 was incurred in connection
with our $15.0&nbsp;million promissory note payable to pSivida, which was repaid in April
2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>Decrease in fair value of preferred stock conversion feature. </I>For the nine months ended
September&nbsp;30, 2010, we recognized a gain of approximately $3.6&nbsp;million related to the
decrease of the fair value of the conversion feature of our preferred stock. The conversion
feature of our preferred stock was eliminated in connection with our IPO in April&nbsp;2010.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Income from discontinued operations</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We recognized income from discontinued operations during the nine months ended
September&nbsp;30, 2010 of $4.0&nbsp;million for a payment we received from Bausch &#038; Lomb. This
payment was related to the exercise by Bausch &#038; Lomb of its option to extend by two years
the period during which it may continue to develop an allergy product acquired from us in
2006. We did not have any income or loss from discontinued operations for the nine months
ended September&nbsp;30, 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Liquidity and Capital Resources</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have incurred recurring losses, negative cash flow from operations, and have
accumulated a deficit of $205.3&nbsp;million from our inception through September&nbsp;30, 2011. Prior
to our IPO in April&nbsp;2010, we funded our operations through the private placement of common
stock, preferred stock, preferred stock warrants and convertible debt, as well as by the
sale of certain assets of the non-prescription business in which we were previously engaged.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&nbsp;21, 2010, our Registration Statement on Form S-1 (as amended) was
declared effective by the SEC for our IPO, pursuant to which we sold 6,550,000 shares of our
common stock at a public offering price of $11.00 per share. We received net proceeds of
approximately $68.4&nbsp;million from this transaction, after deducting underwriting discounts
and commissions. In October&nbsp;2010, we obtained a $32.5&nbsp;million senior secured credit facility
to help fund our working capital requirements. The Credit Facility consisted of a $20.0
million Working Capital Revolver and a $12.5&nbsp;million Term Loan. The Lenders advanced $6.25
million under the Term Loan and the remaining $6.25&nbsp;million was available for funding
following FDA approval of ILUVIEN, but no later than July&nbsp;31, 2011. On May&nbsp;16, 2011, we and
the Lenders amended the terms of the Credit Facility to among other things, extend the FDA
approval deadline for the second advance under the Term Loan to December&nbsp;31, 2011, and to
increase the amount available under the second advance by $4.75&nbsp;million to $11.0&nbsp;million. In
addition, the maturity date of the Term Loan was extended from October&nbsp;31, 2013 to April&nbsp;30,
2014. We may draw on the Working Capital Revolver against eligible, domestic accounts
receivable, but as of September&nbsp;30, 2011, no amounts under the Working Capital Revolver were
outstanding or available to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of September&nbsp;30, 2011, we had approximately $38.6&nbsp;million in cash, cash
equivalents and investments in marketable securities. We believe that we have sufficient
funds available to fund our operations through the projected launch of ILUVIEN and the
expected generation of revenue in early 2012. The commercialization of ILUVIEN is dependent
upon approval by the FDA, however, we cannot be sure that ILUVIEN will be approved by
the FDA or that, if approved, future sales of ILUVIEN will generate enough revenue to fund
the Company&#146;s operations beyond its launch. Due to the uncertainty around FDA approval,
management cannot be certain that we will not need additional funds for the launch of
ILUVIEN. If ILUVIEN is not approved, or if approved, does not generate sufficient revenue,
we may adjust our commercial plans so that we can continue to operate with our existing cash
resources or seek to raise additional financing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In the event additional financing is needed or desired, we may seek to fund our
operations through the sale of equity securities, strategic collaboration agreements and
debt financing. We cannot be sure that additional financing from any of these sources will
be available when needed or that, if available, the additional financing will be obtained on
terms favorable to us or our stockholders especially in light of the current difficult
financial environment. If we raise additional funds by issuing equity securities,
substantial dilution to existing stockholders would likely result and the terms of any new
equity securities may have a preference over our common stock. If we attempt to raise
additional funds through strategic collaboration agreements and debt financing, we may not
be successful in obtaining collaboration agreements, or in receiving milestone or royalty
payments under those agreements, or the terms of the debt may involve significant cash
payment obligations as well as covenants and specific financial ratios that may restrict our
ability to commercialize our product candidates or operate our business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As of September&nbsp;30, 2011, we had $38.6&nbsp;million in cash, cash equivalents and
investments in marketable securities. We have invested a substantial portion of our
available cash in money market funds placed with a reputable financial institution for which
credit loss is not anticipated. We have established guidelines relating to diversification
and maturities of our investments to preserve principal and maintain liquidity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the nine months ended September&nbsp;30, 2011, cash used in our continuing operations of
$16.1&nbsp;million was primarily due to our net loss from continuing operations of $16.4&nbsp;million
offset by non-cash stock-based compensation and other expense of $1.9&nbsp;million. Further
increasing our cash used in continuing operations was a decrease in accounts payable,
accrued expenses and other current liabilities of $1.5&nbsp;million, and an increase in prepaid
expenses and other current assets of $160,000. The decrease in accounts payable, accrued
expenses and other current liabilities was primarily due to decreases of $1.4
million in amounts due to our clinical sites for the FAME Study and $450,000
in amounts due to our CROs, offset by an increase of $270,000 in amounts
payable to third party professional services firms in connection with legal counsel and accounting and audit
services and $140,000 to our third party
reading center for the analysis of retinal images. The increase in prepaid expenses and other current assets was primarily due to advanced payments made in connection with participation in industry
tradeshows and events.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the nine months ended September&nbsp;30, 2010, cash used in our continuing
operations of $16.0&nbsp;million was primarily due to our net loss from continuing operations of
$11.6&nbsp;million increased by non-cash gains of $3.6&nbsp;million related to the change in fair
value of our preferred stock conversion feature and $1.3&nbsp;million associated with the
repayment of our $15.0&nbsp;million promissory note to pSivda in April&nbsp;2010, offset by non-cash
charges of $560,000 for stock compensation expense and $150,000 for depreciation and
amortization expense. Further increasing our net cash used in continuing operations was an
increase in prepaid and other current assets of $320,000 offset by an increase in accounts
payable and accrued expenses and other current liabilities of $180,000. The increase in
prepaid and other current assets was primarily due to an increase of $180,000 of advances
made to the third party manufacturer of ILUVIEN to scale up commercialization and an
increase of $150,000 of prepaid annual directors&#146; and officers&#146; insurance premiums, offset
by a reduction of $100,000 of prepaid costs related to our FAME Study and other ancillary
clinical studies as work on these studies continued. The increase in accounts payable and
accrued expenses and other current liabilities was primarily due to an increase of $250,000
of amounts payable to providers of corporate communications and medical marketing services
as pre-launch activities continued.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the nine months ended September&nbsp;30, 2011, net cash provided by our investing
activities was $25.7&nbsp;million, which was primarily due to the maturities of investments of
marketable securities. For the nine months ended September&nbsp;30, 2010, net cash used in our
investing activities was $36.1&nbsp;million, which was primarily due to the purchase of $40.0
million of investments of marketable securities and the purchase of $120,000 of computer
equipment and software to facilitate the filing of our NDA and for use by new employees,
offset by the receipt of $4.0&nbsp;million from Bausch &#038; Lomb upon the exercise by Bausch &#038; Lomb
of its option to extend by two years the period during which it may continue to develop an
allergy product acquired from us in 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">For the nine months ended September&nbsp;30, 2011, cash provided by financing activities was
$17,000. This was primarily due to proceeds of $340,000 from the exercise of
stock options and from the purchase of our stock in connection with our employee stock
purchase plan, offset by $270,000 in principal payments to Silicon Valley Bank and MidCap Financial. For the nine months ended September&nbsp;30, 2010 net cash provided by our financing
activities was $62.0&nbsp;million, which was due primarily to the receipt of net proceeds of
$68.4&nbsp;million, after underwriting discounts and commissions, from our IPO, net proceeds of
$10.0&nbsp;million from the exercise of warrants to purchase shares of our Series&nbsp;C-1 preferred
stock, and $520,000 from the exercise of options and warrants to purchase shares of our
stock offset by the payment of $1.9&nbsp;million of costs related to our IPO and by the repayment
of our $15.0&nbsp;million promissory note to pSivida.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Contractual Obligations and Commitments</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Other
than the amendments to our Credit Facility described below,
there have been no other material changes to our contractual obligations and
commitments outside the ordinary course of business from those disclosed in our Annual
Report on Form 10-K for the year ended December&nbsp;31, 2010, filed with the SEC on March&nbsp;25,
2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Our Credit Facility</I></B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Term Loan</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On October&nbsp;14, 2010 (&#147;Effective Date&#148;), we entered into a Loan and Security Agreement
(&#147;Term Loan Agreement&#148;) with Silicon Valley Bank and MidCap Financial LLP (&#147;Lenders&#148;).
Pursuant to the original terms of the Term Loan Agreement, we were entitled to borrow up to
$12.5&nbsp;million, of which $6.25&nbsp;million (&#147;Term Loan A&#148;) was advanced to us on the Effective
Date. We were entitled to draw down the remaining $6.25&nbsp;million under the Term Loan (&#147;Term
Loan B&#148; and together with Term Loan A, the &#147;Term Loan&#148;) if the FDA approved our NDA for
ILUVIEN prior to or on July&nbsp;31, 2011. On May&nbsp;16, 2011, the Lenders and we amended the Term
Loan Agreement (&#147;Term Loan Modification&#148;) to, among other things, extend until December&nbsp;31,
2011 the date by which the FDA must approve the NDA in order for us to draw down Term Loan B
and increase the amount of Term Loan B by $4.75&nbsp;million to $11.0&nbsp;million. In addition, the
maturity date of the Term Loan was extended from October&nbsp;31, 2013 to April&nbsp;30, 2014 (the
&#147;Term Loan Maturity Date&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We were required to pay interest on Term Loan A at a rate of 11.5% on a monthly basis
through July&nbsp;31, 2011, and then beginning August 2011 we are required to repay the principal in 33 equal monthly
installments plus interest at a rate of 11.5%. We are required to
pay interest at a rate of 12.5% on the amount borrowed, if any, under Term Loan B through
April&nbsp;30, 2012, and thereafter we will be required to repay the principal in equal monthly
installments through the Term Loan Maturity Date, plus interest at a rate of 12.5%.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If we repay Term Loan A prior to maturity, we must pay to the Lenders a prepayment
fee equal to 5.0% of the total amount of principal then outstanding if the prepayment had occurred
within one year after the funding date of Term Loan A (&#147;Term Loan A Funding Date&#148;), 3.0% of
such amount if the prepayment occurs between one year and two years after the Term Loan A
Funding Date and 1.0% of such amount if the prepayment occurs thereafter (subject to a 50%
reduction in the event that the prepayment occurs in connection with an acquisition of us).
If Term Loan B is advanced to us, then the amount of the prepayment fee on both Term Loan A
and Term Loan B will be reset to 5.0% and the time-based reduction of the prepayment fee
will be measured from the funding date of Term Loan B (subject to the same 50% reduction in
the event of an acquisition of us), rather than from the Term Loan A Funding Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Term Loan Agreement, we
granted to the Lenders a first priority security interest in all of our assets, including
our intellectual property, however, the lien on our intellectual property will be released
if we meet certain financial conditions. The occurrence of an event of default could result
in the acceleration of our obligations under the Term Loan Agreement and an increase to the
applicable interest rate, and would permit the Lenders to exercise remedies with respect to
the collateral under the Term Loan Agreement. We also agreed not to pledge or otherwise
encumber our intellectual property assets. Additionally, we must seek the Lenders&#146; approval
prior to the payment of any cash dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On the Effective Date, we issued to the Lenders warrants to purchase an aggregate of up
to 39,773 shares of our common stock. Each of the warrants is exercisable immediately, has a
per-share exercise price of $11.00 and has a term of 10&nbsp;years. We estimated the fair value
of warrants granted using the Black-Scholes option pricing model. The aggregate fair value
of the warrants was estimated to be $389,000. We allocated a portion of the proceeds from
the Term Loan Agreement to the warrants in accordance with ASC 470-20-25-2, <I>Debt Instruments
with Detachable Warrants</I>. As a result, we recorded a discount of $366,000 which is being
amortized to interest expense using the effective interest method. The Lenders also hold
warrants to purchase an aggregate of up to 69,999 shares of our common stock. Each of these
warrants is exercisable only if Term Loan B is advanced to us, has a per share exercise
price of $11.00 and has a term of 10&nbsp;years. In addition, the Lenders will have certain
registration rights with respect to the shares of common stock issuable upon exercise of all
of their warrants. We paid to the Lenders an upfront fee of $62,500 on the Effective Date
and an additional fee of $50,000 in connection with the Term Loan Modification. In
accordance with ASC 470-50-40-17, <I>Debt &#151; Modifications and Extinguishments</I>, we are
amortizing the unamortized discount on Term Loan A and the $50,000 modification fee over the
remaining term of Term Loan A, as modified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are required to maintain its primary operating and other deposit accounts and
securities accounts with Silicon Valley Bank, which accounts must represent at least 50% of
the dollar value of our accounts at all financial institutions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%"><B><I>Working
Capital Revolver</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Also on the Effective Date, we entered into a Loan and Security Agreement with Silicon
Valley Bank, pursuant to which we obtained a secured revolving line of credit (&#147;Working
Capital Revolver&#148;) from Silicon Valley Bank with borrowing availability up to $20,000,000
(the &#147;Revolving Loan Agreement&#148;). On May&nbsp;16, 2011, the Lenders and we amended the Revolving
Loan Agreement to extend the maturity date of the Working Capital Revolver from October&nbsp;31,
2013 to April&nbsp;30, 2014.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Working Capital Revolver is a working capital-based revolving line of credit in an
aggregate amount of up to the lesser of (i) $20,000,000, or (ii)&nbsp;85% of eligible domestic
accounts receivable. As of September&nbsp;30, 2011, no amounts under the Working Capital Revolver
were available to us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Amounts advanced under the Working Capital Revolver will bear interest at an annual
rate equal to Silicon Valley Bank&#146;s prime rate plus 2.50% (with a rate floor of 6.50%).
Interest on the Working Capital Revolver will be due monthly, with the balance due at the
maturity date. On the Effective Date, we paid to Silicon Valley Bank an upfront fee of
$100,000. In addition, if we terminate the Working Capital Revolver prior to maturity, we
will pay to Silicon Valley Bank a fee of $400,000 if the termination had occurred within one year
after the Effective Date and a fee of $200,000 if the termination occurs more than one year
after the Effective Date (each a &#147;Termination Fee&#148;), provided in each case that such
Termination Fee will be reduced by 50% in the event we are acquired.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Revolving Loan
Agreement, we granted to Silicon Valley Bank a first priority security interest in all of
our assets, including our intellectual property, however, the lien on our intellectual
property will be released if we meet certain financial conditions. The occurrence of an
event of default could result in the acceleration of our obligations under the Revolving
Loan Agreement and an increase to the applicable interest rate, and would permit Silicon
Valley Bank to exercise remedies with respect to the collateral under the Revolving Loan
Agreement. We also agreed not to pledge or otherwise encumber our intellectual property
assets. Additionally, we must seek Silicon Valley Bank&#146;s approval prior to the payment of
any cash dividends.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>Off-Balance Sheet Arrangements</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not have any relationships with unconsolidated entities or financial
partnerships, such as entities often referred to as structured finance or special purpose
entities, that would have been established for the purpose of facilitating off-balance sheet
arrangements (as that term is defined in Item&nbsp;303(a)(4)(ii) of Regulation&nbsp;S-K) or other
contractually narrow or limited purposes. As such, we are not exposed to any financing,
liquidity, market or credit risk that could arise if we had engaged in those types of
relationships. We enter into guarantees in the ordinary course of business related to the
guarantee of our own performance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 1%"><B><I>New Accounting Pronouncements</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">From time to time, new accounting pronouncements are issued by the Financial Accounting
Standards Board, or FASB, or other standard setting bodies that are adopted by us as of the
specified effective date. Unless otherwise discussed, we believe that the impact of recently
issued standards that are not yet effective will not have a material impact on our financial
position or results of operations upon adoption.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C23183108"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 3</B></TD>
    <TD>&nbsp;</TD>
    <TD><B><I>Qualitative and Quantitative Disclosures about Market Risk</I></B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We are exposed to market risk related to changes in interest rates. As of September&nbsp;30,
2011, we had approximately $38.6&nbsp;million in cash, cash equivalents and investments in
marketable securities. Our primary exposure to market risk is interest income sensitivity,
which is affected by changes in the general level of U.S. interest rates, particularly
because our investments are in short-term securities. Due to the short-term duration of our
investment portfolio and the low risk profile of our investments, an immediate 10% change in
interest rates would not have a material effect on the fair market value of our portfolio.
Accordingly, we would not expect our operating results or cash flows to be affected to any
significant degree by the effect of a sudden change in market interest rates on our
securities portfolio.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We contract for the conduct of some of our clinical trials and other research and
development activities with contract research organizations and investigational sites in the
U.S., Europe and India. We may be exposed to fluctuations in foreign exchange rates in
connection with these agreements. We do not hedge our foreign currency exposures. We have
not used derivative financial instruments for speculation or trading purposes.
</DIV>
<DIV align="left">
<A name="C23183109"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 4</B></TD>
    <TD>&nbsp;</TD>
    <TD><B><I>Controls and Procedures</I></B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Evaluation of Disclosure Controls and Procedures</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We maintain disclosure controls and procedures that are designed to ensure that
information required to be disclosed in our periodic reports filed with the SEC is recorded,
processed and summarized and reported within the time periods specified in the rules and
forms of the SEC and that such information is accumulated and communicated to our
management, including our Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow for timely decisions regarding required disclosure. In designing and
evaluating the disclosure controls and procedures, our management recognizes that any
controls and procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives, and no evaluation of
controls and procedures can provide absolute assurance that all control issues and instances
of fraud, if any, have been detected. Our management is required to apply its judgment in
evaluating the cost-benefit relationship of possible controls and procedures. Under the
supervision and with the participation of the our management, including the Chief Executive
Officer and Chief Financial Officer, we evaluated the effectiveness of the design and
operation of our disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and
15d-15(e) under the Exchange Act) as of September&nbsp;30, 2011. Based upon that evaluation, our
Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls
and procedures are effective as of September&nbsp;30, 2011, the end of the period covered by this
Quarterly Report on Form 10-Q, to ensure that the information required to be disclosed by us
in the reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the SEC&#146;s rules and forms, and
that such information is accumulated and communicated to our management, including our Chief
Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Changes in Internal Control over Financial Reporting</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">There has been no change in our internal control over financial reporting (as defined
in Rules&nbsp;13a-15(f) and 15d-15(f) of the Exchange Act) during the three months ended
September&nbsp;30, 2011 that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C23183110"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PART II. OTHER INFORMATION</B>
</DIV>

<DIV align="left">
<A name="C23183111"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 1A</B></TD>
    <TD>&nbsp;</TD>
    <TD><B><I>Risk Factors</I></B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2010, filed
with the SEC on March&nbsp;25, 2011, we identify under Item&nbsp;1A
of Part I important factors which could
affect our business, financial condition, results of operations and future operations and
could cause our actual results for future periods to differ materially from our anticipated
results or other expectations, including those expressed in any forward-looking statements
made in this Form 10-Q. There have been no material changes in our risk factors subsequent
to the filing of our Form 10-K for the fiscal year ended December&nbsp;31, 2010. However, the
risks described in our Form 10-K are not the only risks we face. Additional risks and
uncertainties that we currently deem to be immaterial or not currently known to us, as well
as other risks reported from time to time in our reports to the SEC, also could cause our
actual results to differ materially from our anticipated results or other expectations.
</DIV>
<DIV align="left">
<A name="C23183112"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 2</B></TD>
    <TD>&nbsp;</TD>
    <TD><B><I>Unregistered Sales of Equity Securities and Use of Proceeds</I></B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Recent
Sales of Unregistered Securites</i></b>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In September 2011, we issued 4,411 shares
of our common stock upon the exercise of warrants for an aggregate of
$19,000. No underwriters were involved in the sale
of such securities.  The issuance of the securities was deemed to be exempt from registration under the Securities Act in
reliance on Section 4(2) thereof.  The recipient of the securities represented their intention to acquire the securities
for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate
legends were affixed to the warrant agreements and securities issued in such transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><b><i>Use of Proceeds</i></b>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&nbsp;21, 2010, our Registration Statement on Form S-1 (File No.&nbsp;333-162782) was
declared effective by the SEC for our IPO, pursuant to which we sold 6,550,000 shares of our
common stock at a public offering price of $11.00 per share. We received net proceeds of
approximately $66.1&nbsp;million from this transaction, after deducting underwriting discounts,
commissions and other offering costs. On April&nbsp;27, 2010 we paid $15.2&nbsp;million to pSivida to
satisfy our $15.0&nbsp;million note payable and accrued but unpaid interest thereon.
There have been no material changes in our use or planned use of proceeds from the IPO
from that described in our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31,
2010, filed with the SEC on June&nbsp;7, 2010.
</DIV>
<DIV align="left">
<A name="C23183113"></A>
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>ITEM 6</B></TD>
    <TD>&nbsp;</TD>
    <TD><B><I>Exhibits</I></B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of the Principal
Executive Officer, as required by
Section&nbsp;302 of the Sarbanes-Oxley
Act of 2002.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of the Principal
Financial Officer, as required by
Section&nbsp;302 of the Sarbanes-Oxley
Act of 2002.</DIV></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of the Chief
Executive Officer and Chief
Financial Officer, as required by
Section&nbsp;906 of the Sarbanes-Oxley
Act of 2002.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>



</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The certification attached as Exhibit&nbsp;32.1 that accompanies this Quarterly Report on
Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be
incorporated by reference into any filing of Alimera Sciences, Inc. under the Securities Act
of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before
or after the date of this Quarterly Report on Form 10-Q, irrespective of any general
incorporation language contained in such filing.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">



<DIV align="left">
<A name="C23183114"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alimera Sciences, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ C. Daniel Myers
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<B>C. Daniel Myers</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Chief Executive Officer and President<BR>
(Principal executive officer)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">November&nbsp;7, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Richard S. Eiswirth, Jr.
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<B>Richard S. Eiswirth, Jr.</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="white-space: nowrap"><B>Chief Operating Officer and Chief Financial Officer</B></FONT><BR>
<B>(Principal financial and accounting officer)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">November&nbsp;7, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#C23183tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ALIMERA SCIENCES, INC.</B>
</DIV>

<DIV align="left">
<A name="C23183115"></A>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT INDEX</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of the Principal Executive
Officer, as required by Section&nbsp;302 of
the Sarbanes-Oxley Act of 2002.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of the Principal Financial
Officer, as required by Section&nbsp;302 of
the Sarbanes-Oxley Act of 2002.</DIV></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Certification of the Chief Executive
Officer and Acting Chief Financial
Officer, as required by Section&nbsp;906 of
the Sarbanes-Oxley Act of 2002.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The certification attached as Exhibit&nbsp;32.1 that accompanies this Quarterly Report on
Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be
incorporated by reference into any filing of Alimera Sciences, Inc. under the Securities Act
of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before
or after the date of this Quarterly Report on Form 10-Q, irrespective of any general
incorporation language contained in such filing.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>c23183exv31w1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT 31.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">I, C. Daniel Myers, certify that:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Quarterly Report on Form 10-Q of Alimera Sciences, Inc.;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and
15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating
to the registrant, is made known to us by others within those
entities, particularly during the period in which this report
is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;paragraph deleted in accordance with SEC release no. 34-47986&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>evaluated the effectiveness of the registrant&#146;s disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this
report based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>disclosed in this report any change in the registrant&#146;s
internal control over financial reporting that occurred during
the registrant&#146;s most recent fiscal quarter (the registrant&#146;s
fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially
affect, the registrant&#146;s internal control over financial
reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all significant deficiencies and material weaknesses
in the design or operation of internal control over
financial reporting which are reasonably likely to
adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information;
and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any fraud, whether or not material, that involves
management or other employees who have a significant
role in the registrant&#146;s internal control over
financial reporting.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">Date: November&nbsp;7, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ C. Daniel Myers
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>C. Daniel Myers</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Chief Executive Officer and President<br>
(Principal Executive Officer)</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>c23183exv31w2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 31.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT 31.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">I, Richard S. Eiswirth, Jr., certify that:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Quarterly Report on Form 10-Q of Alimera Sciences, Inc.;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and
15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating
to the registrant, is made known to us by others within those
entities, particularly during the period in which this report
is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;paragraph deleted in accordance with SEC release no. 34-47986&#093;</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>evaluated the effectiveness of the registrant&#146;s disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this
report based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>disclosed in this report any change in the registrant&#146;s
internal control over financial reporting that occurred during
the registrant&#146;s most recent fiscal quarter (the registrant&#146;s
fourth fiscal quarter in the case of an annual report) that
has materially affected, or is reasonably likely to materially
affect, the registrant&#146;s internal control over financial
reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all significant deficiencies and material weaknesses in the
design or operation of internal control over financial
reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and
report financial information; and</TD>
</TR>

<TR>
    <TD style="font-size: 8pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any fraud, whether or not material, that involves
management or other employees who have a significant role
in the registrant&#146;s internal control over financial
reporting.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">Date: November&nbsp;7, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Richard S. Eiswirth, Jr.
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Richard S. Eiswirth, Jr.</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="white-space: nowrap"><B>Chief Operating Officer and Chief Financial Officer</B></FONT><br>
<B>(Principal Financial and Accounting Officer)</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>c23183exv32w1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 32.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>EXHIBIT 32.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Certification</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>(Subsections (a)&nbsp;and (b)&nbsp;of Section&nbsp;1350, Chapter&nbsp;63 of Title 18, United States Code)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b)&nbsp;of
section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers
of Alimera Sciences, Inc. (the Company), does hereby certify, to the best of such officer&#146;s
knowledge, that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The
Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2011 (the Form 10-Q)
of the Company fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly
presents, in all material respects, the financial condition and results of operations of the
Company.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">Date: November&nbsp;7, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ C. Daniel Myers
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>C. Daniel Myers</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Chief Executive Officer and President<br>
(Principal Executive Officer)</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">Date: November&nbsp;7, 2011&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Richard S. Eiswirth, Jr.
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Richard S. Eiswirth, Jr.</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="white-space: nowrap"><B>Chief Operating Officer and Chief Financial Officer</B></FONT><br>
<B>(Principal Financial and Accounting Officer)</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">A signed original of this written statement required by Section&nbsp;906 has been provided
to the Company and will be retained by the Company and furnished to the Securities and
Exchange Commission or its staff upon request. This certification &#147;accompanies&#148; the Form
10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by
reference into any filing of the Company under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended (whether made before or after the date of
the Form 10-Q), irrespective of any general incorporation language contained in such filing.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>alim-20110930.xml
<DESCRIPTION>EX-101 INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:alim="http://alimerasciences.com/20110930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="alim-20110930.xsd" />
<!-- Context Section -->
<context id="BalanceAsOf_03Nov2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<instant>2011-11-03</instant>
</period>
</context>
<context id="BalanceAsOf_30Jun2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<instant>2010-06-30</instant>
</period>
</context>
<context id="BalanceAsOf_30Sep2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<instant>2011-09-30</instant>
</period>
</context>
<context id="BalanceAsOf_31Dec2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<instant>2010-12-31</instant>
</period>
</context>
<context id="ThreeMonthsEnded_30Sep2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<startDate>2011-07-01</startDate>
<endDate>2011-09-30</endDate>
</period>
</context>
<context id="ThreeMonthsEnded_30Sep2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<startDate>2010-07-01</startDate>
<endDate>2010-09-30</endDate>
</period>
</context>
<context id="NineMonthsEnded_30Sep2011">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<startDate>2011-01-01</startDate>
<endDate>2011-09-30</endDate>
</period>
</context>
<context id="NineMonthsEnded_30Sep2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<startDate>2010-01-01</startDate>
<endDate>2010-09-30</endDate>
</period>
</context>
<context id="BalanceAsOf_31Dec2009">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<instant>2009-12-31</instant>
</period>
</context>
<context id="BalanceAsOf_30Sep2010">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001267602</identifier>
</entity>
<period>
<instant>2010-09-30</instant>
</period>
</context>
<!--Unit Section-->
 <unit id="USDEPS">
   <divide>
     <unitNumerator>
       <measure>iso4217:USD</measure>
     </unitNumerator>
     <unitDenominator>
       <measure>xbrli:shares</measure>
     </unitDenominator>
   </divide>
 </unit>
 <unit id="Shares">
   <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>

<!-- Element Section -->
<!--Document Information-->
<dei:EntityRegistrantName contextRef="NineMonthsEnded_30Sep2011">ALIMERA SCIENCES INC</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="NineMonthsEnded_30Sep2011">0001267602</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="NineMonthsEnded_30Sep2011">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityWellKnownSeasonedIssuer contextRef="NineMonthsEnded_30Sep2011">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="NineMonthsEnded_30Sep2011">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="NineMonthsEnded_30Sep2011">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory contextRef="NineMonthsEnded_30Sep2011">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:DocumentType contextRef="NineMonthsEnded_30Sep2011">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="NineMonthsEnded_30Sep2011">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="NineMonthsEnded_30Sep2011">2011-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="NineMonthsEnded_30Sep2011">Q3</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="NineMonthsEnded_30Sep2011">2011</dei:DocumentFiscalYearFocus>
<dei:EntityPublicFloat contextRef="BalanceAsOf_30Jun2010" decimals="0" unitRef="USD">17376806</dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_03Nov2011" decimals="INF" unitRef="Shares">31427355</dei:EntityCommonStockSharesOutstanding>
<!-- Instance Elements for BALANCE_SHEETS -->
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">38107000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">28514000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:MarketableSecuritiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">502000</us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">26330000</us-gaap:MarketableSecuritiesCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">1236000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1078000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:DeferredFinanceCostsCurrentNet contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">231000</us-gaap:DeferredFinanceCostsCurrentNet>
<us-gaap:DeferredFinanceCostsCurrentNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">272000</us-gaap:DeferredFinanceCostsCurrentNet>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">40076000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">56194000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">218000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">220000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">40294000</us-gaap:Assets>
<us-gaap:Assets contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">56414000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">1950000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1677000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">1459000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">2731000</us-gaap:AccruedLiabilitiesCurrent>
<alim:OutsourcedServicesPayable contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">393000</alim:OutsourcedServicesPayable>
<alim:OutsourcedServicesPayable contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">841000</alim:OutsourcedServicesPayable>
<us-gaap:NotesPayableCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">2386000</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">1157000</us-gaap:NotesPayableCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">11000</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">11000</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">6199000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">6417000</us-gaap:LiabilitiesCurrent>
<us-gaap:LongTermNotesPayable contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">3501000</us-gaap:LongTermNotesPayable>
<us-gaap:LongTermNotesPayable contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">4767000</us-gaap:LongTermNotesPayable>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">9000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">18000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:TemporaryEquityCarryingAmount contextRef="BalanceAsOf_30Sep2011" unitRef="USD" xsi:nil="true" />
<us-gaap:TemporaryEquityCarryingAmount contextRef="BalanceAsOf_31Dec2010" unitRef="USD" xsi:nil="true" />
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="BalanceAsOf_30Sep2011" unitRef="USDEPS" decimals="INF">.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">10000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">10000000</us-gaap:TemporaryEquitySharesAuthorized>
<us-gaap:TemporaryEquitySharesIssued contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" xsi:nil="true" />
<us-gaap:TemporaryEquitySharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" xsi:nil="true" />
<us-gaap:TemporaryEquitySharesOutstanding contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" xsi:nil="true" />
<us-gaap:TemporaryEquitySharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" xsi:nil="true" />
<us-gaap:CommonStockValue contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">314000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">313000</us-gaap:CommonStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_30Sep2011" unitRef="USDEPS" decimals="INF">.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2010" unitRef="USDEPS" decimals="INF">.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">31407383</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">31255953</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_30Sep2011" unitRef="Shares" decimals="INF">31407383</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="Shares" decimals="INF">31255953</us-gaap:CommonStockSharesOutstanding>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">235155000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">233338000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">415000</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">415000</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">-205299000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">-188854000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">30585000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">45212000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_30Sep2011" unitRef="USD" decimals="-3">40294000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">56414000</us-gaap:LiabilitiesAndStockholdersEquity>
<!-- Instance Elements for STMNT_OPERATIONS -->
<us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">2224000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">3276000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">5732000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">10481000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">1421000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1260000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">4827000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">3338000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:MarketingExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">2612000</us-gaap:MarketingExpense>
<us-gaap:MarketingExpense contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1583000</us-gaap:MarketingExpense>
<us-gaap:MarketingExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">5038000</us-gaap:MarketingExpense>
<us-gaap:MarketingExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2209000</us-gaap:MarketingExpense>
<us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">6257000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">6119000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">15597000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">16028000</us-gaap:OperatingExpenses>
<us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">37000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">15000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">53000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InterestExpense contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">284000</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">863000</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">618000</us-gaap:InterestExpense>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1343000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<alim:IncreaseDecreaseInFairValueOfPreferredStockConversionFeature contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">3644000</alim:IncreaseDecreaseInFairValueOfPreferredStockConversionFeature>
<us-gaap:IncomeLossFromContinuingOperations contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-6540000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromContinuingOperations contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-6082000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromContinuingOperations contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-16445000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromContinuingOperations contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-11606000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-6540000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-6082000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-16445000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-7606000</us-gaap:NetIncomeLoss>
<us-gaap:TemporaryEquityIssuePeriodIncreaseOrDecrease contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">466000</us-gaap:TemporaryEquityIssuePeriodIncreaseOrDecrease>
<us-gaap:RedeemablePreferredStockDividends contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2638000</us-gaap:RedeemablePreferredStockDividends>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-6540000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-6082000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-16445000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-10710000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2010" unitRef="USDEPS" decimals="2">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="NineMonthsEnded_30Sep2011" unitRef="USDEPS" decimals="2">-0.52</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="NineMonthsEnded_30Sep2010" unitRef="USDEPS" decimals="2">-0.56</us-gaap:EarningsPerShareBasicAndDiluted>
<alim:WeightedAverageSharesOutstandingBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">31396517</alim:WeightedAverageSharesOutstandingBasicAndDiluted>
<alim:WeightedAverageSharesOutstandingBasicAndDiluted contextRef="ThreeMonthsEnded_30Sep2010" unitRef="Shares" decimals="0">31145856</alim:WeightedAverageSharesOutstandingBasicAndDiluted>
<alim:WeightedAverageSharesOutstandingBasicAndDiluted contextRef="NineMonthsEnded_30Sep2011" unitRef="Shares" decimals="0">31342752</alim:WeightedAverageSharesOutstandingBasicAndDiluted>
<alim:WeightedAverageSharesOutstandingBasicAndDiluted contextRef="NineMonthsEnded_30Sep2010" unitRef="Shares" decimals="0">19120860</alim:WeightedAverageSharesOutstandingBasicAndDiluted>
<!-- Instance Elements for STMNT_CASH_FLOWS_#1 -->
<us-gaap:Depreciation contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">106000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">145000</us-gaap:Depreciation>
<alim:StockCompensationAndOther contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-1478000</alim:StockCompensationAndOther>
<alim:StockCompensationAndOther contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-567000</alim:StockCompensationAndOther>
<us-gaap:AmortizationOfFinancingCosts contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">318000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:UnrealizedGainLossOnInvestments contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">4000</us-gaap:UnrealizedGainLossOnInvestments>
<alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">158000</alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
<alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">320000</alim:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">273000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">231000</us-gaap:IncreaseDecreaseInAccountsPayable>
<alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-1720000</alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
<alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-53000</alim:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">2000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">-16148000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-16025000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">39962000</us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">25828000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">104000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">121000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">25724000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-40083000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">4000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">25724000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">-36083000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">210000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">28000</us-gaap:ProceedsFromStockOptionsExercised>
<alim:ProceedsFromExerciseOfPreferredStockWarrants contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">9997000</alim:ProceedsFromExerciseOfPreferredStockWarrants>
<alim:ProceedsFromExerciseOfCommonStockWarrants contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">19000</alim:ProceedsFromExerciseOfCommonStockWarrants>
<alim:ProceedsFromExerciseOfCommonStockWarrants contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">489000</alim:ProceedsFromExerciseOfCommonStockWarrants>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">111000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">68395000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">1942000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:RepaymentsOfNotesPayable contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">15000000</us-gaap:RepaymentsOfNotesPayable>
<alim:RepaymentOfNotesPayable contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">265000</alim:RepaymentOfNotesPayable>
<us-gaap:PaymentsOfDebtRestructuringCosts contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">50000</us-gaap:PaymentsOfDebtRestructuringCosts>
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">8000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">6000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">17000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">61961000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">9593000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">9853000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2009" unitRef="USD" decimals="-3">4858000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_30Sep2010" unitRef="USD" decimals="-3">14711000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<!-- Instance Elements for STMNT_CASH_FLOWS_#2 -->
<us-gaap:InterestPaid contextRef="NineMonthsEnded_30Sep2011" unitRef="USD" decimals="-3">508000</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">525000</us-gaap:InterestPaid>
<us-gaap:FairValueOfAssetsAcquired contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">36000</us-gaap:FairValueOfAssetsAcquired>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">36528000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<alim:IpoIssuanceCostsChargedToEquity contextRef="NineMonthsEnded_30Sep2010" unitRef="USD" decimals="-3">4228000</alim:IpoIssuanceCostsChargedToEquity>
<!-- Begin Block Tagged Note -->
<us-gaap:NatureOfOperations contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations--&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;&lt;b&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;&lt;b&gt;&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;1. Nature of Operations&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Alimera Sciences, Inc. (&amp;#8220;Company&amp;#8221;) is a biopharmaceutical company that specializes in
   the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The Company
   was formed on June&amp;#160;4, 2003 under the laws of the State of Delaware.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On April&amp;#160;21, 2010, the Company&amp;#8217;s Registration Statement on Form S-1 (as amended) was
   declared effective by the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for the Company&amp;#8217;s
   initial public offering (&amp;#8220;IPO&amp;#8221;), pursuant to which the Company sold 6,550,000 shares of its
   common stock at a public offering price of $11.00 per share. The Company received net
   proceeds of approximately $68,395,000 from this transaction, after deducting underwriting
   discounts and commissions.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;During the year ended December&amp;#160;31, 2006, management and the board of directors of the
   Company approved a plan to discontinue the operations of its non-prescription business (see
   Note 3). As a result of the completion of the disposal of its non-prescription business in
   July&amp;#160;2007, the Company no longer has active products and will not have active products until
   and unless the Company receives U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) approval and
   launches its initial prescription product (see Note 4).
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company is presently focused on diseases affecting the back of the eye, or retina,
   because the Company&amp;#8217;s management believes these diseases are not well treated with current
   therapies and represent a significant market opportunity. The Company&amp;#8217;s most advanced
   product candidate is ILUVIEN, which is being developed for the treatment of diabetic macular
   edema (&amp;#8220;DME&amp;#8221;). DME is a disease of the retina which affects individuals with diabetes and
   can lead to severe vision loss and blindness. The Company has completed  two Phase 3
   pivotal clinical trials (collectively referred to as the &amp;#8220;FAME Study&amp;#8221;) for ILUVIEN involving
   956 patients in sites across the U.S., Canada, Europe and India to assess the efficacy and
   safety of ILUVIEN in the treatment of DME.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In June&amp;#160;2010, the Company submitted a New Drug Application (&amp;#8220;NDA&amp;#8221;) for ILUVIEN to the FDA that included data through
   month 24 of the FAME Study. In December&amp;#160;2010, the FDA issued a Complete Response Letter (&amp;#8220;CRL&amp;#8221;) in response to the
   Company&amp;#8217;s NDA. In the CRL, the FDA communicated its decision that the NDA could not be approved in its then present
   form. The FDA asked for analyses of the safety and efficacy data through month 36 of the FAME Study, including
   exploratory analyses in addition to those previously submitted in the NDA, to further assess the relative benefits and
   risks of ILUVIEN. The FDA also sought additional information regarding controls and specifications concerning the
   manufacturing, packaging and sterilization of ILUVIEN. In a February&amp;#160;2011 meeting with the FDA, the FDA requested
   additional data related to the use of the commercial version of the ILUVIEN inserter for which approval was sought in
   the NDA. In May&amp;#160;2011, the Company submitted to the FDA a complete response to the CRL. The FDA classified the response
   as a Class&amp;#160;2 resubmission with a Prescription Drug User Fee Act (&amp;#8220;PDUFA&amp;#8221;) date of November&amp;#160;12, 2011. The PDUFA date is
   the date by which the Company can reasonably expect to have received the FDA&amp;#8217;s response. In July&amp;#160;2011, the FDA notified
   the Company that it will not call an advisory committee during its review of the Company&amp;#8217;s complete response to the
   CRL. In September&amp;#160;2011, the Company enrolled its first patient in a physician utilization study aimed at providing the
   additional data requested by the FDA with respect to the commercial version of the ILUVIEN inserter. The Company has
   enrolled 54 patient eyes in this study evaluating the safety and utility of the commercial version of the inserter and
   is targeting to enroll 100 patient eyes before commercial launch.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In July&amp;#160;2010, using the Decentralized Procedure, the Company submitted a Marketing
   Authorization Application for ILUVIEN to the Medicines and Healthcare products Regulatory
   Agency (&amp;#8220;MHRA&amp;#8221;) in the United Kingdom, which serves as the Reference Member State, and to
   regulatory authorities in Austria, France, Germany, Italy, Portugal and Spain. In November
   2010, the Company received the Preliminary Assessment Report from the MHRA followed by
   additional comments from the other health authorities in December&amp;#160;2010. In July&amp;#160;2011, the
   Company submitted its draft responses to the clinical, non-clinical, and quality questions
   to the MHRA. The submission included the additional safety and efficacy data through the
   final readout at the end of the FAME Study.
   In September 2011, the MHRA provided comments to the Company&amp;#8217;s clinical responses and indicated that there
   were no further comments to the Company&amp;#8217;s non-clinical and
   quality responses.  The Company is preparing, and
   plans to submit in November 2011, its final response to the Preliminary Assessment Report from the MHRA and to the additional comments from the other health authorities.
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:NatureOfOperations>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;2. Basis of Presentation&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company has prepared the accompanying unaudited interim financial statements and
   notes thereto in accordance with accounting principles generally accepted in the United
   States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and the instructions to
   Form 10-Q and Article&amp;#160;10-01 of Regulation&amp;#160;S-X of the SEC. Accordingly, they do not include
   all of the information and disclosures required by U.S. GAAP for complete financial
   statements. In the opinion of management, the accompanying unaudited interim financial
   statements reflect all adjustments, which include normal recurring adjustments, necessary to
   present fairly the Company&amp;#8217;s interim financial information.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The accompanying unaudited interim financial statements and related notes should be
   read in conjunction with the Company&amp;#8217;s audited financial statements for the year ended
   December&amp;#160;31, 2010 and related notes included in the Company&amp;#8217;s Annual Report on Form 10-K,
   which was filed with the SEC on March&amp;#160;25, 2011. The financial results for any interim period
   are not necessarily indicative of the expected financial results for the full year.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On April&amp;#160;21, 2010, the Company effected a 1 for 3.4 reverse split of the Company&amp;#8217;s
   common and preferred stock. All share and per share amounts in the accompanying financial
   statements and notes have been retroactively adjusted for all periods presented to give
   effect to the reverse stock split.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;3. Discontinued Operations&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In October&amp;#160;2006, management and the board of directors of the Company approved a plan
   to discontinue the operations of its non-prescription ophthalmic pharmaceutical business
   (&amp;#8220;OTC Business&amp;#8221;). The plan included the sale of the assets of the Company&amp;#8217;s OTC Business and
   also the termination of its sales and marketing personnel. The Company previously determined
   that the discontinued OTC Business comprised operations and cash flows that could be clearly
   distinguished, operationally and for financial reporting purposes, from the rest of the
   Company. Accordingly, the results of operations for the discontinued OTC Business have been
   presented as discontinued operations. During the nine months ended September&amp;#160;30, 2010, the
   Company received a $4,000,000 option payment from the acquirer of the assets of the OTC
   Business to provide it with an additional two years to develop one of the acquired products.
   In July 2011, the acquirer of the assets of the OTC Business notified the Company that it will discontinue the development of the acquired products and not seek FDA approval.
   There were no revenues or expenses from discontinued operations during the nine month period
   ended September&amp;#160;30, 2011. The following table presents basic and diluted earnings per share
   from discontinued operations for the nine months ended September&amp;#160;30, 2010:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="86%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net income from discontinued operations (in thousands)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;4,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Net income from discontinued operations per share &amp;#8212; Basic and diluted
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;0.21&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Weighted-average shares outstanding &amp;#8212; Basic and diluted
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;19,120,860&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<alim:FactorsAffectingOperationsTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - alim:FactorsAffectingOperationsTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;4. Factors Affecting Operations&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;To date the Company has incurred recurring losses, negative cash flow from operations,
   and has accumulated a deficit of $205,299,000 from the Company&amp;#8217;s inception through September
   30, 2011. The Company does not expect to generate revenues from its product, ILUVIEN, until
   early 2012, if at all, and therefore does not expect to have cash flow from operations until
   2012, if at all. As of September&amp;#160;30, 2011, the Company had
   approximately $38,609,000 in
   cash, cash equivalents, and investments in marketable securities. In October&amp;#160;2010, the
   Company obtained a $32,500,000 senior secured credit facility (&amp;#8220;Credit Facility&amp;#8221;) to help
   fund its working capital requirements (see note 7). The Credit Facility consisted of a
   $20,000,000 working capital revolver and a $12,500,000 term loan. The lenders advanced
   $6,250,000 under the term loan and the remaining $6,250,000 was available to be advanced
   following FDA approval of ILUVIEN, but no later than July&amp;#160;31, 2011. In May&amp;#160;2011, the Company
   and its lenders amended the terms of the Credit Facility to, among other things, extend the
   FDA approval deadline for the second advance under the term loan to December&amp;#160;31, 2011, and
   to increase the amount available under the second advance of the term loan from $6,250,000
   to $11,000,000. Management believes it has sufficient funds available to fund its operations
   through the projected launch of ILUVIEN and the expected generation of revenue in early
   2012. The commercialization of ILUVIEN is dependent upon approval by the FDA, however, and
   management cannot be sure that ILUVIEN will be approved by the FDA or that, if approved,
   future sales of ILUVIEN will generate enough revenue to fund the Company&amp;#8217;s operations beyond
   its launch. Due to the uncertainty around FDA approval, management also cannot be certain
   that the Company will not need additional funds for the launch of ILUVIEN. If ILUVIEN is not
   approved, or if approved, does not generate sufficient revenue, the Company may adjust its
   commercial plans so that it can continue to operate with its existing cash resources or seek
   to raise additional financing.
   &lt;/div&gt;
   &lt;/div&gt;
</alim:FactorsAffectingOperationsTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;5. Accrued Expenses&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Accrued expenses consisted of the following:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="72%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Accrued clinical investigator expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;518&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,911&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Accrued compensation expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;873&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;730&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Other accrued expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;68&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;90&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Total accrued expenses
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;1,459&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2,731&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:CollaborativeArrangementDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;6. pSivida Agreement&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In March&amp;#160;2008, in connection with the Company&amp;#8217;s collaboration agreement with pSivida
   U.S., Inc. (&amp;#8220;pSivida&amp;#8221;), the licensor of the ILUVIEN technology, the Company and pSivida
   amended and restated the agreement to provide the Company with 80% of the net profits and
   pSivida with 20% of the net profits derived by the Company from the
   sale of ILUVIEN.
   In connection with the amended and restated agreement,
   the Company also agreed to:
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;pay $12.0&amp;#160;million to pSivida upon the execution of the March&amp;#160;2008 agreement;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;issue a $15.0&amp;#160;million promissory note to pSivida;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;forgive all outstanding development payments, penalties and interest as of
   the effective date of the March&amp;#160;2008 agreement, which totaled $6.8&amp;#160;million;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;continue responsibility for regulatory, clinical, preclinical,
   manufacturing, marketing and sales for the remaining development and
   commercialization of the products;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;assume all financial responsibility for the development of the products and
   assume 80% of the commercialization costs of the products (instead of 50%
   as provided under the February&amp;#160;2005 agreement); and&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;make an additional milestone payment of $25.0&amp;#160;million after the first
   product under the March&amp;#160;2008 agreement has been approved by the FDA.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The $15,000,000 promissory note accrued interest at 8% payable quarterly and was
   payable in full to pSivida upon the earlier of a liquidity event as defined in the note
   (including an initial public offering of the Company&amp;#8217;s common stock greater than
   $75,000,000), the occurrence of an event of default under the Company&amp;#8217;s agreement with
   pSivida or September&amp;#160;30, 2012. If the note was not paid in full by March&amp;#160;31, 2010, the
   interest rate was to increase to 20% effective as of April&amp;#160;1, 2010, and the Company would be
   required to begin making principal payments of $500,000 per month. On April&amp;#160;27, 2010, the
   Company paid pSivida $15,225,000 in principal and interest to satisfy the note payable. As a
   result, the Company recognized a gain of $1,343,000 on the extinguishment of this debt in
   the accompanying financial statements for the nine month period ended September&amp;#160;30, 2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company&amp;#8217;s license rights to pSivida&amp;#8217;s proprietary delivery device could revert to
   pSivida if the Company were to (i)&amp;#160;fail twice to cure its breach of an obligation to make
   certain payments to pSivida following receipt of written notice thereof; (ii)&amp;#160;fail to cure
   other breaches of material terms of its agreement with pSivida within 30&amp;#160;days after notice
   of such breaches or such longer period (up to 90&amp;#160;days) as may be reasonably necessary if the
   breach cannot be cured within such 30-day period; (iii)&amp;#160;file for protection under the
   bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer
   appointment of a receiver or trustee over its property, file a petition under any bankruptcy
   or insolvency act or have any such petition filed against it and such proceeding remains
   undismissed or unstayed for a period of more than 60&amp;#160;days; or (iv)&amp;#160;notify pSivida in writing
   of its decision to abandon its license with respect to a certain product using pSivida&amp;#8217;s
   proprietary delivery device. The Company was not in breach of its agreement with pSivida as
   of September&amp;#160;30, 2011.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Upon commercialization of ILUVIEN, the Company must share 20% of net profits of
   ILUVIEN, as defined by the agreement, with pSivida. In connection with this arrangement the
   Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the
   agreement, incurred prior to product profitability out of pSivida&amp;#8217;s share of net profits. As
   of September&amp;#160;30, 2011 and December&amp;#160;31, 2010 the Company was owed $3,556,000 and $2,224,000,
   respectively, in commercialization costs. Due to the uncertainty of FDA approval of the NDA
   for ILUVIEN, the Company has fully reserved these amounts in the accompanying financial
   statements.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:DebtDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:DebtDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;7. Term Loan and Working Capital Revolver&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;&lt;i&gt;Term Loan&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On October&amp;#160;14, 2010 (&amp;#8220;Effective Date&amp;#8221;), the Company entered into a Loan and Security
   Agreement (&amp;#8220;Term Loan Agreement&amp;#8221;) with Silicon Valley Bank and MidCap Financial LLP
   (&amp;#8220;Lenders&amp;#8221;). Pursuant to the original terms of the Term Loan Agreement, the Company was
   entitled to borrow up to $12.5&amp;#160;million, of which $6.25&amp;#160;million (&amp;#8220;Term Loan A&amp;#8221;) was advanced
   to the Company on the Effective Date. The Company was entitled to draw down the remaining
   $6.25&amp;#160;million under the Term Loan (&amp;#8220;Term Loan B&amp;#8221; and together with Term Loan A, the &amp;#8220;Term
   Loan&amp;#8221;) if the FDA approved the Company&amp;#8217;s NDA for ILUVIEN prior to or on July&amp;#160;31, 2011. On
   May&amp;#160;16, 2011, the Company and the Lenders amended the Term Loan Agreement (&amp;#8220;Term Loan
   Modification&amp;#8221;) to, among other things, extend until December&amp;#160;31, 2011 the date by which the
   FDA must approve the NDA in order for the Company to draw down Term Loan B and increase the
   amount of Term Loan B by $4.75&amp;#160;million to $11.0&amp;#160;million. In addition, the maturity date of
   the Term Loan was extended from October&amp;#160;31, 2013 to April&amp;#160;30, 2014 (&amp;#8220;Term Loan Maturity
   Date&amp;#8221;).
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The
   Company was required to pay interest on Term Loan A at a rate of 11.5% on a monthly
   basis through July&amp;#160;31, 2011, and then beginning August&amp;#160;2011,
   the Company is required to repay the principal in 33 equal monthly
   installments plus interest at a rate of 11.5%. The Company is
   required to pay interest at a rate of 12.5% on the amount borrowed, if any, under Term Loan
   B through April&amp;#160;30, 2012, and thereafter will be required to repay the principal in equal
   monthly installments through the Term Loan Maturity Date, plus interest at a rate of 12.5%.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;If the Company repays Term Loan A prior to maturity, the Company must pay to the
   Lenders a prepayment fee equal to 5.0% of the total amount of principal then outstanding if
   the prepayment had occurred within one year after the funding date of Term Loan A (&amp;#8220;Term Loan A
   Funding Date&amp;#8221;), 3.0% of such amount if the prepayment occurs between one year and two years
   after the Term Loan A Funding Date and 1.0% of such amount if the prepayment occurs
   thereafter (subject to a 50% reduction in the event that the prepayment occurs in connection
   with an acquisition of the Company). If Term Loan B is advanced to the Company, then the
   amount of the prepayment fee on both Term Loan A and Term Loan B will be reset to 5.0% and
   the time-based reduction of the prepayment fee will be measured from the funding date of
   Term Loan B (subject to the same 50% reduction in the event of an acquisition of the
   Company), rather than from the Term Loan A Funding Date.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;To secure the repayment of any amounts borrowed under the Term Loan Agreement, the
   Company granted to the Lenders a first priority security interest in all of its assets,
   including its intellectual property, however, the lien on the Company&amp;#8217;s intellectual
   property will be released if the Company meets certain financial conditions. The occurrence
   of an event of default could result in the acceleration of the Company&amp;#8217;s obligations under
   the Term Loan Agreement and an increase to the applicable interest rate, and would permit
   the Lenders to exercise remedies with respect to the collateral under the Term Loan
   Agreement. The Company also agreed not to pledge or otherwise encumber its intellectual
   property assets. Additionally, the Company must seek the Lenders&amp;#8217; approval prior to the
   payment of any cash dividends.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On the Effective Date, the Company issued to the Lenders warrants to purchase an
   aggregate of up to 39,773 shares of the Company&amp;#8217;s common stock. Each of the warrants is
   exercisable immediately, has a per-share exercise price of $11.00 and has a term of 10
   years. The Company estimated the fair value of warrants granted using the Black-Scholes
   option pricing model. The aggregate fair value of the warrants was estimated to be $389,000.
   The Company allocated a portion of the proceeds from the Term Loan Agreement to the warrants
   in accordance with Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) 470-20-25-2, &lt;i&gt;Debt Instruments
   with Detachable Warrants&lt;/i&gt;. As a result, the Company recorded a discount of $366,000 which is
   being amortized to interest expense using the effective interest method. The Lenders also
   hold warrants to purchase an aggregate of up to 69,999 shares of the Company&amp;#8217;s common stock,
   which are exercisable only if Term Loan B is advanced to the Company. Each of these warrants
   has a per share exercise price of $11.00 and a term of 10&amp;#160;years. In addition, the Lenders
   will have certain registration rights with respect to the shares of common stock issuable
   upon exercise of all of their warrants. The Company paid to the Lenders an upfront fee of
   $62,500 on the Effective Date and an additional fee of $50,000 in connection with the Term
   Loan Modification. In accordance with ASC 470-50-40-17, &lt;i&gt;Debt &amp;#8212; Modifications and
   Extinguishments&lt;/i&gt;, the Company is amortizing the unamortized discount on Term Loan A and the
   $50,000 modification fee over the remaining term of Term Loan A, as modified.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company is required to maintain its primary operating and other deposit accounts
   and securities accounts with Silicon Valley Bank, which accounts must represent at least 50%
   of the dollar value of the Company&amp;#8217;s accounts at all financial institutions.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;&lt;i&gt;Working Capital Revolver&lt;/i&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Also on the Effective Date, the Company and Silicon Valley Bank entered into a Loan and
   Security Agreement, pursuant to which the Company obtained a secured revolving line of
   credit (&amp;#8220;Working Capital Revolver&amp;#8221;) from Silicon Valley Bank with borrowing availability up
   to $20,000,000 (&amp;#8220;Revolving Loan Agreement&amp;#8221;). On
   May&amp;#160;16, 2011, the Company and Silicon Valley Bank
   amended the Revolving Loan Agreement to extend the maturity date of the Working Capital
   Revolver from October&amp;#160;31, 2013 to April&amp;#160;30, 2014.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Working Capital Revolver is a working capital-based revolving line of credit in an
   aggregate amount of up to the lesser of (i) $20,000,000, or (ii)&amp;#160;85% of eligible domestic
   accounts receivable. As of September&amp;#160;30, 2011, no amounts under the Working Capital Revolver
   were outstanding or available to the Company.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Amounts advanced under the Working Capital Revolver will bear interest at an annual
   rate equal to Silicon Valley Bank&amp;#8217;s prime rate plus 2.50% (with a rate floor of 6.50%).
   Interest on the Working Capital Revolver will be due monthly, with the balance due at the
   maturity date. On the Effective Date, the Company paid to Silicon Valley Bank an upfront fee
   of $100,000. In addition, if the Company terminates the Working Capital Revolver prior to
   maturity, it would have paid to Silicon Valley Bank a fee of $400,000 if the
   termination occured
   within one year after the Effective Date and a fee of $200,000 if the termination occurs
   more than one year after the Effective Date (each a &amp;#8220;Termination Fee&amp;#8221;), provided in each
   case that such Termination Fee will be reduced by 50% in the event of an acquisition of the
   Company.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;To secure the repayment of any amounts borrowed under the Revolving Loan Agreement, the
   Company granted to Silicon Valley Bank a first priority security interest in all of its
   assets, including its intellectual property, however, the lien on the Company&amp;#8217;s intellectual
   property will be released if the Company meets certain financial conditions. The occurrence
   of an event of default could result in the acceleration of the Company&amp;#8217;s obligations under
   the Revolving Loan Agreement and an increase to the applicable interest rate, and would
   permit Silicon Valley Bank to exercise remedies with respect to the collateral under the
   Revolving Loan Agreement. The Company also agreed not to pledge or otherwise encumber its
   intellectual property assets. Additionally, the Company must seek Silicon Valley Bank&amp;#8217;s
   approval prior to the payment of any cash dividends.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:EarningsPerShareTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 8 - us-gaap:EarningsPerShareTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;8. Earnings (Loss) Per Share (EPS)&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Basic EPS is calculated in accordance with ASC 260, &lt;i&gt;Earnings per Share, &lt;/i&gt;by dividing net
   income or loss attributable to common stockholders by the weighted average common stock
   outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted
   average common shares outstanding for the dilutive effect of common stock options, warrants,
   convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In
   periods where a net loss from continuing operations is recorded, no effect is given to
   potentially dilutive securities, since the effect would be anti-dilutive. Total securities
   that could potentially dilute basic EPS in the future that were not included in the
   computation of diluted EPS because to do so would have been anti-dilutive were as follows:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;Nine Months Ended&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Series&amp;#160;A preferred stock and
   convertible accrued dividends
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,002,205&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Series&amp;#160;B preferred stock
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,063,383&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Series&amp;#160;C preferred stock
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,488,762&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Series&amp;#160;C-1 preferred stock
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,187,651&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Series&amp;#160;C-1 Preferred stock warrants
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;56,723&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Common stock warrants
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;28,086&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;77,114&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;29,366&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;112,644&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Stock options
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,502,469&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,633,441&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,573,106&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,669,748&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,530,555&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,710,555&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,602,472&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11,581,116&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:EarningsPerShareTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<alim:TemporaryEquityDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 9 - alim:TemporaryEquityDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;9. Preferred Stock&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Prior to the Company&amp;#8217;s IPO, the Company had four series of preferred stock. On April
   27, 2010 and in connection with the IPO, all outstanding shares of the Company&amp;#8217;s preferred
   stock were converted into 22,863,696 shares of common stock and all preferred stock
   dividends were eliminated. Significant terms of all series of the preferred stock were as
   follows:
   &lt;/div&gt;
   &lt;div style="margin-top: 10pt"&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Dividends were cumulative and accrued on a daily basis at
   the rate of 8% per annum beginning on the date of issuance
   and based on the original issue price, as adjusted for any
   stock dividend, stock split, combination, or other event
   involving the preferred stock. Dividends accrued, whether
   or not declared, annually and were due and payable when and
   if declared by the Board of Directors, upon a liquidating
   event upon redemption of the preferred stock or on the date
   that the preferred stock was otherwise acquired by the
   Company.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Upon any liquidation, dissolution, or winding up of the
   Company, the preferred stockholders were entitled to a
   liquidation preference payment equal to (i)&amp;#160;the sum of the
   liquidation value plus all accumulated, accrued, and unpaid
   dividends and (ii)&amp;#160;the pro rata share of any remaining
   amounts such holder would have been entitled to receive had
   such holder&amp;#8217;s shares been converted into common stock
   immediately prior to the liquidation, dissolution, or
   winding up.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
       &lt;td style="font-size: 8pt"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"&gt;
       &lt;td width="4%" style="background: transparent"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%" nowrap="nowrap" align="left"&gt;&lt;b&gt;&amp;#8226;&lt;/b&gt;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;At any time subsequent to March&amp;#160;17, 2013, the holders of a
   majority of the preferred stock could have required the
   Company to redeem all or any portion of the preferred
   stock. If the preferred stock was redeemed, the redemption
   would have occurred in equal installments over a three-year
   period. The price paid by the Company to redeem the shares
   would have been the greater of (i)&amp;#160;the original issue
   price, plus all accumulated, accrued, and unpaid dividends,
   and (ii)&amp;#160;the fair market value of the preferred stock being
   redeemed at the time of the redemption.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Because the preferred stock provided the holders the right to require the Company to
   redeem such shares for cash after March&amp;#160;17, 2013 at the greater of (i)&amp;#160;the original issue
   price plus any accrued but unpaid dividends and (ii)&amp;#160;the fair market value of the preferred
   stock being redeemed, the embedded conversion feature required separate accounting.
   Consequently, the conversion feature had to be bifurcated from the preferred stock and
   accounted for separately at each issuance date. The carrying value of the embedded
   derivative
   was adjusted to fair value at the end of each reporting period and the change in fair
   value was recognized in the statement of operations.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;On January&amp;#160;8, 2010 warrants to purchase shares of the Company&amp;#8217;s Series&amp;#160;C-1 preferred
   stock were exercised resulting in $10,000,000 in cash proceeds and the issuance of 1,935,700
   additional shares of Series&amp;#160;C-1 preferred stock. The Company recorded a derivative liability
   of $3,471,000 upon the exercise of the warrants and the issuance of 1,935,700 shares of
   Series&amp;#160;C-1 preferred stock in January&amp;#160;2010.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;At each reporting date, the Company adjusted the carrying value of the embedded
   derivatives to estimated fair value and recognized the change in such estimated value in its
   statement of operations. The estimated fair value of the derivatives at April&amp;#160;27, 2010 was
   $36,528,000. The Company recognized a gain of $3,644,000 associated with the change in fair
   value for the nine months ended September&amp;#160;30, 2010. In connection with the IPO, the embedded
   derivatives were eliminated.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In connection with the Company&amp;#8217;s IPO in April&amp;#160;2010, the Company authorized 10,000,000
   shares of $0.01 par value preferred stock. No shares of preferred stock were issued or
   outstanding at September&amp;#160;30, 2011 and December&amp;#160;31, 2010, respectively.
   &lt;/div&gt;
   &lt;/div&gt;
</alim:TemporaryEquityDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 10 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;10. Stock Options&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;During the three months ended September&amp;#160;30, 2011 and 2010, the Company recorded
   compensation expense related to stock options of approximately $417,000 and $189,000,
   respectively. During the nine months ended September&amp;#160;30, 2011 and 2010, the Company recorded
   stock compensation expense of approximately $1,416,000 and $447,000, respectively. As of
   September&amp;#160;30, 2011, the total unrecognized compensation cost related to non-vested stock
   options granted was $4,220,000 and is expected to be recognized over a weighted average
   period of 2.9&amp;#160;years. The following table presents a summary of stock option transactions for
   the three and nine months ended September&amp;#160;30, 2011 and 2010:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="36%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="5%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Three Months Ended September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Nine Months Ended September 30,&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options at
   beginning of period
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,677,474&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3.98&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,281,311&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2.39&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,741,985&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3.81&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,225,778&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;2.14&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Grants
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;90,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7.95&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;108,500&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;6.74&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;155,000&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7.83&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;173,500&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;8.34&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Forfeitures
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(13,708&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5.20&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(7,500&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;11.00&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14,444&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;5.11&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Exercises
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(10,000&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.04&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(5,879&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1.40&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(132,011&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1.59&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="left"&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;(14,610&lt;/td&gt;
       &lt;td nowrap="nowrap"&gt;)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1.94&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Options at end of
   period
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,757,474&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,370,224&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,757,474&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,370,224&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Weighted average
   per share fair
   value of options
   granted during the
   period
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5.81&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5.35&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;5.67&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;6.74&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The following table provides additional information as of September&amp;#160;30,
   2011:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="11%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Outstanding
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,757,474&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;4.12&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;6.53 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;12,089&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Exercisable
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,972,951&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2.61&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;5.70 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;10,921&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected to vest
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;721,005&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7.92&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;8.64 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,053&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The following table provides additional information as of December&amp;#160;31,
   2010:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="11%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Outstanding
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;2,741,985&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;3.81&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;6.99 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;18,338&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Exercisable
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1,722,281&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;1.88&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;5.88 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;14,638&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Expected to vest
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;963,754&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;7.24&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="center" valign="bottom"&gt;8.92 years&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;3,334&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 11 - us-gaap:IncomeTaxDisclosureTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;11. Income Taxes&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In accordance with ASC 740 the Company recognizes deferred tax assets and liabilities
   for temporary differences between the financial reporting basis and the tax basis of its
   assets and liabilities. The Company records a valuation allowance against its net deferred
   tax asset to reduce the net carrying value to an amount that is more likely than not to be
   realized.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Income tax positions are considered for uncertainty in accordance with FASB
   Interpretation No.&amp;#160;48, Accounting for Uncertainty in Income Taxes &amp;#8212; an interpretation of
   ASC 740-10. The Company believes that its income tax filing positions and deductions will be
   sustained on audit and does not anticipate any adjustments that will result in a material
   change to its financial position; therefore, no ASC 740-10 liabilities have been recorded.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;Significant management judgment is involved in determining the provision for income
   taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net
   deferred tax assets. Due to uncertainties with respect to the realization of deferred tax
   assets due to the history of operating losses, a valuation allowance has been established
   against the entire net deferred tax asset balance. The valuation allowance is based on
   management&amp;#8217;s estimates of taxable income in the jurisdictions in which the Company operates
   and the period over which deferred tax assets will be recoverable. In the event that actual
   results differ from these estimates or the Company adjusts these estimates in future
   periods, a change in the valuation allowance may be needed, which could materially impact
   the Company&amp;#8217;s financial position and results of operations.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;At September&amp;#160;30, 2011 and December&amp;#160;31, 2010, the Company had federal net operating loss
   (&amp;#8220;NOL&amp;#8221;) carry-forwards of approximately $112,141,000 and $97,813,000 and state NOL
   carry-forwards of approximately $95,604,000 and $80,995,000, respectively, that are
   available to reduce future income unless otherwise taxable. If not utilized, the federal NOL
   carry-forwards will expire at various dates between 2023 and 2030, and the state NOL
   carry-forwards will expire at various dates between 2020 and 2030.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;NOL carry-forwards may be subject to annual limitations under Internal Revenue Code
   Section&amp;#160;382 (or comparable provisions of state law) in the event that certain changes in
   ownership of the Company were to occur. The Company has not yet completed a formal
   evaluation of the impact of its IPO (Note 1) on the Company&amp;#8217;s NOL carry-forwards and whether
   certain changes in ownership have occurred that would limit the Company&amp;#8217;s ability to utilize
   a portion of its NOL carry-forwards.
   &lt;/div&gt;
   &lt;!-- Folio --&gt;
   &lt;!-- /Folio --&gt;
   &lt;/div&gt;
   &lt;!-- PAGEBREAK --&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="center" style="font-size: 10pt; margin-top: 0pt"&gt;
   &lt;b&gt;
   &lt;/b&gt;
   &lt;/div&gt;
   &lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
<!-- End Block Tagged Note -->
<!-- Begin Block Tagged Note -->
<us-gaap:FairValueDisclosuresTextBlock contextRef="NineMonthsEnded_30Sep2011">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 12 - us-gaap:FairValueDisclosuresTextBlock--&gt;
   &lt;div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; "&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt"&gt;&lt;b&gt;12. Fair Value&lt;/b&gt;
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The Company adopted Statement of Financial Accounting Standards No.&amp;#160;157, Fair Value
   Measurements (ASC 820), effective January&amp;#160;1, 2008. Under this standard, fair value is
   defined as the price that would be received to sell an asset or paid to transfer a liability
   (i.e., the &amp;#8220;exit price&amp;#8221;) in an orderly transaction between market participants at the
   measurement date.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;In determining fair value, the Company uses various valuation approaches. The hierarchy
   of those valuation approaches is broken down into three levels based on the reliability of
   inputs as follows:
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%"&gt;Level 1 inputs are quoted prices in active markets for identical assets or
   liabilities that the reporting entity has the ability to access at the measurement date.
   An active market for the asset or liability is a market in which transactions for the
   asset or liability occur with sufficient frequency and volume to provide pricing
   information on an ongoing basis. The valuation under this approach does not entail a
   significant degree of judgment.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are
   observable for the asset or liability, either directly or indirectly. Level 2 inputs
   include: quoted prices for similar assets or liabilities in active markets, inputs other
   than quoted prices that are observable for the asset or liability, (e.g., interest rates
   and yield curves observable at commonly quoted intervals or current market) and
   contractual prices for the underlying financial instrument, as well as other relevant
   economic measures.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%"&gt;Level 3 inputs are unobservable inputs for the asset or liability. Unobservable
   inputs shall be used to measure fair value to the extent that observable inputs are not
   available, thereby allowing for situations in which there is little, if any, market
   activity for the asset or liability at the measurement date.
   &lt;/div&gt;
   &lt;div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"&gt;The following table presents information about the Company&amp;#8217;s assets measured at fair
   value on a recurring basis:
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;September 30, 2011&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14"&gt;&lt;b&gt;(Unaudited)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash equivalents(1)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;37,437&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;37,437&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Investments in marketable debt securities(2)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;502&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;502&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Assets measured at fair value
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;37,437&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;502&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;37,939&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="center"&gt;
   &lt;table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td width="44%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="9%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;December 31, 2010&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 10pt" valign="bottom"&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" align="center" colspan="14"&gt;&lt;b&gt;(In thousands)&lt;/b&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Cash equivalents(1)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;27,393&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;27,393&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;Investments in marketable debt securities(2)
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;26,330&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="right"&gt;26,330&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom"&gt;&lt;!-- Blank Space --&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="bottom" style="background: #cceeff"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:30px; text-indent:-15px"&gt;Assets measured at fair value
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;27,393&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;26,330&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;&amp;#8212;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td align="left"&gt;$&lt;/td&gt;
       &lt;td align="right"&gt;53,723&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 1px"&gt;
       &lt;td&gt;
   &lt;div style="margin-left:15px; text-indent:-15px"&gt;&amp;#160;
   &lt;/div&gt;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
           &lt;td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;/div&gt;
   &lt;div align="left"&gt;
   &lt;div style="font-size: 3pt; margin-top: 10pt; width: 18%; border-top: 1px solid #000000"&gt;&amp;#160;
   &lt;/div&gt;
   &lt;/div&gt;
   &lt;table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"&gt;
   &lt;tr style="font-size: 6pt"&gt;
       &lt;td width="3%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="1%"&gt;&amp;#160;&lt;/td&gt;
       &lt;td width="96%"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(1)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size: 3pt"&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr valign="top"&gt;
       &lt;td nowrap="nowrap" align="left"&gt;(2)&lt;/td&gt;
       &lt;td&gt;&amp;#160;&lt;/td&gt;
       &lt;td&gt;Valuations are based on quoted prices in markets that are not active or for which all significant
   inputs are observable, either directly or indirectly. These prices include broker or dealer
   quotations, or alternative pricing sources with reasonable levels of price transparency. Pricing
   sources include industry standard data providers, security master files from large financial
   institutions, and other third party sources which are input into a distribution-curve-based
   algorithm to determine a daily market value. This creates a &amp;#8220;consensus price&amp;#8221; or a weighted average
   price for each security.&lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
<!-- End Block Tagged Note -->
<!--Footnote Section-->

</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>alim-20110930.xsd
<DESCRIPTION>EX-101 SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://alimerasciences.com/20110930" xmlns:alim="http://alimerasciences.com/20110930" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://xbrl.sec.gov/us-types/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://alimerasciences.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>01 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>011 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>02 - Statement - Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>03 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>06001 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>06002 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
        <link:definition>06003 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/FactorsAffectingOperations" id="FactorsAffectingOperations">
        <link:definition>06004 - Disclosure - Factors Affecting Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>06005 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/PsividaAgreement" id="PsividaAgreement">
        <link:definition>06006 - Disclosure - pSivida Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/TermLoanAndWorkingCapitalRevolver" id="TermLoanAndWorkingCapitalRevolver">
        <link:definition>06007 - Disclosure - Term Loan and Working Capital Revolver</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/EarningsLossPerShareEPS" id="EarningsLossPerShareEPS">
        <link:definition>06008 - Disclosure - Earnings (Loss) Per Share (EPS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/PreferredStock" id="PreferredStock">
        <link:definition>06009 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/StockOptions" id="StockOptions">
        <link:definition>06010 - Disclosure - Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>06011 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alimerasciences.com/role/FairValue" id="FairValue">
        <link:definition>06012 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="alim-20110930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="alim-20110930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="alim-20110930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <!-- elements -->
  <element name="DocumentAndEntityInformationAbstract" id="alim_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true" />
  <element name="OutsourcedServicesPayable" id="alim_OutsourcedServicesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" id="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="WeightedAverageSharesOutstandingBasicAndDiluted" id="alim_WeightedAverageSharesOutstandingBasicAndDiluted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="StockCompensationAndOther" id="alim_StockCompensationAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" id="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" id="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ProceedsFromExerciseOfPreferredStockWarrants" id="alim_ProceedsFromExerciseOfPreferredStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="ProceedsFromExerciseOfCommonStockWarrants" id="alim_ProceedsFromExerciseOfCommonStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="RepaymentOfNotesPayable" id="alim_RepaymentOfNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="IpoIssuanceCostsChargedToEquity" id="alim_IpoIssuanceCostsChargedToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="FactorsAffectingOperationsTextBlock" id="alim_FactorsAffectingOperationsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="FactorsAffectingOperationsAbstract" id="alim_FactorsAffectingOperationsAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="PsividaAgreementAbstract" id="alim_PsividaAgreementAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="TemporaryEquityDisclosureTextBlock" id="alim_TemporaryEquityDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>alim-20110930_cal.xml
<DESCRIPTION>EX-101 CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#DocumentAndEntityInformation" roleURI="http://alimerasciences.com/role/DocumentAndEntityInformation" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
  <roleRef roleURI="http://alimerasciences.com/role/BalanceSheets" xlink:href="alim-20110930.xsd#BalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://alimerasciences.com/role/BalanceSheetsParenthetical" xlink:href="alim-20110930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://alimerasciences.com/role/StatementsOfOperations" xlink:href="alim-20110930.xsd#StatementsOfOperations" xlink:type="simple" />
  <roleRef roleURI="http://alimerasciences.com/role/StatementsOfCashFlows" xlink:href="alim-20110930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:role="http://alimerasciences.com/role/BalanceSheets" xlink:title="01 - Statement - Balance Sheets" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_MarketableSecuritiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_MarketableSecuritiesCurrent" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_DeferredFinanceCostsCurrentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_DeferredFinanceCostsCurrentNet" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_OutsourcedServicesPayable" xlink:label="alim_OutsourcedServicesPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="alim_OutsourcedServicesPayable" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_NotesPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_NotesPayableCurrent" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_CapitalLeaseObligationsCurrent" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_LiabilitiesCurrent" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_LongTermNotesPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_LongTermNotesPayable" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_OtherLiabilitiesNoncurrent" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="loc_TemporaryEquityCarryingAmount" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_TemporaryEquityCarryingAmount" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_WarrantsAndRightsOutstanding" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="19" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="20" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://alimerasciences.com/role/StatementsOfOperations" xlink:title="02 - Statement - Statements of Operations (Unaudited)" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="21" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_GeneralAndAdministrativeExpense" order="22" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_MarketingExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_MarketingExpense" order="23" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_IncomeLossFromContinuingOperations" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperations" xlink:to="loc_OperatingExpenses" order="24" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperations" xlink:to="loc_InvestmentIncomeInterest" order="25" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_InterestExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperations" xlink:to="loc_InterestExpense" order="26" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_GainsLossesOnExtinguishmentOfDebt" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperations" xlink:to="loc_GainsLossesOnExtinguishmentOfDebt" order="27" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_IncomeLossFromContinuingOperations" xlink:to="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" order="28" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeLossFromContinuingOperations" order="29" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="30" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_NetIncomeLoss" order="31" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="loc_TemporaryEquityIssuePeriodIncreaseOrDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_TemporaryEquityIssuePeriodIncreaseOrDecrease" order="32" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_RedeemablePreferredStockDividends" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_RedeemablePreferredStockDividends" order="33" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://alimerasciences.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Statements of Cash Flows (Unaudited)" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NetIncomeLoss" order="34" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="35" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" order="36" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_GainsLossesOnExtinguishmentOfDebt" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_GainsLossesOnExtinguishmentOfDebt" order="37" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_Depreciation" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_Depreciation" order="38" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_StockCompensationAndOther" xlink:label="alim_StockCompensationAndOther" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="alim_StockCompensationAndOther" order="39" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_AmortizationOfFinancingCosts" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AmortizationOfFinancingCosts" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_UnrealizedGainLossOnInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_UnrealizedGainLossOnInvestments" order="41" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" order="42" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="43" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="44" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_IncreaseDecreaseInOtherOperatingLiabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInOtherOperatingLiabilities" order="45" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="46" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_PaymentsToAcquireMarketableSecurities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_PaymentsToAcquireMarketableSecurities" order="47" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="48" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="49" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="50" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="51" use="optional" weight="1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="52" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromStockOptionsExercised" order="53" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_ProceedsFromExerciseOfPreferredStockWarrants" xlink:label="alim_ProceedsFromExerciseOfPreferredStockWarrants" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="alim_ProceedsFromExerciseOfPreferredStockWarrants" order="54" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_ProceedsFromExerciseOfCommonStockWarrants" xlink:label="alim_ProceedsFromExerciseOfCommonStockWarrants" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="alim_ProceedsFromExerciseOfCommonStockWarrants" order="55" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="56" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_PaymentsOfStockIssuanceCosts" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PaymentsOfStockIssuanceCosts" order="57" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_RepaymentsOfNotesPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RepaymentsOfNotesPayable" order="58" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_RepaymentOfNotesPayable" xlink:label="alim_RepaymentOfNotesPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="alim_RepaymentOfNotesPayable" order="59" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_PaymentsOfDebtRestructuringCosts" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PaymentsOfDebtRestructuringCosts" order="60" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="61" use="optional" weight="-1" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="62" use="optional" weight="1" />
  </calculationLink>
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#NatureOfOperations" roleURI="http://alimerasciences.com/role/NatureOfOperations" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/NatureOfOperations" xlink:title="06001 - Disclosure - Nature of Operations" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#BasisOfPresentation" roleURI="http://alimerasciences.com/role/BasisOfPresentation" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/BasisOfPresentation" xlink:title="06002 - Disclosure - Basis of Presentation" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#DiscontinuedOperations" roleURI="http://alimerasciences.com/role/DiscontinuedOperations" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/DiscontinuedOperations" xlink:title="06003 - Disclosure - Discontinued Operations" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#FactorsAffectingOperations" roleURI="http://alimerasciences.com/role/FactorsAffectingOperations" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/FactorsAffectingOperations" xlink:title="06004 - Disclosure - Factors Affecting Operations" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#AccruedExpenses" roleURI="http://alimerasciences.com/role/AccruedExpenses" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/AccruedExpenses" xlink:title="06005 - Disclosure - Accrued Expenses" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#PsividaAgreement" roleURI="http://alimerasciences.com/role/PsividaAgreement" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/PsividaAgreement" xlink:title="06006 - Disclosure - pSivida Agreement" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#TermLoanAndWorkingCapitalRevolver" roleURI="http://alimerasciences.com/role/TermLoanAndWorkingCapitalRevolver" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/TermLoanAndWorkingCapitalRevolver" xlink:title="06007 - Disclosure - Term Loan and Working Capital Revolver" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#EarningsLossPerShareEPS" roleURI="http://alimerasciences.com/role/EarningsLossPerShareEPS" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/EarningsLossPerShareEPS" xlink:title="06008 - Disclosure - Earnings (Loss) Per Share (EPS)" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#PreferredStock" roleURI="http://alimerasciences.com/role/PreferredStock" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/PreferredStock" xlink:title="06009 - Disclosure - Preferred Stock" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#StockOptions" roleURI="http://alimerasciences.com/role/StockOptions" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/StockOptions" xlink:title="06010 - Disclosure - Stock Options" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#IncomeTaxes" roleURI="http://alimerasciences.com/role/IncomeTaxes" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/IncomeTaxes" xlink:title="06011 - Disclosure - Income Taxes" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#FairValue" roleURI="http://alimerasciences.com/role/FairValue" />
  <calculationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/FairValue" xlink:title="06012 - Disclosure - Fair Value" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>alim-20110930_lab.xml
<DESCRIPTION>EX-101 LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="alim_DocumentAndEntityInformationAbstract" xlink:href="alim-20110930.xsd#alim_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="alim_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:label="alim_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Investments in marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable Securities, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Deferred Finance Costs, Current, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT - at cost less accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT - at cost less accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses (Note 5)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_OutsourcedServicesPayable" xlink:label="alim_OutsourcedServicesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_OutsourcedServicesPayable" xlink:to="alim_OutsourcedServicesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_OutsourcedServicesPayable_lbl" xml:lang="en-US">Outsourced Services Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_OutsourcedServicesPayable_lbl" xml:lang="en-US">Outsourced services payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_OutsourcedServicesPayable_lbl" xml:lang="en-US">Outsourced services payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable (Note 7)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital Lease Obligations, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Capital lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable, net of discount - less current portion (Note 7)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="us-gaap_TemporaryEquityCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmount" xlink:to="us-gaap_TemporaryEquityCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmount_lbl" xml:lang="en-US">Preferred stock, $.01 par value - 10,000,000 shares authorized and no shares issued and outstanding at September 30, 2011 and at December 31, 2010</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmount_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.01 par value - 100,000,000 shares authorized and 31,407,383 shares issued and outstanding at September 30, 2011 and 100,000,000 shares authorized and 31,255,953 shares issued and outstanding at December 31, 2010</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">MARKETING EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">MARKETING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">OPERATING EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">OPERATING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">INTEREST INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">INTEREST EXPENSE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">INTEREST EXPENSE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">GAIN ON EARLY EXTINGUISHMENT OF DEBT (NOTE 6)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gains (Losses) on Extinguishment of Debt</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:to="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_lbl" xml:lang="en-US">Increase Decrease in Fair Value of Preferred Stock Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_lbl" xml:lang="en-US">DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_lbl" xml:lang="en-US">(INCREASE) DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_lbl" xml:lang="en-US">DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">LOSS FROM CONTINUING OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">INCOME FROM DISCONTINUED OPERATIONS (NOTE 3)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">INCOME FROM DISCONTINUED OPERATIONS (NOTE 3)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:to="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xml:lang="en-US">REDEEMABLE PREFERRED STOCK ACCRETION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease_lbl" xml:lang="en-US">REDEEMABLE PREFERRED STOCK ACCRETION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="us-gaap_RedeemablePreferredStockDividends" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">REDEEMABLE PREFERRED STOCK DIVIDENDS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">Redeemable Preferred Stock Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">REDEEMABLE PREFERRED STOCK DIVIDENDS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS APPLICABLE TO COMMON SHAREHOLDERS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS APPLICABLE TO COMMON SHAREHOLDERS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Basic and diluted</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_WeightedAverageSharesOutstandingBasicAndDiluted" xlink:label="alim_WeightedAverageSharesOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_WeightedAverageSharesOutstandingBasicAndDiluted" xlink:to="alim_WeightedAverageSharesOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_WeightedAverageSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Shares Outstanding Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_WeightedAverageSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED-AVERAGE SHARES OUTSTANDING - Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_WeightedAverageSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED-AVERAGE SHARES OUTSTANDING -- Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alim_WeightedAverageSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED-AVERAGE SHARES OUTSTANDING - Basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xml:lang="en-US">Income from discontinued operations (Note 3)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature_lbl" xml:lang="en-US">Change in fair value of preferred stock conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain from early extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_StockCompensationAndOther" xlink:label="alim_StockCompensationAndOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_StockCompensationAndOther" xlink:to="alim_StockCompensationAndOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_StockCompensationAndOther_lbl" xml:lang="en-US">Stock Compensation and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_StockCompensationAndOther_lbl" xml:lang="en-US">Stock compensation and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_StockCompensationAndOther_lbl" xml:lang="en-US">Stock compensation and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="alim_StockCompensationAndOther_lbl" xml:lang="en-US">Stock compensation and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Financing Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Non-cash investment gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Non-cash investment gain</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Increase Decrease in Accrued Expenses and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchases of investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchases of investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from maturities of investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities of continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities of continuing operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by investing activities of discontinued operations (Note 3)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by investing activities of discontinued operations (Note 3)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercises of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_ProceedsFromExerciseOfPreferredStockWarrants" xlink:label="alim_ProceedsFromExerciseOfPreferredStockWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_ProceedsFromExerciseOfPreferredStockWarrants" xlink:to="alim_ProceedsFromExerciseOfPreferredStockWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_ProceedsFromExerciseOfPreferredStockWarrants_lbl" xml:lang="en-US">Proceeds from Exercise of Preferred Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_ProceedsFromExerciseOfPreferredStockWarrants_lbl" xml:lang="en-US">Proceeds from exercise of Series C-1 preferred warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_ProceedsFromExerciseOfPreferredStockWarrants_lbl" xml:lang="en-US">Proceeds from exercise of Series C-1 preferred warrants</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_ProceedsFromExerciseOfCommonStockWarrants" xlink:label="alim_ProceedsFromExerciseOfCommonStockWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_ProceedsFromExerciseOfCommonStockWarrants" xlink:to="alim_ProceedsFromExerciseOfCommonStockWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_ProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Proceeds from Exercise of Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_ProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_ProceedsFromExerciseOfCommonStockWarrants_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of common stock offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of common stock offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of pSivida note payable (Note 6)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of pSivida note payable (Note 6)</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_RepaymentOfNotesPayable" xlink:label="alim_RepaymentOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_RepaymentOfNotesPayable" xlink:to="alim_RepaymentOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_RepaymentOfNotesPayable_lbl" xml:lang="en-US">Repayment of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_RepaymentOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable (Note 7)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_RepaymentOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable (Note 7)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="alim_RepaymentOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable (Note 7)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xml:lang="en-US">Payment of debt modification costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xml:lang="en-US">Payments of Debt Restructuring Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xml:lang="en-US">Payment of debt modification costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on capital lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on capital lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET INCREASE IN CASH</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET INCREASE IN CASH</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH - Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH - End of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental schedule of noncash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental schedule of noncash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Property and equipment acquired under capital leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Fair Value of Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Property and equipment acquired under capital leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Reclassification of fair value of preferred stock conversion feature to additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Reclassification of fair value of preferred stock conversion feature to additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IpoIssuanceCostsChargedToEquity" xlink:label="alim_IpoIssuanceCostsChargedToEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_IpoIssuanceCostsChargedToEquity" xlink:to="alim_IpoIssuanceCostsChargedToEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_IpoIssuanceCostsChargedToEquity_lbl" xml:lang="en-US">Ipo Issuance Costs Charged to Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_IpoIssuanceCostsChargedToEquity_lbl" xml:lang="en-US">IPO issuance costs charged to equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_IpoIssuanceCostsChargedToEquity_lbl" xml:lang="en-US">IPO issuance costs charged to equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="alim_IpoIssuanceCostsChargedToEquity_lbl" xml:lang="en-US">IPO issuance costs charged to equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Operations/Basis of Presentation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Operations/Basis of Presentation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_FactorsAffectingOperationsTextBlock" xlink:label="alim_FactorsAffectingOperationsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_FactorsAffectingOperationsTextBlock" xlink:to="alim_FactorsAffectingOperationsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_FactorsAffectingOperationsTextBlock_lbl" xml:lang="en-US">Factors Affecting Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_FactorsAffectingOperationsTextBlock_lbl" xml:lang="en-US">Factors Affecting Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_FactorsAffectingOperationsTextBlock_lbl" xml:lang="en-US">Factors Affecting Operations</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_FactorsAffectingOperationsAbstract" xlink:label="alim_FactorsAffectingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_FactorsAffectingOperationsAbstract" xlink:to="alim_FactorsAffectingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_FactorsAffectingOperationsAbstract_lbl" xml:lang="en-US">Factors Affecting Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_FactorsAffectingOperationsAbstract_lbl" xml:lang="en-US">Factors Affecting Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_FactorsAffectingOperationsAbstract_lbl" xml:lang="en-US">Factors Affecting Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">pSivida Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_PsividaAgreementAbstract" xlink:label="alim_PsividaAgreementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_PsividaAgreementAbstract" xlink:to="alim_PsividaAgreementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_PsividaAgreementAbstract_lbl" xml:lang="en-US">pSivida Agreement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_PsividaAgreementAbstract_lbl" xml:lang="en-US">pSivida Agreement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_PsividaAgreementAbstract_lbl" xml:lang="en-US">pSivida Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Term Loan and Working Capital Revolver</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Term Loan and Working Capital Revolver [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Term Loan and Working Capital Revolver [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Share (EPS)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Share (EPS) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Share (EPS) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_TemporaryEquityDisclosureTextBlock" xlink:label="alim_TemporaryEquityDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alim_TemporaryEquityDisclosureTextBlock" xlink:to="alim_TemporaryEquityDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alim_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US">Temporary Equity Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alim_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US">Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alim_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Preferred Stock [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Preferred Stock [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Options [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock Options [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value [Abstract]</label>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements of Cash Flows [Abstract]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>alim-20110930_pre.xml
<DESCRIPTION>EX-101 PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://alimerasciences.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="alim-20110930.xsd#DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#NatureOfOperations" roleURI="http://alimerasciences.com/role/NatureOfOperations" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#BasisOfPresentation" roleURI="http://alimerasciences.com/role/BasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#DiscontinuedOperations" roleURI="http://alimerasciences.com/role/DiscontinuedOperations" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#FactorsAffectingOperations" roleURI="http://alimerasciences.com/role/FactorsAffectingOperations" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#AccruedExpenses" roleURI="http://alimerasciences.com/role/AccruedExpenses" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#PsividaAgreement" roleURI="http://alimerasciences.com/role/PsividaAgreement" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#TermLoanAndWorkingCapitalRevolver" roleURI="http://alimerasciences.com/role/TermLoanAndWorkingCapitalRevolver" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#EarningsLossPerShareEPS" roleURI="http://alimerasciences.com/role/EarningsLossPerShareEPS" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#PreferredStock" roleURI="http://alimerasciences.com/role/PreferredStock" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#StockOptions" roleURI="http://alimerasciences.com/role/StockOptions" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#IncomeTaxes" roleURI="http://alimerasciences.com/role/IncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#FairValue" roleURI="http://alimerasciences.com/role/FairValue" />
  <presentationLink xlink:role="http://alimerasciences.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_DocumentAndEntityInformationAbstract" xlink:label="alim_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="5.03" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="5.05" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="5.04" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="5.01" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="5.02" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="5.08" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="5.09" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="5.10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="5.11" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="5.12" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5.14" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.13" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5.07" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="5.06" use="optional" />
  </presentationLink>
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#BalanceSheets" roleURI="http://alimerasciences.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#BalanceSheetsParenthetical" roleURI="http://alimerasciences.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#StatementsOfOperations" roleURI="http://alimerasciences.com/role/StatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="alim-20110930.xsd#StatementsOfCashFlows" roleURI="http://alimerasciences.com/role/StatementsOfCashFlows" />
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/BalanceSheets" xlink:title="01 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsCurrentAbstract" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_MarketableSecuritiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_MarketableSecuritiesCurrent" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_DeferredFinanceCostsCurrentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_DeferredFinanceCostsCurrentNet" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_OutsourcedServicesPayable" xlink:label="alim_OutsourcedServicesPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="alim_OutsourcedServicesPayable" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_NotesPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_NotesPayableCurrent" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_CapitalLeaseObligationsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_CapitalLeaseObligationsCurrent" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_LiabilitiesNoncurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesNoncurrentAbstract" order="17.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_LongTermNotesPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesNoncurrentAbstract" xlink:to="loc_LongTermNotesPayable" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesNoncurrentAbstract" xlink:to="loc_OtherLiabilitiesNoncurrent" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_StockholdersEquityAbstract" order="18.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityCarryingAmount" xlink:label="loc_TemporaryEquityCarryingAmount" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_TemporaryEquityCarryingAmount" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_WarrantsAndRightsOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_WarrantsAndRightsOutstanding" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="12.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_Assets" order="13.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="19.375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/BalanceSheetsParenthetical" xlink:title="011 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_TemporaryEquityParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_TemporaryEquityParOrStatedValuePerShare" order="20.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_TemporaryEquitySharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_TemporaryEquitySharesAuthorized" order="20.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_TemporaryEquitySharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_TemporaryEquitySharesIssued" order="20.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_TemporaryEquitySharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_TemporaryEquitySharesOutstanding" order="20.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="21.1" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="21.2" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesIssued" order="21.3" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="21.4" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_StockholdersEquityAbstract" order="20" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/StatementsOfOperations" xlink:title="02 - Statement - Statements of Operations (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_GeneralAndAdministrativeExpense" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_MarketingExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_MarketingExpense" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_OperatingExpenses" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_InvestmentIncomeInterest" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_InterestExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_InterestExpense" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_GainsLossesOnExtinguishmentOfDebt" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_GainsLossesOnExtinguishmentOfDebt" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_IncomeLossFromContinuingOperations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeLossFromContinuingOperations" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="10.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLoss" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease" xlink:label="loc_TemporaryEquityIssuePeriodIncreaseOrDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_TemporaryEquityIssuePeriodIncreaseOrDecrease" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_RedeemablePreferredStockDividends" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_RedeemablePreferredStockDividends" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_NetIncomeLossAvailableToCommonStockholdersBasic" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_WeightedAverageSharesOutstandingBasicAndDiluted" xlink:label="alim_WeightedAverageSharesOutstandingBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeStatementAbstract" xlink:to="alim_WeightedAverageSharesOutstandingBasicAndDiluted" order="16.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/StatementsOfCashFlows" xlink:title="03 - Statement - Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetIncomeLoss" order="2.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="3.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" xlink:label="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature" order="4.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_GainsLossesOnExtinguishmentOfDebt" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_GainsLossesOnExtinguishmentOfDebt" order="5.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_Depreciation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_Depreciation" order="6.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_StockCompensationAndOther" xlink:label="alim_StockCompensationAndOther" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alim_StockCompensationAndOther" order="7.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_AmortizationOfFinancingCosts" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AmortizationOfFinancingCosts" order="8.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_UnrealizedGainLossOnInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_UnrealizedGainLossOnInvestments" order="9.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="10.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:label="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" order="11.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="12.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" order="13.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_IncreaseDecreaseInOtherOperatingLiabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInOtherOperatingLiabilities" order="14.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="15.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="16.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_PaymentsToAcquireMarketableSecurities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireMarketableSecurities" order="17.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="18.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="19.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" order="21.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="22.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="23.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_ProceedsFromStockOptionsExercised" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromStockOptionsExercised" order="24.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_ProceedsFromExerciseOfPreferredStockWarrants" xlink:label="alim_ProceedsFromExerciseOfPreferredStockWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alim_ProceedsFromExerciseOfPreferredStockWarrants" order="25.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_ProceedsFromExerciseOfCommonStockWarrants" xlink:label="alim_ProceedsFromExerciseOfCommonStockWarrants" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alim_ProceedsFromExerciseOfCommonStockWarrants" order="26.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="27.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_PaymentsOfStockIssuanceCosts" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PaymentsOfStockIssuanceCosts" order="28.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_RepaymentsOfNotesPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_RepaymentsOfNotesPayable" order="29.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_RepaymentOfNotesPayable" xlink:label="alim_RepaymentOfNotesPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alim_RepaymentOfNotesPayable" order="30.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="loc_PaymentsOfDebtRestructuringCosts" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_PaymentsOfDebtRestructuringCosts" order="31.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_RepaymentsOfLongTermCapitalLeaseObligations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_RepaymentsOfLongTermCapitalLeaseObligations" order="32.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="33.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="34.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="35.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="36.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_SupplementalCashFlowInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_SupplementalCashFlowInformationAbstract" order="37.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_InterestPaid" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_InterestPaid" order="38.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SupplementalCashFlowInformationAbstract" xlink:to="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="39.1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_FairValueOfAssetsAcquired" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_FairValueOfAssetsAcquired" order="40.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="41.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_IpoIssuanceCostsChargedToEquity" xlink:label="alim_IpoIssuanceCostsChargedToEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alim_IpoIssuanceCostsChargedToEquity" order="42.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/NatureOfOperations" xlink:title="06001 - Disclosure - Nature of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_NatureOfOperations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_NatureOfOperations" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/BasisOfPresentation" xlink:title="06002 - Disclosure - Basis of Presentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/DiscontinuedOperations" xlink:title="06003 - Disclosure - Discontinued Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/FactorsAffectingOperations" xlink:title="06004 - Disclosure - Factors Affecting Operations">
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_FactorsAffectingOperationsAbstract" xlink:label="alim_FactorsAffectingOperationsAbstract" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_FactorsAffectingOperationsTextBlock" xlink:label="alim_FactorsAffectingOperationsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_FactorsAffectingOperationsAbstract" xlink:to="alim_FactorsAffectingOperationsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/AccruedExpenses" xlink:title="06005 - Disclosure - Accrued Expenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PayablesAndAccrualsAbstract" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/PsividaAgreement" xlink:title="06006 - Disclosure - pSivida Agreement">
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_PsividaAgreementAbstract" xlink:label="alim_PsividaAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_CollaborativeArrangementDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alim_PsividaAgreementAbstract" xlink:to="loc_CollaborativeArrangementDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/TermLoanAndWorkingCapitalRevolver" xlink:title="06007 - Disclosure - Term Loan and Working Capital Revolver">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_DebtDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DebtDisclosureAbstract" xlink:to="loc_DebtDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/EarningsLossPerShareEPS" xlink:title="06008 - Disclosure - Earnings (Loss) Per Share (EPS)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_EarningsPerShareTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EarningsPerShareAbstract" xlink:to="loc_EarningsPerShareTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/PreferredStock" xlink:title="06009 - Disclosure - Preferred Stock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="alim-20110930.xsd#alim_TemporaryEquityDisclosureTextBlock" xlink:label="alim_TemporaryEquityDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityAbstract" xlink:to="alim_TemporaryEquityDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/StockOptions" xlink:title="06010 - Disclosure - Stock Options">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/IncomeTaxes" xlink:title="06011 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_IncomeTaxDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeTaxDisclosureAbstract" xlink:to="loc_IncomeTaxDisclosureTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alimerasciences.com/role/FairValue" xlink:title="06012 - Disclosure - Fair Value">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_FairValueDisclosuresTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_FairValueDisclosuresAbstract" xlink:to="loc_FairValueDisclosuresTextBlock" order="1.0" use="optional" priority="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EADAE"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) (USD $)<br /></strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value</a></td><td class="nump">$ 0.01<span /></td><td class="nump">$ 0.01<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized</a></td><td class="nump">10,000,000<span /></td><td class="nump">10,000,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td><td class="nump">$ 0.01<span /></td><td class="nump">$ 0.01<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td><td class="nump">100,000,000<span /></td><td class="nump">100,000,000<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td><td class="nump">31,407,383<span /></td><td class="nump">31,255,953<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td><td class="nump">31,407,383<span /></td><td class="nump">31,255,953<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 30<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityParOrStatedValuePerShare</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 3, 4, 5, 6, 7, 8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesAuthorized</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesIssued</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph b<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquitySharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2LAG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) (USD $)<br />In Thousands, except Share data</strong></div></th><th class="th" colspan="2">3 Months Ended</th><th class="th" colspan="2">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td><td class="nump">$ 2,224<span /></td><td class="nump">$ 3,276<span /></td><td class="nump">$ 5,732<span /></td><td class="nump">$ 10,481<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td><td class="nump">1,421<span /></td><td class="nump">1,260<span /></td><td class="nump">4,827<span /></td><td class="nump">3,338<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">MARKETING EXPENSES</a></td><td class="nump">2,612<span /></td><td class="nump">1,583<span /></td><td class="nump">5,038<span /></td><td class="nump">2,209<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">OPERATING EXPENSES</a></td><td class="nump">6,257<span /></td><td class="nump">6,119<span /></td><td class="nump">15,597<span /></td><td class="nump">16,028<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">INTEREST INCOME</a></td><td class="nump">1<span /></td><td class="nump">37<span /></td><td class="nump">15<span /></td><td class="nump">53<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">INTEREST EXPENSE</a></td><td class="num">(284)<span /></td><td class="text">&#xA0;<span /></td><td class="num">(863)<span /></td><td class="num">(618)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">GAIN ON EARLY EXTINGUISHMENT OF DEBT (NOTE 6)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">1,343<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature', window );">DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">3,644<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">LOSS FROM CONTINUING OPERATIONS</a></td><td class="num">(6,540)<span /></td><td class="num">(6,082)<span /></td><td class="num">(16,445)<span /></td><td class="num">(11,606)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">INCOME FROM DISCONTINUED OPERATIONS (NOTE 3)</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">4,000<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td><td class="num">(6,540)<span /></td><td class="num">(6,082)<span /></td><td class="num">(16,445)<span /></td><td class="num">(7,606)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease', window );">REDEEMABLE PREFERRED STOCK ACCRETION</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(466)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">REDEEMABLE PREFERRED STOCK DIVIDENDS</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="num">(2,638)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS APPLICABLE TO COMMON SHAREHOLDERS</a></td><td class="num">$ (6,540)<span /></td><td class="num">$ (6,082)<span /></td><td class="num">$ (16,445)<span /></td><td class="num">$ (10,710)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDERS - Basic and diluted</a></td><td class="num">$ (0.21)<span /></td><td class="num">$ (0.20)<span /></td><td class="num">$ (0.52)<span /></td><td class="num">$ (0.56)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_WeightedAverageSharesOutstandingBasicAndDiluted', window );">WEIGHTED-AVERAGE SHARES OUTSTANDING - Basic and diluted</a></td><td class="nump">31,396,517<span /></td><td class="nump">31,145,856<span /></td><td class="nump">31,342,752<span /></td><td class="nump">19,120,860<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(INCREASE) DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_WeightedAverageSharesOutstandingBasicAndDiluted"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>WEIGHTED-AVERAGE SHARES OUTSTANDING -- Basic and diluted</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_WeightedAverageSharesOutstandingBasicAndDiluted</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>num:perShareItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 470<br /><br /> -SubTopic 50<br /><br /> -Section 40<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 26<br /><br /> -Paragraph 20, 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 470<br /><br /> -SubTopic 50<br /><br /> -Section 40<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.4)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the parent which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 18<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4613673-111683<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph b(1)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.13)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the overall income (loss) from a disposal group apportioned to the parent that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 19<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph b(2)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeStatementAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 835<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 942<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.9-04.9)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 34<br /><br /> -Paragraph 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 9<br /><br /> -Article 9<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher OTS<br /><br /> -Name Federal Regulation (FR)<br /><br /> -Number Title 12<br /><br /> -Chapter V<br /><br /> -Section 563c.102<br /><br /> -Paragraph 9<br /><br /> -Subsection II<br /><br /> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 7<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 115<br /><br /> -Paragraph 14<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.7(b))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.4)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_MarketingExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 128<br /><br /> -Paragraph 9<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OperatingExpenses</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1377-109256<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Article 3<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RedeemablePreferredStockDividends</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 985<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 730<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 141<br /><br /> -Paragraph 51<br /><br /> -Subparagraph g<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 2<br /><br /> -Paragraph 12, 13<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 86<br /><br /> -Paragraph 11, 12<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the value of each type or class of stock classified as temporary equity during the period. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 28<br /><br /> -Subparagraph c<br /><br /> -Article 5<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityIssuePeriodIncreaseOrDecrease</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0EAWAE"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information (USD $)<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th><th class="th" colspan="1" /><th class="th" colspan="1" /></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Nov. 03, 2011</div></th><th class="th"><div>Jun. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td><td class="text">ALIMERA SCIENCES INC<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td><td class="text">0001267602<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td><td class="text">10-Q<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td><td class="text">Sep. 30,
         2011<span /></td><td class="text"><span /></td><td class="text"><span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td><td class="text">false<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td><td class="text">2011<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td><td class="text">Q3<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td><td class="text">--12-31<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td><td class="text">No<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td><td class="text">No<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td><td class="text">Yes<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td><td class="text">Non-accelerated Filer<span /></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td><td class="nump">$ 17,376,806<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td><td class="text">&#xA0;<span /></td><td class="nump">31,427,355<span /></td><td class="text">&#xA0;<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_DocumentAndEntityInformationAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_DocumentAndEntityInformationAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_AmendmentFlag</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:booleanItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_CurrentFiscalYearEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gMonthDayItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:fiscalPeriodItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentFiscalYearFocus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:gYearItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentPeriodEndDate</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:dateItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_DocumentType</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:submissionTypeItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCentralIndexKey</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:centralIndexKeyItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:sharesItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityCurrentReportingStatus</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityFilerCategory</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:filerCategoryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityPublicFloat</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation 12B<br /><br /> -Number 240<br /><br /> -Section 12b<br /><br /> -Subsection 1<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityRegistrantName</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:normalizedStringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityVoluntaryFilers</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>dei</td></tr><tr><td><strong> Data Type:</strong></td><td>dei:yesNoItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan and Working Capital Revolver<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan and Working Capital Revolver [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan and Working Capital Revolver</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 7 - us-gaap:DebtDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>7. Term Loan and Working Capital Revolver</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><i>Term Loan</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On October&#160;14, 2010 (&#8220;Effective Date&#8221;), the Company entered into a Loan and Security
   Agreement (&#8220;Term Loan Agreement&#8221;) with Silicon Valley Bank and MidCap Financial LLP
   (&#8220;Lenders&#8221;). Pursuant to the original terms of the Term Loan Agreement, the Company was
   entitled to borrow up to $12.5&#160;million, of which $6.25&#160;million (&#8220;Term Loan A&#8221;) was advanced
   to the Company on the Effective Date. The Company was entitled to draw down the remaining
   $6.25&#160;million under the Term Loan (&#8220;Term Loan B&#8221; and together with Term Loan A, the &#8220;Term
   Loan&#8221;) if the FDA approved the Company&#8217;s NDA for ILUVIEN prior to or on July&#160;31, 2011. On
   May&#160;16, 2011, the Company and the Lenders amended the Term Loan Agreement (&#8220;Term Loan
   Modification&#8221;) to, among other things, extend until December&#160;31, 2011 the date by which the
   FDA must approve the NDA in order for the Company to draw down Term Loan B and increase the
   amount of Term Loan B by $4.75&#160;million to $11.0&#160;million. In addition, the maturity date of
   the Term Loan was extended from October&#160;31, 2013 to April&#160;30, 2014 (&#8220;Term Loan Maturity
   Date&#8221;).
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The
   Company was required to pay interest on Term Loan A at a rate of 11.5% on a monthly
   basis through July&#160;31, 2011, and then beginning August&#160;2011,
   the Company is required to repay the principal in 33 equal monthly
   installments plus interest at a rate of 11.5%. The Company is
   required to pay interest at a rate of 12.5% on the amount borrowed, if any, under Term Loan
   B through April&#160;30, 2012, and thereafter will be required to repay the principal in equal
   monthly installments through the Term Loan Maturity Date, plus interest at a rate of 12.5%.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">If the Company repays Term Loan A prior to maturity, the Company must pay to the
   Lenders a prepayment fee equal to 5.0% of the total amount of principal then outstanding if
   the prepayment had occurred within one year after the funding date of Term Loan A (&#8220;Term Loan A
   Funding Date&#8221;), 3.0% of such amount if the prepayment occurs between one year and two years
   after the Term Loan A Funding Date and 1.0% of such amount if the prepayment occurs
   thereafter (subject to a 50% reduction in the event that the prepayment occurs in connection
   with an acquisition of the Company). If Term Loan B is advanced to the Company, then the
   amount of the prepayment fee on both Term Loan A and Term Loan B will be reset to 5.0% and
   the time-based reduction of the prepayment fee will be measured from the funding date of
   Term Loan B (subject to the same 50% reduction in the event of an acquisition of the
   Company), rather than from the Term Loan A Funding Date.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Term Loan Agreement, the
   Company granted to the Lenders a first priority security interest in all of its assets,
   including its intellectual property, however, the lien on the Company&#8217;s intellectual
   property will be released if the Company meets certain financial conditions. The occurrence
   of an event of default could result in the acceleration of the Company&#8217;s obligations under
   the Term Loan Agreement and an increase to the applicable interest rate, and would permit
   the Lenders to exercise remedies with respect to the collateral under the Term Loan
   Agreement. The Company also agreed not to pledge or otherwise encumber its intellectual
   property assets. Additionally, the Company must seek the Lenders&#8217; approval prior to the
   payment of any cash dividends.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On the Effective Date, the Company issued to the Lenders warrants to purchase an
   aggregate of up to 39,773 shares of the Company&#8217;s common stock. Each of the warrants is
   exercisable immediately, has a per-share exercise price of $11.00 and has a term of 10
   years. The Company estimated the fair value of warrants granted using the Black-Scholes
   option pricing model. The aggregate fair value of the warrants was estimated to be $389,000.
   The Company allocated a portion of the proceeds from the Term Loan Agreement to the warrants
   in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 470-20-25-2, <i>Debt Instruments
   with Detachable Warrants</i>. As a result, the Company recorded a discount of $366,000 which is
   being amortized to interest expense using the effective interest method. The Lenders also
   hold warrants to purchase an aggregate of up to 69,999 shares of the Company&#8217;s common stock,
   which are exercisable only if Term Loan B is advanced to the Company. Each of these warrants
   has a per share exercise price of $11.00 and a term of 10&#160;years. In addition, the Lenders
   will have certain registration rights with respect to the shares of common stock issuable
   upon exercise of all of their warrants. The Company paid to the Lenders an upfront fee of
   $62,500 on the Effective Date and an additional fee of $50,000 in connection with the Term
   Loan Modification. In accordance with ASC 470-50-40-17, <i>Debt &#8212; Modifications and
   Extinguishments</i>, the Company is amortizing the unamortized discount on Term Loan A and the
   $50,000 modification fee over the remaining term of Term Loan A, as modified.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company is required to maintain its primary operating and other deposit accounts
   and securities accounts with Silicon Valley Bank, which accounts must represent at least 50%
   of the dollar value of the Company&#8217;s accounts at all financial institutions.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><i>Working Capital Revolver</i>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Also on the Effective Date, the Company and Silicon Valley Bank entered into a Loan and
   Security Agreement, pursuant to which the Company obtained a secured revolving line of
   credit (&#8220;Working Capital Revolver&#8221;) from Silicon Valley Bank with borrowing availability up
   to $20,000,000 (&#8220;Revolving Loan Agreement&#8221;). On
   May&#160;16, 2011, the Company and Silicon Valley Bank
   amended the Revolving Loan Agreement to extend the maturity date of the Working Capital
   Revolver from October&#160;31, 2013 to April&#160;30, 2014.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Working Capital Revolver is a working capital-based revolving line of credit in an
   aggregate amount of up to the lesser of (i) $20,000,000, or (ii)&#160;85% of eligible domestic
   accounts receivable. As of September&#160;30, 2011, no amounts under the Working Capital Revolver
   were outstanding or available to the Company.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Amounts advanced under the Working Capital Revolver will bear interest at an annual
   rate equal to Silicon Valley Bank&#8217;s prime rate plus 2.50% (with a rate floor of 6.50%).
   Interest on the Working Capital Revolver will be due monthly, with the balance due at the
   maturity date. On the Effective Date, the Company paid to Silicon Valley Bank an upfront fee
   of $100,000. In addition, if the Company terminates the Working Capital Revolver prior to
   maturity, it would have paid to Silicon Valley Bank a fee of $400,000 if the
   termination occured
   within one year after the Effective Date and a fee of $200,000 if the termination occurs
   more than one year after the Effective Date (each a &#8220;Termination Fee&#8221;), provided in each
   case that such Termination Fee will be reduced by 50% in the event of an acquisition of the
   Company.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To secure the repayment of any amounts borrowed under the Revolving Loan Agreement, the
   Company granted to Silicon Valley Bank a first priority security interest in all of its
   assets, including its intellectual property, however, the lien on the Company&#8217;s intellectual
   property will be released if the Company meets certain financial conditions. The occurrence
   of an event of default could result in the acceleration of the Company&#8217;s obligations under
   the Revolving Loan Agreement and an increase to the applicable interest rate, and would
   permit Silicon Valley Bank to exercise remedies with respect to the collateral under the
   Revolving Loan Agreement. The Company also agreed not to pledge or otherwise encumber its
   intellectual property assets. Additionally, the Company must seek Silicon Valley Bank&#8217;s
   approval prior to the payment of any cash dividends.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.19,20,22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 129<br /><br /> -Paragraph 2, 4<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 19, 20, 22<br /><br /> -Article 5<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 12 - us-gaap:FairValueDisclosuresTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>12. Fair Value</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company adopted Statement of Financial Accounting Standards No.&#160;157, Fair Value
   Measurements (ASC 820), effective January&#160;1, 2008. Under this standard, fair value is
   defined as the price that would be received to sell an asset or paid to transfer a liability
   (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the
   measurement date.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In determining fair value, the Company uses various valuation approaches. The hierarchy
   of those valuation approaches is broken down into three levels based on the reliability of
   inputs as follows:
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">Level 1 inputs are quoted prices in active markets for identical assets or
   liabilities that the reporting entity has the ability to access at the measurement date.
   An active market for the asset or liability is a market in which transactions for the
   asset or liability occur with sufficient frequency and volume to provide pricing
   information on an ongoing basis. The valuation under this approach does not entail a
   significant degree of judgment.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">Level 2 inputs are inputs other than quoted prices included within Level 1 that are
   observable for the asset or liability, either directly or indirectly. Level 2 inputs
   include: quoted prices for similar assets or liabilities in active markets, inputs other
   than quoted prices that are observable for the asset or liability, (e.g., interest rates
   and yield curves observable at commonly quoted intervals or current market) and
   contractual prices for the underlying financial instrument, as well as other relevant
   economic measures.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">Level 3 inputs are unobservable inputs for the asset or liability. Unobservable
   inputs shall be used to measure fair value to the extent that observable inputs are not
   available, thereby allowing for situations in which there is little, if any, market
   activity for the asset or liability at the measurement date.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table presents information about the Company&#8217;s assets measured at fair
   value on a recurring basis:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>September 30, 2011</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 1</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 2</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 3</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Total</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14"><b>(Unaudited)</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14"><b>(In thousands)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Cash equivalents(1)
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">37,437</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">37,437</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Investments in marketable debt securities(2)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">502</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">502</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Assets measured at fair value
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">37,437</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">502</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">37,939</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>December 31, 2010</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 1</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 2</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Level 3</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Total</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14"><b>(In thousands)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Cash equivalents(1)
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">27,393</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">27,393</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Investments in marketable debt securities(2)
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">26,330</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">26,330</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Assets measured at fair value
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">27,393</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">26,330</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">53,723</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left">
   <div style="font-size: 3pt; margin-top: 10pt; width: 18%; border-top: 1px solid #000000">&#160;
   </div>
   </div>
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr style="font-size: 6pt">
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="96%">&#160;</td>
   </tr>
   <tr valign="top">
       <td nowrap="nowrap" align="left">(1)</td>
       <td>&#160;</td>
       <td>The carrying amounts approximate fair value due to the short-term maturities of the cash equivalents.</td>
   </tr>
   <tr style="font-size: 3pt">
   <td>&#160;</td>
   </tr>
   <tr valign="top">
       <td nowrap="nowrap" align="left">(2)</td>
       <td>&#160;</td>
       <td>Valuations are based on quoted prices in markets that are not active or for which all significant
   inputs are observable, either directly or indirectly. These prices include broker or dealer
   quotations, or alternative pricing sources with reasonable levels of price transparency. Pricing
   sources include industry standard data providers, security master files from large financial
   institutions, and other third party sources which are input into a distribution-curve-based
   algorithm to determine a daily market value. This creates a &#8220;consensus price&#8221; or a weighted average
   price for each security.</td>
   </tr>
   </table>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 820<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 159<br /><br /> -Paragraph 17-22, 27, 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 10<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 15C, 15D<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 16<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13504-108611<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 15A<br /><br /> -Subparagraph a-d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 21<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 133<br /><br /> -Paragraph 44A, 44B<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 820<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 825<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 30<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 3, 10, 14, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 107<br /><br /> -Paragraph 15B<br /><br /> -Subparagraph a, b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 157<br /><br /> -Paragraph 32, 33, 34<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>3. Discontinued Operations</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In October&#160;2006, management and the board of directors of the Company approved a plan
   to discontinue the operations of its non-prescription ophthalmic pharmaceutical business
   (&#8220;OTC Business&#8221;). The plan included the sale of the assets of the Company&#8217;s OTC Business and
   also the termination of its sales and marketing personnel. The Company previously determined
   that the discontinued OTC Business comprised operations and cash flows that could be clearly
   distinguished, operationally and for financial reporting purposes, from the rest of the
   Company. Accordingly, the results of operations for the discontinued OTC Business have been
   presented as discontinued operations. During the nine months ended September&#160;30, 2010, the
   Company received a $4,000,000 option payment from the acquirer of the assets of the OTC
   Business to provide it with an additional two years to develop one of the acquired products.
   In July 2011, the acquirer of the assets of the OTC Business notified the Company that it will discontinue the development of the acquired products and not seek FDA approval.
   There were no revenues or expenses from discontinued operations during the nine month period
   ended September&#160;30, 2011. The following table presents basic and diluted earnings per share
   from discontinued operations for the nine months ended September&#160;30, 2010:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="86%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Net income from discontinued operations (in thousands)
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">4,000</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Net income from discontinued operations per share &#8212; Basic and diluted
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">0.21</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Weighted-average shares outstanding &#8212; Basic and diluted
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">19,120,860</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 45<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 360<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 360<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2443-110228<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 144<br /><br /> -Paragraph 43-48<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 45<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 20<br /><br /> -Section 45<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_TemporaryEquityDisclosureTextBlock', window );">Preferred Stock</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 9 - alim:TemporaryEquityDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>9. Preferred Stock</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Prior to the Company&#8217;s IPO, the Company had four series of preferred stock. On April
   27, 2010 and in connection with the IPO, all outstanding shares of the Company&#8217;s preferred
   stock were converted into 22,863,696 shares of common stock and all preferred stock
   dividends were eliminated. Significant terms of all series of the preferred stock were as
   follows:
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>Dividends were cumulative and accrued on a daily basis at
   the rate of 8% per annum beginning on the date of issuance
   and based on the original issue price, as adjusted for any
   stock dividend, stock split, combination, or other event
   involving the preferred stock. Dividends accrued, whether
   or not declared, annually and were due and payable when and
   if declared by the Board of Directors, upon a liquidating
   event upon redemption of the preferred stock or on the date
   that the preferred stock was otherwise acquired by the
   Company.</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>Upon any liquidation, dissolution, or winding up of the
   Company, the preferred stockholders were entitled to a
   liquidation preference payment equal to (i)&#160;the sum of the
   liquidation value plus all accumulated, accrued, and unpaid
   dividends and (ii)&#160;the pro rata share of any remaining
   amounts such holder would have been entitled to receive had
   such holder&#8217;s shares been converted into common stock
   immediately prior to the liquidation, dissolution, or
   winding up.</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="4%" style="background: transparent">&#160;</td>
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>At any time subsequent to March&#160;17, 2013, the holders of a
   majority of the preferred stock could have required the
   Company to redeem all or any portion of the preferred
   stock. If the preferred stock was redeemed, the redemption
   would have occurred in equal installments over a three-year
   period. The price paid by the Company to redeem the shares
   would have been the greater of (i)&#160;the original issue
   price, plus all accumulated, accrued, and unpaid dividends,
   and (ii)&#160;the fair market value of the preferred stock being
   redeemed at the time of the redemption.</td>
   </tr>
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Because the preferred stock provided the holders the right to require the Company to
   redeem such shares for cash after March&#160;17, 2013 at the greater of (i)&#160;the original issue
   price plus any accrued but unpaid dividends and (ii)&#160;the fair market value of the preferred
   stock being redeemed, the embedded conversion feature required separate accounting.
   Consequently, the conversion feature had to be bifurcated from the preferred stock and
   accounted for separately at each issuance date. The carrying value of the embedded
   derivative
   was adjusted to fair value at the end of each reporting period and the change in fair
   value was recognized in the statement of operations.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On January&#160;8, 2010 warrants to purchase shares of the Company&#8217;s Series&#160;C-1 preferred
   stock were exercised resulting in $10,000,000 in cash proceeds and the issuance of 1,935,700
   additional shares of Series&#160;C-1 preferred stock. The Company recorded a derivative liability
   of $3,471,000 upon the exercise of the warrants and the issuance of 1,935,700 shares of
   Series&#160;C-1 preferred stock in January&#160;2010.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At each reporting date, the Company adjusted the carrying value of the embedded
   derivatives to estimated fair value and recognized the change in such estimated value in its
   statement of operations. The estimated fair value of the derivatives at April&#160;27, 2010 was
   $36,528,000. The Company recognized a gain of $3,644,000 associated with the change in fair
   value for the nine months ended September&#160;30, 2010. In connection with the IPO, the embedded
   derivatives were eliminated.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with the Company&#8217;s IPO in April&#160;2010, the Company authorized 10,000,000
   shares of $0.01 par value preferred stock. No shares of preferred stock were issued or
   outstanding at September&#160;30, 2011 and December&#160;31, 2010, respectively.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_TemporaryEquityDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_TemporaryEquityDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 10 - us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>10. Stock Options</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the three months ended September&#160;30, 2011 and 2010, the Company recorded
   compensation expense related to stock options of approximately $417,000 and $189,000,
   respectively. During the nine months ended September&#160;30, 2011 and 2010, the Company recorded
   stock compensation expense of approximately $1,416,000 and $447,000, respectively. As of
   September&#160;30, 2011, the total unrecognized compensation cost related to non-vested stock
   options granted was $4,220,000 and is expected to be recognized over a weighted average
   period of 2.9&#160;years. The following table presents a summary of stock option transactions for
   the three and nine months ended September&#160;30, 2011 and 2010:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="36%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="5%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>Three Months Ended September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="14" style="border-bottom: 1px solid #000000"><b>Nine Months Ended September 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Options</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Options</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Options</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Options</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Options at
   beginning of period
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,677,474</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3.98</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,281,311</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2.39</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,741,985</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3.81</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,225,778</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2.14</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Grants
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">90,000</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">7.95</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">108,500</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">6.74</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">155,000</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">7.83</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">173,500</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">8.34</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Forfeitures
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(13,708</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">5.20</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(7,500</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">11.00</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(14,444</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">5.11</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Exercises
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(10,000</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2.04</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(5,879</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1.40</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(132,011</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1.59</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="left">&#160;</td>
       <td align="right">(14,610</td>
       <td nowrap="nowrap">)</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1.94</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Options at end of
   period
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,757,474</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,370,224</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,757,474</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,370,224</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Weighted average
   per share fair
   value of options
   granted during the
   period
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">5.81</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">5.35</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">5.67</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">6.74</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table provides additional information as of September&#160;30,
   2011:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="11%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center"><b>Weighted</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center"><b>Average</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Aggregate</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center"><b>Contractual</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Intrinsic</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Shares</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"><b>Term</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Value</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>(In thousands)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Outstanding
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,757,474</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">4.12</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">6.53 years</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">12,089</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Exercisable
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,972,951</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2.61</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">5.70 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">10,921</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected to vest
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">721,005</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">7.92</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">8.64 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,053</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table provides additional information as of December&#160;31,
   2010:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="11%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center"><b>Weighted</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center"><b>Average</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Aggregate</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center"><b>Contractual</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>Intrinsic</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Shares</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" style="border-bottom: 1px solid #000000"><b>Term</b></td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Value</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>(In thousands)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Outstanding
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,741,985</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">3.81</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">6.99 years</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">18,338</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Exercisable
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,722,281</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1.88</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">5.88 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">14,638</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Expected to vest
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">963,754</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">7.24</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="center" valign="bottom">8.92 years</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">3,334</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Number 93-6<br /><br /> -Paragraph 53<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /> -Number Topic 14<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph 64, 65, A240<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 40<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 50<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0000950123-11-095929-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950123-11-095929-xbrl.zip
M4$L#!!0````(`"&!9S^X:?_7*DP``"RC`@`1`!P`86QI;2TR,#$Q,#DS,"YX
M;6Q55`D``^Y(N$[N2+A.=7@+``$$)0X```0Y`0``S%U;<^,VEG[?JOT/6,]L
M)JF2+)*ZN]T]I9;E1(E;]ECN=.8I!9&0A`TO"B^VE5^_YP`D15*B2$F4/7E(
M6R2(\^'<#P""U_]\M4SRS%R/._;'"_52N2#,UAV#VXN/%X%7IY[.^<4_/_WW
M?UW_3[U.?OO\>$=^9#9SJ<\,\L+]I;CVA;I_D*&S6KM\L?3)]\,?R&Q-'A_)
MC6/;S#39FM3K42>?J0?/.K;L3;M4PWNO,]<D@,?V/EXL?7]UU6B\O+Q<XN5+
MQUTT-$5I-KCM^=36V85L>65R^X\]S?'V#.A%S5^WVK\T16NUW^\WQ-VH*36Y
M%;?$'S!HX`:PAWF7NF,!`555^DTE>H![3DM3N_O`RQ;1`\#?!:6K^($Y]6:B
M<7A#4*@K:KVIQOBA/WX`>_"NL7D@V;C3D#>CI@;+M/.8?KEPGAMP8Q<2C^_B
M(W2L-G[[<C?5E\RB]1@/")B0:^3OE2=N/;(Y$?R^\M<K]O'"X];*1-SBVM)E
M\X\7R/5ZQ.;+5\^X((U(BX:.[;-7GTR9[H/RACJDAU>Y\?'B,S61],"[G_^N
M-"?.,_:$0*Z9[7-_C7]Q`_^><^82`8NEQA1Q8#C^Y>*3`B/3.MV.HETW-H]A
M)XU-?ROF<L<0/8N1^Y\$YY!YS>M&=`V?V;1LA*#WX6\J/P<V=*6\!WZEKG3J
M3>4T_%.V>C_^*_U3\:LW3'\__JL:6-ZA^)_`B-@7N+#T1K;!C'<0`L!U_1N(
M%:$8NN!#KAN;JP*&D6@@Y11=.W&<;R>LU#B5HG$JQXUSPNW_,'&JYQ!GWC#?
M3YK[AWFD-'=X%Z7_#MX%P!_E779Y]_>*3F6].^0-7VT>YPPB92#7`5["(7V=
MWHP>IC)5(=<&?P8@\@>1K28!)H&^XT97X;K%J!>X[%.8VUU!)]>-Z"*)GF[L
M?%QT>L-LQ^)V3K<BX;OREM1E7EZ_6SU<-S;@99/T0*>BNVB@^TF)O"WN(\VM
ML(<")J1Z"+.WD0G:8&>S-[ASX^B!N#.VYXYKT5A.UY"&7HV$*CRR!?=\%V0]
MH18CH8`?,6/<XR,'=^,OH\<!F0['H\EP-"7CR?"ZD==KFN(0$+G4'$.?K[]`
M,5.29%*I<SN+*`T#UX4[M]S3J?EO1MV1]"=EB=4C.][767I8WZ`T^\5V7NPI
MB,JQF3'VO`",M23%B9,<5DYG:8J_.F9@@R-=WW(3JL[C*&4ZR8A*COR1K1S7
MAS)VZE,_*$WHWZCZ19VE"0H00^#MPG%+:\8$M)KJ.C/#2EITDJ2<ZC4B&!G'
M$U1,92F!?_R7[#CY=-3C`"X8>/'6I(NR7<ZIZ3'99^IY=$LIG`_""Q^HQ\G,
M(;>S+$>DHLLFMW"MM,#_U4Q3V>IH:U`;FSJ($/Y_%ZFXHYB05("'8&9R_=9T
MJ)\BL;LJ)`;3N05R^7@!/]#7BL;"1ZO=9K?34SI)]4KTGC$?Q[(<>^H[^A\R
M2MP'/H95G!'*Q;&IKA,XQI/;!)(HY#35EM9MMMLI*]M#,RKWQ^%$0A0Y/`+A
M@7P>W`W`E_\^_6DT>IJ&422</;D:4F\YL`W\9_1GP)^IB<\-_"%UW35T_2LU
M`[:'MY'HTNQ,C+#>A/'T5*4+?OZZ<1#9"G'&E>E>G%JOK;9.PXF3?,RG,Y-!
MU`Y<[G/FA0[R5"ZV%2V%;0^IDQ&5Y%>GV52.P?3@LA7EQNAUQ6R/`8/O_25S
M!Y['_*JXI6K-3@I:"9J502S'/C"*WBD0;]B<P47C%M):(#UTO+C9A)W,0*VI
MIL#MIU8%KI)*U]6.Q%6I?H&?Z*85+%=.E2I-NZ/V6^7H/K@.E'@0QX"(#]J$
M'FQE5:0=:E9U\VF=CJFD9FC*49@D`T]7"&VG8`ZA5%8%6FHA)5UW(/_W'N@:
MO7%53K7?3K-X-YE3@)1TG9UN]W`@;L",.TYGW*PR+JNM=C^+93>E$^&4]8\9
MQ[T7#JX>76$JZ02NSHPI<Y^YSB(VGISX]9L"RGXJI^`HQY->2RV)(V+:Q/%9
MQ<:C-7OI@+&#QM$02IJ-VNX>`F%(5]RGYAVC'KN'8F@AIIHJ,QPUDVOO(U8%
MK+),.A)6]:X%8GW:M>SW*=4[$X@TW4,`./;BB;E64JU.]B%M)2V0742.!U&.
M#ZUNIWL0")&Y)Y@U<6R]&IU(*T0^G5/1E#26WA%PGIBU<ESJKC$C\]=1,3VP
M,(0?SI]7CU_9W/QXX4.<"W<_G$@J;_`'D'J@[KV+<Z',$+,$#\P5$S>'C@]7
M6S(S1I\N<:WM0+J50MW-GS>`*N>^!H&_=%S^%S,.XF8XOY:%B.XEG=86$*T$
MWPX6OAD^L>IP'.\.L(!RM/;PX6!:9>9A*QU<*8)'CC`QXUO-+&QV;C/3_W&T
MRX6)IMH\AO:;^=`2-"N#>*3O/![B.7WF;IGN<TA'`3O<658`[`0OF0&%IM=M
M]II[,$EB)^$ISZ2FJK7;_?:)>$[UMH<S*;/F=1JR2MF5@VQ@&!S+16H^4&Z,
M[;"83#Q^^JQ"6VVWTQ,^A42K@EAR1JH)__5.@/@-LG:*ZVZV\8A[YX_6O%V5
MG9IFWCY:IV,J66T>B>F1^93;S!A1UX9;WD#7`RLP,4[<L#G7^<G%9UU3VEIF
M3J*8:E48RW&OKO9ZO7;K!(Q"`9>.:3#7D]G>R;F7TNZE9;I-XU@$)76JK:G:
M`0@213RH7?4<V5XN*:)8#;ICEUC*H,O?@S%]^C)Y^OW^8?0X>!K?3[*[,!Z9
MQZBKXU:#&_;,3$<L4X7KP*FQ[-FO7K`VIF4M8@_)BK$5%0=:9B7U#-CR-QWM
MUX-N4WLO:(6[!UH]]3AL\N4T$]H-#(O;8D>GSY]9E0JGMK0TN@*BE>,K8I_6
M4=X"WY&*U^IIW?>$5V2RV83N`'ARCQ!$X4K]6T?=M3MJ0^5T!$4*U>XUJT%P
MK*]2,C*I'$#Q_HM^:0#W*]S5N[GG5:(&'2VSP+E%I@(,16MFJMJO"L.1J@`5
M8;\R/AP;GSJ*UBN/86P_,\_'@#6V=<=B8P``=;5?33!*X<@C51V<(N_9/0^>
MH[7E;>$4Y=[-(^#(:Y5&E%XK@R-%HRSY(V72ZV2Y4"GU0A?6*TO]1ZBKO3O'
M`W.^MT>O:-X!]Y8HK_OY#9M5HA)JLY5F1R'5>$\1*(V+6S>@[!/_CNU;RETQ
M;7X_?W##S:.BGALZ=GC*PRVC?N!6DREU6JW-WJ-3T*1ECJ:`#+AU'0M?\^=V
M`$P(7:QC5Q-.ZQTQCY+2A"+"YX!9-./347K:V\$\TJ3K*JA"UM6^`\S"Z3.(
MW)W*8-YP3Y</,&/3?L+`3I_HZ\#W73X+Q!L#3T[\"IE\Y:6*T;2RBT&5H4MM
MU6/^IM\S65Z*QHG$#[:G(XA79R45$B\:>#>K^KFT,]L!Q'*9?",N\O'W;N3E
M*U'D3AK8(?33\U(&8Q9J=#K<W(B7H6VC$CYJG4PI6D@U5ZR#9\I-:8")U:%P
MZO4S];C^%O96C.+L`SC-9M]N`&>R^_<?0&'<5+IJ92H4+51%6SM$`YS8Y6;@
M9S8!E-7YS!83#3`KEUIBBTD!T<KQ[=\"$^)3SHZOI,;NA-?6W@U>&>ZU.P?!
M$S7*-X9KS,P80/E!%VQK?\/)JKB]RT(1.\3ZG;;:#0NE`T&<%_S^+2("O-IJ
M]Y#9[P:^C!+G,;ZE=5&/_^.P%_)=[:N:TNLHQV,O6K(=#J8__7Y[=_]M^OO?
MU,RJ[0U;N8!&U`R5S,-E<L]D_R?1+9I=R<3=+%W!VW!.PL()('$G>CVYFN#?
M"E^%WD^K(C1%D;P=ONQ1#";>SV1A:?B7N'\_EZ\B@\*)EY&K8%`S,R&WCUX2
MUU<;"@`3=SKBC!FF(??V9D*UDEP_/4M:0'#/M%SZY7<OXG+XEM&.-V>/GNWN
M[9N/*P/C+491N&="J6(4B5F13`^9%VJKX+S6S<YI%Q"M'F'A3L7L2E$)A#DB
M"%^[S1%!8CM1-0ZTNU\A2J-YLQ$5.N%F9>/)%Z=X*%Z7K'@(6U/298EG*ED\
M?>;!=7"FQ/B\_NHQ`YZ-'AOH/G^N4(\Z:JN7+6)+`C@C[,+:NZ-H6Y,'1\`&
MLQ9QZLD9Z'\&W&6[#K2IQ'_W^YVT?I0BG3E*0V?,$//84VKB>3%?<*&(^^O[
M^=&XBWQXNZ=MG?QQ&(R]_,X]LZ.:!+NUG^6YU,^(N7"?FEH!YAQKD)E9RAK.
MM?JEM;N9':BG87KCT14Y(!A:9OM7=<,KV<WNM:RS+**=A.@XR;VW#IX1=9%N
M-3O'ZU9NP,"J]GXE!#)Z9:[.O>-F1;</AE+RP\,NHM4C+#SE[W"`(@M-MHSN
M9G=M1*_J5`&TW^\GYB$.H5X`.;'^<!#>PM.ABM#N('PFJ$4>K7<LUEUJ@XNO
M.(&8>J@2CF;.HBDD6CW"HIUBO6:_?0+&,)NYGXM;4?OR\V9%V5._M3O+WD4P
MO4R^BEOF'B1S+*AV-I[F48N-(VYP!)K"G?/MC2GDT-DM,MQG]P@!QPUTS/<K
MG.[,G#)71#)/<-$A/3E'.%6R3S-7C@7$SXFYR&:KP)R3@L13T=5F;IE3J,H3
M/R/DPCVT_8Y:`>K=1Q"GM_H<M-&HZ'RI=K^YE>R7!7!6X$7I4J]]3N`'GC6M
M](LRD':O!-KS'8E==FVPNW4>7DF<ARRM:IFEU6C#.9X.4$U`V;VA'?L_B6[1
MNPQ:=L/O;KJ)7>!R<2:<W*D$1.8@[%Q:Z5,A_B\(U^R>G-S3&G"'NL\A0<"X
M_(W[RS-MH6]KV>,CJD&W6>Q8.:E4<+BD[H(93\Z.U\F/+3DT+;GPN)]@9#^?
MV8+;Y+.)V?H374`+@GE9QEHF8C#W\X-G[#Y]9_H?\(,R]\.G?S^,R-*W3/+P
M]?/=>$@NZHW&M^:PT;AYNB&__?3TY8ZHEPIY@DK("_G=:(PF%V3'!PZ?'ANO
MV)>*#X=_UOW$DY>&;US`*+Y;^!_$YW%"(+D#5DF=Y`]W1T?XH9X:,"+WUFOV
MEL&?B>>O3?;Q8@[<JL^IQ<WU%?G'$[<@)9BP%_+H6-3^1TU<J'D02.8?B`6"
MXW;=9'/_BBC<_D`NMKH%D2_LCQ<Z0_._2%'Q^%_LBJC*RH^[\IT5]+3R13_8
MQ2SZHS%+=8U?,,JCA7@N2K=^<V2E**E;I-1+(J5/G#G9R/^L"#X0M*0ZM_&+
M6U>D];\"TD!^[)1,PZ^=UB#6Z9?D^^^HM?KPMYZF*1]PTPBUU_$5]<,/A'N$
MDAEW5F#O%M59X'.=FF"NHBGQE]0GW@IWW^`F"H]P6PS`7S+BAJ_WU\"QQ&_W
MUPBU,4A8%LY;X$-R6Q"P9P4/Z"Y?R=^K)?1M6EPG:=+>)7F"SD.L@M@+%6':
MDA^@_3FPF1R"VE$^M&H$OZ$*GLY@KH!ETA</R>'?XDPR_''#X#)UV>6;R>/>
M)H.5R\T-5$U%K*I2$]`RPE"['SP2?<U*<$A@%ZLV\.,6AD^F=95\#[R@^/T>
M9OR`C!'PP;&;%(,SF\_QVUS/#+_D*QBP66Q#N8Q>]26U%X*ZQ3V,/"D-F8Z&
M*>W`Y"@'K"#,(;Z`D,E*?)D&&#UG6`2G^AP_W"?[K$%C%P.-3WR'O"RYODR2
M()YC&J13:[>5&D0G(K]LAB+DOJ2IBYD;D`ZZ9-!.ND4=V*X+J?]=A0BAD!5^
MR@[[2:D6Z*_.@%4&L9DO>EZ%,T7X*%W!KU<(ESXSU^3OG5ZMV6\+1'/7L0`Q
M&(X((%1\"PW4?@X."R1A!#K.>$N%?$'>VPLI)%Q\P*T:L85(`7AOIY,W8HI"
ML'L-IDN$&H%MZ,R:,7>CJ4VAJ4JG!OW:="&U$%'CDS.'N@:RR(`<3?<=-[(V
M@3IBKN`?,A?$`TD^RMK8K+Z(CIQ-=B#%2VS'KJ>\Q"SP(%?P//*]QV3_(O@V
M?[@D`W1<T#8P_<C:T6F9+'(W>`5(KAP/%+200.C7?@[,=<)B%:6;LE;H@)@.
M&)!+EFB(TM9@I"AU*=@7;IK0S(<&<"O;`N3/34$)VP:VB;3];:7TR-?+Z268
MO6.(EC=NL"#)DRPRAGM[,T@9KF0_#!P>%N1,&MCZ$AVX[VW,-LF*$*-@M61S
MZX>W4\VD88)I(3*X#:8WQ\]L2<\/TL32&/@LW5RHRC,*CB`4.%NS&@&GY>(Q
M#[0FT,Z83J&+7*^;T/$9,SE#[D-;CR4(0H!'F;XP$*X/!7K\(?7P-.DH*+J0
MZX>^UF7A($!//>`3GT-X@U^6V((`VH]O[V&"ODZYI30T2,4)-9XQ+3<B'R6D
MI.,.8@.C&W!K?/?UU_%H4@O=*5R9,>1.&)<!:^3(!7895-"`Z0SXI`,D/8``
M(@@P@UDTI5LW7T9)W;HD<$'F#2%_(N9+IH<@I(Q0U\1G+0.([))CDJIDDG3H
MX!Y,1@WT$1X@!EX_<Q&:3'R-#GD)_MTVT$[3'AQM,#1Z&"/Q7QSRL$1`3<DK
M_NSXF,S`TR*K\5V.,+[7'=.4<=)$BY,+5DB>2F-,&M8`!COU`V.]%1A#KL,(
MGQWS.7+S_7:'K,!`Q>0"E`Y08>!8==<)+1T-NT:&H'0&K9%1@-LEQ"#'P"DJ
M47B16X"`#LCU=<PLC\X9U'_`\0WY;<F"A-[.=,?9G&PKR2%>,+.X[XMP@'6+
M=&>K%83M;5\VR?BR)*^!.]@ON#N9FG);-P,,8F`*P+NEZP2+I1BHA04FT5J1
M<FX$>0F<WA'T-JBQ=R[/-J5B"*A?D)Q!+,'S#.Z8CZ$^E5D_WJ6S:AM#DVPN
M(2>#8\K$8;0"D&#7X]T&`68(`>HML@V]-I;OPBS$R+'91#0+(&%"YS1CFZ@+
M`/`1:&1'OE0@P#1:VA"2H-X?H6\`;337'HL3YU#-4"UC%4RR.&1OL[/-WEHH
ME,@@V.O*=,07=-<;,H"/AM,DDD&.AU&2/7,G\,RDPH3J#4.M8<MYX(IM]0D;
M<2&WESDOL]F<^QO/XG+O#R]A*XF1FQXX&QR)'P,!!\$WWZ^%;A>0Z$2G9[J.
M*5V1*(;FH=Z*>0V=B?>88BE#/`GF-%P/@G07PA-=8`/Q.*@.3U9%,330`4IN
MV<P-J)O*05256$P<6R0=:*@@&TUQV9\!@X[EH!/#$1(3[)'N#1\(-OYZ4Z61
M<!HJNK/Q+1YS4=E11T*_'F466)6%'$P4A9$Z?Z&9,>0YA(1%T]B99ZT'+6,C
M/"AV('.><V9$=:AH*T>/<6F(#1+D19XXBPH>P41*'I+)CW!(7V&P(`%&!I@&
M)<S[X>;K;=HG&6%=.0%K2[L151-5GBKABB=)&*=C)HG?4*%M5S\8"UWQ*5XZ
M`S,`VX$XA4P0V61<L80<2SF2B`V"_=D\-N(_L@]\A6!>#&>8+/:YOTEA(69B
M!HD9"/?DAW(M(388@BPET-K0:L&GAZJSR\?EB54Z110M0)ZRE;_MDC-ZPVP7
M8[=TB'/N0GH4!EOA4LAJN?8X:+1-`G]C9A[Z)4(YSB#`$%=BP2MILMLV$UI4
M5$<CWX3>X`A"D1QF0EN9BW2.T7C:K7@@D,-ZTNU!DB6A,S"X@,89;\([BV'*
MA&`_GMB4(^>(!2S.\<I>G1`*Q'DEC63&P/A3/<M:XHT3C(P^0ZC&TDWR`X.Y
M^#RW.+1=;/@`_63Y.4A\$)R`'!V_+I4EF9;L2#V^,`,4S`Z3_)\8-?VECO5!
M7.,]L@6>Y`OV(GM?,!NB9]*??/GI<9#-%T1J"-4`X/L%@!F.%:7S(#<L2<+<
M]!'359SA`R1H+7*>2$Z[^8X,>S$`0N70Q`00$!D$'N;`-7+K8DE1(S\R"'<V
MQ.PQ),KPSP/6)`M9-Y+IBG);V&;DYD3WV^E=RB^!7S4Y?MD>R`]$E!99J3RM
M))H]`?3``^"O:3HOPLRR=BCT32S014\X(O`O!<>S`]N=SNUSA:G9BD2Z@8F6
M2^=^[*N\V-;#,J(FIA$VOY!5?T)]@V8HW`8F!M*Y.O%0I?DGHE"<N6*+Q+@+
M,Z\(^YQC<P@6AA/X),P(F6WL2GC%`TD?2S:N50AB%>X!V+`]"KR[W'E43VU8
MA'"QTI/9:I2@@E7("5PFZN<X>2M#),ECT;WH*>)S3/F2I/RJG#I849EZQ8_]
M?WM?VMPVDB3Z5Q!>=:P<`=&\2=D[&R'+=J]WW&VOI9[9]^D%1!8EM$&`C4.R
MYM=O'G4!!"B*XBDA8F.V+1:JLK(RL_*J3'1!T6I\T$@QBJ0E)O@^":U-*>`>
M0\_,A,4C79Z4%\A4\P<K@6,N\*3B=!\!D*HHW?)QO*_QM1=*N7@.LT<!NASX
MR>DWMBKR+SZ]0'NM*=D:#'@`\!)D.B_UW**`;2L*N&YD;3T:^)0X6+OAX&-V
M,K;LS>X@$%9T$+$\4()V)"-;[*+WP$QE(Q/-LBE)`#H9@$$=C5:80DQ`9+$&
M/([J)DP6CRF=A&T*?HLI0Q`P#RB]B7/-E8A!FX??4?Z.\]<]S4V40-@[`RT+
M9%Y.7R!?\*]G9]_F_"+S@-LFK'+9@^Y'&8IDL4HE@2)*K>;)_]"HLSCU1X'E
MPX%?FBV$1VHS>);ZQXN3_]41MH_G#>>,$`'[1A4"_@HW5D0&A+SD^&X/`J.+
MYF$<:^I/2/6F1!/0O/6^::_:BM";98^8/BGM1XEF<&^PZFN<N^ZC"*`P-7H)
MT65(N_!,MH=VN?)&8=.P+[Q#T"],-K\]-@0M)4GP(I&'H#S$$\^/@_O*NW#A
M*6_71[\B`VDO!#-1<D->JRLA]56/>`)NAS_!LDBUD5Z%#[5JZ6K*U6TB7+1(
M592KU2R!3RMGDE/+@#@+0U!&E!Z@8K3`-W_GL`,3!L6N_4"%"R3+X/#?,'9N
M*:8]VV]@=L8AKD1ZZ>XUIF>4-LB<):,3BKS@7E#*&+K%5&B$?`DYK-ESXY!)
M!M2->-N[,+F,;)/QUB)X.XTN>A[`R`6U&BRV=($#PHX;XV'/M,^?HL@@P&#?
M%"'FGU6\V/&F'+&59)`C_DI1@5,P&9'3YDH(].FD<>2ID`,+!>5ZA;7Y,'78
MB]UBUS"8G02T=Z58ZDU3`)RVON"X4'OY!*I(5*;6O"G]I72.;V>_?GS__>/9
MWP\C2TG/4]`]EE=%MKAJF6J_;FURO8;!!QE7_Q5,TEGR6?G[R]]7O@1#H&,9
M`D]%SD$I_IV&8V]LMSEPH/Y]':51P0_TV#R6JAP6Y=)9(8^E,MM-)Z#0Y+;.
M__7RW'DO?\R'WU$_H)R:G`L)"$Y?]1Z7]5G@D;=GUP8.!<4HEBQB='BH$!5N
M":?GJVVJ?*=X:R51&(H@[]NVPGACP5/I8(-T4XUS)&/#@A=L3"]K+;12PI27
MW#B3(+I+>)J1U"`=,%L\4)Y5CI4JO2[&KIF"S:^0+UQ;_Y$5E#$G#7@6LR:U
MCX;:!\QG-LU;.UJ-@L$6T$JIJMZK5@]L6P#)+<E_9"8%9C,I7"',PG'81&9R
ME810.DU+F\KY/+73UG..NIC91MEMD4P&XB=8!AL>Y^3'Y20&VZ*Y]=:`3:1+
MD0-*:!V'MD\,<S50TZ2A,D\%M&)#PNJ]@7*K-Y0/$_VYEOOR0<`,4"KP51WT
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MVV@DP)0J.Y`JA<M6HEJ]V<^\VG&"?Z+I?A?DZXJF8C&3'),A"7<C<%OR>H[X
MJY&\]&$47UL</3PVQB*E-)BN@56!*#O>I;AA6\@W9KU6A=KOG/=%Z;=WIX(U
ML3=[*%OF%E46]\3CNK@ZR=_J6+SM(WKL49KC:9VZK7;3'?;7RCEYP5@F]-[0
M%?AXS\)3S=/U>!+HT>$GC^RN,Y7.;=9]OIZ"KG/B++OY@_($=!N.W)*C][1;
M=\!EQ)EVMKJ/$4&X+#+R_IHP34"MNS!"<\U.<VUN\IUBKA%V[J,PXA<@NF\W
MYL/+AN'X]*C=[+GMTU/[R5!5<`>C@IS7RQD>6F&FI?):O-K'.!)DT%@I@AQH
M3(6Q,6A=M-ZEK>*:EP+F(0I9S[A"VW7\";VH"F16"\4Z*?NK9#FR7BO19"U0
MF)J>[@"&%A@L;N'(9!9'X4U69^CVFXQ@F8"*T+@,DS"E`%R9G6*J3`-C3G4A
M2+#;U!LY"B"6>)#*S.?HBCNXH_G<:;L]:3^#2>6#)41S8CH-_(^/\;T1I^GE
MDL;YMT_RMUQL%_$K@AF;75G(>4EW4?R#\I'Y0;D*E?*>Z-D.AAV<@?01%>9'
M29KX%';`]VTT-5"IMOSG9\=G#9PPB)MLF4VB4P=8Q@MYH0#M/&#[W$.5H[[;
MEF_XS-M,_:'VP@'X@$9<U_H`@V:>:D^"N,#4=GMR8\O:]K:53NTZ5UE*K[6\
ME-;VBHE@,OK76B);67,\'H+>+#_"U-LR[K8"VM/(Q3@2P,I9/^D-FM8N<%(J
M&`D<C[<W,@9#*$!#6EG50$\1'@,CH12C@*;*&&?+U4X^2EV014[(GT$A+@O=
M9N["HG)_9D5B>7-L:OHC6$X250,P._^XRD])=B89YK=1HBF2>.'(-=4;F2)]
MB#H-#L7:GQP5Y)14^UF,(C`=]I3B4?HTI8Q$46#<ARBIF*1+'S#KE%Y\BS$3
M=-DXV0R#BNK@3+JPZ]Q$=QBJ,ZBWG-`C+Y1/-E"W8B>4FIX\4?9C#BL'F<C!
M2UF<RM]=*27H&3K[:2U@:39]-8B0D*=VK_!<=3=9\OQ*W$<J<QC9@'.`G0^9
M3I3+\"4$"D5,7R0K(D?4>2<\NIH-$N2'>2>QDK0Z'3T4*&Z-#Y&I1K'('`D`
M9^?.#*8PU\@M^8?C'![-+:?Q9=&HQ%G^;IIZ*IJ;>Y\L$Z4Y[9"<ZNQDQ/1^
MXV",)'YE^A"B5?QD#S9?8F`415D\8F\ANA<5B\6>G^12#">J9M.2&83+:J#K
M#1L6BM5C<W8NFV[5&G\)T<*>%2U<$2<'91KT*&B"FW)4@?P=F`,*!&$U%3<*
M46J[R%^X7WK0?DE^Z>>TEPI_7SD]OEK2.;M6_UD8W<7>[&^O^/^_*J;;C")D
MAQ#[Q>5$B'FY`$:B$1Y;=/RM"+C2R1U0Q9\.]W,Z7^UU)I%WPC`"Y+.?#J4[
M.?_&96D+F>9PU>_Y^:^\L69-(`:/_3QZCC_;H;/-(.J91".5HJ.?3['O"ZOF
M6ED'>Q?GZK6&VX_CK`9JRSUM;3@FMTFZL)H';I(<'GL6!K_#06=[RZ\.YJ"S
MX6CYE@4'=ZST"G;27E%&?XLR8G4H3]=-%R7WMSRS-9.`@6P3]T/Q[K>5IAP2
M"RH46_;E^M,N#GPO]['\O:(UF<`+?^`S_Y&PE9@#H:9ZW-:TBDZS^HPOJ<;:
M%BZ-IZILW=[IH>B7;7?06;=^>>A7R+K$;P?$[SC*T'K;W3VR]YLI(Z+UY*35
M+Q)S6SN8%XDK!JK6&T$\CX+`N\)R@OZM.,,N:!Q0?@E1P[X5-7P$'@XJ4MAO
M.+,+K!?K.6?7L:`]/9)-UO20L/@\O]D<NK)(02B6J%$P,B>$"2)J,_R1W".!
MS_5@YXKURR%V5ABG'@0^"((DT@^>='TR,;H)HR"ZOL^G*-"+=FL]E;C$50_H
MW;JLC:)AM%YOY1,Q`/1A\Q>U<BBHEEZNY*8Z/1K;+A\+MY=OY;6HZ766)$VD
MWC/J9`[ZZ^?R`RC=D]X/)\CD<(+I)_0[OK1_(-J;5W_RA&L4++H3[1#MHE!N
M,>J[=+RX2KT'J*IG`5*,XK=*07CGV-XDDDA8'R=,RW1!*R):Y;C7<&DFUC3;
MMUIQ+%!_'Q]"Q3_-O'M,2FPTS0<@R0)945;1(:5G<1Z8&&5V;?@2!C<DLZ12
M7;:;^5,8*BFWJO'V`D^7ZB]3VFFO[(1!E&`A/2QQ2#FOYL3KD]OQR4U`^\$,
M>JKW9+WHL=_2J@Z/KC,3H`KI_B2^;$>&3Z"CB1;;IJV)JKO[(`.KPDPI>B=`
MRA_U&\,Y,JII9<>THG,A9=%%_XISIB?4PD%5,76MTINS6.A_T(2%:MNF.@%5
MVZ9L6)4A:G+-;5K4;0C*4GYEEC$]]*ZI9<?4XL&=,&7!DJMA5:2<BI?[]H-]
MUH1Y/DNCG:>!$;40+LYPC!7U,#T`?N@U?Y&SF2JJ)H>^K*![LV?DU.MW"$Y-
M6;NEK*GW0Q0*5,`5`1<15J10M3#H55>I-L*]GRB#%$N2LR$D&[484EAX7]&+
M""H55I+VWUCF!)?QO6V@("`H:/H)45$K4T$!<ZVGSO`71"A92W\!8\`/LC2+
M:F:F?@5;F^K1E2KS7ASX7//#`X/XK\P?(_-CAC[I#O@0+S3E^Q`8FOM8MZ9P
MJ'Y.>?>RQ97L3?.Q:VH$Q*^+:/JC@<:%--:C$3<(XN<SL":#B%6'Q,3#WE6&
M/DHK'>;\!CD+&_O65CZA:]/C![5W>E"%[QIFV$96(1;HJT"2G5:Q6(P^.7ZF
MX"7Y]T,1F?A&/?.XA&F^H)^>U,N_-''N\D4@95T5>NYU34_T?EBE5/&<I-9(
MG*C>HN&K?BHWTG!*:@D.JJK?$"84*I&&V^V>?$IHK9C32;%\-%P*R>3>(%82
M*[<CD_O`8D!S]=&CZY"*TWO.->@@W)S.[70[7'1'F:BJ>)&YMNBMT56NQ49Y
M%<*R$IAS]6(>KLBRDXY?.9)G_Q9H:QCT2"SVSXT"40/')%(LICH6`1`?_<<M
M=O[CTE!4)S'5E5;E4?OY$E]4E@>6./9?&UQ,/!\+%.%4\!,^Y*2W.5=`]/S`
M"/@XTEWH<0S>'ZQ$\D,F0ZJ6]#*/%JGTTHQ.&#L$IB#UL3;12/"+VVCR#@":
MAXAAH77X*2%#Q.^]\%4LMK<RCQ')+5?J=Z1_`)0=ZRX;>_>)O,@8%EYGXB09
M;-JL%/,?9!<\25;'V0S!.RW,]QH%`CZ1NA)V5Q-3!M<WY;4D=JTW8?2`5D)*
M:W::)S"K7)-0E,,17-A$^4`:J700:N'*2WCACSB;I:-[:A+J.OK:3[!!&Q>\
MDJPC>PDA`O@-;Q3C0^+9+/*1-6-Z&29?:,N_*J;U5&FMF)[KQ5CJ$\0__EN^
MQ88=I&#5$,0>["?U+6B1+`VD?`I8Z#G!U[C820*,'?P+]Q>DY@6C&S,)%YOU
M4,K0HS2V@V@(M[=D`D1+B.];6-5/\-K&=S`Q_!,$R;VJ3:H.&`DLXH>*H=,O
M'/,[_.[8O[4.@TIMW1NN"QV[%:8D3M/0*G(\V/(XXJY52@(4&ZYXAKV4<D4M
M0$KD@U+!JF1$_C&]NAYA9L/D"]A':BJ+'[%O3Y+^,2-#I?K%:N'-(KY6Y$(X
MTD%O.^>EVT5_:6E34B&U?2P65AKESGEL%&CB4W/WL(]5PH!T`[[Y\::\I:8,
M!-@">ZP,0%;WF"<-D+K<`Q`#,F2DR8?W[$G3$=MH8)OBDMN&L97'%-[Y2Y`!
MM^^L+CZ=%NB0VJ$<==Q>KT^Z`7Y^U`;UA&OT*1UCIOH7RJ!4*9XJG^<"R,6'
M\SCD]P]G-+_5]J98BB$AW9$:<&!;&E+HDM4*)==5BY]=CL`CPM)K+D@,.O)+
MR`$8V'6&R_=\4/'^`5S$6$_BBZH)\D]9A>1<5B'Y+JN0["`)`*?TR5)1$-*J
M_E:!^%I2D*;5E7>'G2_P41OA'T#`SJ<-F`YZ:,Z268L:E4:\[!2O>I8IO<=>
MPIR4R<VPB];0C7\!EREPG?,/+PC$O?,>,XQQ_M_\,9RIHZN5.U^^?&.?C+7"
M%RZN8L_:<+Y9_>+)IP*6(75JRI5=*0'.+5ZNM)ZM;H"HBJ,[AZT7#";WYIQ[
M+EEI%$LZZC?:\P.J4)1'C5<HCY/O?*4\`/E#G%=2;=C'L7?GC*.[,!_;8$=4
M.:3&UV3@+(?^O06][&IU+<CFI$.VMLE(+DQ"0!#'V$B0MK?1/$1UY1%L;6MW
MW].Z&R:^5-?R^<INDEP]GU:_K*J4<D9]*:GG4T)+Y7CBQ:*Q;@B;V^\#E7^H
M0M:"FCT<QRBV"J4E$86DQDL\*NT-]2_*.M%VK"YS;!.,=<[2Q64*`LD<(2H*
M!)1O#P4PCKJ-00EA<=6?$M<XM[657G4^@"DV+4-]6\9RM5_++$6D3DA".Q33
M@N9DH$12!Y<N./VDYMVM(.W?Y/JT;E%6;M?]E;.$<-.V$Q3S6[3O,;(/[8PJ
MJ;%+%HX($-_[!4=X[.N3Q8RNJ!^7*I=4SC#:)QNRSY6"HV?9-9"6':C`@7,Y
M5'X>7.RR=2^C9,I]BBZF#I9BPWB*!1JZ)N!Z8`_9+,B27(2@L+-&H<'?G+<X
MAZC\]VV)&:O0%8M\K/:#I7^P]25+Q3Q/O]>(*R>NME4@CYUFJFK3$C@AA'#P
MFI&21XA=X6J>;(EDW858PUUOL3MKWJ-*>TYRU*IEMV+]$G\$(<HT!=92F=NW
MR6+T0DAB@I&]A@G;IOP$10LM@VTB;3L+Q3?RQIH92PS*4(UV.6+HCWI(6=&]
M3*:R2$S;FZS0`EA<R^_F-;..W`4YZ.0&_$D1/`(-PX/I'48(#61(@JJ0/@MN
M#:L-F[T^?=1ZQ+(*7XK0CY/LZD_MD>O!1(`T;BZGS'\.<NE"7O,[R>71T@*Z
M10"6UV?SJ!"'>TTA+?L^\HU.5="G7#[X^>NL``Y2%"QT%>5U&L*1O9)A[D2D
MFOIT23TD03">3D#D4E51A8[R!=5D4[ARR<>M$U\+]$63VV#8J*<"?:"T+#H!
M#E7,H]2^=X`(07#<J"*)&I8J^MGB#1G),II2P;7B\*3`29>3$NBEVFW>%LC=
MM]=@AUL-Z(W$D6W%46BAO)7E0:T[!EL_<C-#\A%3PPE77FPJO.RG+)X#[!J(
M(LNX_75=0,[F)H:NU(/M.;13&^>Q:#(01'>%T-948!\,Y3$W<4*LZ>C+;B*7
MN1"U\F:6A:E53`V#FY:7#]:.O1)FS>W!Q,H2/J02E<\HVE1N-,P%F6DQ;LO-
MF0%64)HO8@XES[#93*IG5T>*S<U_HGLT(3M)C#'=L+R;>T#U0@%+)<24MXSS
M:HF=4(Z1!%1+P$Z[%F2O('O=X>J`Y8R*`17)(W^T3%(-YTRGHP1E=R8U'+$V
M:B'=N';UY:OHO\!&5&APC"YOF*3VR1ZV3W;]SJ=YKT2>$"E/>TZ(WE'(1X:_
MLWAT@XPL.<B[!C:YEAH4>UXZI^Y@T-%M`)9+OVDX'V6D#D?K%:6!(!F>Y<44
M>9ZJ1KM<M1LEQ0D'=;1D`$;A+!VR9)NFQ#=7O$7%FDO<DK:59W^LKC/5#VFP
MFRMFTV4TG89,73@<M,2![P-O]./D8G03!?+%M&J_!+#@H&DT5MVU#-KRT^<V
M3X:S@84*)Q]UAE0D6W<CLH16$(UDZ7)JA)7+><58<5*J#]COA.SEY14XUQ?Y
MS/1%OD`]W(MAXG/+:Y)3GL\NSG->E.Z@>=*&_^N=@-&E?;+H_'8^4U]CLIJ,
M$OE!I$`7=/#_E(`9ORTGZE0FZ<1CKN..O1"DQGC4Z7,@3C;ZY96N!.6031%K
M_V)4ZUM)/H&WSMDD2.E!4Y'>1&,^6JUZP"5"LP,]C*MXJ(Q_^J?NZ>GI(_G'
M[E)K,0(A+@H#2LY83MO.<6)2H`?-;\X2_&;SFK&Y)</->9(DWN31@S;$)>FE
MQ@-(\H$\F,!D,E'9I6^PEDON0\&&N.`<B1E52I*0X\VIFUD#+ZK]%MK@8899
M4;D,82I@*65Z3*2WEDJKESN!E3YD%_L50J;`J8RULC=Q.3]LSDG)J"PRZ<4Y
ML5JO>=)MGK0&15[3=-1^EYO,I%-_S*6O64Q7O#$4WRCVR$+#2(;UPCF+3&DP
M:N-36X1,5(Y-SANNZ2GGL<:L)/I6C'>2[U;TG2&P1+.<'P3B.[Y7M;?E2P;V
M((_%+$HPIT>^Q>8+%1-\=`\#_5ME.$8]C=$#29D$^THV(P>K'2V*5&>V2X$R
M1NVX</.4YJRJ>;G?0ZYK.=Q-:<;&Q_;C>`MCB]L-ZYVAO5#*[_-1BK*(6D44
MC\!5D3S;^)U9,30=2BCK9:$:5W#W!VJ-XH=:4LEV%O9U78E4^PXG+:)L'T2C
M;,$3I7,'`,['R68J4F:WJ;#7_JZ!K(Y*4EKP8X)")6!*)Y()$%4MS*:FZNLP
M%^J@/Q801G,KI*T>[-BN'*LZ=!+NQ4XBVBU6H"A%3:@Q%DT#X[%C#8=<)0+,
M8LKY/_9?VS3A<OZAG0PZ[)%_4\"V?51HQM$4]>(1+Z,$%.=IZ@3NAYK2A)%V
M.AGW0!4J6"O!]&+;_8PYE7:7"UN+VI[PD9O0ZMS#NU'>)B_.!QWPZ$+EO^`.
M$\I!7\)'A0QNL.+Y&PIFM!OHR3QF1S#_?1)$7.>@C[^]5BU@34QL&9"=<294
MH,4UZM&5%Y#R@[]Z)B\QQ[(D.QX2T4K/*T]\L/4]=9D>M51WE)Q*6_#?J2;,
M(EF\3>7@R8'O4DM;<HJ14KP02*U0=J6,E9"P^+5[08_H<M"V5GF4I$Q_U4NT
M\TO,S9[(N)C*-7YX_F-*V/6**0AJUD^B$'+1C_2H]<N(']6,./H-A$`AD<($
MEJ]UG(TX$Q:)]='.]D-PGE?=;0L]Z!5T]2A/.LMF]J;7GO1'>M(K-9+5W>F,
M)'*IEY[OD]SJEMHS#_23?>O2$U5"-(_RK3]PA3'!ECG::R?[,W:RES95+<_%
M76^2\T?9EOV;B"_0:?5\TYR'5IISY:X/*M%YB$Y2WHAS_"5*DM<.;,BA'3G'
M'[]=O'XDP:]#2>#&RK`XVFTC+QC)3J9E/OR+<Z?=;UI>0;V=F=H'_\B>%-"0
M2-ZA<`]%JJ+CV*0;I"2V6P6M.XW]JRQ5MI#M?D4/.#I,Y9.C.]DQVE$=H^VQ
M?-D:(ZOA?.`VT8_:&2[%G=P09+4@B_C"HO/=JG75"5P8-5/V^,\YE3F\`^J-
M<AFS$Q[8%]^JDJ4ZB\5$4!X2?T+WMWQ'CSTMLY!T^46?F(L&#`QUB_O1&&YG
M3.,!Q0R?,=$9D+]!5F$A^]0T_",?)8=$R/256X(_8WF?4#^L!7X-\1E]<&^V
M;]R1KI-@@ULK#**??</64O]$?0-W/F5QF4^E;N,IE6EN)4$YCI*`0YE!D^I^
MBF1\\[,^U"7S[\/P?1*0GE*XQA;%7(F1E[&F-(ZP>Y]E1W&%!AMN7@;?1='S
MWN2%MP[K=I>OO''X[;;JO=1[V?1>^-_/L*/3Y0V8=`ZKJ@[IJD8%>CI4FX8>
MU>PU`_^<3GJU'FB'T^5O3W;X?$BF[@>XD7Z`^[FQ^L1>`DL7.SC^$7K9V`<S
M:PWM&P\4[++#W537205GW>FI'E>/6[K\Z6Y:+UZ(V!>)`?JLU!$XYRU4GD'M
M\MLA]\VWL;)R1O?E\&MP=P4NEKILN^UF;[-\NP7>?%_DS9KI:G#W$UQ@NG['
M[0Q7;J=\$)?E><V0-;B'`6[;[0Z'[J#?/OA;\/RD5;-=#>YA@-MR6\.!V^^M
MNZGNGMV#P)+?"F9C[C%FS9LUN'L';J_O#MH;5E`WP'SG=F+77G)9>^@VA_U#
M(('!P&VUNH<`:?O4[?0/`J>M5MOM=U=&ZGY>>'86Y5[Q6LOM-4&W[Y\>!&FX
M_4['[797UH:VC-E!QVTU#X/IW'[_U!UTAVMFNY+HKV2)-7/81N-X<R%8.^2>
MPV4A`,]Y[.71]UV<>[V/>A]KU$SQESI*7X^KQ^V!7;<7/%*J!G6:;J^W<OAT
MN\`.6@<$;!]5]\'*+OFM`@MT,&R!M;RR.OQ,-4P+:4_2!CJ@#8RC#)-K=J?6
MU)NI-[-&]LYGF)9ECR[3/+KLW7OEX^SUO'P'-$[?7HKI+(J]^/[C7YF?WK^$
M-E^GSHFSY-X/ZA7\:<.*3Y$SCPAKNZ_>O]F%.LJJK'S^]K78]A#;H69P25+`
MC5M,Y,)LIODT0:WZ3LON.J7U.6D5JGYC/21_N(2K7I@6DM$'?((LTT)54<!V
MVQWV.V[_M%]5X91>E@=!:1!?YY/RW`)HD6I1C1O.!1P$E=W$<G>J`Q?.8Y`C
MFQ[DXY#\3)IF7^ZI=%ZOR%.4T5Q(I-GOFQ>]@RX^F5[ZL765&0)05<\"%T(4
MOU7R_9UC.\E)/,S@7,*T3,G2SZE_*76Q%[]>2I<T+V&KGD+HK6J&5:37[K\S
MG/KP&H]X.HM_^I"GME$VQ7(-U%#>JGY`'8[&'H@SV=O(,Z7^5>^;X2]4C@*+
MTDVMED:R+)0JPTBU?569)ER"*Q3*4;J_'-4VYSK%5#.6RT.HULCAO<6!BE]<
M^>]D%OBIB_QV)>N(N;I:$9>$HH_]4!5`*F$9K&.A\")Q@*5;J0T;?1U1JVYL
MHQP`*8Q=68LOX#J6A$JJ;@?_D'WJ\7-3*-2?Z&]5H8WWD1=3M^</?@P"BYI>
M4_%CSPE\N(+&GF[BS(6MZ$>8`.ZI0LN3'/=SUS9U!O+83'N80L9"8I5UHH)J
M!D+Z5%536\ZT*:/3>98=SAYBI0<\$K4H6(<HH%[6>.=J<D/6&0,K1D&F^>C.
MY^LRFY44V7/+J$H5E.'KS&JCZ-&GUFKR2RSCILMXZ:*6QW:14:H>GDUM$.QY
MN%`RU;;$ZQ%8F.4:<:KB9X\:`6))E\*]BS_D:YK*NOPHZSS3D9I+U]O-'U5M
M/ZIDR/N>*V%2Z+F-W>I1RV&)9K[+:1Y2C:#O"\K&7#D>J^5"OC#:HF.E+\W1
MUNS]_-C[+"6"Q6Y90&=7"3"6+)O\FQ>/;LPT+=:@.\S,BGN1WFG6J?<GUY2L
MN&]&AMY-H?5"^4HB_;$04];"Z4J?[X,QIVU3&[*J>XLG1,;FLIOJ7F32-D#I
M9G.J'6"^!2`5LO=@CEB($RQ_2M]S%2<NCLC=$Z@4E+RZY[=ENAL4ER<>QI^O
M8X&5&651Y;RLR>M!#`'K0DO+-"//7*UKS0LU:F@":OX/D>:KRQ<Q3%TW:"*%
M9UFZEPE*?F6POI0$6<;UL>ZZ:ZK"5,D>=7E:F^YI6^A+XM,E@BX<NH46EN!2
M7*.N2N4GN8!N!9LI/*Y"#Y(<L%+G?)VRARZTA\_>TK*YZTJ>Q["8QACQQ5=2
MPKT@/"H#IED_$2!"J1BQ;D73D+(@E#)(50$MF0;-?^ZE<^5/LIA;YNC&."7O
M-)G6>2EI+B@(4#E/J>ZPMD)DJ6GDZI$7Q_>XQQPJU!990P`A<$O&$3.U;9<`
MD%9S('FD6(P>2Z'CDK$@^08+L"S179!'-UYXC:5@:0*:F2=AH3:*P.;_EZZ@
M!CL%D%6!4U,SKBYL>M"%3=??/>R_/3!(8ZOMPE#ZQ4J;&SWL_%KX!J7H$%/%
MB56Q92HF'6+U==U,`EUS*!MUNRO%#YHWL161>]KIN8,F=_^R^O`8>)=X&Y.O
M:6PWF](,#<JQ['W!YCTVGW*[@Q:!2H8V\;/5ALCNOK48=@,LS;T$P(B<N?/#
MP]MBHX*T*+;&\QU2M/![K/SDQI"Z6YHM.<.Q+?3R`I(N5_,9?\&]>R0%ELM&
M.O_2Y51_'0LRD-V%1A_:I7PGG:A'G;[;PQ1O;"10I"T)N>=<8\ERIJ1^MTN4
MY('1-?()".V,KI3_JK)IB.7.IESNC/N@5+?*X,8&E3[OA4=2=#=OC=8J(*Z(
M#R"FB@<$&R^09I;>@-*$!V%D#M.(EAQ'S4836$_W59J3&K]'UNA2I[ILP2CM
M9SN:`%2TH*$)D?D',/ZG9<UF8)`LXP[G$BSJ7&#'!9<,6JVW+K99X.L$<2_"
MA'CNNR#+Y#Q*TH2BD^_1S?N-?3K)\XT>@I`PY;.?B)R#"B^BY.$G`E_YB<`.
MM)X/6:S\^62^+RLTF1WGA8C2%`C>D76`NL]DS">)MUFNRC1Y2[`[P4^Z<L#R
M..J"O=>4O1:/6MP7U)66H\7KCK6)QPC^I?:@'#0E.YD'N.5V6WT#<K<[X(9/
M>7#/++UF0?\F.A,J,IV%UB69`V4442\\C=$P"D_@7DIST5&%8-4`!8VDHZ[;
MYI94'/1-:%<CTX?56E&Z=XI5S2TG#Z*BW3@UN[":SG+TE,['D^6_$_(:>>B-
MYMZ!DQPIL!?1&S'4D\BT#6$218!7.^<77NVZT]]*6>$5/NGM*V#U7O83L'HO
M^PE8O9?]!&Q/]E(1M3S`:K&M[HIE=^?KR#N'4T=\Y5W/U9]?]Z:?#V6M6JM]
M[PM5/V%C^UU:O#ZQEUE:?-_'/:*$?.[X_BDM_5W0YKZ/JW%:X_00QNT>I[7X
MWM$1GK%_MN:*&J4U2@]QW,Y16HON'9W@1YDM57-%C=,:IX<Y;O<XW7OQO?'>
M=G,)-7MY_*OM[1N^8GB6.ZM/[1!W5I_:(>ZL/K65KM&Z^^6^JEWUN'I</:X>
MM]YQ97?`SOL*R+L;'\S0-%;EH(G,R-ZA8"_K(M8?#-SN8(LM,^8J1QP]!N!.
MXW3EDOC;16Q[V'([K2UV1G@:8MN-SD&TG&B[@V[+/1UNL2+P4REV>!#M,8!B
MVSUW,-@B>SV58E?O]+/<Y;&!"^+7_>ON=$J/C0Z!1`>-T\,H!-X<NKW#0&F_
ML<V[_PDH[?4.ATI7[Y*\590..H="I<-&YWGU'_L4Q1/A8U&@_;H+^*N#Z?BX
M$W`?+H6WTEZ.6QUWT%R@?177Q2&O=XG]7J.]1>FQ*;0/%@O!O<-ZJ]78IM#>
M&+5WW>ZBII)[A_=>8W5C?KD[:`/WC,I<V,0MLS'*>,`>V3O*:#>:V_2?;0CM
M/7<X6.`!VCNLMQK=YR`&.VVWN4BP["'>>UMT%&[P^NFW#DG(M!JGZS:!#KU3
M5P6%[$7/SN<WKL9SC>?G-*[&\V8M&?RESIFJQ]7CZG'UN/T8MYSTWEW.E&PQ
M0+/M9;;4H+?E;*GG,JX,F9U!TVVW:V36E+EOR'SFE%EQ#=3^H#WI#7X8XVI$
MUXA^7N-J1-<^H;W#;CVN'E>/J\?M7GJO64;_L]"U1+M]9$]J:FQ&?]/=S52_
M%/JK:IHR-CUF-NLX>MISE=Y>O@/:F:KU1%QV]O`AR*'BLC_8OST=)B[W\S7-
M1N^)0W<:6<=96W^;'E<CNT;V\QQ7(WL#UTN^I%-9N:8WU/TO_Z<-]^4L[YP8
MW?IC;+=LFGK[X22*I]P,TI/-O<OZ(!*<V&_DA;=`['8?W]6JLY5V6Z=;6>6E
M[^5%H6QY9;HNXUV.Z9TWT5@[S!N'\[$XVZ+)6%/Y6JE\AQT<'D/D&P!S98Q=
M7\?BVDM?0HWO?1^W^S+MFR7[<R"!V!NEF1?L`^E_!FC\,/%'+X#T-U[@^`)#
M5W7MYJWN;+5FOR*>[HC[5@/X'Q@$?0$L6H_;KW&K7BO'GT,GO8FRQ`O'R>O-
M$&Y=\WU?J>:YC"M2>QFA[#'X*]T%.WX.EJ5)"C+##Z]WR`][\<3F:<D(W4:K
MO5>,TF_T.LZ]\.)DUZAIM=WF<.4J-LNQS0980QJX>)'M%6NTW--!VSWM[6%^
M6UFUKOX.BK(O8(M>8]!<%UL\X0R;[FE[PP7NMGR3?/PY$R/,$$TCYU8DZ5[Q
MS*#=<IO-/<QB+"V[O5\7R;#1[^X!Q[C-WLJ%GLL89CWI#CC+IRCPHS)3Z$WI
M+Z5S?#O[]>/[[Q_/_EX<;7$BN0LFWM0/[M\Z_W[I3T7B_"[NG._1U`O_W:4_
MN(F(_8G.KB"N=9I^^,YY-3=MN6-G8:(&>BER\USEMW:U>*<[7W6W*2D?Q*B8
MD=+2&2G-.B/E!:4DU'LIKO*B4%:AP=5^X:4Q76>D;!QG=4;*KL?5&2E;PUB=
MD;(WX^J,E*VBK<Y(J3-2ZHR4O4=_G9%2CSNDV[C.2*DS4@Y_7)V14F>DU*VP
MUY61<GJZ)QDI0[?36;GU]G)LLP'6V-^,E$&[[;;WL>)266NGX0Z:KB_,2!D.
M]R"^WG7[FV:).B/%Z@/?[[B#WA[6+RK+2-EF<>ZE,E).V[OGF`[<(6MM$K>>
MC!3SA_]XDR4GUYXW>_O!3T9!E&2Q^#HYCZ8S$2:4E_!=!!XPR'F4I`EYKMY[
MB1A_\^ZG@/SD$KCJ?1"-?OPGS*6`HS\`B-?7P%B_1RD:1>IW-K2J1BA@/H>C
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MDH@T<<#.<`+?N_(#.&#9MW<2Q;#B=!;%7GSOC/T)?"9@D<2Y$NF=$"$M,/%#
M6-GW`E@"AJ:8"W3E)3[/B2-P&?Y+-''\E"<O7[?A7!9@CL<PB$IQR@0BS#>B
MK7K7GA\F*<[HA"+5VZ+I]=;PSH,_9O`!PH(#1UX<WR.87.`3!G@P[Q2N81A]
MX\&,B3.-8@&`_1#!/?XM=,*(IKIBA3,6<(+_$N/&%H^9J`SW-8N8"P$Q`"0(
MBL0?"SQ//+`,4!.G@)GTWO'G2>/3V<5[`O$S7BJS6*2,UM^CAI'1W:'KG,&'
M@!!$$T[[1WY:F^8=_G#8;K7?(2;]_,S1A-:3-'G2:N;/^$H$O@"E1&(>SM(W
M.YT`60``UH:!7,9XFOS/.S\(U)$D68+P`1J02K*QG_+H".;&P_-@,R-_!F+>
MP76]\9_P`8EW7IKFBD62!2DA#LX%]@%T3;./@`:NB5801$/S"K1W2%VQ`%0)
M%Y:SMFN3MW/CW0H`&%B':7N;%'0!,_D3?P2(@"]"[UK@[IT_L_$U_8>/J+^-
M@EM`(2!@+&#[4S]416XILR_!$T5ZX$-2K`9R=QFIXM(?$/ME_*PPHAD;>)46
M*)FYX7Q@SC7DCN@E$H<S1'47?T6XF545+>8FLP71F.?#+V[\)(U`XE'E7Q%[
MQ`1P2R6T@U+8;[R$CQ6T:]!,_.1&RB&U%YP7D.S'(B>K+#EUY04X%7-'V1IP
M/E>HE0!]T]3F##4##MXE"(&/I$O2%J8G'4KRE,\B^\\L]I.Q+YD(_GAWXX]N
M<M<%;UQ>!$J0<XEC)[H5L?RD[-`E4])Y8EX#K(^7)*/@5B@ARW%?*4V1ZQ)Y
MQ3B3.)KBZ$38FXES\#'[)G/#8#.3+`5]@B9F@.G4)`-+#)3A=^JA-(+C$4"$
MKMP@",%@K$4!7`8^K#]BNK3@R9W`O'0@#*I=&K("[&^/_<_2BDIP5`6.("Q-
MRZ647#>'_!L/[AK`4@Q;1&K.<PEMX%AAI-U\]_O7+_I?K7>O^?X]`2ERY^'M
M#OCP9B!=?M(1`HJ/6JVVV^KB0X4FP75T.G"'K8[^-_`82'&8ED7S0].=]MQ^
MLVMF&S;=4_@;_-M5PL*_A9&N)$Q)/-ZMYP?$/4:%8-I2[)2%@4A@113]=WXB
M%+L!N4_HSLE2G]0$1I]"607@Q#?BYPQE!(!QZP'M9L`41-=*XVHWVQW:1;N)
M1Z<X<R%&EIVXJ2?>'E4"R$5P)1\FV=6?4HQ[80BB`FZ2J<]*10*H!URR$H,I
MYM]1L&1(H6,^O`M!TLVBY&';.08A,D(:CDVN>D+3`=$P"@/O[K42$I:PDI>,
ME"(H9FB5Z"X4<7+CSTC66AQR![H`0AZ-1EF<5WCPJD#:N$=-%/X6""I&[U".
M/,M#8<23G)>ECM2?G<_?OCK';%6]1FVG2A"5(!=/^.Y&(,4RJ<QMS-H4:2NT
M!1+QI"61/*23J%R6[_M[NIZ9`9B?'#(/>%.XC7GP%M!=_;XDM[6]?%]2YG%9
M9.JOUYWRR?-CR@TQ*R7/V)_2MOPI"[=^6`Z5=L/!W3B%+)^M74B7.24SFJ%P
MOL"K@6PDD%R?M'9GF<@7&*@E`9LSI%N]@6MMAV#^37AX/FQY'J.=.&PW7[N.
M`-V7%!'GOSVX[N)[:QI4PIK#!ECA>.NE8*`XB5S1Y88E[,KP$V4PD2'L)=)R
M\\G[H<4W*^?"O^600")`/T`7"-DA<$?./)]^(`)%C=S35MP]:W=^0S18J;'T
M//$3+@5:+*?NH3$-,A]3O-"9@G-Z=#EKW0-.Y@>L#/<RF^B(&8_N%S9T#,9(
M:=FFTR5G!AM,Y_7A#"Q#K599I@6JH=[H1KFU;GQ0_^+1#>.0;O8H$:4?D+$7
M1S\`.6.XC]&G@K9I+$!#`;4D,*:@M''U^2A_BQ_.,D1C(I_H)<N]JGLLUG)B
MH?M+.1J_(,A.2\,$NM%?682<1=22L*.*:)])(6$?`T[BCX#3I&49L<YB.U2(
MJAD%ROF('Z6L9^$/EC;BC4:HK\LORLGJK``*>T%Q'L4=!M7HXU3#C!5M"#Q1
M'QM'0WX"TJW8:Y%DDPD0/P(SB<5?F0A']Z2MW49!-B5E4KZM)*2II!#[;67$
MC!9>1]H'6_0F9$:`*&(S'C)8&RP>QV-WFN4M&HMKI#R@6.4LV@P+/H*8VC8Q
MR?\D.XR]M47R&@49>I80TW!0BAYSYEYT!3?=+1D&U4<.8MJG5<9@3(U2D&?D
M"U/_:CAYZ.01T>IO"T#A(@GHT8$7&_K.T?8<5[BYG4H?Q-QNU:Z6W=&Q:%PW
M7';;BB1U\GZ?>U_`C0%DBCY::T:/K)=I%`(.Y/HT`]`:;82,!O(T(NBO<2XV
M.$S.OXT)!(Z(,R#/O'&AH/<LSI#F7!1F=W17J;,&N0>V4LCN&`%31U-_I!A[
M0[Z51Q!IQR;2++2P)_]>?2QXUYOQMD1/;CSVKV4)7]]RN[8>(!V9`)BV8.<7
M1Z"`[?.^#I?]V%?W[!A3[G]04S-OWET8DU<2X$WQ2W^"OEU7'CG/B_2+DFZ!
M%%THCK>E\LV_8Q<):6BYQ^M74;;`[&4FEOL8X[[P2`AJV4H.PPH@*8`UM(2N
M'[N_H-?.]5[JO6QZ+Q49:/OSKF7I=Q2M[JIOSU2<PU'A#>-(6&>>TF&B==5W
M5U)K?CHJ]W9O[6>\M\ZSW-MEE*[C[?#S86Z0F3D$'?\14BZ,&&_HY=DS05/]
M1J]^HU>/>U;C*J35;I]BG'O)C2/^RGP``_T+QZW7&V"D)[Z7&[C=SA:;<S\-
M6BO[M`9Y3VEB.5;<`+M]#O&]TU1Z\J1GDN[6L;A*G01]<>1L/VYO@@\?>S8[
M)I'5P>TUMUBJM\;J.E5UR2F'I"<^K==UA4FYBQ.O]U'O8XV7)_Y26X'UN'K<
M'EB!G68U_YR5AXHY3%S;@T^"=JNJZ$NT`T\[ZVYA=.A:J86P)VD0'=`@QE&&
MYNGN5*%Z,_5FULC>ZZGE4:="E7]SN&DJ]5[JO6QZ+\NK&P<0KUXM04(]Z7;4
M2VX"ILX"J#.AZDRH9[6W.A.J3O$Q8.^AD5R/J\>M>UR%M*I3?!YRX[4';N=T
MY2ZRVX;V`/VD!PCRTVAB.5;<`+O5*3[;`;?==SN=YOY!NN_CUHW)"D8[]!B*
M1-9>9F#4^ZCW46?V[)]HK<>]Y''+<4^=V3,W]E#-P&UKH"_.`NQUW$%[W1;@
MH2NF%L+V,^NBWDR]F>>2W*/E5ID@L$1(I[RZ$R4&P#^&O[QS'J/`5\,V]P=V
M+=E908NRAXJ)1DNG*#TL1?MVK5Z+>K:;M=%?,0=#:6EP/*6[J(CR:=P<MUZO
MARNQ^)=N",--8!*[@+Q=5LWJ$9'<1'%Z@J5!L3F`]#"J:MVC0@2@L?)5V2D6
M9'ZB4KPRNMMK0O<_5"E*KC^GJYC.U0-5A4!U-4/JX<+E$*.8ZLEQ&3JLAF<5
MJZ0UK0IWIN[=@[4;+ZF71+YF)%=AC7'H6,!I<CDWA)9WX>(O7D!EZ`DV69P3
MQ$T6CTQ+$B^)0I(<LGPK4(HLRXOE0F<>-E8"$+Y9I3W5#`H2`#5+TOA>E_[%
M,GF>J@H:`RC2UWT/R$M2;*3A!UA>$=MI!"`KK5Y-$DM)ZJ>9W`<6>U05-'V8
M'*OQWIMM,*Y5L4TN2.L!*@$B_XKF.*$BD2=TI#2_%UQ'`,[-%)E&U=$5^)7G
M!_>J<"JQ%B+?3YP1(`J;$GAV66%L<"3")$OF:@L3[IT[@9<AVEK8;>1:=OX@
MY"*5"*QQJC"S%"<NO+-,9?.%1;>7+&W^*8K2$/\B^Q70#[C(SZLX@/_\/U!+
M`P04````"``A@6<_'8WE@$`+``#J@P``%0`<`&%L:6TM,C`Q,3`Y,S!?8V%L
M+GAM;%54"0`#[DBX3NY(N$YU>`L``00E#@``!#D!``#M75MSVS86?M^9_0]8
M]25YD"79;5IGDNTHOG0\XU@>V=GVK0.11Q8F%*$%2-OJKR]`$I)(`B2H2P5F
M\I18.@?\SO<=7'@(4!]^?9T'Z!D8)S3\V!F<]#L(0H_Z)'SZV(EY%W./D,ZO
M__WWOS[\I]M%?WP:WZ+?(`2&(_#1"XEFR6>?,?N*+NABR<C3+$)O+MZBR1*-
MQ^B2AB$$`2Q1MZL:^82Y\*5AVMKIR2#[+B#AUXGX#@E,(?_8F471XGVO]_+R
M<O(Z8<$)94^]TW[_K*<,.ZGE^U=.<M8O9\IVT/OC\^V#-X,Y[I*01SCTUEZR
M&9W?X/S\O)=\*TPY><\3_UOJX2AAJ187,EK(O[K*K"L_Z@Y.NV>#DU?N=P0'
M"'U@-(`Q3%$"X'VT7,#'#B?S12"!)Y_-&$P_=G!`YJ*%P:!_?M:7_C]<4B^>
M0Q@-0_\JC$BTO`FGE,T3U!TDV_TROEG!E_Y"1J&O$!SXB4?G/6G3JVZFEZ+T
M<.#%0?+9K<"40PNO$80^^`JO;'77RV;MDT@VU>^C+E+VF__%H8]29Z0#K:BU
MIN(3#F3&/,P`(EY'O]8XK]]><-QC)F*=042$"(U`:3WW@_`A$@."U("/IJ.%
M'!X$\;6457OM']D%YK/K@+XT`E9RTN+2=PB[U-=G3I;K8G1$*SA(CIZ),=+E
MV:KG)9@$JH!Z.8-`#F*4Y<//X"4CU13S23)<B;'_">-%3]+2@R#BZI.$J&Y_
MD(U:/V0?_SGD7."YB)G,,76!`$\@2"Y;_+YW!(A223&\R'^N_A^39QQ(A8?1
M!69L*6:\_^$@!@UT2[]52!NY,&3YZ##SU`7$?W/I49XM,HL>C^?I2-8E(@V4
M_Y31N9;:['JT$7C*?&!B!=!!,1>8Z$)>3XX2+R"G].2;8V@F5Q80X4D`#^#%
MC$0$*I*LTMI-?2HA9ZJ<NJ;*/8,%)O[5ZP)"#B*]1F):875#@)67FRI90<_4
M.G--K4N8@H#H7Y-03AT7E*]`WX%.J#H'-S6J0YW)\Z-K\J1!&:?,H]-=Y%F?
M]3^Y1NL]HV))&2WOQ7HIN:L0L]]B;LSY:G/')*@&FRGRSC5%;@F>D*!F"M<9
M':57>AZ-0WG3M)23<\7"UF!XM)0QT[SJP0;(6>+\[%KB"+PL!M\J?RILW5;$
MA#H3Y9?]B5*^WY6?_#F*(TYCYH'_`.R9B%O4+#\*+-<9.TIS'>R,YW/7DO^.
M1E`_"FFM'%7"B%?=A/9=T^`"+TB$@UO`'$:3@#REE2JS''4.#BM3!UV)Y%RI
M8",TL21ZB*CW=48#`9;+Y5&TK%YL&%Q<$*HR&B5;Q=0Q<*Y^<$O#IT=@\\U1
M0">/UJP]DFCA*U&<*Q,D)8V-&.]HZ!D'N"KCU@A4%822R;ER@=7`5CF4_8-@
M'V&^H`RS90I"%9V'<WG_H<%=8W^TS*K/I1KD*IV<*Y-<T/F<ADE\QN<?)1.'
M=2B#5=0[5P\9^CY)H=QCXM^$V<IK(P+=_:V%D\/RV,!7@CE7A_A==&HLGYZ%
M_E@"X?)V,L*AW"ZCD:K:W&&1JH$K>?98D=B//&.(,`G!O\(L%$CYT//BN606
M_$N8$H_H9AP;)X>ELH&O!+,K;;B^:--9J.>D%H6##[W"5HW=]V_4;&/)-G*<
M%C9RK+T0G:*U'WKS)<2Q&"7!?^O.]HX,7_B4/0+5/:_2V!QG&.`@DD_N>KB$
M9PAH\F0DPZ0=`2KMC]8QC)2O^WXE<-4IG"O4I!M(`P%[Z,])2'@DXWP&LT2U
M'NZ*5`M=R>1<D2;=F;(.S;C?9M/$72'*6!7SSE5B;D(QM\`MY?Q:Q'=!0P$[
M%LC+D\N&%C9.1U/'/J)5;::LI]++7)+I'DVP9^"1''W30&_"")CX1"N3R;1%
MXIB#4!HY5^=0$,V#6<FB58(4L"L=S$6/8_65W\3]"I>Q`1^%5Z^RB\>$SV0R
MC::7,-%U&@N?%HEE$8V2;X\E$,-3?P&?R4=]EY#^>Q->8\*2TMEH>L^R/77)
M39>(+3LJ=`TXBIEV8\!N[;5$Q3U$JA1VKHIR!]&:#-U.@_SW1U-,BW,]'M;+
MJ11P;L=''OPEX5Z*'_PU?!']:/J(7X=1Q,@D3C:0/](Q+"A+%DW)*:C:5>).
M;;=!^9T"5/NYG=N.DB-@^(Q)D$:P447/"F2?,"=>72>V:<$-L>UC7>TSRN>*
MDM2YFDCA\>$-YS'<`R/45]/,B*F)IOZY:8U[6\5L%J72VEQ8.=82>`P^P%R&
MGE\F7))GXD/HZZ9="Y^VRFH1FM+27*KI_E,5_O)YT*S`?U99X)=N*/%SL\`O
M-)00[QF5I/N?EE\XB&ZU*L,,O4C((9_2Z*<3:^>C3YANKVD;BE`SSSFW>^G[
MVO90&7"`A:^YB-=\YOQ>?MB_[/LK0YQ]KQ.Z*7&S>N&9N5YX+!DO8<'`([GW
MN.2.&F]^W4)Q\@$H'0Y_6BOKT'-9[T]YR@ZEZT;%"N.645X7CA+`7-0[5D<8
MSN4D^U>"=S1-#ZF+,)-CZKI]GI7F+5.M/B!U.-^Y6MN74,RJ`?D+?#D,RU%X
M%*X??^J4J_5HH7BU,2G]S(6U`RX9\V_GX&HTR,Y!:=^OL%-++1-PIUB5L.Y5
MT<H1%<ZUZV\1ZWQ:)JYE5$K&/>YULNZ>V>%V0Z)M[/^UZZ,-FFN9EKL'K&1V
ML>Y3B"J)846(.0OT"5[AW3+1&\>G-'9NBY7^57/Y!S05S[":N1]-Y6VBW*C2
M6F>(DMFY8VN&(-+E8"X(RYVKNS9XE+=+X66R\GVD0T]D`0/=>_PTL5KZN3:&
M-11W]9XJNVA5JKM7O1(\>`!^4E)_$#U==/S/LG)*HN5H:BMY\S:^%?F;1ZY2
MP;EM<:54-KZ#S:;75SA_*]HW"%F)[E[1SIZ3G>:U5JANN9BQSA?UXDCG2GZ6
M4>D?L1H6MCNTU\+4V#%BE1EVN_2^@1L`+:6*!><.!AJ"6)7TMQD4M<Y'7_')
MYTRCA'9^]0K,(WS]LQ:F%9[>Q[5.7"&6=O6FCTJEZ.&KBIM@%(#B]@;UV@I=
M&;&9?\O4VB)"I=P>"X6-E-O8&MI<-JWSMZ.9-CPEF'-5O\T8Y(YL^>[U7`PU
M`Z;!IV5R6D:E5'2NJ*=NUT;3!*F";]J=4&W>1NTJ`U*RN5>@&L-BA;SF;9IF
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MBN41D=\I^RK7N>FB:`S/-'B69T:LZ;-HZV!\6ER[1/#/18)E(TBVDOQ4=M8.
MRAI"I2BV9UV]CEB>%!#+MH<99G!U_]"`:V,+!V/8>,42K[\4>56NZ(UT?HN$
M.TK\T1O1PMM]=/I<';])ER\X'J[#%RY48NV\R-K*`^6Q;<_2YF.J!ASEW0[&
M4/XR17X&_2(_B3TJXMJ>G?2$^"-^;32]YKP.QDWN*B5J2C<7J3G*H]IE39>=
MF&ZTA%OY''#%MKI&B9/2;8,T1AN(/O2DRT3<(HL__@902P,$%`````@`(8%G
M/[X7\`:!(```C,,!`!4`'`!A;&EM+3(P,3$P.3,P7VQA8BYX;6Q55`D``^Y(
MN$[N2+A.=7@+``$$)0X```0Y`0``W3UKC]LXDM\/N/_`RQZP">!.IR<WNY?!
MS!P<6YTQQK%]MI/L8'$8J&VZ6S>RY)7D3O?^^B.IMR4^]&(Q]V$PG>ZJ4A59
M5605B\4?_^OIZ*)''(2.[_WTXN;UFQ<(>SM_[WCW/[TXAU=VN'.<%__U\[_^
MRX__=G6%_O9^/4<?L(<#.\)[]-6)'MCO/MK!'VCBGYX#Y_XA0B\GK]#=,UJO
MT=3W/.RZ^!E=7:5$WMLAP?6]F-IWKV^2O[F.]\<=^1LB/'GA3R\>HNCTP_7U
MUZ]?7S_=!>YK/[B__N[-F[?7*>"+&/*'I]`I07]]F\+>7/_MXWRS>\!'^\KQ
MPLCV=CD6)5.'=_/NW;MK]E<"&CH_A`Q_[N_LB(V2E"_$A:#_NDK!KNBOKFZ^
MNWI[\_HIW+\@8X#0CX'OXC4^(,;`#]'S"?_T(G2.)Y<RSG[W$.!#/1=N$%Q3
M_&L/W],)HE]X1[]P\Q?ZA3\EOY[;=]A]@2CDI_6,*]"[$JT$Z5H;EUL_LMU6
MK!8Q$WY=^J\YX:O$,7Z*L+?'^Y1G2D0PO^P;3"\844K6WY4(NE1)_""EQ[[Z
MTPO;=8Z_3_W=^8B]:.SM+2]RHN>9=_"#(].I\5T8!?8N*H\=12-C<W/SYMW;
M-VQD&A"ZSEBD/(R#,I]VL$N_17Z4B)U`7.]\8CVGZ,J-1S9&/P3^L86$D=\`
MZ7?WSKV4J"1.@$/_'.QPVW&//T#<`L&DC@][5Y\VC92"#<G/Z;>0[>U1_#54
M^!SZ>_K!__DQ1E'4HY(ML<\?[/".\4!\]+UMGZZIGEQC-PK3WS#-N7ISDWB7
M/R6__GT<AC@*)^<@H(-R,2W)P$E@]>J6$N-4GX2`C75(9=K)PGGGAWA>9%IE
M".OU[>?)I_7:6FS1>+.QMIL?+G6D%Y;=GGB-84<H@39"M2=V^$#,G/[/^L?9
M>;1=PEDXCB9V$#R3'<UGVSU?^HB&N#"JWTBPHBDH(4*91@/FJJ9"D)B7W=$?
M<(ZNW6AZD8+]4$`?(3M"*07$2,"9%=W<X\B^<_$&[\Z!$SDX=1*<,1%BP)B0
M@A!%PQ&`0YF+E*6*>LV\1QQ&=$,2(L=#QXP`"C,*VNVEN1@Y!LI1LI4'SBY6
M`3[9SMYZ.F$OQ,0'+*,'')064<X8*&'"V$D#H8KVHH`&93?*K%44+\%$.$8-
MF:OV*3;:)=L>FY'1;D3=94I0F4@,&5WLZ.#L:HH/F+"POW4\FJ^9^&$FU`+S
M3$J&!&--:J(4#4F,`65#*EQ55"U%0@>&17<R.XJHW5JZ<9]@(8:6F<<($=1!
M)(EP`#@90(D(E8C4B,2#-.%@1**!HP0L,0J]=JDP>K$6C1#C?!AS*R2+!QU8
MG1M3_X2#Z'E%>&1Y3Q)8GH["Y5.,`K45E8M1WH/RX>$VGS*>JCNT]7)EK;>_
MH?%BBJS__C1;?:1)P2N:$J`N&[DX)%O1W>Y\/+OL&&Z/3P'>.2S'#+`5;2YA
M@C)"#"G.EJ=H@`LK^&3I7GR%'@]VN>6OL[`++&\!6&['\R1Q#[2B2I92\!6T
MQ<CILX>Y8]\Y;C$9)3D:$R'`V(U<A*(M\:&A[$O&$?>X;#X;OY_-9]N9!7!F
MUICK`H)9IV?CW<X_>U&XLI]IKE42F'&`@98,(>NE):06$FQ)$7!3=>0),#K%
MT/J7F5;<)M`&Y!4)2\$9[ZL6RY>7!P^FYF(!+C2]'AA0V44,U6D0A<^S[R\7
M?H31]Z\@%+\5YW6NOHWZ<PK!EN<HEG._P<&CL\.I95Z((0,&*!63LI[5AW$A
M!U'C.BU08:.B`CD\2A%23SB(^@KLKRO_8<K_D.O./JF<8V&Q9@'TK4#4@:GM
MKVHA858=`=/%]:8&#&JEX;)2T1(&F>I%LL#\5?\"TY1A<_94$_ODT.@?VR%>
MWKG./3-@R<9*A@159*<B2KFZ3H0!5U8GYZJF$HTA(9=B(3]'`ZBGZ\`^PT(%
M-*Z)Z,DH#SL7D.DQY72(.>DPM328.>DOI;-&-T<S(/?5(.<%FI'N?[!!;'%!
MS*!IMKH.!]Q"^8)PC+6*8(#=\IBJVL-R\>%J:ZT_&I.[5F>]:,HYEA$9[+GO
MW6]Q<"QNIWFBUX("V8&`[9+ZU\"!:3V7%W&,-4(>CI!_0'LG9`EB=!4?D:=Z
M=/(#=E4.+!9K+%D6C.76`&<"K)2WUJXYXHH08,Q!+D+1*/C04*8AXZB:JF+E
MUR[1NRL24!Q!MW0MF>>L"G!VL(G\W1\/OKLG$1HMXXF>)3LD$0*,'<A%*-H!
M'QK*#F0<551ILUU.?OUE.9]:Z\V?63'5]C?]FZ+F;!<0_HQB%#2.HL"Y.\>W
MEB*?+!+&[)*V^$@663MXCEE-;QF.CW0YY@R*!`?&0)0$*=J($`'*3!28JKO$
MDU3SAU3Y1NC?7[^Y(5NL`#W2JZ)D3W7S9O3F#?L/A0]$]T)DGZ,'/W#^29!H
MO:7GIW]PPO"<_-(_1[1'"NW^0@L8-V0"\/&.^/>W;T:(JA.#(G^9XEWRAQOV
MAS?:S;3-L&4XB96.\BNV,9XQ1DG<Q3+81+1@E%W^7>%@0V=+;3#XV$88JDPX
M@<GR4`TQ7C%[<C/.+!C:G!H*4C4L0@#Y`8I)Q!?8$2&"&!5CS(QQ$XXSSZ@V
M.%4L(\R*)XS`G"Y1##&C>K;DYE-9Z:#-2%&0JOG$B&C,E0389&9LS]!D$%(,
M@TRE+(343&)PHTRDR)*R><3[/3-,0R@`URQFM1(`F\0RWSLW&8$2FD'&42..
MU$(*.$:9284O95LI!$1F&(Q<%*[5+/FR:*P7\H]'WV,I$V$WK@H84$T0A]U2
M%=`%#%C=3RT?U>H2!B9(',@R!R3D_X\W?QV]_<^WK3,(2A_Y[OOO1^^^5_@(
M?#*BV=!OXJ%GD"/PQ:S`>\.L@Q(FN-TVR38HH!E@W0V#\[+!PZ48.DN0V(VA
MJ86">(II!2$&N-VHI!,$X`;8B6+T7;8/^!Q":PD2^S`H=U`119@WX$(;8@O\
M?`$'U!@;$(;9M?H/E"1HQ7E)[XW:4*EF!L0HAJB_)",@@C?&$.3A<ZTU0*8!
MVLMP81=&Q/_C_=ZA]7VVN[*=_<Q+[CH4A.0,@PHBT*UL99%*U[.E6&#WM!4Y
MJUY[SA`1;3%ZY7AH%^/JO['=@PP4D[9-3G!'J&A6<!;TQ0X"FW88]_9K^MB.
MPO(B1H&Q&A4QBO8B@H>R%#E/PN4%?4WPM9M'"\93%):`BY',6%'6.+(=#^\M
M._`((^$X[[4VQ0=GY_!JVE0086Q#7:2BA<BQH.Q$E;.Z1AJ%OGD,4KNMM&8^
M140I)GI9E"=!'N:"@_1BZI!3`EGES1&W#M"4JNXZ6ZY"F5/%+>SC5U?#;4`)
M=_?2;=#KJ@-,`LA]5;+?4#99.1KXK56A.)R+J[4X!MQ=%?#%T;+"U576_=8(
MTV\I40$MZT9,2R?,N**N9VYT;ME#3"R./ILUQ8_8]5F3Y>1%$NZ&18@#M5%7
M$*2\1Q<@P&W/I4Q5-[?6QAJO)[\P[9I:GZWY,NY\;?UM92TVEOXFR*VD2'"8
MS1>PTM=QX$PD?F/9)<*,]T?'<^BML<AYQ&(CD6+!F(FB,$5#D:!`F8H26Q4U
M^V`MK#5M<DUL93S].%O,-MOU>#O[;,&92TM)8BQF+V4\>).)GXDCP:S81JI@
MD`\25MFMOD*8P\`^/7C)1_6AOO'Z5VL[6WR`4VM53E,PGMKJR<+T-JX:&TR<
M,#7XC&7>&Q(U<$#M)'@,E[I(7`*!-8^H9Z3:=F%ET14$TM2464WA4EL;YKQ#
M&E#U-[3ZK"U_P77F[?PCGGG$IY#?<$3D@\/8GHS]H@GR8*$L4<Q/]:W=Q=8B
M0=$6S1:3Y4=+NS4V93<#1S'\"*48D-H><R#>P%6@H'2[EMFR2I=`X#2YA@V^
M`B=>#T"#E=A,H(;9N+V+V?3P/3W@&GY0-284;,<+YWY(UKVE9SW1=?#LA`_4
M`RP/4WS'6U(4\("2"JH"E=(*,B2PQ((:8]6`?#Q;H.4"6>/U_#>B973?\FFV
M^87EXI:W:&J]WZ*7B^760G_1WTNOM504#[V,,5\AWT-E9-I`D*+W^)@&604#
MVF]YBN/_S[Q;VPG8[9+E(;L>RM+P$Y\LGD'H^-XMMJ-SY7Y4#_0`GN3H8P"R
M5SNZ$-/[L$=W3FN6J)@42FG2*D)*-;FL1)0WOV_,**.<-$IH@[P2,L!@3*W)
MVAIO++(O1K?CV1I]'L\_6=0UK=;6K;5>6\GI%)HL%Y^M]69&O-FM-=Y^6@^S
M!9&^-#+`(+PD00$;A5?(N/'@)JF^!8W0&9O0*(FN2+?$9Q)9R7IT)DM2DE7P
M/5XB3`41*H)1%:D<U,BPX.(<-<YJVG%O-NAVO?Q(-8[LH#[1Y$^2!EHN]&?6
M6@L2(\8;IU>(SC;*L5&.SJEQ@LG+Z9HV*%\QI9VNF5!XG\NTP&0+O+6?BC.Q
M]=>8];_V[BV"P"V-ZI&^"9ZGAP'B.Z@.Q,WP8YT%J$E*T`QE;#G3V28Q'K+J
MYK:3A(QO]8>,@PM?=9'%CQ2<)'N(GF[6R9=&6CVF[-C09`71^)@>CO*!X(S4
M!0S0`WIUC):>SBL"@#V:5V6B^N"!M45TU=7_0)X*<S@]RTBMVZ1=3I?A!>ML
MQZ[2KW#@^/LT$%P&:2C($;09"2,ZWBF)*>A^)\0WI!.>`H\U19Y3R_HX?C^W
M*J'Y>$*">+H20+?%:R.7M`_X",4449;*>YF2['E'I'[@!#2?.JO"]Q@?J:\N
MYY6FSJ.SQ]Z>M\8KX$%5ARL*5*X0ER#!58DK,=9$Z::SS[.IM9A"%(NW%";#
MJZ3P,U0H!Z%S@H!V^>-'VW'C2*;0RB&Y%O/>#IV=RNY+A8H!D8*ZL-Q80D["
MB&A#E4WNAAF-5ZOY;,)T>+M$)'K]N%R@S2_CM95<>H*-6-H+6(UI4E(TH"EV
M)$FHC1"C9T"0`S"K^MQ2>F\^[5S)Y*%7CQSW''$[W$FQ8-R.HC!%-R-!@7(K
M2FSQ%6YEK6/]DJL>NHH-C5V%V<?DM3N9=N)F_2BRKJFC@BS3`6619C;-FK\.
MY41?,&V1@_=CHK3V/:YT;A/[BW8D`(J&6HJ9U0DUQ-=;&M2*N6KCI(0*2LC4
MM./79'VRZI^>Y+5F'W[96M.K\6=K/?Y@Q5:W0<M/V\UVO)C20UI=OE-:ZZ-1
M9%TRB^MYC)ICK5'DQ`X?5H%/8^']^^=/(=[/O.Q*T'@7D2B9]5H0/Q/;AA!8
M+-E2Y(MPLB$5P(BR%:?5%GWCS2_H=K[\DA27Y/?!QI/M[#-KJJ'_6=K>Q*,A
M):6$4E+H[AF]I-20X[U"^6V]G*+@V5H]VT+5XS^7_!GN0HB6P@56L;`O5BSX
M>5G72_HB?>]5&_(Q&*I4=/)`_L7*IP^T?/HQ+9\^E9]K0KN\?/HP1/FTNA9T
MN?$0SRVV`_<9X<I]AWW+^P[]+*!33,9\Y]1MI.I!8!:].C:+RUGQ[U`+596'
M:HET`43[2M.1OPY!<^(;CO1&':---J++Z`$'=>Y&``P0"$M9ST)>+J3>X%;"
M1GVK1%1$8#M[A@(2K;838'<I@#^8`-+@TUP)%%?\(070^"3!D>Z^_LGX61YN
M'<_V=F3MG?AAQ"LY$*,`/4.@($;I`0(!/-C3`U*>JOV("RCQ-BG9&1Y2;*)P
M(4"/]1YDR9#0I$X$?2;RR2,[>I>^)47WJ71[N_3R#A(\*Y%BP1B*HC!%6Y&@
M0)F+$EO50-GWKG8T`>#D/4#N";YV"VG'?HZ%6-"4G(L3BRG@0H5_P\Z(UAM,
M%[%\EA=*GD.1Y$F;$`"[@]10Q(M+1HK8@+>(&G'(2;Z$-/MBAR%.GOYP\[;$
M^I.@G66JJ>>E\N5)SX2,(./9:X^)58#I4TEI1[)T_SPY!_2FPI@-NUJN38V2
M$7TEF@@MZ"BA0@:ZEX0ZCVI=)!)Z62>]/`9'"4T4$S6D?40'^5-1<5%4%BJB
M72*J/9RH+;I$?'NRMD[L0X@*N?D9[W;T6DBXLI_ID8WRZE3!,V6KPQ%(O,.Y
M0#)G8U/+6-W+10P*G6(P`W8O:HQS-BV9/*MZ>7K=J)"/!6?,L_C"6Q5J#J0!
M.2.V+(W%%^Q;E&E!;UX:,JJV@TF(BG8P!<J&;&.ZCD0JM&#1<P<6NL6&!E9J
MT&0'93(+"OG>K14%4_8`4B$E^0X>NCG[`@F+U<[?3#==W[N_BG!P'-PF&Z8Z
M&DK#RW4P(?.,Q]#>5J6;B;YY,['DE#,N30B87F):YU+4L<TO*174)++$_CDN
MKTQK]8C9V1FNP:6D_960@MU'!)A`<!\3GSCU4-8N)&24SU$06<'W"*@8YH.D
MG$K+VF>+S];&U++VYN))?%)&4*VL79\)K^QG=C2\]<>[?YR=`,=O0M&$S@:3
M,$FT0U#$A3'41H(5;5,)$<H<&S!737T3?AYL&@C[A\)1O_X-0"<A$ES:?B#!
M1CDZRO&A2C!TS)!&]Q#X.XSW[$[)QG;QV-M_I!<<G.AY>6CB*IK3`7(;;04N
MN9"F1,#<23M&:T[58CKQ%9)C3,(QP-,,(A^EQ)*)*2TJII(3`ES7B0@D=HB>
M5T2PB(P#;>/&'AM6]6,"`H:L\%(1A<L\%]N8M5["H7@Y.27(3'%QB@F_]C<6
MJF8#D-(8(49EQ&2TAI&QPTY`P_R9&/LW>*RB*U'3<P*JCUQTHVA^KJ#!*PM9
M"NQ4#*S/:6#M9(%UGA"CYK++WYW(+R@;G%YH."(-4PVC^G<XC,J*FJLF^IRJ
MXKC4W^[G#'='FC`NM9>!*'K43@2A'&H/3*L9"L\\]#9Z4'"H0XQ(8U_*>;`#
MYOCZF],1$[>HG5<J\[>>W;:9YF\I^]L7&+Q+[&]':/K6;[CI!/<_V;7JKL?C
M0D)&^2,%D17\DH"*8?Y)RJGT>/QVMA@O)H8>CS<73^*A\DX#IAV/%P\0:/N0
MY8GM;JPG'.R<D-MI6P'/@/,MD4#<\ZPZ)"/.K_B,2<YS<`+-MK-Q1S?_!),P
MZD>@N-%-@HHRW!YOZ!3Y3.E?=MG[8@>!76W/T0(?X`Y.&P&S2S=-D/7>LFG.
MF4354B)UK\JGA$!NT?0N*2Y(NL$!7:$F5S>%7I!?AQ17>G_&''E[=RN%YSN:
M^Y1:9&,<BD`TB3>IP33!E7#9:N!'BL_*F.A$VLI8M*A=+&.\VS#1<V@3$F8S
M3]\O)"%'65"%31D'#WXS+Q2(MYFO13)A,R]@3*)_(2W.NM`]T&U\>U%2S$N?
M"%]5MCPP1E(&1;TJQ2BPE6,B,>IJQ>K@H:O#^#SQ2J<JGMD_D!T=7*?*]I*P
M@#W>)F2V4MNJ4G?)U^"3HO-9W%,F%#W1DS2AX8-#/8(K9K_\]FT]+-R3MR)^
M:AZ'/>6Z=-K09U=MY-%#V*3C3'(D^Q?]Q_9M)6$&SA!X769T6;:VN>@0/6<?
M%5JJ&!0@,I:PG<7!'#B]4:^0";$:#*C'BN%L!^8]QGQ9>?\ZC".1!JR&BZ'8
MUFYP*2#"`OK$S!J'47#>T:LQXC;V<C3H\$`L3GV(4(\#'R:(^!+M2NG#/^CH
M[YV#LXM;PT.'"6TD83L)BHA*F*:$"P-/#DRX,/>]^RT.CDE3XSGMKK.\<YU[
M8;UR(PKP086BD+PX0X)N0NBAQ*+`[HA.)EVM7=8/RL]Q00.1=G*58Y-YUO0I
M[=S-R*#E4#*VBU@T3J&)Y76=JYO,+Z>K\S/JV.:7SS6I!\V?WC&OJ+>9:`U+
MYHPJZM4PB7HO9HV]/?T?O;7[:+O4,:YPX/C[RP:"G&%J1@+NVE53,2]O6:GB
M0UZJ:L9C56&M+9HM)FMKO+'(#X@6[X)<A>HH!W,O]#XY^Z%`981B.JBFB2>,
MD_F69NW$N-I$=A`U%VE,G&D0/!/'QYXN%I6+7Z'W^-[Q/'9[]8#BSPXHD>4)
M-YP]R&/1#LT\2?1Y^\WY='(QRT&Z5)Q;U_\Z\PY^<(R?F13?UE#&AO'Q#84K
MNG=%5"C/WHB]ZNN@GU:KN?716FS'<S2=;2;SY>;3VMIH=^P=Q2A@QWZ=XJ,"
M`2,N5LP\$C7C,%K9#N\.11D$JFUYE<UR7_+\[W"-QR]YJ%_HV;LW1`M(^!`C
M`#05EW*:@B`*`]40O*?QU!N>4#-?$(TF/^;W*;U]31A&[X*[?G@.L&0EZTX6
M+HSI8S@N0YLN-"'#G>Y\BY>9</>`]^>X[M*+OU.\BNOM:Z-Y_=<9!QJ+;)4=
MH81RX<HUE;[V>F-.7K`@Z_%XWY".Z/.IM[83L)!E>8A?E$NZN/&V*P)X&"\H
M%:#HWKC`4'Y+PE!=Z71-?SRB2C$6.GM[^O!/\1A#?U*XJ5`4'C$$:C8Q2MKU
M$&AW!#$O^HQ^O/_?<]*L=NN/]WN'!DRV2[>",R\Y/9OXQ&T%D7/G8GIL_\6)
M'N)?A03V%M.>L+P<<'_D85Q*W\-3]$!]T89R6/WR7W/NO'/M,,P+/8A#.%#W
M\)BZA_QF9EQ!OLLHHT-,FO9,M3/.6`!SY61GN]J]X<`C5B#/FL7F@M,OT-=4
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MU^_MT`F3+D49]:$SKR*C-WX$OA'?D:>CJ1]D;G"($:_]S#?H403#U9MSJ?G&
M-^EGN')4#*[6MKXMEZ(N;/$S+'>2?XAE>4O^A8Q)]C&4?ZUT_&7$!H8P=/)#
MV_T0^.=3./-V[GGO>/?UC=/5G4YWLC!.IJ_A*#J5KC2AG$@_?%?L2.<[`B*W
M,9QXC"R*Z8Y01IGW@L+(2*]0,PC$GY8'31+`-*8"9O-MA+TP\28D`"VZ.9NJ
M!@P954`)UB&E?TOH^4$X/ASP+BJ]]<1;6]71`%+[#<3)TOL*.'I3_,H,U90L
M,$R4H:JFJK3D^H>1"R;/KT>600R;LUPJ8QEEUG7+H2***48M60[$-CWL8M?>
MH@T6JH-M=Y`*L*QJM_//]+Y>W+*(;$?(;P*RN9@[]IWC7I25RD+JUM2`BJ:Z
M"5^JD6I'"JPDJ@N[U7J>&!=93R?L051O]BX.HY9VA&.ILU3&`D7S8N*$X3`=
M`-N5Q;]"#+`F7S(A+OI[\<`!6WN)69):$&2@.BCW&F]>^2[YM$]7V$<\IAWN
M[UF"6WTU:T0!Z#Y5<R%+5Z?4T<%N235EL:*=:9/7\7V`&:K^VTV=92A10`42
M?:Y!O*=?0C9^V?")0D0^+,3#+A+&\W=<.(":GVT1<B%7:^AXSW3^Y<^M=!0`
M\"P$WS58U[C00&<;8N9+9QCUH&!G%2)V*OI"V_RAN6_'1_%?_.`/UN8TN5^U
MQH^^2[ZI_URBD1#L#H9Q<4]9!MF1'P?8!.T7'N#50IJA^Q)7J:;ZH*=S6L71
M9QF6'=`N5+0?U^;!EJ\-`G@8^Y`*4#01+C"4E4@8JFA6"H]>SOTP?$6;O2&&
MB%Y:JXW^YT%:\Y\S;L8*<2F(9(W@@YMA!:)U@@=KB@U(G*O$!"`7"6V2=(C6
MM_AX\@,[>(ZO8<FC`F4L@`A>79@LEI>CZ(WJ5?FIV60DB,D-3-5=MY98O[54
M%R]1PP3Z0W&O<3ECC,L6L0L@H*6KEM72@E6"`%NF:KB0*0#H8M0OOWH+=V-S
M8P^OTB,C9JEK[-*7$]AE8K9,OK=#O$^?.E"HYN]&%:ZPMX?!N"ST[4`2LO"W
M,]O53F=,[9<GL/K]`60J;`3B]X<SNB@A''=Q&,6[S:L[2AQE;X:8$9`I#\U=
M<6@4JOF[$#7<!PB'HI4+J*5HO`<0<"UV`-#U_V#2Z6P?O?./>&L_J9]'B5&@
MVDO+Q2BWF^;#P[6?EO%4T^29HB""`U#%UXE?\PZE:L21+%]"#&/L0+3P",`-
ML@*)4RT:`>2*,1CG`*UZ<Q&DD9P$![AEKTB0VK:]=0C@K7OY3`DZW<(UY6W%
M;F%%,"7HJ1-(LB:(4<PQ!M&J(((WR12D-W@RU0)<%89B7&P%"1-[[/P^)H')
MG@8GMZY]S[>2$.]>W_N/UP0E-A#RPZ5=U)#3J]%<>:CZ5O[86%=YHU8_3XT5
MY.>,**)46\_HY!P$E#.B4+;[&[8#R]M/25#:?7+YE/7/LTS*=,IY<%UF7TRS
MNR(D]%'\`42_P)YLH]]HK1;3Y!QME;XQUX].<,CJ5PBA?*DVU`)U404!P>YZ
MD!)/7XGL30>V!*Z_J8^IP<UX49K+B:9_ZV-^<SH]3BLEVGHN+2]RHN<)H1/8
M[LS;XZ=?\7/W2>60U3^[0OG2::X%ZC+?`H+=)SXFCA+JB)%'A'Y7'?"/1]]C
MR6.6<@Z7YRB,;(^V@.I-(83?`-,.!<DO5$6`T8/>2*GWIT3L4W$A0'(T&*+"
MY[KJ5+P%6>.3']#V!K2CX#GL39LXU,'T2"CMA0;5PO:@.P*Z_6E-LK/,OH+B
MSW34EEO'Q<&$[$SN_:"W->B"*)1NU,I65HD22'=-J"'7FP(PVB@EWG':U_C>
MH?D'+UK8QQXVE/54H2:^7KKRS)=AND]]';W>YCXGCBCUCI/_V7?/7F0'L;KV
MMC14R$)-/T>^\OQ?`'57@%J"O6E`1CWV`UW=_A?LNK]Z_E=O@^W0]_">/B&"
M!;GV9JK`)0^E$A)YRZK!`>ZN(D+"O:D*_<K5'_0S*/T.BC_446E6YSO7V=VZ
MOAWUI2@EDE#*42-762$*`-V5H$*LMXF/*2-&NG.B*<Y@QNFK6_*['I8)`6FX
M%!17SLM\5`6PC^04AVB/F:HD$YWD(=DW>M(-FMP>1#,*A*'UHB)CO59D8/WI
MQ`7)_C6"G4VTT(<^S^&SUPX*[RVL_)`]DB@YCU=#A3F7;R)6\7Q>!4_;K;GF
M3-6\^>&R]^4V#Y@^RVQ"(51<F97)I%0(6`,-603(9;Y:`%@!U:X]0CYJRJBS
MUT\N7G`S0'4*AC"QPP>RS?HJ*QH2HX`[)ZX8'*=4@8=T1AQF)#I%L1!#X^A4
M\O.<?)S\F_R+_$!O`I!__!]02P,$%`````@`(8%G/Y6(FIQ)$@``?`L!`!4`
M'`!A;&EM+3(P,3$P.3,P7W!R92YX;6Q55`D``^Y(N$[N2+A.=7@+``$$)0X`
M``0Y`0``[5W=<]LV$G^_F?L?>.Y+^B#;BINFSB374?S1\=2U-;;3])XZ$`G)
MO%"$"I*.W;_^`)(@*1(`09$V`%Z>;$N[\.[^=A=?"^#]SX_KP'F`./)1^&%O
MNG^XY\#019X?KC[L)=$$1*[O[_W\[W_^X_V_)A/GCX\WE\XO,(08Q-!SOOKQ
M??K9;P!_<4[0Y@G[J_O8>77RO;-X<FYNG%,4AC`(X),SF;!&/H*(\*(P:^WU
M_C3_+O##+PORG4-D"J-WCY'_8>\^CC?O#@Z^?OVZ__5H'^'5P>O#P^G!'[]=
MWKKW<`TF?AC%('3AGD/HWT7IAY?(!7&J4(7]<8$#UL#10?&_A!3TKPDCF]"/
M)M/7DZ/I_F/D[64B*K2_QY2A'_#4F1X?'Q^DW^X1&SC.>XP">`.7#OWYZ>:B
MX`&!OR9F)W@0@&"T[Z+U`:4Y.$5NLH9A/`N]LS#VXZ>+<(GP.K4`^?>TZ7?Q
MTP9^V(O\]2:`[+-[#)<?]FBS1+OI]/#XZ)#J]IV\O8-M*;LW?P7B!,/KY?6&
M.A%I,]I3UY7'W%LBXH]^=+V<8Q@1M7,]E47B<O>6Z=2/7$2L'R;0V\E2H@9Z
M2W8.W!CA:+9<0I<TO]I).EDCO26<N2XF6I\];F`8P2YB-3A[RS*/_`??`[,5
MAI`&50=AFJR]I;F#>'V)0$A"^S/"7XCA3\#&CT%P`Q]00+J!#N(IM-5;WC.`
M0])P=(FB:`[Q[3W`\&Q^VT%*80O]D26?0XRA=QLC]TL77&N,O25)V[G>=(W!
M;;;>4ER08<,:WH''3A&WQ35`;O+Q[R!(8*=45/#D_W]32>67Y-_E_Y12#]0;
M^S%MZO#0F3B,OOHK"#TG8W:$?3E\C&'H02\;-1"I`^1N$01T$(1PF\GH)W_*
MA)XMHAB3=,T:"L`"!EE+BGP'G43,#9P.IR+H[J_0PX$'_0,J-?TE%7]R.,V'
M8M^1CPHY[DBS-3F;7Q?B5'&>X6W1`'990^37+>B;@[V<XF!#DDL83]Q[/_`8
M]Q*C=2=KY5(@GN@(>Q!_V'NS?WBTYR01D0FE\0N"E[#RC`CB46'.`[#BF+GV
MO55VKLE>&OJ-!D,S!4B'Y2.B@W=*9EL2OZ[1665X@0XE`#]H`""3_@:N?"IT
M&%^!-<_^?#*KS,]7H;3^5)OU3X@F&`07I)-[_!4^"<W?H+/0_@T=2@!>:P#@
M),%4T7,RA03!?R#`XA0D)K4*!K$:)1(_:0N%SS`(?@W1U_`6@@B%T+N(H@1B
M84@(Z:W"I$67$IAC;<#\CH*$6!$_G?L!Q)$0D`:=A4`T="@`F![JZR2RN+V!
M&X3I.M(ML60BQD%$;B$<(E5*5/1UW:F'G)#TN4)8W''7J"S$H*9!:7H=G7;N
M%FB]1F&ZM).N=47724PW2.B&CC@LI$P6`B-7J,1)W]QBGBP"WST/$*@OK`AH
M+$1A2_[2Z#J6+I@2V0`OFVN>D\]X786$UBH0)'J48Z>WVL&@HVTU*"J4%@-1
MT:*$X4<!#.\/ZHO1_3<[`[I=?GL/8=QEH;[&-\"F:Z6]>6KT>QC[+M5]-Z%J
MC0RPK4)Z=HI;M.-FM:B!024[`=$]2;%?=Q6LPB_?_JAM.W3:%*DYS_8NR-29
M.(5$#BT/28F=G'KG=+0$T2*-[R2:K`#89#D)!G'$/JDGI_SC/PMIKI?G?DB$
M\4G^1)$OV0XATBBR[9Y?=U=H%D7$E/F40:*!@$Y'ME4W:)EL)2KDJ98S5=VP
M[=C+S`Y"F5.!'R!>H`BFM)371YAT`J1A/<#2Z"5=$?UQ]E?B/X"`1O4L/@$8
M/Y'!;KZQV0!:D4\7\%)_94@KZI`CWYR260T\+;B#,5@$\!:Z"1'%A\Q>'+BE
MU$:#+)4\A[8YH;`:VCF&&^"S(B3BX==D4(.WK,6!6(G+:*B5-,@A;T[<K8;\
M-)<]Z^7@"8H*E:\@#^TV!J.!;A.>38MZ8AQ#;`[";>%K4Z#R0[(YA>T(%XI!
M8`I<ESY8^$&UMY&,FF7$-@V=97JP\7/?H#0L\<Y<%R4A73MXHF,,27P*"'7A
MV^Z@1;0*)!_IC"@OX6[:AP^JB-8*7$7",VB;.X":H!64G=)=&91@%WJW$#_X
M+F1.RJLUE1";#5:;]`RMD<U0KU`,V_,JE\IL/(5B,R!'-A_-CW5<0A#!ZT7@
MK[)U;#&F;0SFP]NF`4.Z[S34J"F*4I=I9U\IZR1[3S,-G;=<H=#M,G7AT5LZ
M>^&IPN!^NS^R*<PE"E?T+%ZU2^(AS24S('3%?EH@RQ6]`'1<<*:+GESS<$"5
M$5L!K4P!!G"S[MIJ@-.JM'L4$.4BNF\5/TFWE,7$-B5GF1X%SOMO1Y::[^!Z
M@S#`3YG*;&-RMJ8+,ART6^CU`=[FL0SF%@785NS(EIPJU:;"_?8&B?E@-F5F
M^!FSKC30DJ'G^9DB<^![%V$^^ZOHSUL[5&`R'V,5+1CJ(UN?^DR2$Z`%(Z%W
M0R\MDE3*4TO)R<U'6BX_PWAD2U<W,`9^"#UV"\C,=9-U$M"[JT[ATG=]7B^L
MPF0^WBI:,-1'M8S5-)'2N-H&3'E2,PQ'M8PUQV@#<?PT#T!6:D^4W:R%U3!R
M<IOF27)-BIVBWFM81D5L5D\B+(JQ"T$F<[$9U']6:U1H5A9KB'\J)=MV%IL`
M;M>&07^\?_3<V(O.!SWW&8[:69N\=7:@0WZBPWFUQ?W]MQ,>1JXJZELG(^YQ
MC5-3>^G"`[NWKWW%3,QI_N!.695B%6V?MPY321%]IFX&N$%V<GN6Q/=$I;_+
M="6&O\EA'>Q-%4JX>0LP8X,[O=U%&6I&;2G,3/P28M[ZR]@@EJ^SM;-8"C9W
MO>UPG[?V8C'BE97C#MVX$I?YN"NI46RBC*W[;ERZ(NVZI=1602WNLJ=CZ[(;
M6@N[:R&EA=#6N^GIV+KI#I=&<0UD6?>L=#L40?DENF8+%KP4:G>X%1V#FNH%
M%[I$U[9L+W*]KJUQE5P.6CHEG_/J4P@2SR<#`2TK7=D%^X5TDE4A(:6>G=L(
M$I>F%SR<P@<8H'07)#\;SMVTE=+KBK<6ZY>;M5+IV8+R_K.'V<N"G#TD%1"M
M9][:#],KJ&/_`8IA;N4P'.A6^5E"'1O4V3T>I(,58]LD,1S,IL#L0I)AT:MN
MUFHI2<\ZLT)/WE8MA\9P]#@2L\M%!H:OLH6G`[Z+\`%&,35%9IF+D#@4^80[
M!!"1&@ZF6/#RCL5Q)52FH3B?-BB,Q[`F+[M89"#HCC/H0KBBJW(ZASW`#],'
MR<C,,SQ[I#DH\:/[;%IV"A>\R%3@,1Q>!0URP-^:$ZN"BPN(RIB>#3Z%V<^+
ML'A%+'T)LO*^VPD*\^=5SV'Z>&4-W`':,QCX`;3+G>*G<8VI,MO1<#@G]CS)
M7NJL/80IF*'+F0QV!E45<L2/QS8,JVK.?Y[U"I)<>`<>9W&,_462WGMXAXHW
M'L[2&Z=;':-7VU;Y3R]-BPN0QI59B/:ED3B^4OO><+QKTA8W&XTK-]0*!M(-
MI^S"?M9W7F/6>[;73+2P&XYX-V7*DOB131)NH`?AFJ:N[1'2*7T4&H8>+[05
M>`P'7T&#LK!^9(AOI;K9`_"#K..J;%?FNW#TR7FW+;6KM&"X-W36I[B7:5S=
M`SO#QXJ(4FWI7I$?)#&W_**5PW#D6^4O;F\R9?`F6"GX#.EA6^C-R+06K&"C
MWD`.Y6Y-&(SM;@HQL(=:"12"K:G*H/(&RW:1P9&TR("R.2F?[B*#2EE)H8O:
M,1H.N::^ETHRQXB.,[R/3Y\B2,:;Q1[1S(W)""0]\R56:Y=&#"@$$B)6Z88[
MZU64+(SLKA!+9M>[^[-\XCUP78+NM9)O:W+/[$7#+]<9-.W[MCGT;+XSW+[1
M4%-!8Y8)1K9[W#_'J&\L#S59-,873B&1V/53K#BP;W]M+\+;>@Q<%O)\50)Y
M9EK3<I;,V/F;5KPL+R&V$[@VK08N]C`F)F=K.F[Y.]6V.&41KM)7KC@Q*B>W
M$_IVO9ZGJ$-_5=ZGD(Q4`GH*D/9*M%.Z#LO:1![^K1SVND"K:@,7>AB3`IH#
MU\)J^06;\F,XRLSV^D87+<M"#6,6DY2G?O.M1RTCUOVQ]RIX-Y_U:DGCVG]'
MEY=,\]14';H6Q.#T47O#32EK-'CL<@U%I8:N_WC)FN'\!3>!FU?NF5-+$!V:
ML\L5^NL[=,V(,>--CD&I#0JKBIU(`(>8VRZ?Z:S><Y6.Z*\&51RI]=K0M'DH
MVD7+YRH[T5Q@)#!!-EGKN?TM;<3B[6^I7F7%BC%3EF$\A0R\TLG['9JY?R4^
MAMDA:#H8NX5N@D6I1)'/L"RB$`#%S=UJ"I;/T(ULTD),YT+HI?N\MR"`9#CV
M&]V)(_I<+U6=I'L;%CM,=V7+E[)&-HQM!(_P'GR5U")AMMA=.FA97D`^LB2C
M;D;%$Y5]&[37G_IJ7MY@.JJ1L*)-^)5,'`?KV9Z]_M53\?(6OO^'Z3C',+V2
ME<V.TT7+XFFZ<24A@0F*3?0^TW%I(Q9/QZ5Z%<_;C6XZ7IU$T%J;ZU2OZ.P1
M8M>/N&?#%'@,RQX*CL^=5?&5*UZ],V<6)=@RJBK#%*A7OK)W'7E[1-WX[01]
M!T6+)_,L=8#*\=?NZ'.91P<]5TN&NT&5H\/W`O2^!/K8UI8-6GH!`8^=7J&H
M'',&@RX;&W8M[7J9:LK4%]6?RLDM=@&I7@S]H592C5DANX&;0O$K%$-)R9"8
MU%[4Q3HQQ`U:$Q5T^H4.4@3EI'8B*->)'0`<:L71F)@M4Q4]K70#B6$2E^X$
MB4\-M+/8Z0%JNC%/&%WE9S5]7:)P=0?Q.B]RNDQOOEH$_DJXUMR)VU[_Z*0F
M<Y71W0^F;L=>:X,V.TH7+9F?#'UUOP';6;/0HS_H_O`#"&C<;%^G)[E8L!N[
M#:O'W31B7C&R^\3X1IB1:,'XB01&>L1>V1T:?/;Z04,5Y@`#+Q5N4G\C\N)X
MK&[PYW1$CD"58:XP\.IAY@IGH<ZQQ&VRV02IP4#`#'81+A%>9XA);O)2Y;3!
M%9258:[P=FS;B>P)CCGP>3N'VU]K@[2;M]:?%\F$9Q".[%D!9H\K%+KDU[)H
M(O0XPUY:?!.@*,%0$N+]F[3,4?HKS)SKN'=^J/J3]NQ0N7TI.X.;5Z+R4H6$
M5I<[#!4;S$\D*K*[IT;VM,#,^V^27]YPAV:>YV<ZT8QZ$>9+,-E-7+&_""!=
MOOOLQ_=MMYQ18P[7]%C<:SB+,&\TII92=$)Z@[:VZ4[N`5Y![PYE+P'P-D!:
M6<;@#6J:,I2?_8K.%[PD^2KU8-DSS#\>'DZ=B5,:D/R1<6T_PZSC5N1KO`)A
M?@42"<L(!;['+L&:5XQ5>8N[O.!9,B(;J%TMJ]9"0*NKTQPB77$\*(;%PC1'
MP9=[X_D%XY?>Y!ZEA7A%RYP`?ET/X)2-QN\6X[<(-B&">XE>HGQ''.ICP"]-
M&_Y?C"I[#&^>4>8>^1&M2OHYJJ>?*J?F(01?B?1MC&B#(A#\@E&RD:6:SBUH
MN<=V2Y:+T`T2^A`(7W:U)-*_25U)8T?,B\MR>RL^RG1P3DR%<#1;+J$;<X\%
M5U+"#_64D',[!?O.>4$P]Q6+)XAM9:Y!IN;B?R2*074V'7'6T>;%+%Q)H5'&
M3^VV-4[0O*D'3<[B%#QZ:BMI]2A-GZDX()!UEE)J+2NNV_<=,KF(RY1WEZGU
MASNWI*L;5$"N6"K=5;=11NH\HH]E@MD*0UB],J42JC_60W5SF_(X)=,@Q]=J
MDLBZ,C&MEGU4%!#A$,WM#W!&#Y"M4JG48JT3M[;NKPV=8C^TBS:CC"A:87R)
M`)U@?T;X2WGSY`U\0,%#^:!#)<3>UD.,-N+05AP0>D[>CI,WY!0M:7E%9%$!
M4S:7%!#J>?IDH1B-0DIM$SRIO<M'3P1BCS+$V(.O])4`]NCKV?R6$U@_U0.+
ML3JO*//W#F%W4G[G%6E!RWN8]>=K)3$E)C7AI6%97$EH=456F]U%SPN//;JV
M;T+@!-5Q/:@*#B=CT>&+Z<:V+'1J!(.L=-S!]8:,=?!3UGI[%Z/,I2THN'8L
MEC141!]E4%2OAVF&Q/2P'A(IO<,8-&T&9-*D=QD4;VK=P(`>1DO+0M)TM@`1
M]-@QRI:]@3X-:MHJ4)/Y8U7FEIV"?BWJW"CH[P^5?8-^9AAEDL@>L+T#C[PE
MSVFC]"@C=S)Z/>]!9.(JS>>DU/K>8]X22!:Y<G*-#U:T8;#]/+)(@5$&5%$U
MS0FG1B$0)78R:IWU[J5,LMY43JZU8+\BD2R>6NAU!90*#HVB?+X*FD/J_0$5
MEG;'Y(__`5!+`P04````"``A@6<_=2=1%+T&``!G,0``$0`<`&%L:6TM,C`Q
M,3`Y,S`N>'-D550)``/N2+A.[DBX3G5X"P`!!"4.```$.0$``.U:76_;-A1]
M'[#_P/DI!2;+3M9N">(6CI,4`=PX2-*U;P4M7=M$)%(CJ<3^][ND/BS+LF0O
M2Y=B?DDL\M[#>\\A*5+DZ8=Y&)!'D(H)WFMUVYT6`>X)G_%IKQ4KARJ/L=:'
M]S__=/J+XY"O9[=#\A$X2*K!)T],SVS9)RH?R$!$"\FF,TT.!F_(>$%N;\FY
MX!R"`!;$<3*0,ZK05_`$[;#=3>N4-X.0$HR(JUYKIG5TXKI/3T_MIZ.VD%/W
ML-/INE\_#>^L72LQ/)F/9<!6S$U)YG#D,JXTY1YD]@'C#S7FIGJ,`>;P:_9I
M--WCXV/7UK:(IG(*^IJ&H"+J06Y.`Q8B5<@AD@JJ[8D06^EV.\='G:P!8[.E
M`P00`M>70H;G,*%QH'NMOV+TF3#P6X1J+=DXUK!B$/."R9(R7^>-%@EXZR:5
MF2EV`;V(0*T:*_#:4_'H9K4V1J?3=8ZZF2-'X>.PFFA?2]?XN6CDH!5(YN5^
MS4ZI`W890DXIYT)3C=W7/IN2*&)\(M)'+#`:G4@1P#VZ$_/C\^U5+>7&QCT7
M7FSH[G/_@FNF%U>(*D/;5HLPO]>JM<C;SR+P8<(XLY%V.L0AF7?Q)^4^2:!(
M`>O4+0.4L6,<42/^WOZ.)"C$LIY#+$B]4Y,ZSV4#N_EY-/#BH*'!M#33X=GR
MG-'`#.N[&8!6B1ZK1;4"X)Q#[I`C2!5(74GBNR>\B?`;*C'E&6B&L52POUI?
M+T6]%N1@!>O-7IL*;7+ZU&@RBLS;&9M/1\6&NEI-#DN2+#&(F)`E"CGXS&GL
M,UP,[(5I$F9`U>PR$$\5NBRK:F4YJI7%@!"+LI>E099KJF,)ZV.EHKQ6D'<=
M^R8Y9\H+A$)7?$@P5L?)7H3*%XIBV/=O"MEF;Y+UBB89#LLR6!"C0A%FKT/5
M0A=I$[CHY#$V4QH0&^J:U#@JJU'$V8^+>CTNJ:>%5/W)!#QD;%K6I*:^29??
MRKJD6"0'VXM3+T[?\R3VX8MY!%Q!JDBYL$F&MV494@"2(>RIKZ#^1K%'YM/^
M5()=]"3<KY4VD?^N3'YT9Q%(#K%GOX+]>Y#A4%#>Y_X7(1]PJAC0B&D:W,*C
M"!Y!)G(TFS7I\WM9'P-)#*;]/)*BDA269+A[T2I$NZ"2(UEJ*)2Z`7DWPZWT
MQ<U=(M6FRB:!_B@+E`&1`P/UAB`8L6CD`/'V.Y#*R4S"!*0$_TX+[R&=RE;+
MFG0X+NN0^Q,+L.>]<D..S(RBE>\CA9(&SKN=,N?6FZ3N>\8K&+_B^!/NZ3Q;
M+14+FOA>VUTGSL1Z[^FNW#TP^2<-8L@V"]EC$]5K.VCC2JSO_X!H\\><^]W"
MA-A3O1-SV-1K*19&@3D-M&4SG&%[+<.]DQW+?<-TV_,PR$P,?LWYHM6HS%#:
M<`9!I;>&LG;JB"`"MVJ:@7*SX#,`S;1Q+W[Y(*8=]2NA`4;J_FO)(_.[)E\2
MZX5R'RQ;>:'4`SK>-75T@>`%DQX:_,IT3]WBL2@^K1Z;GF*V0FK"UXZPZP[4
MDP/[H?`L4(V+>7(R/\<4.=U#YZC;GBL_BW&7$);I[Q9"YO>\$-9.HK>*HNQE
M8C@V,73?/2N&XA'Z;G$(?OT/0YE0-;9@E1<`-D1A(RAZ3BF-K*,+@58YEK/$
MVCV:'//YP9B2G6-9N1[A`]LZEK*/^;&I=7.))KT+HI*[,UB8%MB8ZJ\F],=*
M2^JEWT_,I/9M._-D9K07;DZP#+=\5QI"\S+%W&(T8SHV'A^EB*/,D*$)3E/V
M-TY?3/CW%L:/9?K)GZ8-]%I:FF4+9P%.E&8^2Y[=J@1'L58BEAYNED`^,EP"
MW="%\2ID56-33"44'#25BZV3*0>XGEPRU^FL:IR<:/=:'F[.F-Z0$BYM)>#L
M=`[)_RN>+][L84AA;S@0/+VT=0GVN*F0]?-@7IB8I>J[,/,%S+4R\/L8+9V"
M_;:@C+I(LKFJ9LYZ/.R[YRR(M;GGE).QL^=*'[?6+Y)]99JI)J'Y!IP,/>Z/
M]"S[M&83JK%YE=*M]T;L@A%E^<?R+/Y!+,TUC[Y2^7V>#=UY.X`?A(W2T4$I
MF2&C8Q8PL^:KI60'E/^*%Q_&&VFYD<(#\-6E%.'%'*3'U-I<]85*B5-JD8?=
MW'Z<Q'%X8X"[95WI\QI3OL7!NS#/H\FUT%6O[8T6KW-(1^)*J=A8#H32:C`S
MEX']>W'Q5XP+J>*P;;)\E?EM/FV^A[D^"_*OUS;'K:R3/),;PB<Z*_]^[]G-
M058LC;<Q+J]@G[%0?G9RY?/0BI0VF[RF1.[!;+)P""3#8_EILJK?;6/\G;O=
MJ9OL]_#GWU!+`0(>`Q0````(`"&!9S^X:?_7*DP``"RC`@`1`!@```````$`
M``"D@0````!A;&EM+3(P,3$P.3,P+GAM;%54!0`#[DBX3G5X"P`!!"4.```$
M.0$``%!+`0(>`Q0````(`"&!9S\=C>6`0`L``.J#```5`!@```````$```"D
M@75,``!A;&EM+3(P,3$P.3,P7V-A;"YX;6Q55`4``^Y(N$YU>`L``00E#@``
M!#D!``!02P$"'@,4````"``A@6<_OA?P!H$@``",PP$`%0`8```````!````
MI($$6```86QI;2TR,#$Q,#DS,%]L86(N>&UL550%``/N2+A.=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`(8%G/Y6(FIQ)$@``?`L!`!4`&````````0``
M`*2!U'@``&%L:6TM,C`Q,3`Y,S!?<')E+GAM;%54!0`#[DBX3G5X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`"&!9S]U)U$4O08``&<Q```1`!@```````$`
M``"D@6R+``!A;&EM+3(P,3$P.3,P+GAS9%54!0`#[DBX3G5X"P`!!"4.```$
:.0$``%!+!08`````!0`%`+\!``!TD@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (EPS)<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share (EPS) [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Share (EPS)</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 8 - us-gaap:EarningsPerShareTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>8. Earnings (Loss) Per Share (EPS)</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Basic EPS is calculated in accordance with ASC 260, <i>Earnings per Share, </i>by dividing net
   income or loss attributable to common stockholders by the weighted average common stock
   outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted
   average common shares outstanding for the dilutive effect of common stock options, warrants,
   convertible preferred stock and accrued but unpaid convertible preferred stock dividends. In
   periods where a net loss from continuing operations is recorded, no effect is given to
   potentially dilutive securities, since the effect would be anti-dilutive. Total securities
   that could potentially dilute basic EPS in the future that were not included in the
   computation of diluted EPS because to do so would have been anti-dilutive were as follows:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="44%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Three Months Ended</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>Nine Months Ended</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>(Unaudited)</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>(Unaudited)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Series&#160;A preferred stock and
   convertible accrued dividends
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">3,002,205</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Series&#160;B preferred stock
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">3,063,383</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Series&#160;C preferred stock
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">2,488,762</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Series&#160;C-1 preferred stock
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,187,651</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Series&#160;C-1 Preferred stock warrants
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">&#8212;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">56,723</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Common stock warrants
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">28,086</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">77,114</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">29,366</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">112,644</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Stock options
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,502,469</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,633,441</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,573,106</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,669,748</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,530,555</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,710,555</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">1,602,472</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">11,581,116</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 52<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 128<br /><br /> -Paragraph 40<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1278-109256<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.21)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations/Basis of Presentation [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations-->
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b>
   </div>
   <div align="left">
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>1. Nature of Operations</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Alimera Sciences, Inc. (&#8220;Company&#8221;) is a biopharmaceutical company that specializes in
   the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The Company
   was formed on June&#160;4, 2003 under the laws of the State of Delaware.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&#160;21, 2010, the Company&#8217;s Registration Statement on Form S-1 (as amended) was
   declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) for the Company&#8217;s
   initial public offering (&#8220;IPO&#8221;), pursuant to which the Company sold 6,550,000 shares of its
   common stock at a public offering price of $11.00 per share. The Company received net
   proceeds of approximately $68,395,000 from this transaction, after deducting underwriting
   discounts and commissions.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">During the year ended December&#160;31, 2006, management and the board of directors of the
   Company approved a plan to discontinue the operations of its non-prescription business (see
   Note 3). As a result of the completion of the disposal of its non-prescription business in
   July&#160;2007, the Company no longer has active products and will not have active products until
   and unless the Company receives U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval and
   launches its initial prescription product (see Note 4).
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company is presently focused on diseases affecting the back of the eye, or retina,
   because the Company&#8217;s management believes these diseases are not well treated with current
   therapies and represent a significant market opportunity. The Company&#8217;s most advanced
   product candidate is ILUVIEN, which is being developed for the treatment of diabetic macular
   edema (&#8220;DME&#8221;). DME is a disease of the retina which affects individuals with diabetes and
   can lead to severe vision loss and blindness. The Company has completed  two Phase 3
   pivotal clinical trials (collectively referred to as the &#8220;FAME Study&#8221;) for ILUVIEN involving
   956 patients in sites across the U.S., Canada, Europe and India to assess the efficacy and
   safety of ILUVIEN in the treatment of DME.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In June&#160;2010, the Company submitted a New Drug Application (&#8220;NDA&#8221;) for ILUVIEN to the FDA that included data through
   month 24 of the FAME Study. In December&#160;2010, the FDA issued a Complete Response Letter (&#8220;CRL&#8221;) in response to the
   Company&#8217;s NDA. In the CRL, the FDA communicated its decision that the NDA could not be approved in its then present
   form. The FDA asked for analyses of the safety and efficacy data through month 36 of the FAME Study, including
   exploratory analyses in addition to those previously submitted in the NDA, to further assess the relative benefits and
   risks of ILUVIEN. The FDA also sought additional information regarding controls and specifications concerning the
   manufacturing, packaging and sterilization of ILUVIEN. In a February&#160;2011 meeting with the FDA, the FDA requested
   additional data related to the use of the commercial version of the ILUVIEN inserter for which approval was sought in
   the NDA. In May&#160;2011, the Company submitted to the FDA a complete response to the CRL. The FDA classified the response
   as a Class&#160;2 resubmission with a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) date of November&#160;12, 2011. The PDUFA date is
   the date by which the Company can reasonably expect to have received the FDA&#8217;s response. In July&#160;2011, the FDA notified
   the Company that it will not call an advisory committee during its review of the Company&#8217;s complete response to the
   CRL. In September&#160;2011, the Company enrolled its first patient in a physician utilization study aimed at providing the
   additional data requested by the FDA with respect to the commercial version of the ILUVIEN inserter. The Company has
   enrolled 54 patient eyes in this study evaluating the safety and utility of the commercial version of the inserter and
   is targeting to enroll 100 patient eyes before commercial launch.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In July&#160;2010, using the Decentralized Procedure, the Company submitted a Marketing
   Authorization Application for ILUVIEN to the Medicines and Healthcare products Regulatory
   Agency (&#8220;MHRA&#8221;) in the United Kingdom, which serves as the Reference Member State, and to
   regulatory authorities in Austria, France, Germany, Italy, Portugal and Spain. In November
   2010, the Company received the Preliminary Assessment Report from the MHRA followed by
   additional comments from the other health authorities in December&#160;2010. In July&#160;2011, the
   Company submitted its draft responses to the clinical, non-clinical, and quality questions
   to the MHRA. The submission included the additional safety and efficacy data through the
   final readout at the end of the FAME Study.
   In September 2011, the MHRA provided comments to the Company&#8217;s clinical responses and indicated that there
   were no further comments to the Company&#8217;s non-clinical and
   quality responses.  The Company is preparing, and
   plans to submit in November 2011, its final response to the Preliminary Assessment Report from the MHRA and to the additional comments from the other health authorities.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Publisher AICPA<br /><br /> -Number 94-6<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 275<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NatureOfOperations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Factors Affecting Operations<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_FactorsAffectingOperationsAbstract', window );"><strong>Factors Affecting Operations [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_FactorsAffectingOperationsTextBlock', window );">Factors Affecting Operations</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - alim:FactorsAffectingOperationsTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>4. Factors Affecting Operations</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">To date the Company has incurred recurring losses, negative cash flow from operations,
   and has accumulated a deficit of $205,299,000 from the Company&#8217;s inception through September
   30, 2011. The Company does not expect to generate revenues from its product, ILUVIEN, until
   early 2012, if at all, and therefore does not expect to have cash flow from operations until
   2012, if at all. As of September&#160;30, 2011, the Company had
   approximately $38,609,000 in
   cash, cash equivalents, and investments in marketable securities. In October&#160;2010, the
   Company obtained a $32,500,000 senior secured credit facility (&#8220;Credit Facility&#8221;) to help
   fund its working capital requirements (see note 7). The Credit Facility consisted of a
   $20,000,000 working capital revolver and a $12,500,000 term loan. The lenders advanced
   $6,250,000 under the term loan and the remaining $6,250,000 was available to be advanced
   following FDA approval of ILUVIEN, but no later than July&#160;31, 2011. In May&#160;2011, the Company
   and its lenders amended the terms of the Credit Facility to, among other things, extend the
   FDA approval deadline for the second advance under the term loan to December&#160;31, 2011, and
   to increase the amount available under the second advance of the term loan from $6,250,000
   to $11,000,000. Management believes it has sufficient funds available to fund its operations
   through the projected launch of ILUVIEN and the expected generation of revenue in early
   2012. The commercialization of ILUVIEN is dependent upon approval by the FDA, however, and
   management cannot be sure that ILUVIEN will be approved by the FDA or that, if approved,
   future sales of ILUVIEN will generate enough revenue to fund the Company&#8217;s operations beyond
   its launch. Due to the uncertainty around FDA approval, management also cannot be certain
   that the Company will not need additional funds for the launch of ILUVIEN. If ILUVIEN is not
   approved, or if approved, does not generate sufficient revenue, the Company may adjust its
   commercial plans so that it can continue to operate with its existing cash resources or seek
   to raise additional financing.
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_FactorsAffectingOperationsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Factors Affecting Operations</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_FactorsAffectingOperationsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_FactorsAffectingOperationsTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Factors Affecting Operations</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_FactorsAffectingOperationsTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>5. Accrued Expenses</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Accrued expenses consisted of the following:
   </div>
   <div align="center">
   <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">
   <!-- Begin Table Head -->
   <tr valign="bottom">
       <td width="72%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="3%">&#160;</td>
       <td width="1%">&#160;</td>
       <td width="9%">&#160;</td>
       <td width="1%">&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>September 30,</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2"><b>December 31,</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 10pt" valign="bottom">
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" align="center" colspan="6"><b>(In thousands)</b></td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Accrued clinical investigator expenses
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">518</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,911</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Accrued compensation expenses
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">873</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">730</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom" style="background: #cceeff">
       <td>
   <div style="margin-left:15px; text-indent:-15px">Other accrued expenses
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">68</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="right">90</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom"><!-- Blank Space -->
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
   </tr>
   <tr valign="bottom">
       <td>
   <div style="margin-left:30px; text-indent:-15px">Total accrued expenses
   </div></td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">1,459</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td align="left">$</td>
       <td align="right">2,731</td>
       <td>&#160;</td>
   </tr>
   <tr style="font-size: 1px">
       <td>
   <div style="margin-left:15px; text-indent:-15px">&#160;
   </div></td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
           <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000">&#160;</td>
       <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -Article 5<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 20, 24<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.19(a),20,24)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PayablesAndAccrualsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>pSivida Agreement<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_PsividaAgreementAbstract', window );"><strong>pSivida Agreement [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">pSivida Agreement</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - us-gaap:CollaborativeArrangementDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>6. pSivida Agreement</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In March&#160;2008, in connection with the Company&#8217;s collaboration agreement with pSivida
   U.S., Inc. (&#8220;pSivida&#8221;), the licensor of the ILUVIEN technology, the Company and pSivida
   amended and restated the agreement to provide the Company with 80% of the net profits and
   pSivida with 20% of the net profits derived by the Company from the
   sale of ILUVIEN.
   In connection with the amended and restated agreement,
   the Company also agreed to:
   </div>
   <div style="margin-top: 10pt">
   <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left">
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>pay $12.0&#160;million to pSivida upon the execution of the March&#160;2008 agreement;</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>issue a $15.0&#160;million promissory note to pSivida;</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>forgive all outstanding development payments, penalties and interest as of
   the effective date of the March&#160;2008 agreement, which totaled $6.8&#160;million;</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>continue responsibility for regulatory, clinical, preclinical,
   manufacturing, marketing and sales for the remaining development and
   commercialization of the products;</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>assume all financial responsibility for the development of the products and
   assume 80% of the commercialization costs of the products (instead of 50%
   as provided under the February&#160;2005 agreement); and</td>
   </tr>
   <tr>
       <td style="font-size: 8pt">&#160;</td>
   </tr>
   <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent">
       <td width="3%" nowrap="nowrap" align="left"><b>&#8226;</b></td>
       <td width="1%">&#160;</td>
       <td>make an additional milestone payment of $25.0&#160;million after the first
   product under the March&#160;2008 agreement has been approved by the FDA.</td>
   </tr>
   </table>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The $15,000,000 promissory note accrued interest at 8% payable quarterly and was
   payable in full to pSivida upon the earlier of a liquidity event as defined in the note
   (including an initial public offering of the Company&#8217;s common stock greater than
   $75,000,000), the occurrence of an event of default under the Company&#8217;s agreement with
   pSivida or September&#160;30, 2012. If the note was not paid in full by March&#160;31, 2010, the
   interest rate was to increase to 20% effective as of April&#160;1, 2010, and the Company would be
   required to begin making principal payments of $500,000 per month. On April&#160;27, 2010, the
   Company paid pSivida $15,225,000 in principal and interest to satisfy the note payable. As a
   result, the Company recognized a gain of $1,343,000 on the extinguishment of this debt in
   the accompanying financial statements for the nine month period ended September&#160;30, 2010.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company&#8217;s license rights to pSivida&#8217;s proprietary delivery device could revert to
   pSivida if the Company were to (i)&#160;fail twice to cure its breach of an obligation to make
   certain payments to pSivida following receipt of written notice thereof; (ii)&#160;fail to cure
   other breaches of material terms of its agreement with pSivida within 30&#160;days after notice
   of such breaches or such longer period (up to 90&#160;days) as may be reasonably necessary if the
   breach cannot be cured within such 30-day period; (iii)&#160;file for protection under the
   bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer
   appointment of a receiver or trustee over its property, file a petition under any bankruptcy
   or insolvency act or have any such petition filed against it and such proceeding remains
   undismissed or unstayed for a period of more than 60&#160;days; or (iv)&#160;notify pSivida in writing
   of its decision to abandon its license with respect to a certain product using pSivida&#8217;s
   proprietary delivery device. The Company was not in breach of its agreement with pSivida as
   of September&#160;30, 2011.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Upon commercialization of ILUVIEN, the Company must share 20% of net profits of
   ILUVIEN, as defined by the agreement, with pSivida. In connection with this arrangement the
   Company is entitled to recover 20% of commercialization costs of ILUVIEN, as defined in the
   agreement, incurred prior to product profitability out of pSivida&#8217;s share of net profits. As
   of September&#160;30, 2011 and December&#160;31, 2010 the Company was owed $3,556,000 and $2,224,000,
   respectively, in commercialization costs. Due to the uncertainty of FDA approval of the NDA
   for ILUVIEN, the Company has fully reserved these amounts in the accompanying financial
   statements.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_PsividaAgreementAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>pSivida Agreement</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_PsividaAgreementAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 07-1<br /><br /> -Paragraph 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 808<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0ECFBG"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) (USD $)<br />In Thousands</strong></div></th><th class="th" colspan="2">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Sep. 30, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td><td class="num">$ (16,445)<span /></td><td class="num">$ (7,606)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations (Note 3)</a></td><td class="text">&#xA0;<span /></td><td class="num">(4,000)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature', window );">Change in fair value of preferred stock conversion feature</a></td><td class="text">&#xA0;<span /></td><td class="num">(3,644)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain from early extinguishment of debt</a></td><td class="text">&#xA0;<span /></td><td class="num">(1,343)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td><td class="nump">106<span /></td><td class="nump">145<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_StockCompensationAndOther', window );">Stock compensation and other</a></td><td class="nump">1,478<span /></td><td class="nump">567<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td><td class="nump">318<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Non-cash investment gain</a></td><td class="text">&#xA0;<span /></td><td class="num">(4)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td><td class="num">(158)<span /></td><td class="num">(320)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td><td class="nump">273<span /></td><td class="nump">231<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td><td class="num">(1,720)<span /></td><td class="num">(53)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other long-term liabilities</a></td><td class="text">&#xA0;<span /></td><td class="nump">2<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td><td class="num">(16,148)<span /></td><td class="num">(16,025)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td><td class="text">&#xA0;<span /></td><td class="num">(39,962)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of investments</a></td><td class="nump">25,828<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td><td class="num">(104)<span /></td><td class="num">(121)<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities of continuing operations</a></td><td class="nump">25,724<span /></td><td class="num">(40,083)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by investing activities of discontinued operations (Note 3)</a></td><td class="text">&#xA0;<span /></td><td class="nump">4,000<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td><td class="nump">25,724<span /></td><td class="num">(36,083)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td><td class="nump">210<span /></td><td class="nump">28<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ProceedsFromExerciseOfPreferredStockWarrants', window );">Proceeds from exercise of Series C-1 preferred warrants</a></td><td class="text">&#xA0;<span /></td><td class="nump">9,997<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_ProceedsFromExerciseOfCommonStockWarrants', window );">Proceeds from exercise of common stock warrants</a></td><td class="nump">19<span /></td><td class="nump">489<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td><td class="nump">111<span /></td><td class="nump">68,395<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td><td class="text">&#xA0;<span /></td><td class="num">(1,942)<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of pSivida note payable (Note 6)</a></td><td class="text">&#xA0;<span /></td><td class="num">(15,000)<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_RepaymentOfNotesPayable', window );">Repayment of notes payable (Note 7)</a></td><td class="num">(265)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Payment of debt modification costs</a></td><td class="num">(50)<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on capital lease obligations</a></td><td class="num">(8)<span /></td><td class="num">(6)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td><td class="nump">17<span /></td><td class="nump">61,961<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE IN CASH</a></td><td class="nump">9,593<span /></td><td class="nump">9,853<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH - Beginning of period</a></td><td class="nump">28,514<span /></td><td class="nump">4,858<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH - End of period</a></td><td class="nump">38,107<span /></td><td class="nump">14,711<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td><td class="nump">508<span /></td><td class="nump">525<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing and financing activities:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Property and equipment acquired under capital leases</a></td><td class="text">&#xA0;<span /></td><td class="nump">36<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Reclassification of fair value of preferred stock conversion feature to additional paid-in capital</a></td><td class="text">&#xA0;<span /></td><td class="nump">36,528<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_IpoIssuanceCostsChargedToEquity', window );">IPO issuance costs charged to equity</a></td><td class="text">&#xA0;<span /></td><td class="nump">$ 4,228<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(INCREASE) DECREASE IN FAIR VALUE OF PREFERRED STOCK CONVERSION FEATURE</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_IncreaseDecreaseInFairValueOfPreferredStockConversionFeature</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_IpoIssuanceCostsChargedToEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>IPO issuance costs charged to equity</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_IpoIssuanceCostsChargedToEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ProceedsFromExerciseOfCommonStockWarrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of common stock warrants</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_ProceedsFromExerciseOfCommonStockWarrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_ProceedsFromExerciseOfPreferredStockWarrants"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of Series C-1 preferred warrants</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_ProceedsFromExerciseOfPreferredStockWarrants</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_RepaymentOfNotesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of notes payable (Note 7)</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_RepaymentOfNotesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_StockCompensationAndOther"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock compensation and other</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_StockCompensationAndOther</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to Additional Paid in Capital resulting from the recognition of deferred taxes for the temporary difference of the convertible debt with a beneficial conversion feature. A beneficial conversion feature is a nondetachable conversion feature that is in-the-money.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 55<br /><br /> -Paragraph 51<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6909077&amp;loc=d3e34017-109320<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Beneficial Conversion Feature<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 05-8<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.3-04)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 505<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Alternate captions include Noncash Interest Expense.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.8)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 8<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 8<br /><br /> -Article 9<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 02<br /><br /> -Paragraph 1<br /><br /> -Article 5<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7<br /><br /> -Footnote 1<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 8, 9<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 210<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 7, 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Cash Equivalents<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents cash provided by or used in the investing activities of the entity's discontinued operations during the period. This element is only used by those entities that separately report cash flows attributable to discontinued operations. If using this element, it is an indication that the cash flows of the entity which are detailed in reconciling to cash provided by or used in investing activities reflect only cash flows attributable to continuing operations.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 12<br /><br /> -Paragraph 5<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Depreciation</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 5<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 32<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_FairValueOfAssetsAcquired</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 470<br /><br /> -SubTopic 50<br /><br /> -Section 40<br /><br /> -Paragraph 4<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /> -Number 26<br /><br /> -Paragraph 20, 21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 470<br /><br /> -SubTopic 50<br /><br /> -Section 40<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the overall income (loss) from a disposal group apportioned to the parent that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 19<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph b(2)<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 29<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -Subparagraph (e)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_InterestPaid</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from financing activity for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from investing activity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash from (used in) the entity's investing activities specifically EXCLUDING the cash flows derived by the entity from its discontinued operations, if any. This element is only to be used when the entity reports its cash flows attributable to discontinued operations separately from the cash flow provided by or used in investing activities. Such reporting would necessitate the entity to use the Net Cash provided by or used in Discontinued Operations, Total element provided in the taxonomy.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -Footnote 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 26<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 24<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 25<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.22)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 225<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (SX 210.5-03.18)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 260<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 220<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 6<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph A7<br /><br /> -Appendix A<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 130<br /><br /> -Paragraph 10, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Other Comprehensive Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 38<br /><br /> -Subparagraph d<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /> -Number 87-21<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Net Income<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 944<br /><br /> -SubTopic 225<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.7-04.19)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Article 5<br /><br /> -Section 03<br /><br /> -Paragraph 19<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28, 29, 30<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 04<br /><br /> -Paragraph 20<br /><br /> -Article 9<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NetIncomeLoss</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18, 19, 20<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsOfDebtRestructuringCosts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18, 19, 20<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (a),(b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 13<br /><br /> -Subparagraph (c)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 17<br /><br /> -Subparagraph c<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Investing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 320<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 11<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 12<br /><br /> -Subparagraph (a),(b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 16<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 16<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 718<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -Subparagraph (j)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 123R<br /><br /> -Paragraph A240<br /><br /> -Subparagraph i<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 14<br /><br /> -Subparagraph (a)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 19<br /><br /> -Subparagraph a<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 26, 31<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 15<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 18<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 20<br /><br /> -Subparagraph b<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Glossary Financing Activities<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 95<br /><br /> -Paragraph 28<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 230<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 28<br /><br /> -Subparagraph (b)<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_UnrealizedGainLossOnInvestments</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations/Basis of Presentation [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>2. Basis of Presentation</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has prepared the accompanying unaudited interim financial statements and
   notes thereto in accordance with accounting principles generally accepted in the United
   States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to
   Form 10-Q and Article&#160;10-01 of Regulation&#160;S-X of the SEC. Accordingly, they do not include
   all of the information and disclosures required by U.S. GAAP for complete financial
   statements. In the opinion of management, the accompanying unaudited interim financial
   statements reflect all adjustments, which include normal recurring adjustments, necessary to
   present fairly the Company&#8217;s interim financial information.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The accompanying unaudited interim financial statements and related notes should be
   read in conjunction with the Company&#8217;s audited financial statements for the year ended
   December&#160;31, 2010 and related notes included in the Company&#8217;s Annual Report on Form 10-K,
   which was filed with the SEC on March&#160;25, 2011. The financial results for any interim period
   are not necessarily indicative of the expected financial results for the full year.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On April&#160;21, 2010, the Company effected a 1 for 3.4 reverse split of the Company&#8217;s
   common and preferred stock. All share and per share amounts in the accompanying financial
   statements and notes have been retroactively adjusted for all periods presented to give
   effect to the reverse stock split.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 720<br /><br /> -SubTopic 15<br /><br /> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 8<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Name Statement of Position (SOP)<br /><br /> -Publisher AICPA<br /><br /> -Number 94-6<br /><br /> -Paragraph 10<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 272<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name FASB Staff Position (FSP)<br /><br /> -Number FAS140-4/FIN46(R)-8<br /><br /> -Paragraph 8, C1, C7<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Name FASB Interpretation (FIN)<br /><br /> -Publisher FASB<br /><br /> -Number 46R<br /><br /> -Paragraph 4, 14, 15<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 852<br /><br /> -SubTopic 10<br /><br /> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br /><br /><br /><br />Reference 10: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 275<br /><br /> -SubTopic 10<br /><br /> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br /><br /><br /><br />Reference 11: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher AICPA<br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /> -Number 51<br /><br /> -Paragraph 2-6<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 12: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 915<br /><br /> -SubTopic 235<br /><br /> -Section 50<br /><br /> -Paragraph 1<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br /><br /><br /><br />Reference 13: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 10<br /><br /> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br /><br /><br /><br />Reference 14: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 205<br /><br /> -SubTopic 10<br /><br /> -Section 45<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br /><br /><br /><br />Reference 15: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br /><br /><br /><br />Reference 16: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 810<br /><br /> -SubTopic 10<br /><br /> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E2H"><tr><th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br /></strong></div></th><th class="th" colspan="1">9 Months Ended</th></tr><tr><th class="th"><div>Sep. 30, 2011</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td><td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 11 - us-gaap:IncomeTaxDisclosureTextBlock-->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="left" style="font-size: 10pt; margin-top: 10pt"><b>11. Income Taxes</b>
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In accordance with ASC 740 the Company recognizes deferred tax assets and liabilities
   for temporary differences between the financial reporting basis and the tax basis of its
   assets and liabilities. The Company records a valuation allowance against its net deferred
   tax asset to reduce the net carrying value to an amount that is more likely than not to be
   realized.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Income tax positions are considered for uncertainty in accordance with FASB
   Interpretation No.&#160;48, Accounting for Uncertainty in Income Taxes &#8212; an interpretation of
   ASC 740-10. The Company believes that its income tax filing positions and deductions will be
   sustained on audit and does not anticipate any adjustments that will result in a material
   change to its financial position; therefore, no ASC 740-10 liabilities have been recorded.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Significant management judgment is involved in determining the provision for income
   taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net
   deferred tax assets. Due to uncertainties with respect to the realization of deferred tax
   assets due to the history of operating losses, a valuation allowance has been established
   against the entire net deferred tax asset balance. The valuation allowance is based on
   management&#8217;s estimates of taxable income in the jurisdictions in which the Company operates
   and the period over which deferred tax assets will be recoverable. In the event that actual
   results differ from these estimates or the Company adjusts these estimates in future
   periods, a change in the valuation allowance may be needed, which could materially impact
   the Company&#8217;s financial position and results of operations.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At September&#160;30, 2011 and December&#160;31, 2010, the Company had federal net operating loss
   (&#8220;NOL&#8221;) carry-forwards of approximately $112,141,000 and $97,813,000 and state NOL
   carry-forwards of approximately $95,604,000 and $80,995,000, respectively, that are
   available to reduce future income unless otherwise taxable. If not utilized, the federal NOL
   carry-forwards will expire at various dates between 2023 and 2030, and the state NOL
   carry-forwards will expire at various dates between 2020 and 2030.
   </div>
   <div align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">NOL carry-forwards may be subject to annual limitations under Internal Revenue Code
   Section&#160;382 (or comparable provisions of state law) in the event that certain changes in
   ownership of the Company were to occur. The Company has not yet completed a formal
   evaluation of the impact of its IPO (Note 1) on the Company&#8217;s NOL carry-forwards and whether
   certain changes in ownership have occurred that would limit the Company&#8217;s ability to utilize
   a portion of its NOL carry-forwards.
   </div>
   <!-- Folio -->
   <!-- /Folio -->
   </div>
   <!-- PAGEBREAK -->
   <div style="font-family: 'Times New Roman',Times,serif; margin-left: 0in; ">
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   <div align="center" style="font-size: 10pt; margin-top: 0pt">
   <b>
   </b>
   </div>
   </div>
<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 2<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 136, 172<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /> -Number 109<br /><br /> -Paragraph 43, 44, 45, 46, 47, 48, 49<br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher SEC<br /><br /> -Name Regulation S-X (SX)<br /><br /> -Number 210<br /><br /> -Section 08<br /><br /> -Paragraph h<br /><br /> -Article 4<br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 3<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 9<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 740<br /><br /> -SubTopic 10<br /><br /> -Section 50<br /><br /> -Paragraph 15<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /> -Publisher FASB<br /><br /> -Name Accounting Standards Codification<br /><br /> -Topic 235<br /><br /> -SubTopic 10<br /><br /> -Section S99<br /><br /> -Paragraph 1<br /><br /> -Subparagraph (SX 210.4-08.(h))<br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>nonnum:textBlockItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<?xml version="1.0" encoding="us-ascii"?><html><head><link rel="StyleSheet" type="text/css" href="report.css" /><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head><body><span style="display: none;">v2.3.0.15</span><table class="report" border="0" cellspacing="2" id="ID0E5EAG"><tr><th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (USD $)<br />In Thousands</strong></div></th><th class="th"><div>Sep. 30, 2011</div></th><th class="th"><div>Dec. 31, 2010</div></th></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td><td class="nump">$ 38,107<span /></td><td class="nump">$ 28,514<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td><td class="nump">502<span /></td><td class="nump">26,330<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td><td class="nump">1,236<span /></td><td class="nump">1,078<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td><td class="nump">231<span /></td><td class="nump">272<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td><td class="nump">40,076<span /></td><td class="nump">56,194<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT - at cost less accumulated depreciation</a></td><td class="nump">218<span /></td><td class="nump">220<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td><td class="nump">40,294<span /></td><td class="nump">56,414<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td><td class="nump">1,950<span /></td><td class="nump">1,677<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (Note 5)</a></td><td class="nump">1,459<span /></td><td class="nump">2,731<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alim_OutsourcedServicesPayable', window );">Outsourced services payable</a></td><td class="nump">393<span /></td><td class="nump">841<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable (Note 7)</a></td><td class="nump">2,386<span /></td><td class="nump">1,157<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations</a></td><td class="nump">11<span /></td><td class="nump">11<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td><td class="nump">6,199<span /></td><td class="nump">6,417<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of discount - less current portion (Note 7)</a></td><td class="nump">3,501<span /></td><td class="nump">4,767<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td><td class="nump">9<span /></td><td class="nump">18<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td><td class="text">&#xA0;<span /></td><td class="text">&#xA0;<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmount', window );">Preferred stock, $.01 par value - 10,000,000 shares authorized and no shares issued and outstanding at September 30, 2011 and at December 31, 2010</a></td><td class="text">&nbsp;<span /></td><td class="text">&nbsp;<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value - 100,000,000 shares authorized and 31,407,383 shares issued and outstanding at September 30, 2011 and 100,000,000 shares authorized and 31,255,953 shares issued and outstanding at December 31, 2010</a></td><td class="nump">314<span /></td><td class="nump">313<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td><td class="nump">235,155<span /></td><td class="nump">233,338<span /></td></tr><tr class="re"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrants</a></td><td class="nump">415<span /></td><td class="nump">415<span /></td></tr><tr class="ro"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td><td class="num">(205,299)<span /></td><td class="num">(188,854)<span /></td></tr><tr class="reu"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td><td class="nump">30,585<span /></td><td class="nump">45,212<span /></td></tr><tr class="rou"><td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td><td class="nump">$ 40,294<span /></td><td class="nump">$ 56,414<span /></td></tr></table><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alim_OutsourcedServicesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outsourced services payable</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>alim_OutsourcedServicesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>alim</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19(a))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccountsPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.30(a)(1))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 12<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Concepts (CON)<br /><br /><br /><br /> -Number 6<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 18<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.18)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_Assets</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 9<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.9)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (b)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 840<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 13<br /><br /><br /><br /> -Paragraph 7, 10, 13<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.1)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7<br /><br /><br /><br /> -Footnote 1<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 230<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 8, 9<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 6: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (a)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 7: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br /><br /><br /><br /><br /><br /><br /><br />Reference 8: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 95<br /><br /><br /><br /> -Paragraph 7, 26<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 9: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Glossary Cash Equivalents<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 30<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_CommonStockValue</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.8)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 21<br /><br /><br /><br /> -Paragraph 16<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 835<br /><br /><br /><br /> -SubTopic 30<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 3<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_DeferredFinanceCostsCurrentNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 32<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.32)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 25<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 21<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.21)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 22<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.22)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_LongTermNotesPayable</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (f)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.2)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 320<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_MarketableSecuritiesCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 19, 20<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.19,20)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_NotesPayableCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 24<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.24)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 43<br /><br /><br /><br /> -Section A<br /><br /><br /><br /> -Paragraph 4<br /><br /><br /><br /> -Chapter 3<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Section 45<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.13)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 7<br /><br /><br /><br /> -Section 03<br /><br /><br /><br /> -Paragraph 8<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 13<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Statement of Financial Accounting Standard (FAS)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 5<br /><br /><br /><br /> -Subparagraph b, c<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 360<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section 50<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>debit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.31(a)(3))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Principles Board Opinion (APB)<br /><br /><br /><br /> -Number 12<br /><br /><br /><br /> -Paragraph 10<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 04<br /><br /><br /><br /> -Article 3<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.29-31)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher AICPA<br /><br /><br /><br /> -Name Accounting Research Bulletin (ARB)<br /><br /><br /><br /> -Number 51<br /><br /><br /><br /> -Paragraph A3<br /><br /><br /><br /> -Appendix A<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 29, 30, 31<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Staff Accounting Bulletin (SAB)<br /><br /><br /><br /> -Number Topic 4<br /><br /><br /><br /> -Section E<br /><br /><br /><br /><br /><br /><br /><br />Reference 5: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 310<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -Subparagraph (SAB TOPIC 4.E)<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquity</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:stringItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>na</td></tr><tr><td><strong> Period Type:</strong></td><td>duration</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmount"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value (book value) of an entity's issued and outstanding stock which is not included within permanent equity in Stockholders Equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 210<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.5-02.27(b))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number D-98<br /><br /><br /><br /> -Paragraph 2<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 4<br /><br /><br /><br /> -Section 08<br /><br /><br /><br /> -Paragraph i<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Section 02<br /><br /><br /><br /> -Paragraph 28<br /><br /><br /><br /> -Subparagraph a<br /><br /><br /><br /> -Article 5<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_TemporaryEquityCarryingAmount</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding"><tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr><tr><td><div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of warrants and rights outstanding. "Equity warrants and rights outstanding" represents derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Accounting Standards Codification<br /><br /><br /><br /> -Topic 235<br /><br /><br /><br /> -SubTopic 10<br /><br /><br /><br /> -Section S99<br /><br /><br /><br /> -Paragraph 1<br /><br /><br /><br /> -Subparagraph (SX 210.4-08.(i))<br /><br /><br /><br /> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br /><br /><br /><br /><br /><br /><br /><br />Reference 2: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher SEC<br /><br /><br /><br /> -Name Regulation S-X (SX)<br /><br /><br /><br /> -Number 210<br /><br /><br /><br /> -Article 4<br /><br /><br /><br /> -Section 08<br /><br /><br /><br /> -Paragraph i<br /><br /><br /><br /><br /><br /><br /><br />Reference 3: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number 00-27<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br />Reference 4: http://www.xbrl.org/2003/role/presentationRef<br /><br /><br /><br /> -Publisher FASB<br /><br /><br /><br /> -Name Emerging Issues Task Force (EITF)<br /><br /><br /><br /> -Number 98-5<br /><br /><br /><br /> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br /><br /><br /><br /><br /><br /><br /><br /></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"><tr><td><strong> Name:</strong></td><td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td></tr><tr><td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td><td>us-gaap</td></tr><tr><td><strong> Data Type:</strong></td><td>xbrli:monetaryItemType</td></tr><tr><td><strong> Balance Type:</strong></td><td>credit</td></tr><tr><td><strong> Period Type:</strong></td><td>instant</td></tr></table></div></div></td></tr></table></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.15</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>10</ContextCount>
  <ElementCount>102</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>01 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>011 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>02 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>03 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>06001 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>06002 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>06003 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>06004 - Disclosure - Factors Affecting Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/FactorsAffectingOperations</Role>
      <ShortName>Factors Affecting Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>06005 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>06006 - Disclosure - pSivida Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/PsividaAgreement</Role>
      <ShortName>pSivida Agreement</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>06007 - Disclosure - Term Loan and Working Capital Revolver</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/TermLoanAndWorkingCapitalRevolver</Role>
      <ShortName>Term Loan and Working Capital Revolver</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>06008 - Disclosure - Earnings (Loss) Per Share (EPS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/EarningsLossPerShareEPS</Role>
      <ShortName>Earnings (Loss) Per Share (EPS)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>06009 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/PreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>06010 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>06011 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>06012 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alimerasciences.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 01 - Statement - Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 011 - Statement - Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 02 - Statement - Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 03 - Statement - Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>alim-20110930.xml</File>
    <File>alim-20110930.xsd</File>
    <File>alim-20110930_cal.xml</File>
    <File>alim-20110930_lab.xml</File>
    <File>alim-20110930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>31
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%L86YC95]3:&5E
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"86QA
M;F-E7U-H965T<U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT<U]O9E]/<&5R871I;VYS7U5N
M875D/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1A
M=&5M96YT<U]O9E]#87-H7T9L;W=S7U5N875D/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3F%T=7)E7V]F7T]P97)A=&EO;G,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,#8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"87-I<U]O9E]0
M<F5S96YT871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y$:7-C;VYT:6YU961?3W!E<F%T:6]N<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D9A8W1O<G-?069F96-T:6YG7T]P97)A
M=&EO;G,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!
M8V-R=65D7T5X<&5N<V5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^<%-I=FED85]!9W)E96UE;G0\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y497)M7TQO86Y?86YD7U=O<FMI;F=?0V%P
M:71A;%\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y%
M87)N:6YG<U],;W-S7U!E<E]3:&%R95]%4%,\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y0<F5F97)R961?4W1O8VL\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]/<'1I;VYS/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A
M>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1F%I
M<E]686QU93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE
M<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z
M06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T
M<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T
M96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC
M96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\
M8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@
M36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V1C-38V-35D7V1F.35?-&%B
M8U\Y9C=E7S!D,6(X93AC-V%D-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]D8S4V-C4U9%]D9CDU7S1A8F-?.68W95\P9#%B.&4X8S=A9#<O5V]R
M:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%05=!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N
M("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.
M;W8N(#`S+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO
M;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/D%,24U%4D$@4T-)14Y#15,@24Y#/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C`P,#$R-C<V,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@
M1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4V5P(#,P+`T*
M"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&
M:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#Y1,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&PM
M:VYO=VX@4V5A<V]N960@27-S=65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0W5R<F5N="!297!O
M<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y9
M97,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^3F]N+6%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4'5B
M;&EC($9L;V%T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S
M<#LD(#$W+#,W-BPX,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L
M-#(W+#,U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9&,U-C8U-61?9&8Y-5\T86)C7SEF-V5?,&0Q8CAE.&,W860W#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1C-38V-35D7V1F.35?-&%B8U\Y
M9C=E7S!D,6(X93AC-V%D-R]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4U14%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)A;&%N8V4@4VAE
M971S("A54T0@)FYB<W`[)"D\8G(^26X@5&AO=7-A;F1S/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-5
M4E)%3E0@05-31513.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#,X+#$P-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@
M,C@L-3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E<W1M96YT<R!I;B!M87)K971A8FQE('-E8W5R:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#,S,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D
M(&9I;F%N8VEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P+#`W-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#$Y-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4%)/4$525%D@04Y$
M($5154E0345.5"`M(&%T(&-O<W0@;&5S<R!A8V-U;75L871E9"!D97!R96-I
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1/5$%,($%34T544SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#`L,CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-38L-#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-54E)%3E0@3$E!0DE,251)15,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U
M;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M.34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PV-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,@*$YO=&4@-2D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#4Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW,S$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U='-O=7)C960@
M<V5R=FEC97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.;W1E<R!P87EA8FQE("A.;W1E(#<I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#,X-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,34W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L(&QE87-E
M(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPQ.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0Q-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,3TY'+51%
M4DT@3$E!0DE,251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYO=&5S('!A>6%B;&4L(&YE="!O9B!D:7-C;W5N="`M
M(&QE<W,@8W5R<F5N="!P;W)T:6]N("A.;W1E(#<I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S8W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!L;VYG+71E<FT@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E463H\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K
M+"`F;F)S<#LD+C`Q('!A<B!V86QU92`M(#$P+#`P,"PP,#`@<VAA<F5S(&%U
M=&AO<FEZ960@86YD(&YO('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG
M(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,2!A;F0@870@1&5C96UB97(@,S$L(#(P
M,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"`F;F)S<#LD+C`Q('!A<B!V86QU92`M(#$P,"PP
M,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&%N9"`S,2PT,#<L,S@S('-H87)E
M<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%T(%-E<'1E;6)E<B`S,"P@,C`Q
M,2!A;F0@,3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960@86YD(#,Q+#(U
M-2PY-3,@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@1&5C96UB
M97(@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(S-2PQ-34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S,L,S,X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Q
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C`U+#(Y.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q.#@L.#4T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1/5$%,(%-43T-+2$],
M1$524R<@15%52519/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,"PU.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-2PR,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y43U1!3"!,24%"24Q)5$E%4R!!3D0@4U1/0TM(3TQ$
M15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N
M8G-P.R0@-#`L,CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)FYB<W`[)"`U-BPT,30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V1C-38V-35D7V1F.35?-&%B8U\Y9C=E
M7S!D,6(X93AC-V%D-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D
M8S4V-C4U9%]D9CDU7S1A8F-?.68W95\P9#%B.&4X8S=A9#<O5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%041!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY"86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@*%531"`F
M;F)S<#LD*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%DZ/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XF;F)S<#LD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S
M=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O
M8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,"XP,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,"XP,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,2PT,#<L,S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,C4U+#DU,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Q+#0P-RPS.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,2PR-34L.34S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D8S4V-C4U9%]D9CDU7S1A8F-?.68W
M95\P9#%B.&4X8S=A9#<-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M9&,U-C8U-61?9&8Y-5\T86)C7SEF-V5?,&0Q8CAE.&,W860W+U=O<FMS:&5E
M=',O4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13),04<^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A5;F%U9&ET960I
M("A54T0@)FYB<W`[)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@
M9&%T83PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y215-%05)#2"!!3D0@1$5614Q/4$U%3E0@15A014Y315,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,BPR,C0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S
M<#LD(#,L,C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)FYB<W`[)"`U+#<S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,3`L-#@Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'14Y%4D%,
M($%.1"!!1$U)3DE35%)!5$E612!%6%!%3E-%4SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PT,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(V,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#(W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DU!4DM%5$E.
M1R!%6%!%3E-%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV
M,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPR,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/4$52051)3D<@15A014Y315,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C4W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PU.3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPP
M,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DE.5$5215-4($E.0T]-13PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^24Y415)%4U0@15A014Y313PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@V,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'04E.($].($5!4DQ9
M($585$E.1U5)4TA-14Y4($]&($1%0E0@*$Y/5$4@-BD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$14-214%312!)3B!&04E2(%9!
M3%5%($]&(%!2149%4E)%1"!35$]#2R!#3TY615)324].($9%05154D4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C0T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3$]34R!&4D]-
M($-/3E1)3E5)3D<@3U!%4D%424].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-BPU-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-BPP.#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,38L-#0U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#8P-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.0T]-12!&
M4D]-($1)4T-/3E1)3E5%1"!/4$52051)3TY3("A.3U1%(#,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!,3U-3/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#4T,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#`X,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPT-#4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-RPV,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2141%14U!0DQ%(%!2149%4E)%1"!35$]#2R!!0T-2151)3TX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0V-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)%1$5%34%"
M3$4@4%)%1D524D5$(%-43T-+($1)5DE$14Y$4SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPV,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($Q/4U,@05!03$E#04),12!4
M3R!#3TU-3TX@4TA!4D5(3TQ$15)3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B9N8G-P.R0@*#8L-30P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H-BPP.#(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@Q
M-BPT-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XF;F)S<#LD("@Q,"PW,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.150@3$]34R!015(@4TA!4D4@05!0
M3$E#04),12!43R!#3TU-3TX@4TA!4D5(3TQ$15)3("T@0F%S:6,@86YD(&1I
M;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H
M,"XR,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B9N8G-P.R0@*#`N,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#`N-3(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@P+C4V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5T5)1TA4140M059%4D%'12!32$%215,@3U544U1!3D1)3D<@+2!"87-I8R!A
M;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L
M,SDV+#4Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,Q+#$T-2PX-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,2PS-#(L-S4R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,3(P+#@V,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&,U-C8U-61?9&8Y
M-5\T86)C7SEF-V5?,&0Q8CAE.&,W860W#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V1C-38V-35D7V1F.35?-&%B8U\Y9C=E7S!D,6(X93AC-V%D
M-R]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5#1D)'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-T871E;65N=',@;V8@0V%S:"!&;&]W<R`H
M56YA=61I=&5D*2`H55-$("9N8G-P.R0I/&)R/DEN(%1H;W5S86YD<SPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(
M($9,3U=3($923TT@3U!%4D%424Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@*#$V+#0T-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P
M.R0@*#<L-C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YC;VUE(&9R;VT@9&ES8V]N=&EN=65D(&]P97)A=&EO
M;G,@*$YO=&4@,RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L
M,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@<')E9F5R<F5D('-T;V-K
M(&-O;G9E<G-I;VX@9F5A='5R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,RPV-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'86EN(&9R;VT@96%R;'D@97AT:6YG=6ES:&UE;G0@
M;V8@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PS-#,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$97!R96-I871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VL@8V]M<&5N<V%T:6]N(&%N9"!O=&AE<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-S@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO
M;B!O9B!D969E<G)E9"!F:6YA;F-I;F<@8V]S=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+6-A<V@@:6YV97-T;65N="!G86EN
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M:&%N9V5S(&EN(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS
M97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X
M<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<R,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&QO;F<M
M=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#$T."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPP,C4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!)3E9%4U1)3D<@04-4259)5$E%
M4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4'5R8VAA<V5S(&]F(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S.2PY-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&UA='5R:71I97,@
M;V8@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U+#@R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,C$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&-A<V@@<')O=FED960@8GD@*'5S960@:6XI(&EN=F5S=&EN9R!A8W1I=FET
M:65S(&]F(&-O;G1I;G5I;F<@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C4L-S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-#`L,#@S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED
M960@8GD@:6YV97-T:6YG(&%C=&EV:71I97,@;V8@9&ES8V]N=&EN=65D(&]P
M97)A=&EO;G,@*$YO=&4@,RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@*'5S960@:6XI(&EN
M=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-2PW,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S-BPP.#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!&
M24Y!3D-)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!E>&5R8VES97,@;V8@
M<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@4V5R:65S($,M,2!P
M<F5F97)R960@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDL.3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C:7-E(&]F(&-O;6UO;B!S
M=&]C:R!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!C;VUM;VX@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X+#,Y-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N
M="!O9B!C;VUM;VX@<W1O8VL@;V9F97)I;F<@8V]S=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$L.30R*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT(&]F('!3:79I
M9&$@;F]T92!P87EA8FQE("A.;W1E(#8I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q-2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297!A>6UE;G0@;V8@;F]T97,@<&%Y86)L
M92`H3F]T92`W*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&%Y;65N="!O9B!D96)T(&UO9&EF:6-A=&EO;B!C;W-T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!O;B!C87!I
M=&%L(&QE87-E(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C$L.38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3D54($E.0U)%05-%($E.($-!4T@\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDL-3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.2PX-3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-!4T@@+2!"96=I;FYI;F<@
M;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR."PU
M,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#@U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0T%32"`M($5N9"!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,X+#$P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#<Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY355!03$5-
M14Y404P@1$E30TQ/4U5215,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L
M96UE;G1A;"!S8VAE9'5L92!O9B!N;VYC87-H(&EN=F5S=&EN9R!A;F0@9FEN
M86YC:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@86-Q=6ER
M960@=6YD97(@8V%P:71A;"!L96%S97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296-L87-S:69I8V%T:6]N(&]F(&9A:7(@=F%L=64@
M;V8@<')E9F5R<F5D('-T;V-K(&-O;G9E<G-I;VX@9F5A='5R92!T;R!A9&1I
M=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S8L-3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)4$\@:7-S=6%N8V4@8V]S=',@8VAA<F=E9"!T
M;R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P
M.R0@-"PR,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V1C-38V-35D7V1F.35?-&%B8U\Y9C=E7S!D,6(X93AC-V%D-PT*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D8S4V-C4U9%]D9CDU7S1A8F-?
M.68W95\P9#%B.&4X8S=A9#<O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F%T=7)E(&]F($]P
M97)A=&EO;G,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.871U<F4@;V8@3W!E<F%T:6]N<R]"87-I<R!O9B!0<F5S
M96YT871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.871U<F4@;V8@3W!E<F%T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),
M24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B
M:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I
M=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.
M;W1E(#$@+2!U<RUG86%P.DYA='5R94]F3W!E<F%T:6]N<RTM/@T*("`@/"$M
M+2!X8G)L+&YS("TM/@T*("`@/"$M+2!X8G)L+&YX("TM/@T*("`@/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L
M<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,'!T)SX\8CX\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T
M/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX\8CX\+V(^#0H@
M("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^,2X@3F%T=7)E(&]F
M($]P97)A=&EO;G,\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P
M=#L@=&5X="UI;F1E;G0Z(#0E)SY!;&EM97)A(%-C:65N8V5S+"!);F,N("@F
M(S@R,C`[0V]M<&%N>28C.#(R,3LI(&ES(&$@8FEO<&AA<FUA8V5U=&EC86P@
M8V]M<&%N>2!T:&%T('-P96-I86QI>F5S(&EN#0H@("!T:&4@<F5S96%R8V@L
M(&1E=F5L;W!M96YT+"!A;F0@8V]M;65R8VEA;&EZ871I;VX@;V8@<')E<V-R
M:7!T:6]N(&]P:'1H86QM:6,@<&AA<FUA8V5U=&EC86QS+B!4:&4@0V]M<&%N
M>0T*("`@=V%S(&9O<FUE9"!O;B!*=6YE)B,Q-C`[-"P@,C`P,R!U;F1E<B!T
M:&4@;&%W<R!O9B!T:&4@4W1A=&4@;V8@1&5L87=A<F4N#0H@("`\+V1I=CX-
M"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY/;B!!<')I
M;"8C,38P.S(Q+"`R,#$P+"!T:&4@0V]M<&%N>28C.#(Q-SMS(%)E9VES=')A
M=&EO;B!3=&%T96UE;G0@;VX@1F]R;2!3+3$@*&%S(&%M96YD960I('=A<PT*
M("`@9&5C;&%R960@969F96-T:79E(&)Y('1H92!396-U<FET:65S(&%N9"!%
M>&-H86YG92!#;VUM:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q.RD@9F]R('1H
M92!#;VUP86YY)B,X,C$W.W,-"B`@(&EN:71I86P@<'5B;&EC(&]F9F5R:6YG
M("@F(S@R,C`[25!/)B,X,C(Q.RDL('!U<G-U86YT('1O('=H:6-H('1H92!#
M;VUP86YY('-O;&0@-BPU-3`L,#`P('-H87)E<R!O9B!I=',-"B`@(&-O;6UO
M;B!S=&]C:R!A="!A('!U8FQI8R!O9F9E<FEN9R!P<FEC92!O9B`F;F)S<#LD
M,3$N,#`@<&5R('-H87)E+B!4:&4@0V]M<&%N>2!R96-E:79E9"!N970-"B`@
M('!R;V-E961S(&]F(&%P<')O>&EM871E;'D@)FYB<W`[)#8X+#,Y-2PP,#`@
M9G)O;2!T:&ES('1R86YS86-T:6]N+"!A9G1E<B!D961U8W1I;F<@=6YD97)W
M<FET:6YG#0H@("!D:7-C;W5N=',@86YD(&-O;6UI<W-I;VYS+@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^1'5R
M:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,#8L(&UA
M;F%G96UE;G0@86YD('1H92!B;V%R9"!O9B!D:7)E8W1O<G,@;V8@=&AE#0H@
M("!#;VUP86YY(&%P<')O=F5D(&$@<&QA;B!T;R!D:7-C;VYT:6YU92!T:&4@
M;W!E<F%T:6]N<R!O9B!I=',@;F]N+7!R97-C<FEP=&EO;B!B=7-I;F5S<R`H
M<V5E#0H@("!.;W1E(#,I+B!!<R!A(')E<W5L="!O9B!T:&4@8V]M<&QE=&EO
M;B!O9B!T:&4@9&ES<&]S86P@;V8@:71S(&YO;BUP<F5S8W)I<'1I;VX@8G5S
M:6YE<W,@:6X-"B`@($IU;'DF(S$V,#LR,#`W+"!T:&4@0V]M<&%N>2!N;R!L
M;VYG97(@:&%S(&%C=&EV92!P<F]D=6-T<R!A;F0@=VEL;"!N;W0@:&%V92!A
M8W1I=F4@<')O9'5C=',@=6YT:6P-"B`@(&%N9"!U;FQE<W,@=&AE($-O;7!A
M;GD@<F5C96EV97,@52Y3+B!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T:6]N
M("@F(S@R,C`[1D1!)B,X,C(Q.RD@87!P<F]V86P@86YD#0H@("!L875N8VAE
M<R!I=',@:6YI=&EA;"!P<F5S8W)I<'1I;VX@<')O9'5C="`H<V5E($YO=&4@
M-"DN#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E
M;G0Z(#0E)SY4:&4@0V]M<&%N>2!I<R!P<F5S96YT;'D@9F]C=7-E9"!O;B!D
M:7-E87-E<R!A9F9E8W1I;F<@=&AE(&)A8VL@;V8@=&AE(&5Y92P@;W(@<F5T
M:6YA+`T*("`@8F5C875S92!T:&4@0V]M<&%N>28C.#(Q-SMS(&UA;F%G96UE
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M<F5A=&UE;G0@;V8@9&EA8F5T:6,@;6%C=6QA<@T*("`@961E;6$@*"8C.#(R
M,#M$344F(S@R,C$[*2X@1$U%(&ES(&$@9&ES96%S92!O9B!T:&4@<F5T:6YA
M('=H:6-H(&%F9F5C=',@:6YD:79I9'5A;',@=VET:"!D:6%B971E<R!A;F0-
M"B`@(&-A;B!L96%D('1O('-E=F5R92!V:7-I;VX@;&]S<R!A;F0@8FQI;F1N
M97-S+B!4:&4@0V]M<&%N>2!H87,@8V]M<&QE=&5D("!T=V\@4&AA<V4@,PT*
M("`@<&EV;W1A;"!C;&EN:6-A;"!T<FEA;',@*&-O;&QE8W1I=F5L>2!R969E
M<G)E9"!T;R!A<R!T:&4@)B,X,C(P.T9!344@4W1U9'DF(S@R,C$[*2!F;W(@
M24Q55DE%3B!I;G9O;'9I;F<-"B`@(#DU-B!P871I96YT<R!I;B!S:71E<R!A
M8W)O<W,@=&AE(%4N4RXL($-A;F%D82P@175R;W!E(&%N9"!);F1I82!T;R!A
M<W-E<W,@=&AE(&5F9FEC86-Y(&%N9`T*("`@<V%F971Y(&]F($E,559)14X@
M:6X@=&AE('1R96%T;65N="!O9B!$344N#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN
M+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY);B!*=6YE)B,Q-C`[,C`Q
M,"P@=&AE($-O;7!A;GD@<W5B;6ET=&5D(&$@3F5W($1R=6<@07!P;&EC871I
M;VX@*"8C.#(R,#M.1$$F(S@R,C$[*2!F;W(@24Q55DE%3B!T;R!T:&4@1D1!
M('1H870@:6YC;'5D960@9&%T82!T:')O=6=H#0H@("!M;VYT:"`R-"!O9B!T
M:&4@1D%-12!3='5D>2X@26X@1&5C96UB97(F(S$V,#LR,#$P+"!T:&4@1D1!
M(&ES<W5E9"!A($-O;7!L971E(%)E<W!O;G-E($QE='1E<B`H)B,X,C(P.T-2
M3"8C.#(R,3LI(&EN(')E<W!O;G-E('1O('1H90T*("`@0V]M<&%N>28C.#(Q
M-SMS($Y$02X@26X@=&AE($-23"P@=&AE($9$02!C;VUM=6YI8V%T960@:71S
M(&1E8VES:6]N('1H870@=&AE($Y$02!C;W5L9"!N;W0@8F4@87!P<F]V960@
M:6X@:71S('1H96X@<')E<V5N=`T*("`@9F]R;2X@5&AE($9$02!A<VME9"!F
M;W(@86YA;'ES97,@;V8@=&AE('-A9F5T>2!A;F0@969F:6-A8WD@9&%T82!T
M:')O=6=H(&UO;G1H(#,V(&]F('1H92!&04U%(%-T=61Y+"!I;F-L=61I;F<-
M"B`@(&5X<&QO<F%T;W)Y(&%N86QY<V5S(&EN(&%D9&ET:6]N('1O('1H;W-E
M('!R979I;W5S;'D@<W5B;6ET=&5D(&EN('1H92!.1$$L('1O(&9U<G1H97(@
M87-S97-S('1H92!R96QA=&EV92!B96YE9FET<R!A;F0-"B`@(')I<VMS(&]F
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M97(@9F]R('=H:6-H(&%P<')O=F%L('=A<R!S;W5G:'0@:6X-"B`@('1H92!.
M1$$N($EN($UA>28C,38P.S(P,3$L('1H92!#;VUP86YY('-U8FUI='1E9"!T
M;R!T:&4@1D1!(&$@8V]M<&QE=&4@<F5S<&]N<V4@=&\@=&AE($-23"X@5&AE
M($9$02!C;&%S<VEF:65D('1H92!R97-P;VYS90T*("`@87,@82!#;&%S<R8C
M,38P.S(@<F5S=6)M:7-S:6]N('=I=&@@82!0<F5S8W)I<'1I;VX@1')U9R!5
M<V5R($9E92!!8W0@*"8C.#(R,#M01%5&028C.#(R,3LI(&1A=&4@;V8@3F]V
M96UB97(F(S$V,#LQ,BP@,C`Q,2X@5&AE(%!$549!(&1A=&4@:7,-"B`@('1H
M92!D871E(&)Y('=H:6-H('1H92!#;VUP86YY(&-A;B!R96%S;VYA8FQY(&5X
M<&5C="!T;R!H879E(')E8V5I=F5D('1H92!&1$$F(S@R,3<[<R!R97-P;VYS
M92X@26X@2G5L>28C,38P.S(P,3$L('1H92!&1$$@;F]T:69I960-"B`@('1H
M92!#;VUP86YY('1H870@:70@=VEL;"!N;W0@8V%L;"!A;B!A9'9I<V]R>2!C
M;VUM:71T964@9'5R:6YG(&ET<R!R979I97<@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!C;VUP;&5T92!R97-P;VYS92!T;R!T:&4-"B`@($-23"X@26X@4V5P
M=&5M8F5R)B,Q-C`[,C`Q,2P@=&AE($-O;7!A;GD@96YR;VQL960@:71S(&9I
M<G-T('!A=&EE;G0@:6X@82!P:'ES:6-I86X@=71I;&EZ871I;VX@<W1U9'D@
M86EM960@870@<')O=FED:6YG('1H90T*("`@861D:71I;VYA;"!D871A(')E
M<75E<W1E9"!B>2!T:&4@1D1!('=I=&@@<F5S<&5C="!T;R!T:&4@8V]M;65R
M8VEA;"!V97)S:6]N(&]F('1H92!)3%56245.(&EN<V5R=&5R+B!4:&4@0V]M
M<&%N>2!H87,-"B`@(&5N<F]L;&5D(#4T('!A=&EE;G0@97EE<R!I;B!T:&ES
M('-T=61Y(&5V86QU871I;F<@=&AE('-A9F5T>2!A;F0@=71I;&ET>2!O9B!T
M:&4@8V]M;65R8VEA;"!V97)S:6]N(&]F('1H92!I;G-E<G1E<B!A;F0-"B`@
M(&ES('1A<F=E=&EN9R!T;R!E;G)O;&P@,3`P('!A=&EE;G0@97EE<R!B969O
M<F4@8V]M;65R8VEA;"!L875N8V@N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY);B!*=6QY)B,Q-C`[,C`Q,"P@
M=7-I;F<@=&AE($1E8V5N=')A;&EZ960@4')O8V5D=7)E+"!T:&4@0V]M<&%N
M>2!S=6)M:71T960@82!-87)K971I;F<-"B`@($%U=&AO<FEZ871I;VX@07!P
M;&EC871I;VX@9F]R($E,559)14X@=&\@=&AE($UE9&EC:6YE<R!A;F0@2&5A
M;'1H8V%R92!P<F]D=6-T<R!296=U;&%T;W)Y#0H@("!!9V5N8WD@*"8C.#(R
M,#M-2%)!)B,X,C(Q.RD@:6X@=&AE(%5N:71E9"!+:6YG9&]M+"!W:&EC:"!S
M97)V97,@87,@=&AE(%)E9F5R96YC92!-96UB97(@4W1A=&4L(&%N9"!T;PT*
M("`@<F5G=6QA=&]R>2!A=71H;W)I=&EE<R!I;B!!=7-T<FEA+"!&<F%N8V4L
M($=E<FUA;GDL($ET86QY+"!0;W)T=6=A;"!A;F0@4W!A:6XN($EN($YO=F5M
M8F5R#0H@("`R,#$P+"!T:&4@0V]M<&%N>2!R96-E:79E9"!T:&4@4')E;&EM
M:6YA<GD@07-S97-S;65N="!297!O<G0@9G)O;2!T:&4@34A202!F;VQL;W=E
M9"!B>0T*("`@861D:71I;VYA;"!C;VUM96YT<R!F<F]M('1H92!O=&AE<B!H
M96%L=&@@875T:&]R:71I97,@:6X@1&5C96UB97(F(S$V,#LR,#$P+B!);B!*
M=6QY)B,Q-C`[,C`Q,2P@=&AE#0H@("!#;VUP86YY('-U8FUI='1E9"!I=',@
M9')A9G0@<F5S<&]N<V5S('1O('1H92!C;&EN:6-A;"P@;F]N+6-L:6YI8V%L
M+"!A;F0@<75A;&ET>2!Q=65S=&EO;G,-"B`@('1O('1H92!-2%)!+B!4:&4@
M<W5B;6ES<VEO;B!I;F-L=61E9"!T:&4@861D:71I;VYA;"!S869E='D@86YD
M(&5F9FEC86-Y(&1A=&$@=&AR;W5G:"!T:&4-"B`@(&9I;F%L(')E861O=70@
M870@=&AE(&5N9"!O9B!T:&4@1D%-12!3='5D>2X@#0H@("!);B!397!T96UB
M97(@,C`Q,2P@=&AE($U(4D$@<')O=FED960@8V]M;65N=',@=&\@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;&EN:6-A;"!R97-P;VYS97,@86YD(&EN9&EC871E
M9"!T:&%T('1H97)E(`T*("`@=V5R92!N;R!F=7)T:&5R(&-O;6UE;G1S('1O
M('1H92!#;VUP86YY)B,X,C$W.W,@;F]N+6-L:6YI8V%L(&%N9"`-"B`@('%U
M86QI='D@<F5S<&]N<V5S+B`@5&AE($-O;7!A;GD@:7,@<')E<&%R:6YG+"!A
M;F0@#0H@("!P;&%N<R!T;R!S=6)M:70@:6X@3F]V96UB97(@,C`Q,2P@:71S
M(&9I;F%L(')E<W!O;G-E('1O('1H92!0<F5L:6UI;F%R>2!!<W-E<W-M96YT
M(%)E<&]R="!F<F]M('1H92!-2%)!(&%N9"!T;R!T:&4@861D:71I;VYA;"!C
M;VUM96YT<R!F<F]M('1H92!O=&AE<B!H96%L=&@@875T:&]R:71I97,N#0H@
M("`\+V1I=CX-"B`@(#PO9&EV/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D)A<VES(&]F(%!R97-E;G1A=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYA='5R92!O9B!/<&5R871I;VYS
M+T)A<VES(&]F(%!R97-E;G1A=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E
M;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/
M0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N
M<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T14
M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN
M($)L;V-K(%1A9V=E9"!.;W1E(#(@+2!U<RUG86%P.D]R9V%N:7IA=&EO;D-O
M;G-O;&ED871I;VY!;F10<F5S96YT871I;VY/9D9I;F%N8VEA;%-T871E;65N
M='-$:7-C;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R
M9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^,BX@
M0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]B/@T*("`@/"]D:78^#0H@("`\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^5&AE($-O;7!A;GD@:&%S
M('!R97!A<F5D('1H92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&EN=&5R:6T@
M9FEN86YC:6%L('-T871E;65N=',@86YD#0H@("!N;W1E<R!T:&5R971O(&EN
M(&%C8V]R9&%N8V4@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9V5N97)A
M;&QY(&%C8V5P=&5D(&EN('1H92!5;FET960-"B`@(%-T871E<R!O9B!!;65R
M:6-A("@F(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R:6T@9FEN
M86YC:6%L(&EN9F]R;6%T:6]N(&%N9"!T:&4@:6YS=')U8W1I;VYS('1O#0H@
M("!&;W)M(#$P+5$@86YD($%R=&EC;&4F(S$V,#LQ,"TP,2!O9B!296=U;&%T
M:6]N)B,Q-C`[4RU8(&]F('1H92!314,N($%C8V]R9&EN9VQY+"!T:&5Y(&1O
M(&YO="!I;F-L=61E#0H@("!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N9"!D
M:7-C;&]S=7)E<R!R97%U:7)E9"!B>2!5+E,N($=!05`@9F]R(&-O;7!L971E
M(&9I;F%N8VEA;`T*("`@<W1A=&5M96YT<RX@26X@=&AE(&]P:6YI;VX@;V8@
M;6%N86=E;65N="P@=&AE(&%C8V]M<&%N>6EN9R!U;F%U9&ET960@:6YT97)I
M;2!F:6YA;F-I86P-"B`@('-T871E;65N=',@<F5F;&5C="!A;&P@861J=7-T
M;65N=',L('=H:6-H(&EN8VQU9&4@;F]R;6%L(')E8W5R<FEN9R!A9&IU<W1M
M96YT<RP@;F5C97-S87)Y('1O#0H@("!P<F5S96YT(&9A:7)L>2!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&EN=&5R:6T@9FEN86YC:6%L(&EN9F]R;6%T:6]N+@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T
M)2<^5&AE(&%C8V]M<&%N>6EN9R!U;F%U9&ET960@:6YT97)I;2!F:6YA;F-I
M86P@<W1A=&5M96YT<R!A;F0@<F5L871E9"!N;W1E<R!S:&]U;&0@8F4-"B`@
M(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&%U9&ET960@9FEN86YC:6%L('-T871E;65N=',@9F]R('1H92!Y96%R(&5N
M9&5D#0H@("!$96-E;6)E<B8C,38P.S,Q+"`R,#$P(&%N9"!R96QA=&5D(&YO
M=&5S(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@06YN=6%L(%)E
M<&]R="!O;B!&;W)M(#$P+4LL#0H@("!W:&EC:"!W87,@9FEL960@=VET:"!T
M:&4@4T5#(&]N($UA<F-H)B,Q-C`[,C4L(#(P,3$N(%1H92!F:6YA;F-I86P@
M<F5S=6QT<R!F;W(@86YY(&EN=&5R:6T@<&5R:6]D#0H@("!A<F4@;F]T(&YE
M8V5S<V%R:6QY(&EN9&EC871I=F4@;V8@=&AE(&5X<&5C=&5D(&9I;F%N8VEA
M;"!R97-U;'1S(&9O<B!T:&4@9G5L;"!Y96%R+@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^3VX@07!R:6PF(S$V
M,#LR,2P@,C`Q,"P@=&AE($-O;7!A;GD@969F96-T960@82`Q(&9O<B`S+C0@
M<F5V97)S92!S<&QI="!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS#0H@("!C;VUM
M;VX@86YD('!R969E<G)E9"!S=&]C:RX@06QL('-H87)E(&%N9"!P97(@<VAA
M<F4@86UO=6YT<R!I;B!T:&4@86-C;VUP86YY:6YG(&9I;F%N8VEA;`T*("`@
M<W1A=&5M96YT<R!A;F0@;F]T97,@:&%V92!B965N(')E=')O86-T:79E;'D@
M861J=7-T960@9F]R(&%L;"!P97)I;V1S('!R97-E;G1E9"!T;R!G:79E#0H@
M("!E9F9E8W0@=&\@=&AE(')E=F5R<V4@<W1O8VL@<W!L:70N#0H@("`\+V1I
M=CX-"B`@(#PA+2T@1F]L:6\@+2T^#0H@("`\(2TM("]&;VQI;R`M+3X-"B`@
M(#PO9&EV/@T*("`@/"$M+2!004=%0E)%04L@+2T^#0H@("`\9&EV('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I
M9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-"B`@(#QD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P<'0G
M/@T*("`@/&(^#0H@("`\+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1C96YT97(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`P<'0G/@T*("`@/&(^#0H@("`\+V(^#0H@("`\+V1I=CX-"B`@(#PO9&EV
M/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M13)(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1I<V-O;G1I;G5E9"!/<&5R
M871I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1&ES8V]N=&EN=65D($]P97)A=&EO;G,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C
M;VYT:6YU960@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(
M5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O
M5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@
M("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#,@+2!U<RUG86%P.D1I
M<W!O<V%L1W)O=7!S26YC;'5D:6YG1&ES8V]N=&EN=65D3W!E<F%T:6]N<T1I
M<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM
M;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXS+B!$:7-C
M;VYT:6YU960@3W!E<F%T:6]N<SPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/DEN($]C=&]B97(F(S$V,#LR
M,#`V+"!M86YA9V5M96YT(&%N9"!T:&4@8F]A<F0@;V8@9&ER96-T;W)S(&]F
M('1H92!#;VUP86YY(&%P<')O=F5D(&$@<&QA;@T*("`@=&\@9&ES8V]N=&EN
M=64@=&AE(&]P97)A=&EO;G,@;V8@:71S(&YO;BUP<F5S8W)I<'1I;VX@;W!H
M=&AA;&UI8R!P:&%R;6%C975T:6-A;"!B=7-I;F5S<PT*("`@*"8C.#(R,#M/
M5$,@0G5S:6YE<W,F(S@R,C$[*2X@5&AE('!L86X@:6YC;'5D960@=&AE('-A
M;&4@;V8@=&AE(&%S<V5T<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS($]40R!"
M=7-I;F5S<R!A;F0-"B`@(&%L<V\@=&AE('1E<FUI;F%T:6]N(&]F(&ET<R!S
M86QE<R!A;F0@;6%R:V5T:6YG('!E<G-O;FYE;"X@5&AE($-O;7!A;GD@<')E
M=FEO=7-L>2!D971E<FUI;F5D#0H@("!T:&%T('1H92!D:7-C;VYT:6YU960@
M3U1#($)U<VEN97-S(&-O;7!R:7-E9"!O<&5R871I;VYS(&%N9"!C87-H(&9L
M;W=S('1H870@8V]U;&0@8F4@8VQE87)L>0T*("`@9&ES=&EN9W5I<VAE9"P@
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M92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3`L('1H90T*
M("`@0V]M<&%N>2!R96-E:79E9"!A("9N8G-P.R0T+#`P,"PP,#`@;W!T:6]N
M('!A>6UE;G0@9G)O;2!T:&4@86-Q=6ER97(@;V8@=&AE(&%S<V5T<R!O9B!T
M:&4@3U1##0H@("!"=7-I;F5S<R!T;R!P<F]V:61E(&ET('=I=&@@86X@861D
M:71I;VYA;"!T=V\@>65A<G,@=&\@9&5V96QO<"!O;F4@;V8@=&AE(&%C<75I
M<F5D('!R;V1U8W1S+@T*("`@26X@2G5L>2`R,#$Q+"!T:&4@86-Q=6ER97(@
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M92!N:6YE(&UO;G1H('!E<FEO9`T*("`@96YD960@4V5P=&5M8F5R)B,Q-C`[
M,S`L(#(P,3$N(%1H92!F;VQL;W=I;F<@=&%B;&4@<')E<V5N=',@8F%S:6,@
M86YD(&1I;'5T960@96%R;FEN9W,@<&5R('-H87)E#0H@("!F<F]M(&1I<V-O
M;G1I;G5E9"!O<&5R871I;VYS(&9O<B!T:&4@;FEN92!M;VYT:',@96YD960@
M4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3`Z#0H@("`\+V1I=CX-"B`@(#QD:78@
M86QI9VX],T1C96YT97(^#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R
M9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M
M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O
M;3X-"B`@("`@("`\=&0@=VED=&@],T0X-B4^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/DYE="!I;F-O;64@9G)O;2!D:7-C;VYT:6YU960@;W!E<F%T
M:6]N<R`H:6X@=&AO=7-A;F1S*0T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P
M.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C0L,#`P/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/DYE="!I;F-O
M;64@9G)O;2!D:7-C;VYT:6YU960@;W!E<F%T:6]N<R!P97(@<VAA<F4@)B,X
M,C$R.R!"87-I8R!A;F0@9&EL=71E9`T*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C`N,C$\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^5V5I9VAT960M879E<F%G92!S:&%R
M97,@;W5T<W1A;F1I;F<@)B,X,C$R.R!"87-I8R!A;F0@9&EL=71E9`T*("`@
M/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ.2PQ
M,C`L.#8P/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@
M(#PO9&EV/@T*("`@/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V1C-38V-35D7V1F.35?-&%B8U\Y9C=E7S!D,6(X
M93AC-V%D-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D8S4V-C4U
M9%]D9CDU7S1A8F-?.68W95\P9#%B.&4X8S=A9#<O5V]R:W-H965T<R]3:&5E
M=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1F%C=&]R<R!!9F9E8W1I;F<@3W!E<F%T:6]N<SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A8W1O<G,@069F96-T
M:6YG($]P97)A=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86-T;W)S($%F9F5C=&EN9R!/<&5R
M871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#
M5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS
M:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$
M+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@
M0FQO8VL@5&%G9V5D($YO=&4@-"`M(&%L:6TZ1F%C=&]R<T%F9F5C=&EN9T]P
M97)A=&EO;G-497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM
M;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXT+B!&86-T
M;W)S($%F9F5C=&EN9R!/<&5R871I;VYS/"]B/@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^5&\@9&%T92!T:&4@
M0V]M<&%N>2!H87,@:6YC=7)R960@<F5C=7)R:6YG(&QO<W-E<RP@;F5G871I
M=F4@8V%S:"!F;&]W(&9R;VT@;W!E<F%T:6]N<RP-"B`@(&%N9"!H87,@86-C
M=6UU;&%T960@82!D969I8VET(&]F("9N8G-P.R0R,#4L,CDY+#`P,"!F<F]M
M('1H92!#;VUP86YY)B,X,C$W.W,@:6YC97!T:6]N('1H<F]U9V@@4V5P=&5M
M8F5R#0H@("`S,"P@,C`Q,2X@5&AE($-O;7!A;GD@9&]E<R!N;W0@97AP96-T
M('1O(&=E;F5R871E(')E=F5N=65S(&9R;VT@:71S('!R;V1U8W0L($E,559)
M14XL('5N=&EL#0H@("!E87)L>2`R,#$R+"!I9B!A="!A;&PL(&%N9"!T:&5R
M969O<F4@9&]E<R!N;W0@97AP96-T('1O(&AA=F4@8V%S:"!F;&]W(&9R;VT@
M;W!E<F%T:6]N<R!U;G1I;`T*("`@,C`Q,BP@:68@870@86QL+B!!<R!O9B!3
M97!T96UB97(F(S$V,#LS,"P@,C`Q,2P@=&AE($-O;7!A;GD@:&%D(`T*("`@
M87!P<F]X:6UA=&5L>2`F;F)S<#LD,S@L-C`Y+#`P,"!I;@T*("`@8V%S:"P@
M8V%S:"!E<75I=F%L96YT<RP@86YD(&EN=F5S=&UE;G1S(&EN(&UA<FME=&%B
M;&4@<V5C=7)I=&EE<RX@26X@3V-T;V)E<B8C,38P.S(P,3`L('1H90T*("`@
M0V]M<&%N>2!O8G1A:6YE9"!A("9N8G-P.R0S,BPU,#`L,#`P('-E;FEO<B!S
M96-U<F5D(&-R961I="!F86-I;&ET>2`H)B,X,C(P.T-R961I="!&86-I;&ET
M>28C.#(R,3LI('1O(&AE;'`-"B`@(&9U;F0@:71S('=O<FMI;F<@8V%P:71A
M;"!R97%U:7)E;65N=',@*'-E92!N;W1E(#<I+B!4:&4@0W)E9&ET($9A8VEL
M:71Y(&-O;G-I<W1E9"!O9B!A#0H@("`F;F)S<#LD,C`L,#`P+#`P,"!W;W)K
M:6YG(&-A<&ET86P@<F5V;VQV97(@86YD(&$@)FYB<W`[)#$R+#4P,"PP,#`@
M=&5R;2!L;V%N+B!4:&4@;&5N9&5R<R!A9'9A;F-E9`T*("`@)FYB<W`[)#8L
M,C4P+#`P,"!U;F1E<B!T:&4@=&5R;2!L;V%N(&%N9"!T:&4@<F5M86EN:6YG
M("9N8G-P.R0V+#(U,"PP,#`@=V%S(&%V86EL86)L92!T;R!B92!A9'9A;F-E
M9`T*("`@9F]L;&]W:6YG($9$02!A<'!R;W9A;"!O9B!)3%56245.+"!B=70@
M;F\@;&%T97(@=&AA;B!*=6QY)B,Q-C`[,S$L(#(P,3$N($EN($UA>28C,38P
M.S(P,3$L('1H92!#;VUP86YY#0H@("!A;F0@:71S(&QE;F1E<G,@86UE;F1E
M9"!T:&4@=&5R;7,@;V8@=&AE($-R961I="!&86-I;&ET>2!T;RP@86UO;F<@
M;W1H97(@=&AI;F=S+"!E>'1E;F0@=&AE#0H@("!&1$$@87!P<F]V86P@9&5A
M9&QI;F4@9F]R('1H92!S96-O;F0@861V86YC92!U;F1E<B!T:&4@=&5R;2!L
M;V%N('1O($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$L(&%N9`T*("`@=&\@:6YC
M<F5A<V4@=&AE(&%M;W5N="!A=F%I;&%B;&4@=6YD97(@=&AE('-E8V]N9"!A
M9'9A;F-E(&]F('1H92!T97)M(&QO86X@9G)O;2`F;F)S<#LD-BPR-3`L,#`P
M#0H@("!T;R`F;F)S<#LD,3$L,#`P+#`P,"X@36%N86=E;65N="!B96QI979E
M<R!I="!H87,@<W5F9FEC:65N="!F=6YD<R!A=F%I;&%B;&4@=&\@9G5N9"!I
M=',@;W!E<F%T:6]N<PT*("`@=&AR;W5G:"!T:&4@<')O:F5C=&5D(&QA=6YC
M:"!O9B!)3%56245.(&%N9"!T:&4@97AP96-T960@9V5N97)A=&EO;B!O9B!R
M979E;G5E(&EN(&5A<FQY#0H@("`R,#$R+B!4:&4@8V]M;65R8VEA;&EZ871I
M;VX@;V8@24Q55DE%3B!I<R!D97!E;F1E;G0@=7!O;B!A<'!R;W9A;"!B>2!T
M:&4@1D1!+"!H;W=E=F5R+"!A;F0-"B`@(&UA;F%G96UE;G0@8V%N;F]T(&)E
M('-U<F4@=&AA="!)3%56245.('=I;&P@8F4@87!P<F]V960@8GD@=&AE($9$
M02!O<B!T:&%T+"!I9B!A<'!R;W9E9"P-"B`@(&9U='5R92!S86QE<R!O9B!)
M3%56245.('=I;&P@9V5N97)A=&4@96YO=6=H(')E=F5N=64@=&\@9G5N9"!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&]P97)A=&EO;G,@8F5Y;VYD#0H@("!I=',@
M;&%U;F-H+B!$=64@=&\@=&AE('5N8V5R=&%I;G1Y(&%R;W5N9"!&1$$@87!P
M<F]V86PL(&UA;F%G96UE;G0@86QS;R!C86YN;W0@8F4@8V5R=&%I;@T*("`@
M=&AA="!T:&4@0V]M<&%N>2!W:6QL(&YO="!N965D(&%D9&ET:6]N86P@9G5N
M9',@9F]R('1H92!L875N8V@@;V8@24Q55DE%3BX@268@24Q55DE%3B!I<R!N
M;W0-"B`@(&%P<')O=F5D+"!O<B!I9B!A<'!R;W9E9"P@9&]E<R!N;W0@9V5N
M97)A=&4@<W5F9FEC:65N="!R979E;G5E+"!T:&4@0V]M<&%N>2!M87D@861J
M=7-T(&ET<PT*("`@8V]M;65R8VEA;"!P;&%N<R!S;R!T:&%T(&ET(&-A;B!C
M;VYT:6YU92!T;R!O<&5R871E('=I=&@@:71S(&5X:7-T:6YG(&-A<V@@<F5S
M;W5R8V5S(&]R('-E96L-"B`@('1O(')A:7-E(&%D9&ET:6]N86P@9FEN86YC
M:6YG+@T*("`@/"]D:78^#0H@("`\+V1I=CX-"CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&,U-C8U-61?9&8Y-5\T86)C7SEF
M-V5?,&0Q8CAE.&,W860W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V1C-38V-35D7V1F.35?-&%B8U\Y9C=E7S!D,6(X93AC-V%D-R]7;W)K<VAE
M971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY!8V-R=65D($5X<&5N<V5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C<G5E9"!%>'!E;G-E<R!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@17AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T14
M1"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM
M/@T*("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`U("T@=7,M9V%A
M<#I!8V-O=6YT<U!A>6%B;&5!;F1!8V-R=65D3&EA8FEL:71I97-$:7-C;&]S
M=7)E5&5X=$)L;V-K+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z
M(#!I;CL@)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^-2X@06-C<G5E9"!%
M>'!E;G-E<SPO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T
M97AT+6EN9&5N=#H@-"4G/D%C8W)U960@97AP96YS97,@8V]N<VES=&5D(&]F
M('1H92!F;VQL;W=I;F<Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C
M96YT97(^#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T
M97AT+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!4
M86)L92!(96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@
M("`\=&0@=VED=&@],T0W,B4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^4V5P=&5M8F5R(#,P+#PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(^/&(^1&5C96UB97(@,S$L/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P
M,#`G/CQB/C(P,3$\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CXR,#$P/"]B/CPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#8^/&(^*$EN('1H;W5S86YD<RD\+V(^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L
M92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@
M/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E
M969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY!8V-R=65D(&-L:6YI8V%L
M(&EN=F5S=&EG871O<B!E>'!E;G-E<PT*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4Q.#PO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#XQ+#DQ,3PO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O
M;3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T
M.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY!8V-R=65D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E<PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XX-S,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C<S,#PO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\
M=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M
M:6YD96YT.BTQ-7!X)SY/=&AE<B!A8V-R=65D(&5X<&5N<V5S#0H@("`\+V1I
M=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C8X/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX]
M,T1R:6=H=#XY,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@
M("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E
M>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\='(@=F%L:6=N/3-$8F]T=&]M/CPA+2T@0FQA;FL@4W!A8V4@+2T^#0H@
M("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X
M.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HS
M,'!X.R!T97AT+6EN9&5N=#HM,35P>"<^5&]T86P@86-C<G5E9"!E>'!E;G-E
M<PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT/C$L-#4Y/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I
M9VAT/C(L-S,Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L
M93X-"B`@(#PO9&EV/@T*("`@/"$M+2!&;VQI;R`M+3X-"B`@(#PA+2T@+T9O
M;&EO("TM/@T*("`@/"]D:78^#0H@("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@
M(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG
M+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I
M;BUT;W`Z(#!P="<^#0H@("`\8CX-"B`@(#PO8CX-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUT;W`Z(#!P="<^#0H@("`\8CX-"B`@(#PO8CX-"B`@(#PO9&EV
M/@T*("`@/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^<%-I=FED
M82!!9W)E96UE;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SYP4VEV:61A($%G<F5E;65N="!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/G!3:79I
M9&$@06=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP
M(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M
M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@
M0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@-B`M('5S+6=A87`Z0V]L;&%B;W)A
M=&EV94%R<F%N9V5M96YT1&ES8VQO<W5R951E>'1";&]C:RTM/@T*("`@/&1I
M=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM
M97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z
M(#$P<'0G/CQB/C8N('!3:79I9&$@06=R965M96YT/"]B/@T*("`@/"]D:78^
M#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^26X@36%R
M8V@F(S$V,#LR,#`X+"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($-O;7!A;GDF
M(S@R,3<[<R!C;VQL86)O<F%T:6]N(&%G<F5E;65N="!W:71H('!3:79I9&$-
M"B`@(%4N4RXL($EN8RX@*"8C.#(R,#MP4VEV:61A)B,X,C(Q.RDL('1H92!L
M:6-E;G-O<B!O9B!T:&4@24Q55DE%3B!T96-H;F]L;V=Y+"!T:&4@0V]M<&%N
M>2!A;F0@<%-I=FED80T*("`@86UE;F1E9"!A;F0@<F5S=&%T960@=&AE(&%G
M<F5E;65N="!T;R!P<F]V:61E('1H92!#;VUP86YY('=I=&@@.#`E(&]F('1H
M92!N970@<')O9FET<R!A;F0-"B`@('!3:79I9&$@=VET:"`R,"4@;V8@=&AE
M(&YE="!P<F]F:71S(&1E<FEV960@8GD@=&AE($-O;7!A;GD@9G)O;2!T:&4@
M#0H@("!S86QE(&]F($E,559)14XN(`T*("`@26X@8V]N;F5C=&EO;B!W:71H
M('1H92!A;65N9&5D(&%N9"!R97-T871E9"!A9W)E96UE;G0L#0H@("!T:&4@
M0V]M<&%N>2!A;'-O(&%G<F5E9"!T;SH-"B`@(#PO9&EV/@T*("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM=&]P.B`Q,'!T)SX-"B`@(#QT86)L92!W:61T:#TS
M1#$P,"4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F
M="<^#0H@("`\='(@=F%L:6=N/3-$=&]P('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@8V]L;W(Z(",P,#`P,#`[(&)A8VMG<F]U;F0Z('1R86YS<&%R96YT
M)SX-"B`@("`@("`\=&0@=VED=&@],T0S)2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1L969T/CQB/B8C.#(R-CL\+V(^/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#YP87D@)FYB<W`[)#$R
M+C`F(S$V,#MM:6QL:6]N('1O('!3:79I9&$@=7!O;B!T:&4@97AE8W5T:6]N
M(&]F('1H92!-87)C:"8C,38P.S(P,#@@86=R965M96YT.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R/@T*("`@("`@(#QT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#AP="<^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$
M=&]P('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@8V]L;W(Z(",P,#`P,#`[
M(&)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SX-"B`@("`@("`\=&0@=VED=&@]
M,T0S)2!N;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/CQB/B8C.#(R-CL\
M+V(^/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#YI<W-U92!A("9N8G-P.R0Q-2XP)B,Q-C`[;6EL;&EO;B!P
M<F]M:7-S;W)Y(&YO=&4@=&\@<%-I=FED83L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<CX-"B`@("`@("`\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1'1O<"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&-O;&]R.B`C,#`P,#`P.R!B86-K9W)O
M=6YD.B!T<F%N<W!A<F5N="<^#0H@("`@("`@/'1D('=I9'1H/3-$,R4@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#X\8CXF(S@R,C8[/"]B/CPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^9F]R9VEV92!A;&P@;W5T<W1A;F1I;F<@9&5V96QO<&UE;G0@<&%Y;65N
M=',L('!E;F%L=&EE<R!A;F0@:6YT97)E<W0@87,@;V8-"B`@('1H92!E9F9E
M8W1I=F4@9&%T92!O9B!T:&4@36%R8V@F(S$V,#LR,#`X(&%G<F5E;65N="P@
M=VAI8V@@=&]T86QE9"`F;F)S<#LD-BXX)B,Q-C`[;6EL;&EO;CL\+W1D/@T*
M("`@/"]T<CX-"B`@(#QT<CX-"B`@("`@("`\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`X<'0G/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG
M;CTS1'1O<"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&-O;&]R.B`C,#`P
M,#`P.R!B86-K9W)O=6YD.B!T<F%N<W!A<F5N="<^#0H@("`@("`@/'1D('=I
M9'1H/3-$,R4@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#X\8CXF(S@R
M,C8[/"]B/CPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^8V]N=&EN=64@<F5S<&]N<VEB:6QI='D@9F]R(')E
M9W5L871O<GDL(&-L:6YI8V%L+"!P<F5C;&EN:6-A;"P-"B`@(&UA;G5F86-T
M=7)I;F<L(&UA<FME=&EN9R!A;F0@<V%L97,@9F]R('1H92!R96UA:6YI;F<@
M9&5V96QO<&UE;G0@86YD#0H@("!C;VUM97)C:6%L:7IA=&EO;B!O9B!T:&4@
M<')O9'5C=',[/"]T9#X-"B`@(#PO='(^#0H@("`\='(^#0H@("`@("`@/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@.'!T)SXF(S$V,#L\+W1D/@T*("`@/"]T
M<CX-"B`@(#QT<B!V86QI9VX],T1T;W`@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!C;VQO<CH@(S`P,#`P,#L@8F%C:V=R;W5N9#H@=')A;G-P87)E;G0G
M/@T*("`@("`@(#QT9"!W:61T:#TS1#,E(&YO=W)A<#TS1&YO=W)A<"!A;&EG
M;CTS1&QE9G0^/&(^)B,X,C(V.SPO8CX\+W1D/@T*("`@("`@(#QT9"!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/F%S<W5M92!A;&P@9FEN
M86YC:6%L(')E<W!O;G-I8FEL:71Y(&9O<B!T:&4@9&5V96QO<&UE;G0@;V8@
M=&AE('!R;V1U8W1S(&%N9`T*("`@87-S=6UE(#@P)2!O9B!T:&4@8V]M;65R
M8VEA;&EZ871I;VX@8V]S=',@;V8@=&AE('!R;V1U8W1S("AI;G-T96%D(&]F
M(#4P)0T*("`@87,@<')O=FED960@=6YD97(@=&AE($9E8G)U87)Y)B,Q-C`[
M,C`P-2!A9W)E96UE;G0I.R!A;F0\+W1D/@T*("`@/"]T<CX-"B`@(#QT<CX-
M"B`@("`@("`\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`X<'0G/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1'1O<"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[(&-O;&]R.B`C,#`P,#`P.R!B86-K9W)O=6YD.B!T
M<F%N<W!A<F5N="<^#0H@("`@("`@/'1D('=I9'1H/3-$,R4@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$;&5F=#X\8CXF(S@R,C8[/"]B/CPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^;6%K
M92!A;B!A9&1I=&EO;F%L(&UI;&5S=&]N92!P87EM96YT(&]F("9N8G-P.R0R
M-2XP)B,Q-C`[;6EL;&EO;B!A9G1E<B!T:&4@9FER<W0-"B`@('!R;V1U8W0@
M=6YD97(@=&AE($UA<F-H)B,Q-C`[,C`P."!A9W)E96UE;G0@:&%S(&)E96X@
M87!P<F]V960@8GD@=&AE($9$02X\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B
M;&4^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E
M;G0Z(#0E)SY4:&4@)FYB<W`[)#$U+#`P,"PP,#`@<')O;6ES<V]R>2!N;W1E
M(&%C8W)U960@:6YT97)E<W0@870@."4@<&%Y86)L92!Q=6%R=&5R;'D@86YD
M('=A<PT*("`@<&%Y86)L92!I;B!F=6QL('1O('!3:79I9&$@=7!O;B!T:&4@
M96%R;&EE<B!O9B!A(&QI<75I9&ET>2!E=F5N="!A<R!D969I;F5D(&EN('1H
M92!N;W1E#0H@("`H:6YC;'5D:6YG(&%N(&EN:71I86P@<'5B;&EC(&]F9F5R
M:6YG(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K(&=R96%T
M97(@=&AA;@T*("`@)FYB<W`[)#<U+#`P,"PP,#`I+"!T:&4@;V-C=7)R96YC
M92!O9B!A;B!E=F5N="!O9B!D969A=6QT('5N9&5R('1H92!#;VUP86YY)B,X
M,C$W.W,@86=R965M96YT('=I=&@-"B`@('!3:79I9&$@;W(@4V5P=&5M8F5R
M)B,Q-C`[,S`L(#(P,3(N($EF('1H92!N;W1E('=A<R!N;W0@<&%I9"!I;B!F
M=6QL(&)Y($UA<F-H)B,Q-C`[,S$L(#(P,3`L('1H90T*("`@:6YT97)E<W0@
M<F%T92!W87,@=&\@:6YC<F5A<V4@=&\@,C`E(&5F9F5C=&EV92!A<R!O9B!!
M<')I;"8C,38P.S$L(#(P,3`L(&%N9"!T:&4@0V]M<&%N>2!W;W5L9"!B90T*
M("`@<F5Q=6ER960@=&\@8F5G:6X@;6%K:6YG('!R:6YC:7!A;"!P87EM96YT
M<R!O9B`F;F)S<#LD-3`P+#`P,"!P97(@;6]N=&@N($]N($%P<FEL)B,Q-C`[
M,C<L(#(P,3`L('1H90T*("`@0V]M<&%N>2!P86ED('!3:79I9&$@)FYB<W`[
M)#$U+#(R-2PP,#`@:6X@<')I;F-I<&%L(&%N9"!I;G1E<F5S="!T;R!S871I
M<V9Y('1H92!N;W1E('!A>6%B;&4N($%S(&$-"B`@(')E<W5L="P@=&AE($-O
M;7!A;GD@<F5C;V=N:7IE9"!A(&=A:6X@;V8@)FYB<W`[)#$L,S0S+#`P,"!O
M;B!T:&4@97AT:6YG=6ES:&UE;G0@;V8@=&AI<R!D96)T(&EN#0H@("!T:&4@
M86-C;VUP86YY:6YG(&9I;F%N8VEA;"!S=&%T96UE;G1S(&9O<B!T:&4@;FEN
M92!M;VYT:"!P97)I;V0@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3`N
M#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z
M(#0E)SY4:&4@0V]M<&%N>28C.#(Q-SMS(&QI8V5N<V4@<FEG:'1S('1O('!3
M:79I9&$F(S@R,3<[<R!P<F]P<FEE=&%R>2!D96QI=F5R>2!D979I8V4@8V]U
M;&0@<F5V97)T('1O#0H@("!P4VEV:61A(&EF('1H92!#;VUP86YY('=E<F4@
M=&\@*&DI)B,Q-C`[9F%I;"!T=VEC92!T;R!C=7)E(&ET<R!B<F5A8V@@;V8@
M86X@;V)L:6=A=&EO;B!T;R!M86ME#0H@("!C97)T86EN('!A>6UE;G1S('1O
M('!3:79I9&$@9F]L;&]W:6YG(')E8V5I<'0@;V8@=W)I='1E;B!N;W1I8V4@
M=&AE<F5O9CL@*&EI*28C,38P.V9A:6P@=&\@8W5R90T*("`@;W1H97(@8G)E
M86-H97,@;V8@;6%T97)I86P@=&5R;7,@;V8@:71S(&%G<F5E;65N="!W:71H
M('!3:79I9&$@=VET:&EN(#,P)B,Q-C`[9&%Y<R!A9G1E<B!N;W1I8V4-"B`@
M(&]F('-U8V@@8G)E86-H97,@;W(@<W5C:"!L;VYG97(@<&5R:6]D("AU<"!T
M;R`Y,"8C,38P.V1A>7,I(&%S(&UA>2!B92!R96%S;VYA8FQY(&YE8V5S<V%R
M>2!I9B!T:&4-"B`@(&)R96%C:"!C86YN;W0@8F4@8W5R960@=VET:&EN('-U
M8V@@,S`M9&%Y('!E<FEO9#L@*&EI:2DF(S$V,#MF:6QE(&9O<B!P<F]T96-T
M:6]N('5N9&5R('1H90T*("`@8F%N:W)U<'1C>2!L87=S+"!M86ME(&%N(&%S
M<VEG;FUE;G0@9F]R('1H92!B96YE9FET(&]F(&-R961I=&]R<RP@87!P;VEN
M="!O<B!S=69F97(-"B`@(&%P<&]I;G1M96YT(&]F(&$@<F5C96EV97(@;W(@
M=')U<W1E92!O=F5R(&ET<R!P<F]P97)T>2P@9FEL92!A('!E=&ET:6]N('5N
M9&5R(&%N>2!B86YK<G5P=&-Y#0H@("!O<B!I;G-O;'9E;F-Y(&%C="!O<B!H
M879E(&%N>2!S=6-H('!E=&ET:6]N(&9I;&5D(&%G86EN<W0@:70@86YD('-U
M8V@@<')O8V5E9&EN9R!R96UA:6YS#0H@("!U;F1I<VUI<W-E9"!O<B!U;G-T
M87EE9"!F;W(@82!P97)I;V0@;V8@;6]R92!T:&%N(#8P)B,Q-C`[9&%Y<SL@
M;W(@*&EV*28C,38P.VYO=&EF>2!P4VEV:61A(&EN('=R:71I;F<-"B`@(&]F
M(&ET<R!D96-I<VEO;B!T;R!A8F%N9&]N(&ET<R!L:6-E;G-E('=I=&@@<F5S
M<&5C="!T;R!A(&-E<G1A:6X@<')O9'5C="!U<VEN9R!P4VEV:61A)B,X,C$W
M.W,-"B`@('!R;W!R:65T87)Y(&1E;&EV97)Y(&1E=FEC92X@5&AE($-O;7!A
M;GD@=V%S(&YO="!I;B!B<F5A8V@@;V8@:71S(&%G<F5E;65N="!W:71H('!3
M:79I9&$@87,-"B`@(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q+@T*("`@
M/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^
M57!O;B!C;VUM97)C:6%L:7IA=&EO;B!O9B!)3%56245.+"!T:&4@0V]M<&%N
M>2!M=7-T('-H87)E(#(P)2!O9B!N970@<')O9FET<R!O9@T*("`@24Q55DE%
M3BP@87,@9&5F:6YE9"!B>2!T:&4@86=R965M96YT+"!W:71H('!3:79I9&$N
M($EN(&-O;FYE8W1I;VX@=VET:"!T:&ES(&%R<F%N9V5M96YT('1H90T*("`@
M0V]M<&%N>2!I<R!E;G1I=&QE9"!T;R!R96-O=F5R(#(P)2!O9B!C;VUM97)C
M:6%L:7IA=&EO;B!C;W-T<R!O9B!)3%56245.+"!A<R!D969I;F5D(&EN('1H
M90T*("`@86=R965M96YT+"!I;F-U<G)E9"!P<FEO<B!T;R!P<F]D=6-T('!R
M;V9I=&%B:6QI='D@;W5T(&]F('!3:79I9&$F(S@R,3<[<R!S:&%R92!O9B!N
M970@<')O9FET<RX@07,-"B`@(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q
M(&%N9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$P('1H92!#;VUP86YY('=A<R!O
M=V5D("9N8G-P.R0S+#4U-BPP,#`@86YD("9N8G-P.R0R+#(R-"PP,#`L#0H@
M("!R97-P96-T:79E;'DL(&EN(&-O;6UE<F-I86QI>F%T:6]N(&-O<W1S+B!$
M=64@=&\@=&AE('5N8V5R=&%I;G1Y(&]F($9$02!A<'!R;W9A;"!O9B!T:&4@
M3D1!#0H@("!F;W(@24Q55DE%3BP@=&AE($-O;7!A;GD@:&%S(&9U;&QY(')E
M<V5R=F5D('1H97-E(&%M;W5N=',@:6X@=&AE(&%C8V]M<&%N>6EN9R!F:6YA
M;F-I86P-"B`@('-T871E;65N=',N#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L
M:6\@+2T^#0H@("`\(2TM("]&;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M
M+2!004=%0E)%04L@+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z
M(#!I;CL@)SX-"B`@(#QD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P<'0G/@T*("`@/&(^#0H@("`\
M+V(^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P<'0G/@T*("`@/&(^
M#0H@("`\+V(^#0H@("`\+V1I=CX-"B`@(#PO9&EV/@T*/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E1E<FT@3&]A;B!A;F0@5V]R:VEN9R!#87!I=&%L(%)E
M=F]L=F5R/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^5&5R;2!,;V%N(&%N9"!7;W)K:6YG($-A<&ET86P@4F5V;VQV
M97(@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y497)M($QO86X@86YD(%=O<FMI;F<@0V%P:71A;"!2979O
M;'9E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U19
M4$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET
M:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X
M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L
M;V-K(%1A9V=E9"!.;W1E(#<@+2!U<RUG86%P.D1E8G1$:7-C;&]S=7)E5&5X
M=$)L;V-K+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM
M97,@3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@
M)SX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#L@;6%R9VEN+71O<#H@,3!P="<^/&(^-RX@5&5R;2!,;V%N(&%N9"!7
M;W)K:6YG($-A<&ET86P@4F5V;VQV97(\+V(^#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SX\:3Y497)M($QO86X\
M+VD^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E
M;G0Z(#0E)SY/;B!/8W1O8F5R)B,Q-C`[,30L(#(P,3`@*"8C.#(R,#M%9F9E
M8W1I=F4@1&%T928C.#(R,3LI+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!,;V%N(&%N9"!396-U<FET>0T*("`@06=R965M96YT("@F(S@R,C`[5&5R
M;2!,;V%N($%G<F5E;65N="8C.#(R,3LI('=I=&@@4VEL:6-O;B!686QL97D@
M0F%N:R!A;F0@36ED0V%P($9I;F%N8VEA;"!,3%`-"B`@("@F(S@R,C`[3&5N
M9&5R<R8C.#(R,3LI+B!0=7)S=6%N="!T;R!T:&4@;W)I9VEN86P@=&5R;7,@
M;V8@=&AE(%1E<FT@3&]A;B!!9W)E96UE;G0L('1H92!#;VUP86YY('=A<PT*
M("`@96YT:71L960@=&\@8F]R<F]W('5P('1O("9N8G-P.R0Q,BXU)B,Q-C`[
M;6EL;&EO;BP@;V8@=VAI8V@@)FYB<W`[)#8N,C4F(S$V,#MM:6QL:6]N("@F
M(S@R,C`[5&5R;2!,;V%N($$F(S@R,C$[*2!W87,@861V86YC960-"B`@('1O
M('1H92!#;VUP86YY(&]N('1H92!%9F9E8W1I=F4@1&%T92X@5&AE($-O;7!A
M;GD@=V%S(&5N=&ET;&5D('1O(&1R87<@9&]W;B!T:&4@<F5M86EN:6YG#0H@
M("`F;F)S<#LD-BXR-28C,38P.VUI;&QI;VX@=6YD97(@=&AE(%1E<FT@3&]A
M;B`H)B,X,C(P.U1E<FT@3&]A;B!")B,X,C(Q.R!A;F0@=&]G971H97(@=VET
M:"!497)M($QO86X@02P@=&AE("8C.#(R,#M497)M#0H@("!,;V%N)B,X,C(Q
M.RD@:68@=&AE($9$02!A<'!R;W9E9"!T:&4@0V]M<&%N>28C.#(Q-SMS($Y$
M02!F;W(@24Q55DE%3B!P<FEO<B!T;R!O<B!O;B!*=6QY)B,Q-C`[,S$L(#(P
M,3$N($]N#0H@("!-87DF(S$V,#LQ-BP@,C`Q,2P@=&AE($-O;7!A;GD@86YD
M('1H92!,96YD97)S(&%M96YD960@=&AE(%1E<FT@3&]A;B!!9W)E96UE;G0@
M*"8C.#(R,#M497)M($QO86X-"B`@($UO9&EF:6-A=&EO;B8C.#(R,3LI('1O
M+"!A;6]N9R!O=&AE<B!T:&EN9W,L(&5X=&5N9"!U;G1I;"!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$Q('1H92!D871E(&)Y('=H:6-H('1H90T*("`@1D1!(&UU
M<W0@87!P<F]V92!T:&4@3D1!(&EN(&]R9&5R(&9O<B!T:&4@0V]M<&%N>2!T
M;R!D<F%W(&1O=VX@5&5R;2!,;V%N($(@86YD(&EN8W)E87-E('1H90T*("`@
M86UO=6YT(&]F(%1E<FT@3&]A;B!"(&)Y("9N8G-P.R0T+C<U)B,Q-C`[;6EL
M;&EO;B!T;R`F;F)S<#LD,3$N,"8C,38P.VUI;&QI;VXN($EN(&%D9&ET:6]N
M+"!T:&4@;6%T=7)I='D@9&%T92!O9@T*("`@=&AE(%1E<FT@3&]A;B!W87,@
M97AT96YD960@9G)O;2!/8W1O8F5R)B,Q-C`[,S$L(#(P,3,@=&\@07!R:6PF
M(S$V,#LS,"P@,C`Q-"`H)B,X,C(P.U1E<FT@3&]A;B!-871U<FET>0T*("`@
M1&%T928C.#(R,3LI+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[
M('1E>'0M:6YD96YT.B`T)2<^5&AE(`T*("`@0V]M<&%N>2!W87,@<F5Q=6ER
M960@=&\@<&%Y(&EN=&5R97-T(&]N(%1E<FT@3&]A;B!!(&%T(&$@<F%T92!O
M9B`Q,2XU)2!O;B!A(&UO;G1H;'D-"B`@(&)A<VES('1H<F]U9V@@2G5L>28C
M,38P.S,Q+"`R,#$Q+"!A;F0@=&AE;B!B96=I;FYI;F<@075G=7-T)B,Q-C`[
M,C`Q,2P@#0H@("!T:&4@0V]M<&%N>2!I<R!R97%U:7)E9"!T;R!R97!A>2!T
M:&4@<')I;F-I<&%L(&EN(#,S(&5Q=6%L(&UO;G1H;'D-"B`@(&EN<W1A;&QM
M96YT<R!P;'5S(&EN=&5R97-T(&%T(&$@<F%T92!O9B`Q,2XU)2X@5&AE($-O
M;7!A;GD@:7,-"B`@(')E<75I<F5D('1O('!A>2!I;G1E<F5S="!A="!A(')A
M=&4@;V8@,3(N-24@;VX@=&AE(&%M;W5N="!B;W)R;W=E9"P@:68@86YY+"!U
M;F1E<B!497)M($QO86X-"B`@($(@=&AR;W5G:"!!<')I;"8C,38P.S,P+"`R
M,#$R+"!A;F0@=&AE<F5A9G1E<B!W:6QL(&)E(')E<75I<F5D('1O(')E<&%Y
M('1H92!P<FEN8VEP86P@:6X@97%U86P-"B`@(&UO;G1H;'D@:6YS=&%L;&UE
M;G1S('1H<F]U9V@@=&AE(%1E<FT@3&]A;B!-871U<FET>2!$871E+"!P;'5S
M(&EN=&5R97-T(&%T(&$@<F%T92!O9B`Q,BXU)2X-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/DEF('1H92!#;VUP
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M00T*("`@1G5N9&EN9R!$871E)B,X,C(Q.RDL(#,N,"4@;V8@<W5C:"!A;6]U
M;G0@:68@=&AE('!R97!A>6UE;G0@;V-C=7)S(&)E='=E96X@;VYE('EE87(@
M86YD('1W;R!Y96%R<PT*("`@869T97(@=&AE(%1E<FT@3&]A;B!!($9U;F1I
M;F<@1&%T92!A;F0@,2XP)2!O9B!S=6-H(&%M;W5N="!I9B!T:&4@<')E<&%Y
M;65N="!O8V-U<G,-"B`@('1H97)E869T97(@*'-U8FIE8W0@=&\@82`U,"4@
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M('=I;&P@8F4@<F5S970@=&\@-2XP)2!A;F0-"B`@('1H92!T:6UE+6)A<V5D
M(')E9'5C=&EO;B!O9B!T:&4@<')E<&%Y;65N="!F964@=VEL;"!B92!M96%S
M=7)E9"!F<F]M('1H92!F=6YD:6YG(&1A=&4@;V8-"B`@(%1E<FT@3&]A;B!"
M("AS=6)J96-T('1O('1H92!S86UE(#4P)2!R961U8W1I;VX@:6X@=&AE(&5V
M96YT(&]F(&%N(&%C<75I<VET:6]N(&]F('1H90T*("`@0V]M<&%N>2DL(')A
M=&AE<B!T:&%N(&9R;VT@=&AE(%1E<FT@3&]A;B!!($9U;F1I;F<@1&%T92X-
M"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M-"4G/E1O('-E8W5R92!T:&4@<F5P87EM96YT(&]F(&%N>2!A;6]U;G1S(&)O
M<G)O=V5D('5N9&5R('1H92!497)M($QO86X@06=R965M96YT+"!T:&4-"B`@
M($-O;7!A;GD@9W)A;G1E9"!T;R!T:&4@3&5N9&5R<R!A(&9I<G-T('!R:6]R
M:71Y('-E8W5R:71Y(&EN=&5R97-T(&EN(&%L;"!O9B!I=',@87-S971S+`T*
M("`@:6YC;'5D:6YG(&ET<R!I;G1E;&QE8W1U86P@<')O<&5R='DL(&AO=V5V
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M.W,@;V)L:6=A=&EO;G,@=6YD97(-"B`@('1H92!497)M($QO86X@06=R965M
M96YT(&%N9"!A;B!I;F-R96%S92!T;R!T:&4@87!P;&EC86)L92!I;G1E<F5S
M="!R871E+"!A;F0@=V]U;&0@<&5R;6ET#0H@("!T:&4@3&5N9&5R<R!T;R!E
M>&5R8VES92!R96UE9&EE<R!W:71H(')E<W!E8W0@=&\@=&AE(&-O;&QA=&5R
M86P@=6YD97(@=&AE(%1E<FT@3&]A;@T*("`@06=R965M96YT+B!4:&4@0V]M
M<&%N>2!A;'-O(&%G<F5E9"!N;W0@=&\@<&QE9&=E(&]R(&]T:&5R=VES92!E
M;F-U;6)E<B!I=',@:6YT96QL96-T=6%L#0H@("!P<F]P97)T>2!A<W-E=',N
M($%D9&ET:6]N86QL>2P@=&AE($-O;7!A;GD@;75S="!S965K('1H92!,96YD
M97)S)B,X,C$W.R!A<'!R;W9A;"!P<FEO<B!T;R!T:&4-"B`@('!A>6UE;G0@
M;V8@86YY(&-A<V@@9&EV:61E;F1S+@T*("`@/"]D:78^#0H@("`\(2TM($9O
M;&EO("TM/@T*("`@/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA
M+2T@4$%'14)214%+("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T
M.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX-"B`@(#QB/@T*("`@
M/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX-"B`@(#QB
M/@T*("`@/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E
M>'0M:6YD96YT.B`T)2<^3VX@=&AE($5F9F5C=&EV92!$871E+"!T:&4@0V]M
M<&%N>2!I<W-U960@=&\@=&AE($QE;F1E<G,@=V%R<F%N=',@=&\@<'5R8VAA
M<V4@86X-"B`@(&%G9W)E9V%T92!O9B!U<"!T;R`S.2PW-S,@<VAA<F5S(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K+B!%86-H(&]F('1H
M92!W87)R86YT<R!I<PT*("`@97AE<F-I<V%B;&4@:6UM961I871E;'DL(&AA
M<R!A('!E<BUS:&%R92!E>&5R8VES92!P<FEC92!O9B`F;F)S<#LD,3$N,#`@
M86YD(&AA<R!A('1E<FT@;V8@,3`-"B`@('EE87)S+B!4:&4@0V]M<&%N>2!E
M<W1I;6%T960@=&AE(&9A:7(@=F%L=64@;V8@=V%R<F%N=',@9W)A;G1E9"!U
M<VEN9R!T:&4@0FQA8VLM4V-H;VQE<PT*("`@;W!T:6]N('!R:6-I;F<@;6]D
M96PN(%1H92!A9V=R96=A=&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N=',@
M=V%S(&5S=&EM871E9"!T;R!B92`F;F)S<#LD,S@Y+#`P,"X-"B`@(%1H92!#
M;VUP86YY(&%L;&]C871E9"!A('!O<G1I;VX@;V8@=&AE('!R;V-E961S(&9R
M;VT@=&AE(%1E<FT@3&]A;B!!9W)E96UE;G0@=&\@=&AE('=A<G)A;G1S#0H@
M("!I;B!A8V-O<F1A;F-E('=I=&@@06-C;W5N=&EN9R!3=&%N9&%R9',@0V]D
M:69I8V%T:6]N("@F(S@R,C`[05-#)B,X,C(Q.RD@-#<P+3(P+3(U+3(L(#QI
M/D1E8G0@26YS=')U;65N=',-"B`@('=I=&@@1&5T86-H86)L92!787)R86YT
M<SPO:3XN($%S(&$@<F5S=6QT+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!A(&1I
M<V-O=6YT(&]F("9N8G-P.R0S-C8L,#`P('=H:6-H(&ES#0H@("!B96EN9R!A
M;6]R=&EZ960@=&\@:6YT97)E<W0@97AP96YS92!U<VEN9R!T:&4@969F96-T
M:79E(&EN=&5R97-T(&UE=&AO9"X@5&AE($QE;F1E<G,@86QS;PT*("`@:&]L
M9"!W87)R86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@=7`@=&\@
M-CDL.3DY('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:RP-"B`@('=H:6-H(&%R92!E>&5R8VES86)L92!O;FQY(&EF(%1E<FT@
M3&]A;B!"(&ES(&%D=F%N8V5D('1O('1H92!#;VUP86YY+B!%86-H(&]F('1H
M97-E('=A<G)A;G1S#0H@("!H87,@82!P97(@<VAA<F4@97AE<F-I<V4@<')I
M8V4@;V8@)FYB<W`[)#$Q+C`P(&%N9"!A('1E<FT@;V8@,3`F(S$V,#MY96%R
M<RX@26X@861D:71I;VXL('1H92!,96YD97)S#0H@("!W:6QL(&AA=F4@8V5R
M=&%I;B!R96=I<W1R871I;VX@<FEG:'1S('=I=&@@<F5S<&5C="!T;R!T:&4@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U86)L90T*("`@=7!O;B!E>&5R
M8VES92!O9B!A;&P@;V8@=&AE:7(@=V%R<F%N=',N(%1H92!#;VUP86YY('!A
M:60@=&\@=&AE($QE;F1E<G,@86X@=7!F<F]N="!F964@;V8-"B`@("9N8G-P
M.R0V,BPU,#`@;VX@=&AE($5F9F5C=&EV92!$871E(&%N9"!A;B!A9&1I=&EO
M;F%L(&9E92!O9B`F;F)S<#LD-3`L,#`P(&EN(&-O;FYE8W1I;VX@=VET:"!T
M:&4@5&5R;0T*("`@3&]A;B!-;V1I9FEC871I;VXN($EN(&%C8V]R9&%N8V4@
M=VET:"!!4T,@-#<P+34P+30P+3$W+"`\:3Y$96)T("8C.#(Q,CL@36]D:69I
M8V%T:6]N<R!A;F0-"B`@($5X=&EN9W5I<VAM96YT<SPO:3XL('1H92!#;VUP
M86YY(&ES(&%M;W)T:7II;F<@=&AE('5N86UO<G1I>F5D(&1I<V-O=6YT(&]N
M(%1E<FT@3&]A;B!!(&%N9"!T:&4-"B`@("9N8G-P.R0U,"PP,#`@;6]D:69I
M8V%T:6]N(&9E92!O=F5R('1H92!R96UA:6YI;F<@=&5R;2!O9B!497)M($QO
M86X@02P@87,@;6]D:69I960N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@
M,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4:&4@0V]M<&%N>2!I<R!R97%U:7)E
M9"!T;R!M86EN=&%I;B!I=',@<')I;6%R>2!O<&5R871I;F<@86YD(&]T:&5R
M(&1E<&]S:70@86-C;W5N=',-"B`@(&%N9"!S96-U<FET:65S(&%C8V]U;G1S
M('=I=&@@4VEL:6-O;B!686QL97D@0F%N:RP@=VAI8V@@86-C;W5N=',@;75S
M="!R97!R97-E;G0@870@;&5A<W0@-3`E#0H@("!O9B!T:&4@9&]L;&%R('9A
M;'5E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@86-C;W5N=',@870@86QL(&9I
M;F%N8VEA;"!I;G-T:71U=&EO;G,N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SX\:3Y7;W)K:6YG($-A<&ET86P@
M4F5V;VQV97(\+VD^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@
M=&5X="UI;F1E;G0Z(#0E)SY!;'-O(&]N('1H92!%9F9E8W1I=F4@1&%T92P@
M=&AE($-O;7!A;GD@86YD(%-I;&EC;VX@5F%L;&5Y($)A;FL@96YT97)E9"!I
M;G1O(&$@3&]A;B!A;F0-"B`@(%-E8W5R:71Y($%G<F5E;65N="P@<'5R<W5A
M;G0@=&\@=VAI8V@@=&AE($-O;7!A;GD@;V)T86EN960@82!S96-U<F5D(')E
M=F]L=FEN9R!L:6YE(&]F#0H@("!C<F5D:70@*"8C.#(R,#M7;W)K:6YG($-A
M<&ET86P@4F5V;VQV97(F(S@R,C$[*2!F<F]M(%-I;&EC;VX@5F%L;&5Y($)A
M;FL@=VET:"!B;W)R;W=I;F<@879A:6QA8FEL:71Y('5P#0H@("!T;R`F;F)S
M<#LD,C`L,#`P+#`P,"`H)B,X,C(P.U)E=F]L=FEN9R!,;V%N($%G<F5E;65N
M="8C.#(R,3LI+B!/;B`-"B`@($UA>28C,38P.S$V+"`R,#$Q+"!T:&4@0V]M
M<&%N>2!A;F0@4VEL:6-O;B!686QL97D@0F%N:PT*("`@86UE;F1E9"!T:&4@
M4F5V;VQV:6YG($QO86X@06=R965M96YT('1O(&5X=&5N9"!T:&4@;6%T=7)I
M='D@9&%T92!O9B!T:&4@5V]R:VEN9R!#87!I=&%L#0H@("!2979O;'9E<B!F
M<F]M($]C=&]B97(F(S$V,#LS,2P@,C`Q,R!T;R!!<')I;"8C,38P.S,P+"`R
M,#$T+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^5&AE(%=O<FMI;F<@0V%P:71A;"!2979O;'9E<B!I<R!A('=O
M<FMI;F<@8V%P:71A;"UB87-E9"!R979O;'9I;F<@;&EN92!O9B!C<F5D:70@
M:6X@86X-"B`@(&%G9W)E9V%T92!A;6]U;G0@;V8@=7`@=&\@=&AE(&QE<W-E
M<B!O9B`H:2D@)FYB<W`[)#(P+#`P,"PP,#`L(&]R("AI:2DF(S$V,#LX-24@
M;V8@96QI9VEB;&4@9&]M97-T:6,-"B`@(&%C8V]U;G1S(')E8V5I=F%B;&4N
M($%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$Q+"!N;R!A;6]U;G1S('5N
M9&5R('1H92!7;W)K:6YG($-A<&ET86P@4F5V;VQV97(-"B`@('=E<F4@;W5T
M<W1A;F1I;F<@;W(@879A:6QA8FQE('1O('1H92!#;VUP86YY+@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^06UO
M=6YT<R!A9'9A;F-E9"!U;F1E<B!T:&4@5V]R:VEN9R!#87!I=&%L(%)E=F]L
M=F5R('=I;&P@8F5A<B!I;G1E<F5S="!A="!A;B!A;FYU86P-"B`@(')A=&4@
M97%U86P@=&\@4VEL:6-O;B!686QL97D@0F%N:R8C.#(Q-SMS('!R:6UE(')A
M=&4@<&QU<R`R+C4P)2`H=VET:"!A(')A=&4@9FQO;W(@;V8@-BXU,"4I+@T*
M("`@26YT97)E<W0@;VX@=&AE(%=O<FMI;F<@0V%P:71A;"!2979O;'9E<B!W
M:6QL(&)E(&1U92!M;VYT:&QY+"!W:71H('1H92!B86QA;F-E(&1U92!A="!T
M:&4-"B`@(&UA='5R:71Y(&1A=&4N($]N('1H92!%9F9E8W1I=F4@1&%T92P@
M=&AE($-O;7!A;GD@<&%I9"!T;R!3:6QI8V]N(%9A;&QE>2!"86YK(&%N('5P
M9G)O;G0@9F5E#0H@("!O9B`F;F)S<#LD,3`P+#`P,"X@26X@861D:71I;VXL
M(&EF('1H92!#;VUP86YY('1E<FUI;F%T97,@=&AE(%=O<FMI;F<@0V%P:71A
M;"!2979O;'9E<B!P<FEO<B!T;PT*("`@;6%T=7)I='DL(&ET('=O=6QD(&AA
M=F4@<&%I9"!T;R!3:6QI8V]N(%9A;&QE>2!"86YK(&$@9F5E(&]F("9N8G-P
M.R0T,#`L,#`P(&EF('1H92`-"B`@('1E<FUI;F%T:6]N(&]C8W5R960-"B`@
M('=I=&AI;B!O;F4@>65A<B!A9G1E<B!T:&4@169F96-T:79E($1A=&4@86YD
M(&$@9F5E(&]F("9N8G-P.R0R,#`L,#`P(&EF('1H92!T97)M:6YA=&EO;B!O
M8V-U<G,-"B`@(&UO<F4@=&AA;B!O;F4@>65A<B!A9G1E<B!T:&4@169F96-T
M:79E($1A=&4@*&5A8V@@82`F(S@R,C`[5&5R;6EN871I;VX@1F5E)B,X,C(Q
M.RDL('!R;W9I9&5D(&EN(&5A8V@-"B`@(&-A<V4@=&AA="!S=6-H(%1E<FUI
M;F%T:6]N($9E92!W:6QL(&)E(')E9'5C960@8GD@-3`E(&EN('1H92!E=F5N
M="!O9B!A;B!A8W%U:7-I=&EO;B!O9B!T:&4-"B`@($-O;7!A;GDN#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY4
M;R!S96-U<F4@=&AE(')E<&%Y;65N="!O9B!A;GD@86UO=6YT<R!B;W)R;W=E
M9"!U;F1E<B!T:&4@4F5V;VQV:6YG($QO86X@06=R965M96YT+"!T:&4-"B`@
M($-O;7!A;GD@9W)A;G1E9"!T;R!3:6QI8V]N(%9A;&QE>2!"86YK(&$@9FER
M<W0@<')I;W)I='D@<V5C=7)I='D@:6YT97)E<W0@:6X@86QL(&]F(&ET<PT*
M("`@87-S971S+"!I;F-L=61I;F<@:71S(&EN=&5L;&5C='5A;"!P<F]P97)T
M>2P@:&]W979E<BP@=&AE(&QI96X@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!I
M;G1E;&QE8W1U86P-"B`@('!R;W!E<G1Y('=I;&P@8F4@<F5L96%S960@:68@
M=&AE($-O;7!A;GD@;65E=',@8V5R=&%I;B!F:6YA;F-I86P@8V]N9&ET:6]N
M<RX@5&AE(&]C8W5R<F5N8V4-"B`@(&]F(&%N(&5V96YT(&]F(&1E9F%U;'0@
M8V]U;&0@<F5S=6QT(&EN('1H92!A8V-E;&5R871I;VX@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!O8FQI9V%T:6]N<R!U;F1E<@T*("`@=&AE(%)E=F]L=FEN
M9R!,;V%N($%G<F5E;65N="!A;F0@86X@:6YC<F5A<V4@=&\@=&AE(&%P<&QI
M8V%B;&4@:6YT97)E<W0@<F%T92P@86YD('=O=6QD#0H@("!P97)M:70@4VEL
M:6-O;B!686QL97D@0F%N:R!T;R!E>&5R8VES92!R96UE9&EE<R!W:71H(')E
M<W!E8W0@=&\@=&AE(&-O;&QA=&5R86P@=6YD97(@=&AE#0H@("!2979O;'9I
M;F<@3&]A;B!!9W)E96UE;G0N(%1H92!#;VUP86YY(&%L<V\@86=R965D(&YO
M="!T;R!P;&5D9V4@;W(@;W1H97)W:7-E(&5N8W5M8F5R(&ET<PT*("`@:6YT
M96QL96-T=6%L('!R;W!E<G1Y(&%S<V5T<RX@061D:71I;VYA;&QY+"!T:&4@
M0V]M<&%N>2!M=7-T('-E96L@4VEL:6-O;B!686QL97D@0F%N:R8C.#(Q-SMS
M#0H@("!A<'!R;W9A;"!P<FEO<B!T;R!T:&4@<&%Y;65N="!O9B!A;GD@8V%S
M:"!D:79I9&5N9',N#0H@("`\+V1I=CX-"B`@(#PA+2T@1F]L:6\@+2T^#0H@
M("`\(2TM("]&;VQI;R`M+3X-"B`@(#PO9&EV/@T*("`@/"$M+2!004=%0E)%
M04L@+2T^#0H@("`\9&EV('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@
M3F5W(%)O;6%N)RQ4:6UE<RQS97)I9CL@;6%R9VEN+6QE9G0Z(#!I;CL@)SX-
M"B`@(#QD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!M87)G:6XM=&]P.B`P<'0G/@T*("`@/&(^#0H@("`\+V(^#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`P<'0G/@T*("`@/&(^#0H@("`\+V(^
M#0H@("`\+V1I=CX-"B`@(#PO9&EV/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D5A<FYI;F=S("A,;W-S*2!097(@4VAA<F4@*$504RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%87)N:6YG
M<R`H3&]S<RD@4&5R(%-H87)E("A%4%,I(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16%R;FEN9W,@*$QO
M<W,I(%!E<B!3:&%R92`H15!3*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(
M5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O
M5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@
M("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#@@+2!U<RUG86%P.D5A
M<FYI;F=S4&5R4VAA<F5497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M
M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXX
M+B!%87)N:6YG<R`H3&]S<RD@4&5R(%-H87)E("A%4%,I/"]B/@T*("`@/"]D
M:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^0F%S
M:6,@15!3(&ES(&-A;&-U;&%T960@:6X@86-C;W)D86YC92!W:71H($%30R`R
M-C`L(#QI/D5A<FYI;F=S('!E<B!3:&%R92P@/"]I/F)Y(&1I=FED:6YG(&YE
M=`T*("`@:6YC;VUE(&]R(&QO<W,@871T<FEB=71A8FQE('1O(&-O;6UO;B!S
M=&]C:VAO;&1E<G,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-T
M;V-K#0H@("!O=71S=&%N9&EN9RX@1&EL=71E9"!%4%,@:7,@8V%L8W5L871E
M9"!I;B!A8V-O<F1A;F-E('=I=&@@05-#(#(V,"!B>2!A9&IU<W1I;F<@=V5I
M9VAT960-"B`@(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!F
M;W(@=&AE(&1I;'5T:79E(&5F9F5C="!O9B!C;VUM;VX@<W1O8VL@;W!T:6]N
M<RP@=V%R<F%N=',L#0H@("!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@
M86YD(&%C8W)U960@8G5T('5N<&%I9"!C;VYV97)T:6)L92!P<F5F97)R960@
M<W1O8VL@9&EV:61E;F1S+B!);@T*("`@<&5R:6]D<R!W:&5R92!A(&YE="!L
M;W-S(&9R;VT@8V]N=&EN=6EN9R!O<&5R871I;VYS(&ES(')E8V]R9&5D+"!N
M;R!E9F9E8W0@:7,@9VEV96X@=&\-"B`@('!O=&5N=&EA;&QY(&1I;'5T:79E
M('-E8W5R:71I97,L('-I;F-E('1H92!E9F9E8W0@=V]U;&0@8F4@86YT:2UD
M:6QU=&EV92X@5&]T86P@<V5C=7)I=&EE<PT*("`@=&AA="!C;W5L9"!P;W1E
M;G1I86QL>2!D:6QU=&4@8F%S:6,@15!3(&EN('1H92!F=71U<F4@=&AA="!W
M97)E(&YO="!I;F-L=61E9"!I;B!T:&4-"B`@(&-O;7!U=&%T:6]N(&]F(&1I
M;'5T960@15!3(&)E8V%U<V4@=&\@9&\@<V\@=V]U;&0@:&%V92!B965N(&%N
M=&DM9&EL=71I=F4@=V5R92!A<R!F;VQL;W=S.@T*("`@/"]D:78^#0H@("`\
M9&EV(&%L:6=N/3-$8V5N=&5R/@T*("`@/'1A8FQE('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<],T0P
M(&)O<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`@
M(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<B!V86QI9VX],T1B
M;W1T;VT^#0H@("`@("`@/'1D('=I9'1H/3-$-#0E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M-CX\8CY4:')E92!-;VYT:',@16YD960\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V
M/CQB/DYI;F4@36]N=&AS($5N9&5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#8@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E-E<'1E
M;6)E<B`S,"P\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY397!T96UB97(@,S`L
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/C(P,3$\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\
M8CXR,#$P/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED
M(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-CX\8CXH56YA=61I
M=&5D*3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#8^/&(^*%5N875D:71E9"D\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M(2TM($5N9"!486)L92!(96%D("TM/@T*("`@/"$M+2!"96=I;B!486)L92!"
M;V1Y("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X\(2TM($)L86YK(%-P
M86-E("TM/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D
M:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C
M8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E-E<FEE<R8C,38P.T$@
M<')E9F5R<F5D('-T;V-K(&%N9"`-"B`@(&-O;G9E<G1I8FQE(&%C8W)U960@
M9&EV:61E;F1S#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C,L,#`R+#(P-3PO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG
M;CTS1&)O='1O;3X-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY397)I97,F(S$V
M,#M"('!R969E<G)E9"!S=&]C:PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R
M,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XS+#`V,RPS
M.#,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C
M965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM
M;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^4V5R:65S)B,Q-C`[0R!P
M<F5F97)R960@<W1O8VL-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L
M:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPT.#@L-S8R/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E-E<FEE
M<R8C,38P.T,M,2!P<F5F97)R960@<W1O8VL-"B`@(#PO9&EV/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,2PQ.#<L-C4Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U
M;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E-E<FEE<R8C
M,38P.T,M,2!0<F5F97)R960@<W1O8VL@=V%R<F%N=',-"B`@(#PO9&EV/CPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^-38L-S(S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-
M"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E
M;G0Z+3$U<'@G/D-O;6UO;B!S=&]C:R!W87)R86YT<PT*("`@/"]D:78^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR."PP.#8\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C<W+#$Q-#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,CDL,S8V/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XQ,3(L-C0T/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U
M;F0Z("-C8V5E9F8G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E-T;V-K(&]P
M=&EO;G,-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,2PU,#(L-#8Y/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ+#8S,RPT-#$\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C$L-3<S+#$P-CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PV-CDL-S0X/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G
M/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L
M:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P
M,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R
M:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O
M;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@
M,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X\
M(2TM($)L86YK(%-P86-E("TM/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C
M,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT
M9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XQ+#4S,"PU-34\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$L
M-S$P+#4U-3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PV,#(L-#<R/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ
M,2PU.#$L,3$V/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T
M86)L93X-"B`@(#PO9&EV/@T*("`@/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4')E9F5R<F5D(%-T;V-K/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')E9F5R<F5D(%-T;V-K(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D(%-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@
M6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R
M9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-
M"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@.2`M(&%L:6TZ5&5M
M<&]R87)Y17%U:71Y1&ES8VQO<W5R951E>'1";&]C:RTM/@T*("`@/&1I=B!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L
M<V5R:68[(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P
M<'0G/CQB/CDN(%!R969E<G)E9"!3=&]C:SPO8CX-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E!R:6]R('1O('1H
M92!#;VUP86YY)B,X,C$W.W,@25!/+"!T:&4@0V]M<&%N>2!H860@9F]U<B!S
M97)I97,@;V8@<')E9F5R<F5D('-T;V-K+B!/;B!!<')I;`T*("`@,C<L(#(P
M,3`@86YD(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@25!/+"!A;&P@;W5T<W1A
M;F1I;F<@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@<')E9F5R<F5D
M#0H@("!S=&]C:R!W97)E(&-O;G9E<G1E9"!I;G1O(#(R+#@V,RPV.38@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@86QL('!R969E<G)E9"!S=&]C:PT*
M("`@9&EV:61E;F1S('=E<F4@96QI;6EN871E9"X@4VEG;FEF:6-A;G0@=&5R
M;7,@;V8@86QL('-E<FEE<R!O9B!T:&4@<')E9F5R<F5D('-T;V-K('=E<F4@
M87,-"B`@(&9O;&QO=W,Z#0H@("`\+V1I=CX-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+71O<#H@,3!P="<^#0H@("`\=&%B;&4@=VED=&@],T0Q,#`E(&)O
M<F1E<CTS1#`@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G/@T*("`@
M/'1R('9A;&EG;CTS1'1O<"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&-O
M;&]R.B`C,#`P,#`P.R!B86-K9W)O=6YD.B!T<F%N<W!A<F5N="<^#0H@("`@
M("`@/'1D('=I9'1H/3-$-"4@<W1Y;&4],T0G8F%C:V=R;W5N9#H@=')A;G-P
M87)E;G0G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#X\8CXF(S@R,C8[/"]B/CPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^1&EV:61E;F1S('=E<F4@8W5M=6QA=&EV92!A;F0@86-C<G5E9"!O;B!A
M(&1A:6QY(&)A<VES(&%T#0H@("!T:&4@<F%T92!O9B`X)2!P97(@86YN=6T@
M8F5G:6YN:6YG(&]N('1H92!D871E(&]F(&ES<W5A;F-E#0H@("!A;F0@8F%S
M960@;VX@=&AE(&]R:6=I;F%L(&ES<W5E('!R:6-E+"!A<R!A9&IU<W1E9"!F
M;W(@86YY#0H@("!S=&]C:R!D:79I9&5N9"P@<W1O8VL@<W!L:70L(&-O;6)I
M;F%T:6]N+"!O<B!O=&AE<B!E=F5N=`T*("`@:6YV;VQV:6YG('1H92!P<F5F
M97)R960@<W1O8VLN($1I=FED96YD<R!A8V-R=65D+"!W:&5T:&5R#0H@("!O
M<B!N;W0@9&5C;&%R960L(&%N;G5A;&QY(&%N9"!W97)E(&1U92!A;F0@<&%Y
M86)L92!W:&5N(&%N9`T*("`@:68@9&5C;&%R960@8GD@=&AE($)O87)D(&]F
M($1I<F5C=&]R<RP@=7!O;B!A(&QI<75I9&%T:6YG#0H@("!E=F5N="!U<&]N
M(')E9&5M<'1I;VX@;V8@=&AE('!R969E<G)E9"!S=&]C:R!O<B!O;B!T:&4@
M9&%T90T*("`@=&AA="!T:&4@<')E9F5R<F5D('-T;V-K('=A<R!O=&AE<G=I
M<V4@86-Q=6ER960@8GD@=&AE#0H@("!#;VUP86YY+CPO=&0^#0H@("`\+W1R
M/@T*("`@/'1R/@T*("`@("`@(#QT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#AP
M="<^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$=&]P
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@8V]L;W(Z(",P,#`P,#`[(&)A
M8VMG<F]U;F0Z('1R86YS<&%R96YT)SX-"B`@("`@("`\=&0@=VED=&@],T0T
M)2!S='EL93TS1"=B86-K9W)O=6YD.B!T<F%N<W!A<F5N="<^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0S)2!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1L969T/CQB/B8C.#(R-CL\+V(^/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#Y5<&]N(&%N>2!L:7%U
M:61A=&EO;BP@9&ES<V]L=71I;VXL(&]R('=I;F1I;F<@=7`@;V8@=&AE#0H@
M("!#;VUP86YY+"!T:&4@<')E9F5R<F5D('-T;V-K:&]L9&5R<R!W97)E(&5N
M=&ET;&5D('1O(&$-"B`@(&QI<75I9&%T:6]N('!R969E<F5N8V4@<&%Y;65N
M="!E<75A;"!T;R`H:2DF(S$V,#MT:&4@<W5M(&]F('1H90T*("`@;&EQ=6ED
M871I;VX@=F%L=64@<&QU<R!A;&P@86-C=6UU;&%T960L(&%C8W)U960L(&%N
M9"!U;G!A:60-"B`@(&1I=FED96YD<R!A;F0@*&EI*28C,38P.W1H92!P<F\@
M<F%T82!S:&%R92!O9B!A;GD@<F5M86EN:6YG#0H@("!A;6]U;G1S('-U8V@@
M:&]L9&5R('=O=6QD(&AA=F4@8F5E;B!E;G1I=&QE9"!T;R!R96-E:79E(&AA
M9`T*("`@<W5C:"!H;VQD97(F(S@R,3<[<R!S:&%R97,@8F5E;B!C;VYV97)T
M960@:6YT;R!C;VUM;VX@<W1O8VL-"B`@(&EM;65D:6%T96QY('!R:6]R('1O
M('1H92!L:7%U:61A=&EO;BP@9&ES<V]L=71I;VXL(&]R#0H@("!W:6YD:6YG
M('5P+CPO=&0^#0H@("`\+W1R/@T*("`@/'1R/@T*("`@("`@(#QT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#AP="<^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\='(@=F%L:6=N/3-$=&]P('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M8V]L;W(Z(",P,#`P,#`[(&)A8VMG<F]U;F0Z('1R86YS<&%R96YT)SX-"B`@
M("`@("`\=&0@=VED=&@],T0T)2!S='EL93TS1"=B86-K9W)O=6YD.B!T<F%N
M<W!A<F5N="<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)2!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/CQB/B8C.#(R-CL\+V(^/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#Y!="!A;GD@=&EM92!S=6)S97%U96YT('1O($UA<F-H)B,Q-C`[,3<L
M(#(P,3,L('1H92!H;VQD97)S(&]F(&$-"B`@(&UA:F]R:71Y(&]F('1H92!P
M<F5F97)R960@<W1O8VL@8V]U;&0@:&%V92!R97%U:7)E9"!T:&4-"B`@($-O
M;7!A;GD@=&\@<F5D965M(&%L;"!O<B!A;GD@<&]R=&EO;B!O9B!T:&4@<')E
M9F5R<F5D#0H@("!S=&]C:RX@268@=&AE('!R969E<G)E9"!S=&]C:R!W87,@
M<F5D965M960L('1H92!R961E;7!T:6]N#0H@("!W;W5L9"!H879E(&]C8W5R
M<F5D(&EN(&5Q=6%L(&EN<W1A;&QM96YT<R!O=F5R(&$@=&AR964M>65A<@T*
M("`@<&5R:6]D+B!4:&4@<')I8V4@<&%I9"!B>2!T:&4@0V]M<&%N>2!T;R!R
M961E96T@=&AE('-H87)E<PT*("`@=V]U;&0@:&%V92!B965N('1H92!G<F5A
M=&5R(&]F("AI*28C,38P.W1H92!O<FEG:6YA;"!I<W-U90T*("`@<')I8V4L
M('!L=7,@86QL(&%C8W5M=6QA=&5D+"!A8V-R=65D+"!A;F0@=6YP86ED(&1I
M=FED96YD<RP-"B`@(&%N9"`H:6DI)B,Q-C`[=&AE(&9A:7(@;6%R:V5T('9A
M;'5E(&]F('1H92!P<F5F97)R960@<W1O8VL@8F5I;F<-"B`@(')E9&5E;65D
M(&%T('1H92!T:6UE(&]F('1H92!R961E;7!T:6]N+CPO=&0^#0H@("`\+W1R
M/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M.R!T97AT+6EN9&5N=#H@-"4G/D)E8V%U<V4@=&AE('!R969E<G)E9"!S=&]C
M:R!P<F]V:61E9"!T:&4@:&]L9&5R<R!T:&4@<FEG:'0@=&\@<F5Q=6ER92!T
M:&4@0V]M<&%N>2!T;PT*("`@<F5D965M('-U8V@@<VAA<F5S(&9O<B!C87-H
M(&%F=&5R($UA<F-H)B,Q-C`[,3<L(#(P,3,@870@=&AE(&=R96%T97(@;V8@
M*&DI)B,Q-C`[=&AE(&]R:6=I;F%L(&ES<W5E#0H@("!P<FEC92!P;'5S(&%N
M>2!A8V-R=65D(&)U="!U;G!A:60@9&EV:61E;F1S(&%N9"`H:6DI)B,Q-C`[
M=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H92!P<F5F97)R960-"B`@('-T
M;V-K(&)E:6YG(')E9&5E;65D+"!T:&4@96UB961D960@8V]N=F5R<VEO;B!F
M96%T=7)E(')E<75I<F5D('-E<&%R871E(&%C8V]U;G1I;F<N#0H@("!#;VYS
M97%U96YT;'DL('1H92!C;VYV97)S:6]N(&9E871U<F4@:&%D('1O(&)E(&)I
M9G5R8V%T960@9G)O;2!T:&4@<')E9F5R<F5D('-T;V-K(&%N9`T*("`@86-C
M;W5N=&5D(&9O<B!S97!A<F%T96QY(&%T(&5A8V@@:7-S=6%N8V4@9&%T92X@
M5&AE(&-A<G)Y:6YG('9A;'5E(&]F('1H92!E;6)E9&1E9`T*("`@9&5R:79A
M=&EV90T*("`@=V%S(&%D:G5S=&5D('1O(&9A:7(@=F%L=64@870@=&AE(&5N
M9"!O9B!E86-H(')E<&]R=&EN9R!P97)I;V0@86YD('1H92!C:&%N9V4@:6X@
M9F%I<@T*("`@=F%L=64@=V%S(')E8V]G;FEZ960@:6X@=&AE('-T871E;65N
M="!O9B!O<&5R871I;VYS+@T*("`@/"]D:78^#0H@("`\(2TM($9O;&EO("TM
M/@T*("`@/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-"B`@(#PA+2T@4$%'
M14)214%+("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I
M;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I;BUL969T.B`P:6X[
M("<^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX-"B`@(#QB/@T*("`@/"]B/@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX-"B`@(#QB/@T*("`@
M/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^3VX@2F%N=6%R>28C,38P.S@L(#(P,3`@=V%R<F%N=',@=&\@
M<'5R8VAA<V4@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@4V5R:65S
M)B,Q-C`[0RTQ('!R969E<G)E9`T*("`@<W1O8VL@=V5R92!E>&5R8VES960@
M<F5S=6QT:6YG(&EN("9N8G-P.R0Q,"PP,#`L,#`P(&EN(&-A<V@@<')O8V5E
M9',@86YD('1H92!I<W-U86YC92!O9B`Q+#DS-2PW,#`-"B`@(&%D9&ET:6]N
M86P@<VAA<F5S(&]F(%-E<FEE<R8C,38P.T,M,2!P<F5F97)R960@<W1O8VLN
M(%1H92!#;VUP86YY(')E8V]R9&5D(&$@9&5R:79A=&EV92!L:6%B:6QI='D-
M"B`@(&]F("9N8G-P.R0S+#0W,2PP,#`@=7!O;B!T:&4@97AE<F-I<V4@;V8@
M=&AE('=A<G)A;G1S(&%N9"!T:&4@:7-S=6%N8V4@;V8@,2PY,S4L-S`P('-H
M87)E<R!O9@T*("`@4V5R:65S)B,Q-C`[0RTQ('!R969E<G)E9"!S=&]C:R!I
M;B!*86YU87)Y)B,Q-C`[,C`Q,"X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/D%T(&5A8V@@<F5P;W)T:6YG(&1A
M=&4L('1H92!#;VUP86YY(&%D:G5S=&5D('1H92!C87)R>6EN9R!V86QU92!O
M9B!T:&4@96UB961D960-"B`@(&1E<FEV871I=F5S('1O(&5S=&EM871E9"!F
M86ER('9A;'5E(&%N9"!R96-O9VYI>F5D('1H92!C:&%N9V4@:6X@<W5C:"!E
M<W1I;6%T960@=F%L=64@:6X@:71S#0H@("!S=&%T96UE;G0@;V8@;W!E<F%T
M:6]N<RX@5&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F('1H92!D97)I=F%T
M:79E<R!A="!!<')I;"8C,38P.S(W+"`R,#$P('=A<PT*("`@)FYB<W`[)#,V
M+#4R."PP,#`N(%1H92!#;VUP86YY(')E8V]G;FEZ960@82!G86EN(&]F("9N
M8G-P.R0S+#8T-"PP,#`@87-S;V-I871E9"!W:71H('1H92!C:&%N9V4@:6X@
M9F%I<@T*("`@=F%L=64@9F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T
M96UB97(F(S$V,#LS,"P@,C`Q,"X@26X@8V]N;F5C=&EO;B!W:71H('1H92!)
M4$\L('1H92!E;6)E9&1E9`T*("`@9&5R:79A=&EV97,@=V5R92!E;&EM:6YA
M=&5D+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^26X@8V]N;F5C=&EO;B!W:71H('1H92!#;VUP86YY)B,X,C$W
M.W,@25!/(&EN($%P<FEL)B,Q-C`[,C`Q,"P@=&AE($-O;7!A;GD@875T:&]R
M:7IE9"`Q,"PP,#`L,#`P#0H@("!S:&%R97,@;V8@)FYB<W`[)#`N,#$@<&%R
M('9A;'5E('!R969E<G)E9"!S=&]C:RX@3F\@<VAA<F5S(&]F('!R969E<G)E
M9"!S=&]C:R!W97)E(&ES<W5E9"!O<@T*("`@;W5T<W1A;F1I;F<@870@4V5P
M=&5M8F5R)B,Q-C`[,S`L(#(P,3$@86YD($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3`L(')E<W!E8W1I=F5L>2X-"B`@(#PO9&EV/@T*("`@/"]D:78^#0H\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VL@3W!T:6]N<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K($]P
M=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#
M+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W
M+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D
M(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO=&4@,3`@+2!U
M<RUG86%P.D1I<V-L;W-U<F5/9D-O;7!E;G-A=&EO;E)E;&%T961#;W-T<U-H
M87)E0F%S961087EM96YT<U1E>'1";&]C:RTM/@T*("`@/&1I=B!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[
M(&UA<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0G/CQB
M/C$P+B!3=&]C:R!/<'1I;VYS/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT
M;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^1'5R:6YG('1H92!T:')E92!M
M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3$@86YD(#(P,3`L
M('1H92!#;VUP86YY(')E8V]R9&5D#0H@("!C;VUP96YS871I;VX@97AP96YS
M92!R96QA=&5D('1O('-T;V-K(&]P=&EO;G,@;V8@87!P<F]X:6UA=&5L>2`F
M;F)S<#LD-#$W+#`P,"!A;F0@)FYB<W`[)#$X.2PP,#`L#0H@("!R97-P96-T
M:79E;'DN($1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R
M)B,Q-C`[,S`L(#(P,3$@86YD(#(P,3`L('1H92!#;VUP86YY(')E8V]R9&5D
M#0H@("!S=&]C:R!C;VUP96YS871I;VX@97AP96YS92!O9B!A<'!R;WAI;6%T
M96QY("9N8G-P.R0Q+#0Q-BPP,#`@86YD("9N8G-P.R0T-#<L,#`P+"!R97-P
M96-T:79E;'DN($%S(&]F#0H@("!397!T96UB97(F(S$V,#LS,"P@,C`Q,2P@
M=&AE('1O=&%L('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S="!R96QA
M=&5D('1O(&YO;BUV97-T960@<W1O8VL-"B`@(&]P=&EO;G,@9W)A;G1E9"!W
M87,@)FYB<W`[)#0L,C(P+#`P,"!A;F0@:7,@97AP96-T960@=&\@8F4@<F5C
M;V=N:7IE9"!O=F5R(&$@=V5I9VAT960@879E<F%G90T*("`@<&5R:6]D(&]F
M(#(N.28C,38P.WEE87)S+B!4:&4@9F]L;&]W:6YG('1A8FQE('!R97-E;G1S
M(&$@<W5M;6%R>2!O9B!S=&]C:R!O<'1I;VX@=')A;G-A8W1I;VYS(&9O<@T*
M("`@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F
M(S$V,#LS,"P@,C`Q,2!A;F0@,C`Q,#H-"B`@(#PO9&EV/@T*("`@/&1I=B!A
M;&EG;CTS1&-E;G1E<CX-"B`@(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D
M97(],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@("`@(#QT9"!W:61T:#TS1#,V)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T
M;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$,30@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/E1H<F5E($UO;G1H<R!%;F1E9"!397!T96UB
M97(@,S`L/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,30@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/DYI;F4@36]N=&AS($5N
M9&5D(%-E<'1E;6)E<B`S,"P\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,3PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/C(P,3`\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0V
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\
M8CXR,#$Q/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^,C`Q,#PO8CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R
M(&-O;'-P86X],T0R/CQB/E=E:6=H=&5D/"]B/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS
M<&%N/3-$,CX\8CY796EG:'1E9#PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(^/&(^5V5I9VAT960\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB
M/E=E:6=H=&5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^079E<F%G93PO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^079E<F%G93PO8CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX]
M,T1C96YT97(@8V]L<W!A;CTS1#(^/&(^079E<F%G93PO8CX\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#(^/&(^079E<F%G93PO8CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R/CQB/D5X97)C:7-E/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\
M8CY%>&5R8VES93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^17AE
M<F-I<V4\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/D5X97)C:7-E
M/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/D]P=&EO;G,\+V(^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P
M)SX\8CY0<FEC93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/D]P=&EO;G,\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CY0<FEC93PO8CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G
M/CQB/D]P=&EO;G,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY0<FEC93PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/D]P=&EO;G,\+V(^/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P
M)SX\8CY0<FEC93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM
M($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M
M/CPA+2T@0FQA;FL@4W!A8V4@+2T^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^
M)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^
M#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ
M-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^3W!T:6]N<R!A="`-"B`@(&)E9VEN
M;FEN9R!O9B!P97)I;V0-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,BPV-S<L-#<T/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1')I9VAT/C,N.3@\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(L,C@Q+#,Q,3PO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1R:6=H=#XR+C,Y/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR+#<T,2PY.#4\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,RXX,3PO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,BPR,C4L-S<X/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(N,30\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V
M86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^1W)A;G1S
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/CDP+#`P,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^-RXY-3PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3`X+#4P
M,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^-BXW-#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,34U+#`P,#PO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^-RXX,SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,3<S+#4P,#PO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^."XS-#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R
M/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD
M.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY&;W)F96ET=7)E
M<PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@Q,RPW,#@\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^-2XR,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1R:6=H=#XH-RPU,#`\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,3$N,#`\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1L969T/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^*#$T+#0T-#PO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XU+C$Q/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D5X97)C
M:7-E<PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F=#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B@Q,"PP,#`\+W1D
M/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$<FEG:'0^,BXP-#PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1R:6=H=#XH-2PX-SD\+W1D/@T*("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`^*3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^,2XT,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&QE9G0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XH,3,R+#`Q,3PO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<#XI/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ
M+C4Y/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$;&5F=#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/B@Q-"PV,3`\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`^*3PO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2XY-#PO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF
M(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P
M,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B
M;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED
M(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<B!V86QI9VX],T1B;W1T;VT^/"$M+2!";&%N:R!3<&%C92`M+3X-"B`@
M("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[
M('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T
M>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY/
M<'1I;VYS(&%T(&5N9"!O9B`-"B`@('!E<FEO9`T*("`@/"]D:78^/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR+#<U-RPT-S0\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C(L,S<P+#(R-#PO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,BPW
M-3<L-#<T/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR+#,W,"PR,C0\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S
M='EL93TS1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I
M=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P
M>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@
M86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE
M(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P
M86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,W!X
M(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X\(2TM($)L86YK(%-P86-E
M("TM/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P
M>#L@=&5X="UI;F1E;G0Z+3$U<'@G/E=E:6=H=&5D(&%V97)A9V4@#0H@("!P
M97(@<VAA<F4@9F%I<B`-"B`@('9A;'5E(&]F(&]P=&EO;G,@#0H@("!G<F%N
M=&5D(&1U<FEN9R!T:&4@#0H@("!P97)I;V0-"B`@(#PO9&EV/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F
M=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XU+C@Q
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P
M.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4N,S4\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-2XV-SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XV+C<T/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q<'@G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*
M("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS
M<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T
M86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@-"4G/E1H92!F;VQL;W=I;F<@=&%B;&4@<')O=FED97,@861D:71I
M;VYA;"!I;F9O<FUA=&EO;B!A<R!O9B!397!T96UB97(F(S$V,#LS,"P-"B`@
M(#(P,3$Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1C96YT97(^#0H@
M("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N
M.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D
M("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0@=VED
M=&@],T0T-"4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q,24^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@]
M,T0Q)3XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P
M86X],T0R/CQB/E=E:6=H=&5D/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\8CY796EG:'1E9#PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS
M1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY!=F5R86=E/"]B/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<CX\8CY!
M=F5R86=E/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,CX\8CY!9V=R96=A=&4\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY%
M>&5R8VES93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(^/&(^0V]N=')A8W1U86P\+V(^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R/CQB/DEN=')I;G-I8SPO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O
M;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S
M;VQI9"`C,#`P,#`P)SX\8CY3:&%R97,\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\
M8CY0<FEC93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@,7!X
M('-O;&ED(",P,#`P,#`G/CQB/E1E<FT\+V(^/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N
M/3-$8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY686QU93PO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0R/CQB/BA);B!T:&]U<V%N9',I/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@
M5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-
M"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^/"$M+2!";&%N:R!3<&%C92`M+3X-
M"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U
M<'@[('1E>'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$8V5N=&5R('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@
M/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM
M,35P>"<^3W5T<W1A;F1I;F<-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^,BPW-3<L-#<T/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1')I9VAT/C0N,3(\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&-E
M;G1E<B!V86QI9VX],T1B;W1T;VT^-BXU,R!Y96%R<SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S
M<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XQ,BPP.#D\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V
M86QI9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^17AE<F-I
M<V%B;&4-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$
M<FEG:'0^,2PY-S(L.34Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR+C8Q/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@86QI9VX],T1C96YT97(@=F%L:6=N/3-$8F]T=&]M/C4N-S`@
M>65A<G,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C$P+#DR
M,3PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E
M969F)SX-"B`@("`@("`\=&0^#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL
M969T.C$U<'@[('1E>'0M:6YD96YT.BTQ-7!X)SY%>'!E8W1E9"!T;R!V97-T
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT
M/C<R,2PP,#4\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!A;&EG;CTS1')I9VAT/C<N.3(\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1&-E;G1E<B!V86QI9VX],T1B;W1T;VT^."XV-"!Y96%R<SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2PP-3,\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/@T*("`@/"]D:78^#0H@("`\
M(2TM($9O;&EO("TM/@T*("`@/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I=CX-
M"B`@(#PA+2T@4$%'14)214%+("TM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA<F=I
M;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX-"B`@(#QB
M/@T*("`@/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX-
M"B`@(#QB/@T*("`@/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P
M<'0[('1E>'0M:6YD96YT.B`T)2<^5&AE(&9O;&QO=VEN9R!T86)L92!P<F]V
M:61E<R!A9&1I=&EO;F%L(&EN9F]R;6%T:6]N(&%S(&]F($1E8V5M8F5R)B,Q
M-C`[,S$L#0H@("`R,#$P.@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$
M8V5N=&5R/@T*("`@/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@
M=&5X="UA;&EG;CH@;&5F="<@8V5L;'-P86-I;F<],T0P(&)O<F1E<CTS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`@(#PA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@
M("`@/'1D('=I9'1H/3-$-#0E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,3$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,R4^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E
M;G1E<B!C;VQS<&%N/3-$,CX\8CY796EG:'1E9#PO8CX\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(^/&(^5V5I
M9VAT960\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X]
M,T0R/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(^/&(^079E<F%G93PO8CX\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C
M96YT97(^/&(^079E<F%G93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#(^/&(^06=G<F5G871E/"]B/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A
M;CTS1#(^/&(^17AE<F-I<V4\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/CQB/D-O;G1R86-T=6%L/"]B
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CY)
M;G1R:6YS:6,\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI
M9VX],T1B;W1T;VT^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^4VAA<F5S/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@
M(S`P,#`P,"<^/&(^4')I8V4\+V(^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY497)M/"]B/CPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^5F%L=64\+V(^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)R!V86QI9VX],T1B;W1T;VT^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A
M;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$,CX\8CXH26X@=&AO=7-A;F1S*3PO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE
M($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/CPA+2T@0FQA;FL@
M4W!A8V4@+2T^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[#0H@("`\
M+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1&-E;G1E<B!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/D]U='-T86YD:6YG#0H@("`\+V1I=CX\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(L-S0Q+#DX-3PO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1R:6=H=#XS+C@Q/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1C96YT97(@=F%L:6=N/3-$8F]T=&]M/C8N.3D@>65A<G,\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,3@L,S,X/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^
M#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#X-"B`@(#QD
M:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U
M<'@G/D5X97)C:7-A8FQE#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1')I9VAT/C$L-S(R+#(X,3PO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,2XX.#PO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$8V5N=&5R('9A;&EG;CTS1&)O
M='1O;3XU+C@X('EE87)S/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R
M:6=H=#XQ-"PV,S@\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R
M;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^17AP96-T
M960@=&\@=F5S=`T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XY-C,L-S4T/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XW+C(T/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1C96YT97(@=F%L:6=N/3-$8F]T=&]M/C@N
M.3(@>65A<G,\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C,L
M,S,T/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@
M("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO
M9&EV/@T*("`@/"]D:78^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC
M;VUE(%1A>&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^26YC;VUE(%1A>&5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE(%1A>&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H
M=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA
M;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL
M,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@
M5&%G9V5D($YO=&4@,3$@+2!U<RUG86%P.DEN8V]M951A>$1I<V-L;W-U<F54
M97AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=4
M:6UE<R!.97<@4F]M86XG+%1I;65S+'-E<FEF.R!M87)G:6XM;&5F=#H@,&EN
M.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T)SX\8CXQ,2X@26YC;VUE(%1A>&5S
M/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD
M96YT.B`T)2<^26X@86-C;W)D86YC92!W:71H($%30R`W-#`@=&AE($-O;7!A
M;GD@<F5C;V=N:7IE<R!D969E<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI
M=&EE<PT*("`@9F]R('1E;7!O<F%R>2!D:69F97)E;F-E<R!B971W965N('1H
M92!F:6YA;F-I86P@<F5P;W)T:6YG(&)A<VES(&%N9"!T:&4@=&%X(&)A<VES
M(&]F(&ET<PT*("`@87-S971S(&%N9"!L:6%B:6QI=&EE<RX@5&AE($-O;7!A
M;GD@<F5C;W)D<R!A('9A;'5A=&EO;B!A;&QO=V%N8V4@86=A:6YS="!I=',@
M;F5T(&1E9F5R<F5D#0H@("!T87@@87-S970@=&\@<F5D=6-E('1H92!N970@
M8V%R<GEI;F<@=F%L=64@=&\@86X@86UO=6YT('1H870@:7,@;6]R92!L:6ME
M;'D@=&AA;B!N;W0@=&\@8F4-"B`@(')E86QI>F5D+@T*("`@/"]D:78^#0H@
M("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M(&UA<F=I;BUT;W`Z(#$P<'0[('1E>'0M:6YD96YT.B`T)2<^26YC;VUE('1A
M>"!P;W-I=&EO;G,@87)E(&-O;G-I9&5R960@9F]R('5N8V5R=&%I;G1Y(&EN
M(&%C8V]R9&%N8V4@=VET:"!&05-"#0H@("!);G1E<G!R971A=&EO;B!.;RXF
M(S$V,#LT."P@06-C;W5N=&EN9R!F;W(@56YC97)T86EN='D@:6X@26YC;VUE
M(%1A>&5S("8C.#(Q,CL@86X@:6YT97)P<F5T871I;VX@;V8-"B`@($%30R`W
M-#`M,3`N(%1H92!#;VUP86YY(&)E;&EE=F5S('1H870@:71S(&EN8V]M92!T
M87@@9FEL:6YG('!O<VET:6]N<R!A;F0@9&5D=6-T:6]N<R!W:6QL(&)E#0H@
M("!S=7-T86EN960@;VX@875D:70@86YD(&1O97,@;F]T(&%N=&EC:7!A=&4@
M86YY(&%D:G5S=&UE;G1S('1H870@=VEL;"!R97-U;'0@:6X@82!M871E<FEA
M;`T*("`@8VAA;F=E('1O(&ET<R!F:6YA;F-I86P@<&]S:71I;VX[('1H97)E
M9F]R92P@;F\@05-#(#<T,"TQ,"!L:6%B:6QI=&EE<R!H879E(&)E96X@<F5C
M;W)D960N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI
M;F1E;G0Z(#0E)SY3:6=N:69I8V%N="!M86YA9V5M96YT(&IU9&=M96YT(&ES
M(&EN=F]L=F5D(&EN(&1E=&5R;6EN:6YG('1H92!P<F]V:7-I;VX@9F]R(&EN
M8V]M90T*("`@=&%X97,L(&1E9F5R<F5D('1A>"!A<W-E=',@86YD(&QI86)I
M;&ET:65S+"!A;F0@86YY('9A;'5A=&EO;B!A;&QO=V%N8V4@<F5C;W)D960@
M86=A:6YS="!N970-"B`@(&1E9F5R<F5D('1A>"!A<W-E=',N($1U92!T;R!U
M;F-E<G1A:6YT:65S('=I=&@@<F5S<&5C="!T;R!T:&4@<F5A;&EZ871I;VX@
M;V8@9&5F97)R960@=&%X#0H@("!A<W-E=',@9'5E('1O('1H92!H:7-T;W)Y
M(&]F(&]P97)A=&EN9R!L;W-S97,L(&$@=F%L=6%T:6]N(&%L;&]W86YC92!H
M87,@8F5E;B!E<W1A8FQI<VAE9`T*("`@86=A:6YS="!T:&4@96YT:7)E(&YE
M="!D969E<G)E9"!T87@@87-S970@8F%L86YC92X@5&AE('9A;'5A=&EO;B!A
M;&QO=V%N8V4@:7,@8F%S960@;VX-"B`@(&UA;F%G96UE;G0F(S@R,3<[<R!E
M<W1I;6%T97,@;V8@=&%X86)L92!I;F-O;64@:6X@=&AE(&IU<FES9&EC=&EO
M;G,@:6X@=VAI8V@@=&AE($-O;7!A;GD@;W!E<F%T97,-"B`@(&%N9"!T:&4@
M<&5R:6]D(&]V97(@=VAI8V@@9&5F97)R960@=&%X(&%S<V5T<R!W:6QL(&)E
M(')E8V]V97)A8FQE+B!);B!T:&4@979E;G0@=&AA="!A8W1U86P-"B`@(')E
M<W5L=',@9&EF9F5R(&9R;VT@=&AE<V4@97-T:6UA=&5S(&]R('1H92!#;VUP
M86YY(&%D:G5S=',@=&AE<V4@97-T:6UA=&5S(&EN(&9U='5R90T*("`@<&5R
M:6]D<RP@82!C:&%N9V4@:6X@=&AE('9A;'5A=&EO;B!A;&QO=V%N8V4@;6%Y
M(&)E(&YE961E9"P@=VAI8V@@8V]U;&0@;6%T97)I86QL>2!I;7!A8W0-"B`@
M('1H92!#;VUP86YY)B,X,C$W.W,@9FEN86YC:6%L('!O<VET:6]N(&%N9"!R
M97-U;'1S(&]F(&]P97)A=&EO;G,N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O
M<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY!="!397!T96UB97(F(S$V,#LS
M,"P@,C`Q,2!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q,"P@=&AE($-O;7!A
M;GD@:&%D(&9E9&5R86P@;F5T(&]P97)A=&EN9R!L;W-S#0H@("`H)B,X,C(P
M.TY/3"8C.#(R,3LI(&-A<G)Y+69O<G=A<F1S(&]F(&%P<')O>&EM871E;'D@
M)FYB<W`[)#$Q,BPQ-#$L,#`P(&%N9"`F;F)S<#LD.3<L.#$S+#`P,"!A;F0@
M<W1A=&4@3D],#0H@("!C87)R>2UF;W)W87)D<R!O9B!A<'!R;WAI;6%T96QY
M("9N8G-P.R0Y-2PV,#0L,#`P(&%N9"`F;F)S<#LD.#`L.3DU+#`P,"P@<F5S
M<&5C=&EV96QY+"!T:&%T(&%R90T*("`@879A:6QA8FQE('1O(')E9'5C92!F
M=71U<F4@:6YC;VUE('5N;&5S<R!O=&AE<G=I<V4@=&%X86)L92X@268@;F]T
M('5T:6QI>F5D+"!T:&4@9F5D97)A;"!.3TP-"B`@(&-A<G)Y+69O<G=A<F1S
M('=I;&P@97AP:7)E(&%T('9A<FEO=7,@9&%T97,@8F5T=V5E;B`R,#(S(&%N
M9"`R,#,P+"!A;F0@=&AE('-T871E($Y/3`T*("`@8V%R<GDM9F]R=V%R9',@
M=VEL;"!E>'!I<F4@870@=F%R:6]U<R!D871E<R!B971W965N(#(P,C`@86YD
M(#(P,S`N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@=&5X="UI
M;F1E;G0Z(#0E)SY.3TP@8V%R<GDM9F]R=V%R9',@;6%Y(&)E('-U8FIE8W0@
M=&\@86YN=6%L(&QI;6ET871I;VYS('5N9&5R($EN=&5R;F%L(%)E=F5N=64@
M0V]D90T*("`@4V5C=&EO;B8C,38P.S,X,B`H;W(@8V]M<&%R86)L92!P<F]V
M:7-I;VYS(&]F('-T871E(&QA=RD@:6X@=&AE(&5V96YT('1H870@8V5R=&%I
M;B!C:&%N9V5S(&EN#0H@("!O=VYE<G-H:7`@;V8@=&AE($-O;7!A;GD@=V5R
M92!T;R!O8V-U<BX@5&AE($-O;7!A;GD@:&%S(&YO="!Y970@8V]M<&QE=&5D
M(&$@9F]R;6%L#0H@("!E=F%L=6%T:6]N(&]F('1H92!I;7!A8W0@;V8@:71S
M($E03R`H3F]T92`Q*2!O;B!T:&4@0V]M<&%N>28C.#(Q-SMS($Y/3"!C87)R
M>2UF;W)W87)D<R!A;F0@=VAE=&AE<@T*("`@8V5R=&%I;B!C:&%N9V5S(&EN
M(&]W;F5R<VAI<"!H879E(&]C8W5R<F5D('1H870@=V]U;&0@;&EM:70@=&AE
M($-O;7!A;GDF(S@R,3<[<R!A8FEL:71Y('1O('5T:6QI>F4-"B`@(&$@<&]R
M=&EO;B!O9B!I=',@3D],(&-A<G)Y+69O<G=A<F1S+@T*("`@/"]D:78^#0H@
M("`\(2TM($9O;&EO("TM/@T*("`@/"$M+2`O1F]L:6\@+2T^#0H@("`\+V1I
M=CX-"B`@(#PA+2T@4$%'14)214%+("TM/@T*("`@/&1I=B!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B<L5&EM97,L<V5R:68[(&UA
M<F=I;BUL969T.B`P:6X[("<^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T)SX-"B`@
M(#QB/@T*("`@/"]B/@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,'!T
M)SX-"B`@(#QB/@T*("`@/"]B/@T*("`@/"]D:78^#0H@("`\+V1I=CX-"CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&,U-C8U
M-61?9&8Y-5\T86)C7SEF-V5?,&0Q8CAE.&,W860W#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V1C-38V-35D7V1F.35?-&%B8U\Y9C=E7S!D,6(X
M93AC-V%D-R]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R2#X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU
M92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!8
M2%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G
M+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*
M("`@/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`Q,B`M('5S+6=A87`Z
M1F%I<E9A;'5E1&ES8VQO<W5R97-497AT0FQO8VLM+3X-"B`@(#QD:78@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=4:6UE<R!.97<@4F]M86XG+%1I;65S+'-E
M<FEF.R!M87)G:6XM;&5F=#H@,&EN.R`G/@T*("`@/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM=&]P.B`Q,'!T
M)SX\8CXQ,BX@1F%I<B!686QU93PO8CX-"B`@(#PO9&EV/@T*("`@/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM
M=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!#;VUP86YY(&%D;W!T
M960@4W1A=&5M96YT(&]F($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)D
M<R!.;RXF(S$V,#LQ-3<L($9A:7(@5F%L=64-"B`@($UE87-U<F5M96YT<R`H
M05-#(#@R,"DL(&5F9F5C=&EV92!*86YU87)Y)B,Q-C`[,2P@,C`P."X@56YD
M97(@=&AI<R!S=&%N9&%R9"P@9F%I<B!V86QU92!I<PT*("`@9&5F:6YE9"!A
M<R!T:&4@<')I8V4@=&AA="!W;W5L9"!B92!R96-E:79E9"!T;R!S96QL(&%N
M(&%S<V5T(&]R('!A:60@=&\@=')A;G-F97(@82!L:6%B:6QI='D-"B`@("AI
M+F4N+"!T:&4@)B,X,C(P.V5X:70@<')I8V4F(S@R,C$[*2!I;B!A;B!O<F1E
M<FQY('1R86YS86-T:6]N(&)E='=E96X@;6%R:V5T('!A<G1I8VEP86YT<R!A
M="!T:&4-"B`@(&UE87-U<F5M96YT(&1A=&4N#0H@("`\+V1I=CX-"B`@(#QD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R
M9VEN+71O<#H@,3!P=#L@=&5X="UI;F1E;G0Z(#0E)SY);B!D971E<FUI;FEN
M9R!F86ER('9A;'5E+"!T:&4@0V]M<&%N>2!U<V5S('9A<FEO=7,@=F%L=6%T
M:6]N(&%P<')O86-H97,N(%1H92!H:65R87)C:'D-"B`@(&]F('1H;W-E('9A
M;'5A=&EO;B!A<'!R;V%C:&5S(&ES(&)R;VME;B!D;W=N(&EN=&\@=&AR964@
M;&5V96QS(&)A<V5D(&]N('1H92!R96QI86)I;&ET>2!O9@T*("`@:6YP=71S
M(&%S(&9O;&QO=W,Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T
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M('!R;W9I9&4@<')I8VEN9PT*("`@:6YF;W)M871I;VX@;VX@86X@;VYG;VEN
M9R!B87-I<RX@5&AE('9A;'5A=&EO;B!U;F1E<B!T:&ES(&%P<')O86-H(&1O
M97,@;F]T(&5N=&%I;"!A#0H@("!S:6=N:69I8V%N="!D96=R964@;V8@:G5D
M9VUE;G0N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+71O<#H@,3!P=#L@;6%R9VEN
M+6QE9G0Z(#0E.R!T97AT+6EN9&5N=#H@-"4G/DQE=F5L(#(@:6YP=71S(&%R
M92!I;G!U=',@;W1H97(@=&AA;B!Q=6]T960@<')I8V5S(&EN8VQU9&5D('=I
M=&AI;B!,979E;"`Q('1H870@87)E#0H@("!O8G-E<G9A8FQE(&9O<B!T:&4@
M87-S970@;W(@;&EA8FEL:71Y+"!E:71H97(@9&ER96-T;'D@;W(@:6YD:7)E
M8W1L>2X@3&5V96P@,B!I;G!U=',-"B`@(&EN8VQU9&4Z('%U;W1E9"!P<FEC
M97,@9F]R('-I;6EL87(@87-S971S(&]R(&QI86)I;&ET:65S(&EN(&%C=&EV
M92!M87)K971S+"!I;G!U=',@;W1H97(-"B`@('1H86X@<75O=&5D('!R:6-E
M<R!T:&%T(&%R92!O8G-E<G9A8FQE(&9O<B!T:&4@87-S970@;W(@;&EA8FEL
M:71Y+"`H92YG+BP@:6YT97)E<W0@<F%T97,-"B`@(&%N9"!Y:65L9"!C=7)V
M97,@;V)S97)V86)L92!A="!C;VUM;VYL>2!Q=6]T960@:6YT97)V86QS(&]R
M(&-U<G)E;G0@;6%R:V5T*2!A;F0-"B`@(&-O;G1R86-T=6%L('!R:6-E<R!F
M;W(@=&AE('5N9&5R;'EI;F<@9FEN86YC:6%L(&EN<W1R=6UE;G0L(&%S('=E
M;&P@87,@;W1H97(@<F5L979A;G0-"B`@(&5C;VYO;6EC(&UE87-U<F5S+@T*
M("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[(&UA<F=I;BUT;W`Z(#$P<'0[(&UA<F=I;BUL969T.B`T
M)3L@=&5X="UI;F1E;G0Z(#0E)SY,979E;"`S(&EN<'5T<R!A<F4@=6YO8G-E
M<G9A8FQE(&EN<'5T<R!F;W(@=&AE(&%S<V5T(&]R(&QI86)I;&ET>2X@56YO
M8G-E<G9A8FQE#0H@("!I;G!U=',@<VAA;&P@8F4@=7-E9"!T;R!M96%S=7)E
M(&9A:7(@=F%L=64@=&\@=&AE(&5X=&5N="!T:&%T(&]B<V5R=F%B;&4@:6YP
M=71S(&%R92!N;W0-"B`@(&%V86EL86)L92P@=&AE<F5B>2!A;&QO=VEN9R!F
M;W(@<VET=6%T:6]N<R!I;B!W:&EC:"!T:&5R92!I<R!L:71T;&4L(&EF(&%N
M>2P@;6%R:V5T#0H@("!A8W1I=FET>2!F;W(@=&AE(&%S<V5T(&]R(&QI86)I
M;&ET>2!A="!T:&4@;65A<W5R96UE;G0@9&%T92X-"B`@(#PO9&EV/@T*("`@
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM=&]P.B`Q,'!T.R!T97AT+6EN9&5N=#H@-"4G/E1H92!F;VQL;W=I
M;F<@=&%B;&4@<')E<V5N=',@:6YF;W)M871I;VX@86)O=70@=&AE($-O;7!A
M;GDF(S@R,3<[<R!A<W-E=',@;65A<W5R960@870@9F%I<@T*("`@=F%L=64@
M;VX@82!R96-U<G)I;F<@8F%S:7,Z#0H@("`\+V1I=CX-"B`@(#QD:78@86QI
M9VX],T1C96YT97(^#0H@("`\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R!T97AT+6%L:6=N.B!L969T)R!C96QL<W!A8VEN9STS1#`@8F]R9&5R
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*("`@/"$M+2!"
M96=I;B!486)L92!(96%D("TM/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`@("`\=&0@=VED=&@],T0T-"4^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D('=I9'1H/3-$,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS
M1#DE/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I
M9'1H/3-$.24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF
M(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0Q-"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^/&(^4V5P
M=&5M8F5R(#,P+"`R,#$Q/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/DQE=F5L(#$\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CY,979E;"`R/"]B/CPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P
M,"<^/&(^3&5V96P@,SPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/E1O=&%L/"]B
M/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT
M97(@8V]L<W!A;CTS1#$T/CQB/BA5;F%U9&ET960I/"]B/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS
M1#$T/CQB/BA);B!T:&]U<V%N9',I/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M
M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!V86QI
M9VX],T1B;W1T;VT^/"$M+2!";&%N:R!3<&%C92`M+3X-"B`@("`@("`\=&0^
M#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD
M96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-E969F)SX-"B`@("`@("`\=&0^
M#0H@("`\9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD
M96YT.BTQ-7!X)SY#87-H(&5Q=6EV86QE;G1S*#$I#0H@("`\+V1I=CX\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^
M,S<L-#,W/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P
M.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@
M86QI9VX],T1R:6=H=#XS-RPT,S<\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT^#0H@("`@
M("`@/'1D/@T*("`@/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T
M97AT+6EN9&5N=#HM,35P>"<^26YV97-T;65N=',@:6X@;6%R:V5T86)L92!D
M96)T('-E8W5R:71I97,H,BD-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&%L:6=N/3-$<FEG:'0^)B,X,C$R.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-3`R/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI
M9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XU,#(\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#%P>"<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL
M93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q
M-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX]
M,T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O
M<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`Q<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/CPA+2T@
M0FQA;FL@4W!A8V4@+2T^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM,35P>"<^)B,Q-C`[
M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G8F%C:V=R
M;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@/&1I=B!S='EL93TS
M1"=M87)G:6XM;&5F=#HS,'!X.R!T97AT+6EN9&5N=#HM,35P>"<^07-S971S
M(&UE87-U<F5D(&%T(&9A:7(@=F%L=64-"B`@(#PO9&EV/CPO=&0^#0H@("`@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF
M;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XS-RPT,S<\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^
M#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^-3`R/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$<FEG
M:'0^,S<L.3,Y/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO
M='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q<'@G/@T*("`@("`@
M(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X
M="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P
M,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z(#-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T
M86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&-E;G1E<CX-"B`@
M(#QT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ
M(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@
M+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9"!W:61T
M:#TS1#0T)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#,E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,R4^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#DE/B8C,38P.SPO=&0^#0H@("`@
M("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED
M=&@],T0S)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$.24^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!W:61T:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y)3XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/'1R('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI
M9VX],T1C96YT97(@8V]L<W!A;CTS1#$T('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(#%P>"!S;VQI9"`C,#`P,#`P)SX\8CY$96-E;6)E<B`S,2P@,C`Q,#PO
M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@
M(#QT<B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O
M;3X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N
M=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P>"!S
M;VQI9"`C,#`P,#`P)SX\8CY,979E;"`Q/"]B/CPO=&0^#0H@("`@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E<B!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`Q<'@@<V]L:60@(S`P,#`P,"<^
M/&(^3&5V96P@,CPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@86QI9VX],T1C96YT97(@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@,7!X('-O;&ED(",P,#`P,#`G/CQB/DQE=F5L(#,\+V(^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$
M8V5N=&5R(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(#%P
M>"!S;VQI9"`C,#`P,#`P)SX\8CY4;W1A;#PO8CX\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0G('9A;&EG;CTS1&)O='1O;3X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R(&-O;'-P86X],T0Q-#X\
M8CXH26X@=&AO=7-A;F1S*3PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@=F%L:6=N/3-$
M8F]T=&]M/CPA+2T@0FQA;FL@4W!A8V4@+2T^#0H@("`@("`@/'1D/@T*("`@
M/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM
M,35P>"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@/"]T<CX-"B`@(#QT<B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G8F%C:V=R;W5N9#H@(V-C965F9B<^#0H@("`@("`@/'1D/@T*("`@
M/&1I=B!S='EL93TS1"=M87)G:6XM;&5F=#HQ-7!X.R!T97AT+6EN9&5N=#HM
M,35P>"<^0V%S:"!E<75I=F%L96YT<R@Q*0T*("`@/"]D:78^/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T
M/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(W+#,Y
M,SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF;F)S<#LD/"]T
M9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@
M(#QT9"!A;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$<FEG:'0^,C<L,SDS/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT
M9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,35P>#L@=&5X="UI
M;F1E;G0Z+3$U<'@G/DEN=F5S=&UE;G1S(&EN(&UA<FME=&%B;&4@9&5B="!S
M96-U<FET:65S*#(I#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/B8C.#(Q,CL\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C(V+#,S,#PO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D
M(&%L:6=N/3-$<FEG:'0^,C8L,S,P/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M<'@G/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO=&0^
M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O<F1E<BUT;W`Z(#%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D
M97(M=&]P.B`Q<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&-O;'-P86X],T0R(&%L:6=N/3-$
M<FEG:'0@<W1Y;&4],T0G8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R
M/@T*("`@/'1R('9A;&EG;CTS1&)O='1O;3X\(2TM($)L86YK(%-P86-E("TM
M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,35P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG<F]U;F0Z("-C8V5E9F8G
M/@T*("`@("`@(#QT9#X-"B`@(#QD:78@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,S!P>#L@=&5X="UI;F1E;G0Z+3$U<'@G/D%S<V5T<R!M96%S=7)E9"!A="!F
M86ER('9A;'5E#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1&QE9G0^)FYB<W`[)#PO=&0^#0H@
M("`@("`@/'1D(&%L:6=N/3-$<FEG:'0^,C<L,SDS/"]T9#X-"B`@("`@("`\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A
M;&EG;CTS1')I9VAT/C(V+#,S,#PO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N
M/3-$;&5F=#XF;F)S<#LD/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H
M=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N
M8G-P.R0\+W1D/@T*("`@("`@(#QT9"!A;&EG;CTS1')I9VAT/C4S+#<R,SPO
M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!X)SX-"B`@("`@("`\=&0^#0H@("`\
M9&EV('-T>6QE/3-$)VUA<F=I;BUL969T.C$U<'@[('1E>'0M:6YD96YT.BTQ
M-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A
M;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H="!S
M='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P
M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(@86QI9VX],T1R:6=H="!S='EL93TS1"=B;W)D97(M=&]P.B`S
M<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(@86QI9VX],T1R:6=H
M="!S='EL93TS1"=B;W)D97(M=&]P.B`S<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\
M+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T/@T*("`@/&1I=B!S='EL93TS
M1"=F;VYT+7-I>F4Z(#-P=#L@;6%R9VEN+71O<#H@,3!P=#L@=VED=&@Z(#$X
M)3L@8F]R9&5R+71O<#H@,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.PT*("`@
M/"]D:78^#0H@("`\+V1I=CX-"B`@(#QT86)L92!W:61T:#TS1#$P,"4@8F]R
M9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F="<^#0H@("`\
M='(@<W1Y;&4],T0G9F]N="US:7IE.B`V<'0G/@T*("`@("`@(#QT9"!W:61T
M:#TS1#,E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q
M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Y-B4^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@=F%L:6=N/3-$=&]P/@T*("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@86QI9VX],T1L969T/B@Q*3PO=&0^#0H@("`@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/E1H92!C87)R>6EN9R!A;6]U
M;G1S(&%P<')O>&EM871E(&9A:7(@=F%L=64@9'5E('1O('1H92!S:&]R="UT
M97)M(&UA='5R:71I97,@;V8@=&AE(&-A<V@@97%U:79A;&5N=',N/"]T9#X-
M"B`@(#PO='(^#0H@("`\='(@<W1Y;&4],T0G9F]N="US:7IE.B`S<'0G/@T*
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@/'1R('9A;&EG;CTS
M1'1O<#X-"B`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$;&5F
M=#XH,BD\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT
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M<FEC92!T<F%N<W!A<F5N8WDN(%!R:6-I;F<-"B`@('-O=7)C97,@:6YC;'5D
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M:&ES(&-R96%T97,@82`F(S@R,C`[8V]N<V5N<W5S('!R:6-E)B,X,C(Q.R!O
M<B!A('=E:6=H=&5D(&%V97)A9V4-"B`@('!R:6-E(&9O<B!E86-H('-E8W5R
M:71Y+CPO=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H\+WAM
M;#X-"BTM+2TM+3U?3F5X=%!A<G1?9&,U-C8U-61?9&8Y-5\T86)C7SEF-V5?
0,&0Q8CAE.&,W860W+2T-"@``
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
